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0.2. Abstract 
 
Aberrant protein-protein interactions (PPIs) are found in many disease states. Consequently, 
there is a need for PPI inhibitors for use as research tools and pharmaceutical lead compounds. 
Computational methods could greatly assist with the search for new PPIs. 
Oligobenzamides are novel PPI inhibitors which can theoretically be produced to display any 
sequence of side chains. Understanding the nature of oligobenzamide binding is important for 
identification of the most efficient strategy of predicting oligobenzamide PPIs. 
The prediction of oligobenzamide affinities using thermodynamic integration and implicit 
solvent methods is described. Affinities of oligobenzamides for Mdm2 predicted using implicit 
solvent methods bore a moderate correlation with measured affinities. Examination of MM-
PBSA results using analysis of variance revealed that it is not necessary to run simulations with 
every member of a large combinatorial library in order to predict their relative affinities because 
within a particular binding site, the degree of interaction between the side chains is small. 
However, it could be useful to separate molecules based on their predicted binding pose because 
oligobenzamides can bind to Mdm2 in many different ways, depending on the choice of side 
chains. This insight will be valuable for future attempts to predict oligobenzamide affinities. 
The 
1
H-
15
N HSQC NMR spectrum peaks of 
15
N-labelled Mdm2 L33E were assigned to 
facilitate the future validation of binding poses. An oligoamide was shown using NMR to bind 
in the correct place. However, NMR testing revealed that oligobenzamides can aggregate in 
aqueous solution despite being soluble. 
A novel FRET-based method was also developed which can be used to test potential inhibitors 
with a low solubility and high absorbance during their development. It was adapted for a 
microwell plate to facilitate future high throughput screening and an assay involving Cherry-
labelled Mdm2 was tested which could be developed into an in vivo assay in the future. 
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0.4. Abbreviations 
 
µM µmol dm-3 
2xYT two times yeast extract and tryptone 
3D 3-dimensional 
AA 4-(4-aminobenzamide)benzoic acid 
Ac acetyl 
Aib aminoisobutyric acid 
AMBER Assisted Model Building with Energy 
Refinement 
ANOVA analysis of variance 
APS ammonium persulfate 
Arg arginine 
Asp aspartate 
ATM ataxia telangiectasia mutated 
ATP adenosine triphosphate 
ATR ataxia telangiectasia and Rad3-
related protein 
BA benzanilide 
BAC2 bimolecular, base-catalysed acyl-
oxygen cleavage 
BFGS Broyden-Fletcher-Goldfarb-Shanno 
BFP blue fluorescent protein 
BME basal medium Eagle 
BMRB Biological Magnetic Resonance Data 
Bank 
BRET bioluminescence resonance energy 
transfer 
BSA bovine serum albumin 
Car aromatic carbon 
cdk4 cyclin-dependent kinase 4 
cdk6 cyclin-dependent kinase 6 
cDNA copy DNA 
CFP cyan fluorescent protein 
CHAPS 3-[(3-cholamidopropyl)dimethylamm
onio]-1-propanesulfonate 
CHARMM Chemistry at Harvard Molecular 
Mechanics 
COX-2 cyclooxygenase 2 
Cp peptide carbon 
CPD composite pulse decoupling 
Cys Cysteine 
D-amino 
acid 
dextrorotatory amino acid 
DFT density functional theory 
DMSO dimethyl sulphoxide 
DNA deoxyribonucleic acid 
DNAse deoxyribonuclease 
D-peptide dextrorotatory peptide 
DPI dual polarisation interferometry 
DsRed Discosoma sp. red fluorescent 
protein  
DTT dithiothreitol 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
eGFP enhanced GFP 
ESP electrostatic potential 
eYFP enhanced YFP 
FA fluorescence anisotropy 
Fmoc fluorenylmethyloxycarbonyl 
FRET Förster resonance energy transfer 
G1 phase gap 1 phase 
G2 phase gap 2 phase 
GAFF general AMBER force field 
GB generalised Born 
GBSA generalised Born surface area 
GFP green fluorescent protein 
Gln glutamine 
Glu glutamate 
G-protein guanine nucleotide-binding protein 
HF Hartree–Fock 
HIPK2 homeodomain-interacting protein 
kinase 2 
His histidine 
HMQC heteronuclear multiple-quantum 
correlation 
HOESY heteronuclear Overhauser effect 
spectroscopy 
HP high performance 
HSQC heteronuclear spin quantum 
correlation 
Hz Hertz 
IC50 half maximal inhibitory 
concentration 
IDIVF (An AMBER force field torsion 
parameter.) 
Ile isoleucine 
IPTG isopropyl β-D-1-
thiogalactopyranoside 
IQR interquartile range 
IS ionic strength 
ITC isothermal titration calorimetry 
jCE Java combinatorial extension 
Ka association constant 
Kcal kilocalorie 
Kd dissociation constant 
kDa kilodalton 
Ki inhibition constant 
LB lysogeny broth 
Leu leucine 
Lys lysine 
14
  
 
 
 
M mol dm-3 
M phase mitosis phase 
mAu milli-absorbance units 
Mdm2 murine double minute 2 protein 
Mdm4 murine double minute 4 protein 
Met methionine 
MHz megahertz 
ml millilitre 
MM molecular mechanics 
MMFF94s Merck molecular force field 94 static 
MM-GBSA (See MM and GBSA.) 
MM-PBSA (See MM and PBSA.) 
MS mass spectrometry 
MUP major urinary protein 
MW molecular weight 
MWCO molecular weight cut-off 
N/A not applicable 
Nam amide nitrogen 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser effect 
spectroscopy 
NPT constant particle number, pressure 
and temperature 
NVT constant particle number, volume 
and temperature 
OPLS Optimized Potentials for Liquid 
Simulations 
p53 protein 53 
PAGE polyacrylamide gel electrophoresis 
PB Poisson-Boltzmann 
PBS phosphate buffered saline 
PBSA Poisson-Boltzmann surface area 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PDB Protein Data Bank 
PEG polyethylene glycol 
pET plasmid expression T7 
PhD Doctor of Philosophy 
Phe phenylalanine 
pHs pH values 
Pip-1 piperidinone 1 
PIPES piperazine-N,N′-bis(2-ethanesulfonic 
acid) 
PK (An AMBER force field torsion 
parameter.) 
pKa -log10 Ka 
PME particle mesh Ewald 
Pmp pyridoxamine phosphate 
PPI protein-protein interaction 
ppm parts per million 
Pro proline 
PSA polar surface area 
QM quantum mechanics 
QSAR quantitative structure-activity 
relationship 
R5C3 Row 5, Column 3 
RanBP2 RAs-related nuclear protein-binding 
protein 2 
RCSB Research Collaboratory for Structural 
Bioinformatics 
RDC residual dipolar coupling 
RED RESP ESP Charge Derive 
RESP restricted electrostatic potential 
RING really interesting new gene 
RMS root mean square 
RMSD root mean square deviation 
S phase synthesis phase 
SA surface area 
SDF structure data file 
SDS sodium dodecyl sulphate 
SE standard error 
Ser serine 
SMILES Simplified Molecular Input Line Entry 
System 
SN2 bimolecular nucleophilic substitution 
SPR surface plasmon resonance 
SPRi surface plasmon resonance imaging 
SS sum of squares 
SWI/SNF switch/sucrose non-fermenting 
SWIB SWI/SNF complex B 
T4 bacteriophage T4 
Taq Thermus aquaticus 
TBE tris-borate EDTA 
tBu tert-Butyl, C(CH3)3 
TE tris-EDTA 
TEMED tetramethylethylenediamine 
TEV Tobacco Etch Virus  
Thr threonine 
TI thermodynamic integration 
TOCSY total correlation spectroscopy 
Trp tryptophan 
Tyr tyrosine 
UCSF University of California, San 
Francisco 
UV ultraviolet 
Val valine 
VBA Visual Basic for Applications 
vdW van der Waals 
VMD Visual Molecular Dynamics 
YFP yellow fluorescent protein 
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1. Introduction 
 
 
 
1.1. Motivation 
 
The aim of this project was to investigate whether computational methods could be used to 
predict the affinity of oligobenzamide inhibitors for the p53 binding site of Mdm2 and to 
develop practical methods which could be used to evaluate computational predictions. This 
section outlines some of the key reasons for studying protein-protein interactions, in particular 
the p53-Mdm2 interaction and the motivation for doing so using computational methods. 
1.1.1. PROTEIN-PROTEIN INTERACTIONS AND THEIR INHIBITION 
Protein-protein interactions (PPIs) are ubiquitous in nature at the intercellular, intracellular and 
subcellular levels. Control systems and signalling pathways frequently depend on these 
interactions and aberrant PPIs have been implicated in many diseases. Consequently, the search 
for molecules which can influence these interactions has in recent years become a key focus of 
research. Inhibitors of protein-protein interactions are in particular demand due to their potential 
to be developed into new research tools and pharmaceuticals.  
1.1.2. HELIX MIMETICS 
McMillan et al.
1
 report the allosteric inhibition of nitric oxide synthase dimerisation by a 480 
Da pyrimidineimidazole derivative. It binds to the haem group at the active site and causes a 
conformational change which is propagated through the enzyme to the part of the protein 
responsible for dimerisation. However, allosteric inhibition is unusual; PPI inhibitors are usually 
competitive inhibitors which bind to the interacting interface of one of the proteins. 
Leung et al.
2
 describe the selective inhibition of lactate dehydrogenase dimerisation and citrate 
synthase dimerisation by cyclodextrin dimers, which bind at multiple sites on the interface. 
However, typically inhibitors bind in a single place to one of the proteins, mimicking an 
interacting element of secondary structure in the other. 
24
  
 
 
 
Smith et al.
3
, produced a beta-sheet proteomimetic to block the active site of HIV-1 protease 
and Burgess
4
 describes the development of beta-turn mimetics which bind to transmembrane 
receptor TrkA, inhibiting its interaction with dimeric nerve growth factor. However, there is 
most interest in inhibitors of PPIs involving an alpha helix. In 2009, Jochim and Arora
5
 
analysed PPIs in the PDB, identifying ones which involved an alpha helix. In their analysis, of 
the 8678 PDB structures containing more than one molecule, most (7066) featured an alpha-
helical protein-protein interface. Furthermore, Keskin et al.
6
 report how alpha helices appear to 
be particularly prevalent at shared binding sites, something they attribute to the ability of alpha 
helices to form a wide variety of different interactions. Consequently, many PPI interfaces of 
considerable scientific interest involving hubs where information is consolidated from many 
different sources might involve alpha-helix-mediated binding. 
In addition to being an important, ubiquitous target, PPIs involving a helix are also tractable 
because it often not necessary to mimic the entire helix to block the interaction; a small 
molecule can be effective if it mimics just the key side chains, as will now be discussed. 
1.1.3. SMALL MOLECULE INHIBITORS 
Most of the PPI inhibitors licensed for clinical use are monoclonal antibodies which have been 
"humanized" to prevent them from triggering immune responses
7
. However, the use of 
antibodies has several drawbacks. Firstly, in therapeutic use, antibodies must be injected, to 
avoid proteolysis following oral administration.  Secondly, because they cannot enter cells, they 
can only be used against extracellular targets
8
. Finally, monoclonal antibodies are expensive to 
produce. 
A PPI involving an alpha helix can sometimes be inhibited using a peptide comprising an 
interacting part of one of the proteins involved
8,9
; however, in vivo, many peptides are 
susceptible to proteolysis making them unsuitable for medical use
10
. Furthermore, peptides with 
fewer than 15 residues do not generally have a stable secondary structure when free in 
solution
11
. However, there are stable peptide analogues referred to as foldamers which cannot be 
broken down by proteases
9
. These include: 
 "Retro-inverso peptides", synthetic peptides composed of D-amino acids in which the 
sequence is the reverse of that to be mimicked, to account for the changed handedness. 
Their dextrorotatory configuration makes these compounds less susceptible to 
proteolysis. 
 Peptoids, in which side chains are attached to the backbone nitrogen atoms. 
 β-peptides, where each backbone amino group is bonded to the β carbon, rather than the 
α carbon, as in naturally occurring amino acids. 
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 Stapled peptides, helical peptides in which a covalent linkage connects two non-natural 
amino acids, holding the peptide in a conformation where the amide linkages are 
inaccessible to proteases
12
. 
 Other natural structures. For example, the p53-Mdm2 interaction inhibitors of Fasan et 
al.
13,14
 are stable beta-hairpins (cyclic peptides) which act as alpha-helix mimetics. 
In addition to foldamers, small molecule inhibitors are also amongst the compounds under 
investigation as possible PPI inhibitors. 
Although protein-protein interfaces typically have a surface area of 15 to 30 nm
2
, a few key 
residues, usually at the centre of the interface, are responsible for most of the free energy 
released during binding
15
. While peptide analogues mimic the whole of a peptide, small 
molecule inhibitors imitate only these important side chains using mimicking groups held in the 
correct position relative to each other by a rigid scaffold. The inflexibility of the scaffold 
increases the specificity of the molecule for the target binding site and the prearrangement of the 
groups potentially makes binding more entropically favourable. 
Small molecule peptidomimetics have several key advantages for development as 
pharmaceutical agents. Their small size makes them potentially cheaper to manufacture, 
increases their bioavailability
16
, meaning that they can be taken orally, and makes it easier to 
modify them to facilitate their entry into the target cells
7,8
. Consequently, the focus of this 
project was the development of small molecule PPI inhibitors. 
1.1.4. THE SIGNIFICANCE OF P53 
p53 is one of a family of tumour suppressor proteins, so called due to their ability to suppress 
uncontrolled cell division, instead allowing cells division only when appropriate. In response to 
different cellular signals, it can trigger either temporary arrest of the cell cycle (quiescence), 
permanent arrest (senescence) or controlled cell death (apoptosis). Its involvement in the control 
of cell division and apoptosis makes it the focus of a significant amount of research into 
potential new cancer treatments. 
p53 controls the G1/S checkpoint, one of the two main points of regulation in the eukaryotic cell 
cycle and the more important of the two in higher organisms such as humans. The four main 
stages of the cell cycle are the gap 1 (G1) phase, the DNA synthesis (S) phase, the gap 2 (G2) 
phase and the mitotic (M) phase
17
. The G1/S checkpoint controls progression from the G1 to the 
S phase. Passing the checkpoint requires cyclin-dependent kinase complexes to be active, cyclin 
D-cdk4, cyclin D-cdk6 and cyclin E-cdk2
18
. p53 stops the cycle primarily by inducing 
expression of p21 (cyclin-dependent kinase inhibitor 1A). p21 binds to and inactivates cyclin-
dependent kinases
19
 and also binds to proliferating cell nuclear antigen (PCNA), which is 
required for DNA polymerisation at the start of the S phase
20
. 
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The regulatory activities of p53 depend upon its ability to form many protein-protein 
interactions, all of which have the potential for study. Some parts of the molecule, the first 
transactivation domain for instance, bind to key protein kinases, which phosphorylate p53, 
activating it, when DNA damage is detected. These include ATM (ataxia telangiectasia 
mutated) protein and ATR (ataxia telangiectasia and Rad3-related protein) which both 
phosphorylate p53 on Ser15
21
. Another protein, homeodomain-interacting protein kinase 2 
(HIPK2), phosphorylates p53 on Ser46
22
. Phosphorylation on Ser37 and Ser46 of p53 is thought 
to affect its affinity for DNA,
21,23
 preventing it from inducing p21 expression. Phosphorylation 
of Ser15 has a less direct effect; it reduces the affinity of p53 for murine double minute protein 
2 (Mdm2)
24
, an E3 ubiquitin-protein ligase which controls p53 activity. One reason for 
investigating p53 is the density of overlapping binding sites which mean that an inhibitor of one 
of these interactions could potentially be adapted to block another interaction involving the 
same part of p53. 
1.1.5. THE INTERACTION OF P53 WITH MDM2 
In normal cells, Mdm2 binds to p53, causing it to become inactive. In cells with damaged DNA 
or other stresses, the p53-Mdm2 complexes dissociate and active p53 triggers quiescence, 
senescence or apoptosis
25
. In roughly 7% of all human tumours there is overexpression of 
Mdm2
9
. This inhibits p53 activity so it fails to induce apoptosis or cell cycle arrest despite there 
being damage. Where low p53 activity in a cancer patient’s tumour is caused by a mutation in 
the mdm2 gene (leading to Mdm2 overexpression) rather than a mutation in the gene for p53 
itself, an effective treatment could be to inhibit the p53-Mdm2 interaction. 
1.1.6. THE POTENTIAL OF COMPUTATIONAL METHODS 
Using high-throughput screening to find protein-protein interaction inhibitors is expensive 
because it requires robotic machinery and it can be time consuming. The synthesis of 
compounds for screening can use large amounts of material and energy. It creates chemical 
waste and some methods involve potential hazards. In silico methods are safer, often quicker 
and potentially cheaper. They can narrow down the number of compounds which need to be 
made for testing, reducing the cost of pharmaceutical development and making screening 
accessible to the academic community. 
Despite their advantages, computational methods involve experimentation with a model rather 
than the real system so, to realise these benefits, research is required to identify which methods 
reproduce experimental results and which do not. 
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1.2. The p53-Mdm2 Interaction 
 
Mdm2 binds to an alpha helix of p53 near to its N-terminal end. Using phage display,  Böttger 
et al.
26
 identified three residues within this region, Phe19, Trp23 and Leu26 as key "hot spots" 
for Mdm2 binding, residues which contribute significantly to the binding energy. Binding of 
Mdm2 to p53 directly prevents p53 from acting as a transcription factor, causes p53 to be 
exported from the nucleus and permits polyubiquitination of p53 by Mdm2, thereby targeting 
p53 for degradation by the proteasome
9
. p53 induces expression of Mdm2 leading to negative 
feedback. 
Modelling can be computationally expensive so it is useful to keep models of a system as small 
as possible, only including the important parts. Developing inhibitors of the p53-Mdm2 
interaction therefore requires a good understanding of the structures of the two interacting 
molecules and how they associate. 
1.2.1. THE STRUCTURE OF P53 
The protein p53 (Figure 1.1) comprises an intrinsically disordered N-terminal region referred to 
as the transactivation domain, followed, after a proline-rich length, by a long, structured DNA-
binding domain (roughly half of the molecule) and then, further down the protein, an 
oligomerisation domain. 
The transactivation domain of p53 contains two subdomains. Proteins involved in replication 
such as the co-activator p300 typically bind to both of these subdomains. Both have regions that 
fold to facilitate binding with a particular target protein. The first subdomain binds to Mdm2 
and its homologue, murine double minute protein 4 (Mdm4). Within it, residues 18 to 25 fold 
during Mdm2 binding
27
. 
When binding to DNA, p53 forms a tetramer through aggregation of a beta strand and alpha 
helix in the oligomerisation domain of different monomers. Dissociation of the tetramer exposes 
a nuclear export signal in the oligomerisation domain which may lead to export of the 
dissociated p53 monomers from the nucleus, preventing them from acting as transcription 
factors. Consequently, control of tetramerisation could play a role in the control of p53 
activity
27
. The extreme C-terminal region after the oligomerisation domain, might also be 
involved in the regulation of p53 activity
27,28
.
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Figure 1.1: The human p53 and Mdm2 polypeptides. The numbers indicate the position of residues within the amino acid sequence. For each protein, the top band shows parts of 
the sequence that fold to make an important region of the protein, in p53, the two subdomains of the transactivation domain (T), the DNA binding domain and the oligomerisation 
domain (Oligo.): in Mdm2, the SWI/SNF (SWItch/Sucrose Non-Fermenting) complex B domain (SWIB), the acidic Asp/Glu rich domain (Acidic) and the Ran-binding protein 2 
(RanBP2) and RING (Really Interesting New Gene) zinc-finger domains. The lower band shows the secondary structure: blue for alpha helix, red for beta strand and khaki for turns. 
This figure was constructed using Microsoft Excel with data from UniProt (www.uniprot.org) (accession codes P04637 and Q00987). 
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1.2.2. THE STRUCTURE OF MDM2 
Mdm2 is a RING-domain family E3-ubiquitin ligase. E3-ubiquitin ligases constitute a diverse 
set of proteins which facilitate transfer of the protein ubiquitin from an E2 ubiquitin ligase to a 
specific substrate
29
. The role of an E3-ubiquitin ligase can be entirely one of recognition; 
however, these molecules can also play a part in catalysis. 
The key parts of Mdm2 (Figure 1.1) are a p53 binding domain at the N-terminus, an acidic 
domain followed by a RanBP2-type zinc finger in the middle and a RING (Really Interesting 
New Gene) domain at the C-terminus
30
. 
Piperidones (derivatives of the compound piperidone) bind in the p53 binding site but at least 
some of their high affinity is thought to be derived from additional interactions made with 
residues 6 to 16 at the extreme N-terminus of Mdm2. This flexible end is thought to be able to 
fold over the p53 binding site
31,32
. 
The acidic domain is where positive and negative regulators appear to bind. It also appears to 
play a critical role in p53 degradation. Mutations to residues in either the 247-258 or 270-274 
regions reduce p53 degradation in the cell; however, only mutations in the former have been 
linked to a reduction in the polyubiquitination of p53 by Mdm2, so Mdm2 may also regulate 
p53 activity via another mechanism
33
. 
In the middle of the p53 protein is a region that folds to form a Zinc finger, a supersecondary 
structure motif stabilised by the coordination of one of more zinc ions. In Mdm2, this region 
forms a 310 helix followed by four beta strands
34
. It contains a binding site for the protein Ran
34
, 
a G-protein associated with the transport of molecules between the cytoplasm and nucleus 
through nuclear pores
35
. 
Mdm2 binds to ubiquitin using the zinc ions in its RING domain. The RING domain of Mdm2 
is also essential for dimerisation
30
.  
Figure 1.2 shows the sequence coverage of the crystal structures of Mdm2 and its homologue 
Mdm4 in the Protein Data Bank (PDB, www.rcsb.org)
36
 at the time of writing. When predicting 
the binding affinity of a compound by computational modelling, the sequence coverage of the 
chosen structure is important; the system must be large enough to contain all of the regions that 
contribute to binding or are required to maintain the stability of the binding parts but too large a 
system makes simulations computationally expensive. 
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Figure 1.2: Protein Data Bank (PDB) structures containing sequences that have over 50% sequence 
identity with part of human p53. Red) Over 95% identity. Purple) 60 to 95% identity. Blue) 50 to 60% 
identity. 
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Structure 1T4F
37
, which was used for docking and molecular dynamics simulations in this 
project, covers residues 17 to 125 of Mdm2. Consequently, like many crystal structures of 
Mdm2, 1T4F lacks the extreme N-terminal residues thought to contribute to the binding affinity 
of piperidones
31,32
. However, this is an assumption made in many laboratory assays where these 
residues are missing from the Mdm2 construct to prevent them from blocking the p53 binding 
site. The construct used in the wet laboratory for testing in this project covers residues 17 to 123 
so computational results and experimental results should be comparable. 
 
 
Figure 1.3: PDB structure 1YCR coloured to indicate residue movement upon ligand binding. 
Structure 1YCR features p53 bound to Mdm2. Each of the PDB structures 1T4E (Mdm2 with a 
benzodiazepine bound), 3IWY (with a dextrorotatory peptide), 3LBL (with an MI-63 analogue), 4ERE 
(with an N-alkylated piperidinone), 4JVR (with a morpholinone) and 4MDN (with a chloroindole 
derivative) was aligned with Mdm2 from the structure 1YCR (unbound Mdm2). These PDB structures 
were chosen to include a diverse range of bound ligands whilst ensuring 100% sequence identity and a 
good degree of coverage. The root mean square distance (RMSD) of each residue’s alpha carbon from the 
average position of the alpha carbon (over all 7 aligned structures) was calculated for residues 27 to 107. 
The residues were coloured according to this RMSD value as indicated in the key. Notably, there is little 
movement around the centre of the binding site where Phe19, Trp23 and Leu26 of p53 interact; however, 
there is a particularly flexible region to one side of the binding site. This part is within the region covered 
by residues 68 to 72, a region absent from 4ERE and partially absent from 4JCR. The red colouration is 
thus based on results from structures 1YCR, 3IWY, 3LBL and 4MDN only. The absence of these residues 
from 4ERE and 4JCR could be partly responsible for the apparently high mobility in this region; 
however, that these residues are missing from some structures is also consistent with them having more 
propensity to move. 
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PDB structures of part of Mdm2 usually feature another ligand such as Mdm4 (2 structures at 
the time or writing), a peptide (16 structures) or a small molecule (31 structures). The vast 
majority were produced by X-ray diffraction; however, the four structures of Mdm2 parts in 
isolation (1Z1M, 2C6A, 2C6B and 2HDP) were produced using nuclear magnetic resonance 
(NMR). This highlights how the flexibility of the unbound protein makes crystallography 
difficult. 
Superimposition of a selection of Mdm2 structures from the PDB gives an indication of which 
parts of the protein are most flexible (Figure 1.3). The results reveal the significant movement 
possible around the p53-binding site and thus highlight the need to consider protein flexibility 
when making binding affinity predictions. 
1.2.3. INHIBITION OF THE P53-MDM2 INTERACTION 
The transactivation domain of p53 is responsible for its action as a transcription factor. A 
transcription factor increases the activity of proteins indirectly by raising the frequency with 
which their genes are transcribed. Mdm2 binds to an alpha helix in the first subdomain of the 
p53 transactivation domain, which lies within the region comprising residues 15 to 29 of the 
human protein
38
. It thereby physically prevents the interaction of this region with DNA. 
Peptides of the residues in this region of p53 will bind to Mdm2 and compounds developed to 
inhibit the p53-Mdm2 interaction (Figure 1.4) are referred to as peptidomimetics, because they 
mimic these helical peptides. 
1.2.3.1. Peptidomimetics 
Small molecule, peptidomimetic inhibitors of the p53-Mdm2 interaction include β-hairpin 
mimetics, terphenyls, nutlins, chalcones (flavanoid precursors), aryl sulphonamides, 
isoindolinones, spiro-oxindoles, 1,4-benzodiazepine-2,5-diones, N
α
-acyl-tryptophanyl-
piperazides and chlorofusin
9,39
. 
PPI inhibitors can be identified by high-throughput screening in the laboratory
15
 and this has 
played a major role in the identification of inhibitors of the Mdm2-p53 interaction. For example, 
in 2004 a group of imidazoline inhibitors of the p53-mdm2 interaction, which are referred to as 
Nutlins, (Figure 1.5) were discovered by the pharmaceutical company Roche using this method. 
The image on the left of Figure 1.4 shows for comparison how p53 and Nutlins appear to bind 
to Mdm2. The stereochemistry shown in Figure 1.5 is necessary for tight binding
40
. 
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Figure 1.4: How p53-Mdm2 interaction inhibitors mimic residues Phe19, Trp23 and Leu26 of 
human p53. The parts of the inhibitors which mimic these residues are shown in red, green and blue 
respectively. PDB structure 1YCR (Mdm2 bound to the p53 transactivation domain) was aligned with 
structure 1RV1 (Mdm2 bound to Nutlin-2) using the Chimera (UCSF) MatchMaker tool which aligns 
residues based on the position of their alpha carbon atoms. On the left is shown the p53 helix (white) 
bound to Mdm2 (grey) from 1YCR and Nutlin-2 from 1RV1 (in colour). On the right are examples of 
four different types of inhibitor, a benzodiazepinedione
9
, a terphenyl
39
, nutlin-2
41
 and an 
oligobenzamide
42
. Evidence of which compound side chains resided in each p53 residue binding site 
(indicated by the colours) came from PDB structure 1T4E (for the benzodiazepine) the modelling of 
Fischer et al.
39
 (for the terphenyl), structure 1RV1 (for the Nutlin) and the modelling of Plante et al.
42
 (for 
the oligobenzamide). Images from Chimera (USCF) and ChemDraw (CambridgeSoft) were combined 
using PowerPoint (Microsoft) and Paint Shop Pro (Corel). 
 
It has been suggested that the rigidity of Nutlins makes their binding to Mdm2 more 
entropically favourable; however, their lack of flexibility also means that they cannot bind to the 
Mdm2 homologue Mdm4
43
. While Nutlins are the most effective known inhibitors of the p53-
Mdm2 interaction in vitro, clinical trials conducted with some Nutlin-3 isomers
44
 suggest that 
they are not effective inhibitors of cell proliferation in vivo, perhaps as a direct result of their 
failure to bind to Mdm4
45,46
. Mdm4 has, like Mdm2, been implicated in the control of cell 
proliferation through negative regulation of p53 activity and it too is often mutated in tumour 
cells
47,48
. Inhibition of the p53-Mdm2 interaction might be insufficient to restore p53 activity in 
vivo; compounds might also need to bind to Mdm4 and inhibit the p53-Mdm4 interaction to be 
effective. 
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Nutlin-1: X=Cl, R1=CH3, R2=C(O)CH3 
Nutlin-2: X=Br, R1=H, R2=CH2CH2OH 
Nutlin-3: X=Cl, R1=CH3, R2=H 
 
Figure 1.5: The Nutlins. Each compound has two chiral centres making 4 possible 4 stereoisomers. The 
stereochemistry of the active isomer of Nutlin-3 is shown. The two leftmost side chains, each attached to 
a chiral centre, project back into the page, away from the plane of the central imidazole ring. The method 
originally used to synthesise Nutlin-3 yields a racemic mixture of the active isomer and its enantiomer. 
The latter binds 100 times less strongly than the active isomer. 
 
Chalcones are another example of a type of p53-Mdm2 interaction inhibitor found to be 
ineffective in vivo. They appear to not only bind to Mdm2 but also other proteins. For example, 
they bind to p53, preventing its interaction with DNA and thus its action as a transcription 
factor, thereby defeating the purpose of inhibiting the p53-Mdm2 interaction: to increase p53 
activity
9
. 
The poor in vivo results obtained with the Nutlins and chalcones epitomise the difficulty with 
which compounds identified in the laboratory are translated into lead compounds for 
pharmaceutical research. They highlight the need to continue the search for inhibitors despite 
the extent to which the p53-Mdm2 interaction has previously been studied. 
1.2.3.2. Oligobenzamides 
Oligobenzamide peptidomimetics (Figure 1.6, p36) have been synthesised in the Leeds 
Chemistry Department by the Wilson group
49
. The scaffold of these small molecules comprises 
alternating amide and phenyl groups. 
One of the unique merits of these compounds is that it should be possible to make a compound 
displaying any combination of side chains with reasonable ease by utilising the hardware which 
already exists for solid state peptide synthesis
50
 (Figure 1.7). Monomers are synthesised first to 
make a library of subunits from which the desired combination can be taken and assembled by 
Fmoc synthesis. The potential to make many compounds is useful, firstly, because the 
validation of computational methods is more easily performed when there is practical data for a 
large number of molecules and, secondly, because modification of the sequence of side chains 
presented could theoretically allow many different interactions to be targeted. 
35
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N1 
 
O1 (X=O) and S1 (X = S) O2 (X=O) and S2 (X = S) 
  
 
 
Figure 1.6: The oligoamide scaffolds used in this project. Each scaffold has three side chains, R1, R2 
and R3. Each side chain is held not by carbon but by an electronegative heteroatom resulting in inductive 
electron withdrawal from the side chain. This can affect the relative stability of side chain tautomers. 
 
 
 
 
Figure 1.7: Synthesis of N-linked oligobenzamides using Fmoc protection 
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The combination of side chains alone is intended to control the specificity so the side chains 
should ideally be held prearranged so the compound cannot adapt to bind to another protein. In 
oligobenzamides where side chains are attached through oxygen substituents on the rings of the 
scaffold, intramolecular hydrogen bonding between the oxygen and amide hydrogen atoms of 
the scaffold restricts internal rotation. For example, attachment at the ortho ring position causes 
rotation about the amide nitrogen to ring carbon bonds in the core to be restricted
49
. In addition 
to its effect on specificity, this intramolecular hydrogen bonding can potentially favour binding 
because it reduces the associated decrease in entropy. 
In this project, 5 different oligobenzamide scaffolds (Figure 1.6) were investigated in silico. 
Some compounds based on the N, O1 and O2 scaffolds shown have been synthesised by the 
collaborating chemistry group. 
The limited flexibility of oligobenzamides means that the scaffold must place side chains close 
to their final intended positions, the locations in which they will most faithfully mimic the 
targeted alpha helix. Azzarito et al.
51
 compared distances in the p53 pose of PDB structure 
1YCR (p53 bound to Mdm2) with those in oligobenzamides poses. In the p53 helix, distances of 
5.79 Å and 5.97 Å separate Phe19 and Trp23 and Trp23 and Leu26 respectively. Similar 
distances exist between the oligobenzamide side chains, specifically between the oxygen atoms 
connecting the side chains to the scaffold. These are, respectively, 6.18 Å and 6.17 Å in the case 
of O1 scaffold and 6.16 Å and 6.21 Å in the case of the O2 scaffold. 
In addition to the distances between side chains, intramolecular angles are also important. In an 
alpha helix there are 3.6 amino acids per turn, corresponding to a 100° twist per residue. 
Moving from one turn to the next along one side of this right-handed helix, each amino acid, i, 
is positioned at an angle of 60°, anticlockwise, from residue i-3. Monte-Carlo modelling by 
Azzarito et al.
51
 suggests that the corresponding angle between side chains in relaxed molecules 
based on the O1 scaffold with isopropyl side chains is less, 35° to 40° and for the O2 scaffold it 
is only 10° to 20°. However, oligobenzamides appear to have sufficient flexibility for effective 
alpha helix mimicry despite the intramolecular hydrogen bonding. For example, in the O1 
scaffold, steric effects mean that the amide carbonyl groups are not quite in the same plane as 
the adjacent rings. The carbonyl groups do not form a conjugated system with the adjacent rings 
so rotation is permitted about the amide carbon to ring carbon bonds
49
. Molecules based on the 
O1 and O2 scaffolds were synthesised and tested by Azzarito et al.
51
. They obtained similar 
results with the two scaffolds despite their different connectivity, a finding which the authors 
attribute to similar side chain presentation enabled by this flexibility. 
The flexibility of oligobenzamides can be increased by the addition of a flexible linker to the 
middle of the oligobenzamide chain. Kulikov et al.
52
 discuss various methods of combining two 
oligobenzamide structures with a spacer to produce double alpha helix mimetics, long 
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molecules bent in the middle which can mimic the supersecondary structure of two adjacent 
alpha helices similarly arranged. 
PPI inhibitors often have a low solubility because they are intended to mimic typically 
hydrophobic residues at PPI interfaces. Dimethylsulphoxide (DMSO) is a polar solvent which is 
aprotic, meaning that it cannot act as a hydrogen bond donor. It dissolves both polar and non-
polar molecules and a small quantity added to an aqueous solution can increase the amount of a 
less polar compound, such as an oligobenzamide, which will dissolve in the solution.  This 
enables investigations which would otherwise be precluded by precipitation to proceed. A 
drawback of using DMSO is that, because it increases the solubility of hydrophobic amino acid 
side chains, the stability of proteins can be adversely affected. This is relevant to binding assays, 
where denaturation can decrease specific binding or increase non-specific binding, and 
structural methods such as NMR and crystallography, where a protein is assumed to be in its 
native state. 
Although oligobenzamides are straighter than the helices they are intended to mimic, 
oligobenzamide scaffolds do have a slight twist, a gradual bend which means that a long 
oligobenzamide would not be straight. The degree of curvature can be tuned by changing 
substituents
53
 and is slightly more pronounced in scaffold O1 (the 3-O-alkylated scaffold) than 
in scaffold O2 (the 2-O-alkylated structure)
51
. Modelling of the scaffolds using isopropyl side 
chains at all three positions suggests angles of inclination of just under 160° that introduce a 
turn in the direction of travel of just over 20° per oligobenzamide unit. Meta-linked 
oligobenzamides have a much greater curvature, forming cyclic
54
 or helical
55
 structures if of 
sufficient length. 
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1.3. Binding Energy 
1.3.1. THE THERMODYNAMICS OF INTERACTIONS 
In preface to the proceeding discussion of binding energy estimation, this section introduces 
binding energy and how it pertains to binding affinity. 
1.3.1.1. Equilibrium Constants 
The binding energy is of a compound is, specifically, the Gibbs free energy of binding, in this 
case, within aqueous solution. 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆  1.1 
Where ΔG is the Gibbs free energy change that accompanies a reaction in which there is an 
enthalpy change of ΔH and an entropy change of ΔS at a temperature of T. 
 
The binding affinity of compounds can be described by the equilibrium constant of their 
binding. 
𝐾 =
[𝐶𝑜𝑚𝑝𝑙𝑒𝑥]
[𝑃𝑟𝑜𝑡𝑒𝑖𝑛][𝐿𝑖𝑔𝑎𝑛𝑑]
 1.2 
 
Where K is the equilibrium constant and the square-bracketed words represent the 
concentrations of the complex, free protein and free ligand. 
∆𝐺° = −𝑅𝑇 ln𝐾 = 𝑅𝑇 ln𝐾𝑑 1.3 
Where ΔG is the free energy of binding and R is the universal gas constant (8.314 J K-1 mol-1). 
The dissociation constant, Kd, is the reciprocal of the association constant, K and is a measure of 
the affinity of two species for each other. The greater the affinity, the smaller the dissociation 
constant and the more negative the standard free energy of binding. 
Kd is temperature dependent. 
𝐾𝑑 = 𝑒
−∆𝐺° 𝑅𝑇⁄  1.4 
1.3.1.2. Factors Affecting Binding Energy 
When factors that affect binding energy are discussed, it can be useful to refer to enthalpic 
contributions to the free energy (due to factors which affect ΔH but not ΔS) and entropic 
contributions (caused by factors affecting ΔS). Table 1.1 lists some enthalpic and entropic 
factors that affect ligand binding. As shown by Equation 1.1 (p39), the higher the temperature, 
the more effect the change in entropy has on the free energy of binding. Entropic effects usually 
make binding less favourable so increasing the temperature tends to cause the dissociation of 
complexes. 
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Table 1.1: Enthalpic and entropic factors that can affect the standard free energy of binding for a 
ligand interacting with a protein 
 Enthalpic contributions Entropic contributions 
Favouring 
binding 
 Electrostatic interactions and/or 
hydrogen bonds, often at the binding 
interface, which are only made when 
binding has occurred or which are 
stronger after binding has occurred56 
 Release of water molecules 
from the solvation shell 
around hydrophobic 
surfaces57 hidden by binding 
Disfavouring 
binding 
 Lack of van der Waals forces with the 
solvent where there is a solvent-free 
void created by binding 
 Steric hindrance (the exchange 
interaction) and torsional stress due to 
the protein or ligand taking up an 
unfavourable conformation to enable 
binding 
 Electrostatic repulsion due to similarly 
charged atoms on the ligand and 
protein being bought together on 
binding 
 Breaking of hydrogen bonds and 
electrostatic interactions between the 
solvent and the binding molecules 
where charged atoms are brought next 
to a hydrophobic region on the other 
molecule 
 Loss of translational 
freedom of the ligand 
relative to the protein. 
 Loss of rotational and 
conformational  freedom of 
the ligand58 
 Increased rigidity within the 
protein upon binding for 
steric reasons or due to new 
interactions forming or 
interactions involving fixed 
ligand atoms as opposed to 
moving solvent. This could 
be at the binding site or 
some distance away in the 
protein. 
 A decrease in osmotic 
pressure upon binding 
 
  
Ligand modifications that increase or decrease the enthalpy change of binding are often 
associated with a compensatory shift in the entropy change of binding and vice versa. This can 
lead to a counterintuitive change in binding energy when a chemical series is traversed
58
. Many 
possible causes of this phenomenon, termed enthalpy-entropy compensation, have been 
proposed but its origin remains unclear
59
 and could be very system-specific. 
As an example, Homans
60
 discusses how, upon ligand binding, the entropically favourable 
displacement of water molecules from the Major Urinary Protein (MUP) ligand binding site is 
offset by the enthalpically unfavourable breaking of hydrogen bonds between the displaced 
water molecules. This is a result of the MUP binding site being only partially hydrated. The 
entropic effect would be expected to make the binding of larger ligands less favourable because 
this leads to the displacement of more solvent molecules; however, its compensation means that 
the dispersion force between the protein and ligand has the potential to predominate, favouring 
larger molecules with a shape complementary to that of the binding site. 
Despite such observations, enthalpy-entropy compensation could, to a greater
59
 or lesser
61
 
extent, be an artefact of binding data processing. Due to the difficulties of estimating enthalpic 
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and entropic components and the tendency for compensation, Chodera and Mobley
59
 believe it 
can be most useful to focus on direct assessment of binding free energy during computational 
ligand development rather than estimate changes in enthalpy and entropy. 
1.3.1.3. Protein-protein interactions 
PPIs
6
 typically have a free energy of binding that is between 25 and 80 kJ mol
-1
. The 
entropically favourable burying of hydrophobic residues in the interface is thought to largely 
drive the association of interacting proteins
62
. Consistent with this hypothesis, proteins which 
are permanently part of a homodimer have hydrophobic interfaces that resemble the core of a 
protein
63
. Furthermore, comparison of the interacting and non-interacting surfaces of proteins 
that fold separately and then bind to form a heteromer reveals that the interacting surfaces are 
flatter and have a larger solvent accessible surface area than the non-interacting surfaces
64
, 
features which will maximise the number of water molecules displaced (and thus the increase in 
entropy) upon binding. 
Although the binding interfaces of heteromers have fewer charged residues
64
, in some 
heteromers, residues forming electrostatic interactions at the interface promote binding
65–67
. The 
hydrophobic environment around charged and polar residues on an interacting surface is 
thought to increase the strength of electrostatic interactions by excluding bulk solvent, 
decreasing the dielectric constant
68
. Charged and polar residues might also have an important 
role in the stabilisation of unbound monomers, which would otherwise become denatured due to 
their having an excessively hydrophobic interface region
62,63
. The need to ensure monomer 
stability could also explain why heteromeric complexes have smaller interacting interfaces than 
proteins forming homomers
69
. 
Interacting surfaces can be divided into regions of differing residue frequency. Li et al. 
compared the centre of PPI interfaces to their periphery and observed that the centre was 
generally more hydrophobic, estimating a typical reduction of 190 J mol
-1
 Å
-2
 to the free energy 
of binding due to the exclusion of solvent from the surface of hydrophobic residues in the 
centre
70
. 
Within the core, some residues are particularly important for binding
71
. These have been termed 
hotspots. Wells et al.
72
 suggest that a hotspot is a residue contributing 2 kcal mol
-1
 (8.4 kJ mol
-1
) 
or more to the binding energy as measured by alanine scanning. There is evidence that hotspots 
are found clustered together in tightly packed “hot regions”73. Dense packing in hot regions 
could partly explain why hotspots tend to be highly conserved in evolution
74
. 
Solvent exclusion by the tight packing of hot regions could increase the strength of electrostatic 
interactions involving hotspot residues
6
. The simulations of Keskin et al.
6
 indicate that 
conserved residues at interfaces are less mobile so, in addition to its effect on solvation, tight 
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packing could make binding more entropically favourable by causing residue prearrangement. 
The results of molecular dynamics simulations by Rajamani et al.
75
 are consistent with this 
hypothesis. In general, Smith et al.
76
, found reduced flexibility in core interface residues as 
opposed to peripheral interface residues and on a larger scale, hotspots appear to occur in 
preformed pockets complementary to the shape of the binding partner so little conformational 
change is necessary for binding
77
. 
Despite the clear rigidity at some PPI interfaces, many proteins forming PPIs are intrinsically 
unstructured
78
 and this project concerns the binding of Mdm2 to the intrinsically unstructured 
p53 transactivation domain. While the region this domain binds on Mdm2 is not unstructured, it 
too has considerable flexibility. 
This is not the only respect in which the p53-Mdm2 interaction is atypical. While PPIs generally 
appear to be entropically driven by the hydrophobic effect, the binding of cytochrome c to 
cytochrome c peroxidase being a classic example
67
, isothermal titration calorimetry reveals that 
binding of the p53 transactivation domain peptide to Mdm2 is entropically unfavourable with 
enthalpy being the driving force
79
. This enthalpy change could stem from the formation of 
hydrogen bonds within the p53 helix upon binding; although, analysis of simulations using the 
MM-PBSA method (p86) suggests that Trp23 on p53 also hydrogen bonds with Mdm2 and 
interacts via van der Walls forces with many nearby Mdm2 residues
80
. While the binding of 
wild type p53 peptide to Mdm2 might be enthalpically driven, mutations can change the balance 
between enthalpy and entropy, particularly if they change the orientation of Mdm2 residue 
Tyr100 upon binding because this has a big impact on the size of the binding site
79
. 
1.3.2. VALIDATION: PRACTICAL METHODS OF DETERMINING BINDING 
AFFINITY 
 
In order to demonstrate that computational methods can be used to predict the binding affinity 
of oligobenzamides, accurate in silico predictions are needed; however, accurately measured 
affinities to test the predictions are also important. 
A precursor to the successful estimation of ligand affinity is the successful identification of 
binding pose. In the case of oligobenzamides, this step is potentially challenging because, as 
discussed in the computational results chapter (p153), many binding positions are possible 
depending on the choice of side chains. Consequently, methods of determining where ligands 
bind to a protein in the laboratory are also important for validation.  
This section discusses different methods in which the binding location and affinity of a ligand 
can be investigated experimentally. 
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1.3.2.1. Methods for the Assessment of Binding Affinity 
 
The complex formed when a ligand binds to a protein is typically much larger than the ligand 
alone. This difference in size is exploited by many laboratory assays that detect binding. These 
include fluorescence anisotropy, microscale thermophoresis and surface plasmon resonance 
(SPR). 
In fluorescence anisotropy, polarised light is used to excite a fluorescently labelled ligand. As a 
result of the time delay between excitation and emission of the fluorophore, the polarisation of 
the emitted light (the anisotropy of the fluorescence) depends on the correlation time of the 
particle, the average amount of time which must have elapsed for the particle to have rotated 
one radian in any direction
81
. Larger particles tumble more slowly increasing the fluorescence 
anisotropy. Consequently, the binding of fluorescently labelled ligand molecules to a protein 
can be detected. 
A relatively new technique, microscale thermophoresis, can be used to separate particles 
according to their size. When placed in a temperature gradient, particles are encouraged to move 
down the gradient because the particles hitting them on the warmer side have more kinetic 
energy (and therefore exert a greater force upon collision) than the particles hitting them on the 
cooler side
82
. Larger particles move more slowly down the gradient and may even move towards 
the heat source, driven by the pressure difference caused by smaller particles moving quickly 
around them down the gradient. 
In both of the methods above, finding the ligand concentration at which there is half maximal 
inhibition of the protein-protein interaction involves testing a number of different concentrations 
of the ligand and producing a titration curve. 
The dissociation constant (Kd) of a protein-ligand interaction can theoretically be calculated 
using the rates of association (ka) and dissociation (kd)
83(p46)
. 
𝐾𝑑 =
𝑘𝑑
𝑘𝑎
 1.5 
Surface plasmon resonance (SPR) spectroscopy can be employed to measure ka and kd.  This 
technique exploits the change in refractive index of a thin metal film when species bind to its 
surface
84
. The ligand is bound to the metallic surface, typically gold, which coats a prism. Light 
is directed onto the back of a gold film and the electrons involved in the surface plasmon 
(electrons cyclically oscillating at the air-metal interface) become excited. This causes the 
absorption of light at a particular angle of incidence dependent on the refractive index at the 
surface and an attendant lower intensity band in the totally internally reflected light. If a solution 
of the protein is passed over the top of the film, any ligand protein binding changes the 
refractive index of the surface and this alters the angle of the lower intensity band
84
. The angle 
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can be measured (scanning angle SPR)
85
; however, in the last few years, a technique known as 
surface plasmon resonance imaging (SPRi) has been developed, in which the intensity of the 
reflected light is measured at a fixed angle
86
. The latter enables parallel testing of a large 
number of species arrayed on the chip. A problem with the use of SPR to study the binding of 
small molecules to a protein is that attachment of the compounds to the chip could affect their 
affinity for the protein. 
The methods above detect a change in particle size when binding occurs. However, other 
methods exist which do not rely on this. One such method is dual polarisation interferometry 
(DPI). DPI is similar to SPR, but the refractive index of the metal surface is detected by 
interferometry
84
. Total internal reflection occurs multiple times at both the solvent-covered and 
opposite prism surfaces as the light, which is polarised, bounces down the long, thin prism 
waveguide. The refractive index determines the number of reflections and thus path length of 
the lower intensity light, which in turn determines the polarisation phase of the light relative to 
that of a second beam from a reference waveguide with which it is mixed at the prism end to 
create an interference pattern
87
. Unlike SPR, DPI can sometimes detect conformational changes 
in a protein
87
. 
Unlike the methods described above, isothermal titration calorimetry (ITC) can be used to 
identify the enthalpic and entropic components of binding energy
88
. The method involves 
measurement of the energy required to maintain the temperature of a solution of one binding 
component as a solution of a second binding component is titrated in to it
88
. The energy 
difference is quantified by way of its comparison with the energy required to maintain the 
temperature of a reference solution. The entropic (temperature dependent) and enthalpic 
(temperature independent) components of the binding energy can be determined by repetition of 
the titration at different temperatures
88
. ITC cannot be used for high throughput screening 
because, for ITC to work, a large amount of protein must be used per compound in order for the 
energy change to be large enough to be measured accurately
89
. 
In this project, binding affinity was assessed using Förster resonance energy transfer (FRET). In 
this method, the proximity of two fluorophore labels is detected as a result of the non-radiative 
transfer of energy between the molecules. This causes excitation of the donor fluorophore to 
cause emission from the acceptor fluorophore. FRET does not require attachment of the ligand 
to a surface as in SPR, nor large amounts of compound as in SPR. FRET is also better evidence 
of binding than a decrease in fluorescence anisotropy. 
The methods of fluorescence anisotropy and FRET are now described in more detail. 
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1.3.2.2. Fluorescence Based Methods 
When a molecule absorbs a photon of light, an electron in the molecule can be elevated to an 
excited state. Because only certain electronic configurations are possible in a molecule, the 
electronic energy is quantised; its level is restricted to a discrete number of quite broadly spaced 
values (quanta). Photon induced electronic transitions, because they involve a rapid change in 
the state of an electron, can destabilise a molecule and result in an oscillating motion.  This 
concerted electronic and vibrational excitation (vibronic excitation) increases the number of 
different photon energies (wavelengths of light) which can be absorbed
90(p5)
; although, only 
vibrational modes which are compatible with both the ground and excited electronic states can 
occur (the Franck-Condon principle)
90(p7)
. 
The vibrational energy is transferred to adjacent molecules when collisions occur, increasing the 
temperature of the surroundings. The electronic energy released when the excited electron 
returns to its ground state can be converted to further vibrational energy or, alternatively, lost in 
the form of a photon, a phenomenon known as fluorescence. Because re-emission occurs after 
some energy has been lost, the emitted photon has less energy and consequently a longer 
wavelength than that of the incident light. A third mechanism of losing this electronic energy is 
through FRET, a phenomenon that can occur when an excited fluorophore (a fluorescent 
compound that can re-emit light upon light excitation) is close to another fluorophore in the 
ground state. 
1.3.2.2.1. FRET 
Following the excitation of a fluorophore, the transition dipole of the excited electron can exert 
a force on a nearby dipole as the molecule returns to its ground electronic state. Where two 
fluorophores are very close together, the resulting interaction (coupling) of the two dipoles (one 
in each fluorophore) can cause the concerted motion (resonance) of the dipoles resulting in the 
non-radiative transfer of energy from one fluorophore (the donor) to the other (the acceptor). 
This is known as Förster Resonance Energy Transfer (FRET). 
The relative rates of FRET and normal emission from a fluorophore determine what is known as 
the FRET efficiency, EFRET, the probability of FRET occurring after a photon has been absorbed 
by the donor fluorophore. The rate of FRET depends on the relative orientation of the 
fluorescent centres, the distance between them and the extent to which the emission spectrum of 
the donor and the absorption spectrum of the acceptor overlap
91
. FRET is extremely sensitive to 
small increases in separation distance because the rate of this energy transfer is inversely 
proportional to the sixth power of the distance between the donor and acceptor. This occurs 
because the dipole-dipole interaction energy is inversely proportional to the distance cubed and 
the probability of energy transfer is proportional to the square of this interaction energy
92
. 
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𝐸𝐹𝑅𝐸𝑇 =
1
1 + (
𝑟
𝑅0
)
6 1.6 
Where r is the distance between the donor and acceptor and R0 is the distance of 50% FRET 
efficiency, the Förster distance. In the first part of the FRET work in this project, enhanced 
green fluorescent protein (eGFP) was used as the donor and enhanced yellow fluorescent 
protein (eYFP) was used as the acceptor. The Förster distance, the distance at which there is 
50% transfer efficiency, is approximately 5.6 nm for this pair
93
. 
𝑅0 = √
9(ln 10)𝜅2𝑄𝐷𝐽
128𝑁𝐴𝜋5𝑛4
6
 1.7 
Where QD is the quantum yield of the donor (the proportion of absorbed light reemitted), NA is 
Avogadro’s number (6.022  1023 mol-1) and κ is the dipole orientation factor, a variable 
describing the relative orientation of the donor and acceptor that ranges from 0 (dipoles 
antiparallel) to 2 (dipoles parallel)
94(p13)
. For a donor and acceptor tumbling rapidly with respect 
to the time period between absorption and reemission by the donor, the time-averaged 
orientation factor is two thirds. J is the spectral overlap. 
𝐽 = ∫ 𝜆4𝐹𝐷(𝜆)𝜀𝐴(𝜆)d𝜆
∞
0
 1.8 
Where FD is the normalised fluorescence of the donor at the wavelength λ. The overlap is scaled 
by the wavelength to the power 4 because the efficiency of transfer is proportional to λ4. εA is 
the extinction coefficient of the fluorophore solution. An extinction coefficient describes the 
rate at which the intensity of light entering a medium is exponentially diminished. 
− log10
𝐼
𝐼0
= 𝐴 = 𝜀𝑐𝑙 1.9 
Where 𝐼 is the intensity of light a distance 𝑙 into a solution of concentration c, extinction 
coefficient ε and therefore absorbance A if it enters at an intensity of 𝐼0. 
Unlike the other methods outlined in section 1.3.2.1 above, FRET can be used to carry out in 
vivo assays since if both the binding components are proteins with a fluorescent protein label, 
they can be synthesised in a cell. FRET is also very amenable to high-throughput screening. 
Different compounds can be tested in the wells of microwell plates, which can in theory be 
pipetted out and tested robotically
95
. Also, it is possible to perform competition assays in which 
a ligand competes with a labelled species (p53 for example), to bind to the second labelled 
molecule (Mdm2 for example). These have the advantage that the ligands do not have to be 
labelled, a process which might affect the binding capacity of each compound differently. 
In this project, the hybrid proteins p53-YFP and p53-Cherry were used to investigate the 
binding of p53 to GFP-Mdm2. Figure 1.8 shows diagrammatically how fluorescent labelling of 
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Mdm2 and p53 can result in FRET. On binding, the YFP labelled C-terminal end of the p53 is 
brought into close proximity with the GFP, bringing about FRET. 
 
A B 
 
  
Figure 1.8: Diagrams showing how fluorescent labelling of Mdm2 and p53 can result in FRET. 
 A) A computer generated structure of Mdm2 produced using PDB structure 1T4F showing the C-
terminal end of p53 (dark grey) in red and the N (blue) and C (red) termini of Mdm2. The N-terminal end 
of Mdm2 was fluorescently labelled because it is closer to p53 than the C-terminal end. B) A diagram 
showing the principle of the FRET experiment. Binding of p53 and Mdm2 brings the GFP and YFP labels 
together causing FRET to occur. 
 
Many assumptions are made when carrying out FRET measurements.  
In this project, it was assumed that the YFP, GFP and Cherry labels had no effect on the binding 
of the peptide; however, GFP, YFP and Cherry are all considerably larger than the peptide and 
could get in the way of binding, reducing the binding affinity. For more details regarding these 
fluorescent labels see p49. 
In a titration monitored using FRET, it is usually presumed that there are two FRET states, one 
in which the fluorophores are close and there is considerable FRET, and another in which the 
fluorophores are separated, resulting in little or no FRET. As the titration proceeds, the emission 
spectrum is assumed to transform from that one of these states to that of the other and between 
these points, the amount of FRET is assumed to be directly proportional to the number of donor-
acceptor complexes remaining. In reality, there could be intermediate states with their own 
emission spectra. 
A further assumption is that the FRET donor and acceptor come together as predicted, which 
might not be the case. For example, rather than binding with specificity, molecules might 
become denatured, exposing hydrophobic surfaces, leading to non-specific aggregation. 
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In addition, the conformational changes occurring during FRET experiments may differ from 
those expected. For example, differences in FRET could reflect a variation in the relative 
orientation of the FRET donor and acceptor rather than a change in the distance between the 
fluorophores. Kon et al.
96
 describe their use of FRET to monitor conformational change within 
cytoplasmic dynein, specifically the distance between the tail (labelled with GFP) and the AAA 
domains of the head (labelled with BFP). They discuss the possibility that some of the FRET 
change observed might be due to conformational changes within the tail and not a change in the 
distance between the fluorophores. Furthermore, it is unclear which AAA domain the GFP 
fluorophore is closest to when the fluorophores are brought together. 
In a titration, an assumption is made that the intensity of the fluorescence being measured is 
unaffected by factors such as the absorbance or direct fluorescence of the titrant, the 
concentration of which may be very high by the end of the experiment. Adding large quantities 
of a ligand and its solvent, for example DMSO in the case of a low solubility compound, can 
change the properties of the solution being observed. The resulting changes in pH or 
hydrophobicity could affect the fluorescence. For example, the presence of DMSO could cause 
partial unfolding of a protein, increasing the solvent exposure of an attached fluorophore. 
The volume of solution excited by the incident light and from which fluorescence is detected 
also has a direct effect on the observed fluorescence. In a spectrofluorimeter cuvette, this 
volume is unlikely to vary. However, in a plate reader well, the volume excited by the incident 
light depends on the shape of the meniscus, which is affected by factors such as DMSO 
concentration. 
Kon et al.
96
 used FRET to investigate the effect of excess ATP on the distance between domains 
of dynein. To check that ATP did not alter the fluorescence of either fluorophore in isolation, 
they carried out controls in which ATP was added to each polypeptide-fluorophore complex in 
the absence of the other. 
1.3.2.2.2. Fluorescence Anisotropy 
Fluorescence anisotropy is another fluorescence-based method which can be used to monitor the 
binding of a ligand to a protein. Only the ligand is fluorescently labelled. When excited by 
polarised light, a rapidly tumbling ligand rotates in the time interval between absorption and re-
emission, emitting light in many directions. However, if the ligand binds to a large protein, the 
labelled ligand, as part of the complex, tumbles much more slowly. It is only excited in some 
orientations and rotates little before re-emission, causing fluorescence anisotropy, polarisation 
of the emitted light. 
The fluorescence anisotropy, r, of a sample can be calculated from the fluorescence emitted 
parallel, F, and perpendicular, F|, to the plane of polarisation of the exciting light
81
. 
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𝑟 =
𝐹∥ − 𝐹⊥
𝐹∥ + 2𝐹⊥
 1.10 
There are two planes perpendicular to the plane of the exciting light and light in only one of 
these is detected. Consequently, the denominator of this equation is equal to the total amount of 
light emitted. 
Sometimes the fluorescence polarisation, P, is quoted instead. 
𝑃 =
𝐹∥ − 𝐹⊥
𝐹∥ + 𝐹⊥
=
3𝑟
𝑟 + 2
 1.11 
Tumbling is not the only factor affecting the anisotropy. Some polarisation is lost if the 
emission dipole moment is at a different angle to the absorption dipole moment in the 
fluorophore used. Even where these two moments are parallel, the anisotropy is much less than 
1; the fact that dipoles are excited at many different angles coupled with the angular dependence 
of the probability of fluorophore excitation limits the maximum anisotropy to 0.4
90(p358)
. 
An advantage of fluorescence anisotropy compared to FRET is the high signal to noise ratio. 
Unlike FRET, the results are insensitive to changes in the total intensity of the fluorescence. 
However, fluorescence anisotropy is also a less direct measure of binding because factors other 
than the displacement of the ligand from its receptor can affect the correlation time. 
In this project, a FRET-based assay was developed to test potential inhibitors of the p53-Mdm2 
interaction. A fluorescence anisotropy competition assay using p53-fluorescein
97
 has previously 
been tested and attempts have been made to use it with oligobenzamides
42,51,98
; however, there 
was evidence that, as well binding to Mdm2, these compounds bound weakly to the p53 
peptide, affecting its final anisotropy. This meant that the titration curves produced could not be 
used to calculate dissociation constants.  
1.3.2.2.3. Fluorescent Proteins Used in This Project 
In this project, the fluorescent proteins GFP, YFP and mCherry were used. 
Green fluorescent protein (GFP) is a naturally occurring protein from the jellyfish Aequorea 
victoria which has been mutated to increase its fluorescence
99
 and to make homologous proteins 
of different colours that include blue fluorescent protein (BFP), cyan fluorescent protein (CFP), 
yellow fluorescent protein (YFP)
100
. The donor and acceptor fluorophores used in a FRET 
experiment are known as the FRET pair. BFP and GFP are commonly used as a FRET pair, as 
are CFP and YFP
101
. 
In GFP, the fluorophore is formed by an auto-catalytic reaction beginning with nucleophilic 
attack of the nitrogen of Gly67 on the amide carbonyl group of Ser65 (cyclisation). Dehydration 
and oxidation then occur to form a 5-oxoimidazole moiety which together with the phenolic 
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ring of Tyr66 forms the large conjugated system responsible for the fluorescence
102,103
 (Figure 
1.9). 
 
 
Figure 1.9: A possible mechanism for GFP fluorophore biosynthesis
102,103
. An alternative mechanism 
has been suggested where oxidation precedes dehydration
104
. 
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mCherry is a mutated version of the DsRed protein, a homologue of GFP found in coral 
anemones of the genus Discosoma,
105
. The fluorophore of DsRed is similar to that of GFP and 
forms from residues Gln66, Tyr67 and Gly68 by a mechanism which could be analogous to that 
of GFP maturation
106
. 
1.3.2.3. Nuclear Magnetic Resonance (NMR) 
This section introduces the theory of NMR, a method which enables solution state systems to be 
investigated at atomic resolution in a non-disruptive manner over a broad range of timescales. 
The dynamics of interacting proteins and the binding of PPI inhibitors to a protein can be 
studied by NMR so it can be used to validate predictions based on in silico work. 
1.3.2.3.1. The principles of NMR 
The wavefunction of some particles interacts with an externally applied magnetic field. These 
particles have a property known as spin and are said to have a magnetic moment. In NMR, a 
sample is placed in a strong magnetic field causing the nuclei with spin to arrange themselves 
relative to the field according to what is referred to as their spin state. Typically this means that 
a nucleus either lines up parallel (β) or antiparallel (α) to the field. The energy of the nuclei in 
parallel orientations is lower than that of those in antiparallel orientations. This splitting of the 
spin state energy levels by the magnetic field is known as Zeeman splitting
107(p23)
. The small 
difference in energy leads to there being slightly more nuclei antiparallel than parallel (roughly 
10001 antiparallel for every to 10000 parallel for a spin ½ nucleus in a 600 MHz (14 T) 
spectrometer
108(p6)
. This confers a small net magnetisation on the sample which opposes the 
external field. 
Excitation of the nuclei is possible using radio frequency electromagnetic pulses, which are 
applied through coils around the sample. These cause the nuclei to resonate and change state 
from α to β, changing in orientation (spin state). The net magnetisation of the sample is said to 
precess from the z-axis (that parallel to the external field) into the perpendicular xy-plane (and 
beyond, back on to the z-axis given a pulse of sufficient length). The net magnetisation vector 
of the sample precesses around the external magnetic field vector (z-axis) as a result of the 
rotation of the magnetic moment of each of the excited nuclei. The component of the net 
magnetisation in the xy plane is detected. The frequency at which this perpendicular component 
oscillates as the nuclei precess reflects their resonant frequency. Consequently, excitation of a 
sample and then detection of the frequency components in the resulting magnetisation as it 
decays facilitates the production of a spectrum that shows the resonant frequencies of the nuclei 
in the sample. As the resonant frequency of an atom depends on the difference in energy 
between its spin states, which in turn depends on the nature and environment of the nucleus, an 
51
  
 
 
 
5
2
 
NMR spectrum contains information about the molecular structure and state of the species in a 
sample. 
The inherent spin of a particle, a fixed property, is quantised and described by its spin quantum 
number, I
107(p24)
. 
𝑰 ∈ {0, 0.5, 1, 1.5, 2, 2.5,…} 1.12 
The value of I for a particular nucleus depends on the numbers of protons and neutrons in the 
nucleus so different isotopes of a particular atom have different spin quantum numbers. 
Table 1.2 shows the spin of some nuclei commonly used in NMR experiments. 
Table 1.2: Nuclei often used for NMR 
Nucleus Spin γ /10-7 rad s-1T-1 
Natural 
abundance (%) 
500 MHz spectrometer 
frequency /MHz 
1H ½ 26.75 100 500.0 
2H 1 4.11 0.015 76.7 
13C ½ 6.73 1.1 125.7 
15N ½ -2.71 0.37 50.7 
19F ½ 25.17 100 470.6 
31P ½ 10.83 100 202.6 
 
γ, the gyromagnetic ratio indicates the size of the magnetic moment and, in the case of the ratio for 
nitrogen, indicates the directionality of precession. The rightmost column indicates the resonant 
frequency of the nucleus in the magnetic field of a 500 MHz NMR spectrometer 
(11.74 T)
107(p25),109(p3)
. 
 
Most nuclei chosen for NMR have a spin, I, of ½ because this leads to the production of a 
single, narrow peak on a simple NMR spectrum. Nuclei have 2I + 1 possible spin states (each 
with a different energy level), which results in 2I observed changes of spin state. If I is greater 
than ½, the increased number of peaks creates a very complicated spectrum with many peaks. 
Furthermore, nuclei with a spin greater than ½ also have problematically broad peaks because 
their anisotropic charge distribution interacts with their surrounding electrons to cause spin-state 
transitions (spin-lattice quadrupolar relaxation
110
). 
The rightmost column of Table 1.2 gives the frequency of the radio frequency pulses required to 
excite each nucleus in a 500 MHz spectrometer (one with a magnetic field of exactly the 
strength required for hydrogen nuclei to be excited at 500 MHz). In a sample, nuclei of a 
particular type may be found in various functional groups. For example, hydrogen is involved in 
both C-H bonds and O-H bonds in ethanol. The resonant frequencies of the nuclei in different 
environments such as these differ slightly because the frequency is affected by the distribution 
of electrons near the nuclei and their associated local magnetic fields. These small differences 
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are usually quoted as a chemical shift, σ. The chemical shift of a nucleus is its resonant 
frequency relative to that of a standard expressed in parts per million (ppm). 
𝜎 = (1 −
𝜈𝜎
𝜈0
) × 1,000,000 1.13 
Where νσ is the resonant frequency of nuclei with a chemical shift of σ where ν0 is the resonant 
frequency of the reference nuclei, which, by definition, have a chemical shift of 0. In the case of 
1
H-NMR, the standard resonant frequency is that of the hydrogen nuclei in tetramethylsilane. 
Due to the suseptibility of the chemical shift to changes in the magnetic field acting on a 
nucleus, it is important that all of the nuclei in a sample experience exactly the same external 
magnetic field. Solution state NMR is limited to small species, which rotate rapidly (have a low 
correlation time), because time-averaging of the magnetic field over all orientations of the 
species is necessary to ensure that each nucleus experiences a uniform, isotropic magnetic field 
and thus produces strong, easily distinguishable spectrum peaks
111
. 
In NMR experiments, the excited nuclei are often manipulated so that they transfer their 
magnetisation to others in the surroundings, so the specific nuclei excited in an experiment often 
differ from those which are detected at the end and contribute to the spectrum. Complex 
sequences of pulses targeting different nuclei allow two, three and even four dimensional 
spectra to be produced. These multidimensional spectra are constructed via the production of a 
series of one-dimensional spectra, each with a slightly different time delay between certain 
specific pairs of pulses. 
An overview of the experiments used in this project follows. 
1.3.2.3.2. The HSQC (heteronuclear single quantum coherence) Experiments 
Protein NMR projects often begin with the production of a 
1
H-
15
N HSQC spectrum (hereinafter 
referred to as a 
15
N-HSQC), which is typically obtained as a two-dimensional spectrum. An 
HSQC experiment detects pairs of bonded nuclei, in the case of a 
15
N-HSQC spectrum, the 
primary and secondary amino groups in a sample. The spin state of a nucleus affects the spin 
state energies of any other nucleus with which it shares bonding electrons. This through-bond 
effect is known as J-coupling or scalar coupling
107(p35)
. 
Production of a 
15
N-HSQC requires the generation of many 1D 
1
H-NMR spectra, each 
modulated by 
15
N nuclei with a specific resonant frequency selected by the adjustment of a 
specific delay length in the pulse sequence. Most of the amino acid residues in a protein bestow 
a single peak on its 
15
N-HSQC spectrum because they have a single amide group. However, 
proline residues produce no peak because they have no amide hydrogen and tryptophan, 
histidine, arginine, lysine, asparagine and glutamine all have amino groups in their side chains 
which could potentially produce additional peaks. In practice, it is only in glutamine, asparagine 
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and tryptophan that the protons are not exchanged too quickly with the solution and have 
resonances in the range typically covered in the production of an HSQC spectrum to locate the 
backbone amide peaks. The N terminal amine of a polypeptide chain also exchanges its protons 
with water too fast for their detection. 
Figure 1.10 shows the complex sequence of radio frequency pulses typically applied to the 
sample in an HSQC experiment. The black bars represent the pulses. Appendix B describes the 
exact effect of the pulses and delays on the net magnetisation of the sample and how this leads 
to production of the spectrum. 
 
 
Figure 1.10: An HSQC pulse sequence
107(p242)
. The black bars represent pulses (90° for the thin bands 
and 180° for the thick bands). Pulses on both the hydrogen and nitrogen channels (pulses at frequencies 
that will excite hydrogen and nitrogen nuclei respectively) are shown. The white spaces are delays and the 
expression in their centre indicates the length of the delay. The delays last for milliseconds whereas the 
pulses are of the order of microseconds. The sequence is repeated many times with different values of t1 
to traverse the indirect dimension. The exponentially decaying wave in the proton channel shows the loss 
of magnetisation perpendicular to the external magnetic field. This magnetisation, which oscillates due to 
the precession (rotation) of the nuclei, is measured and Fourier transformed to generate a 1D spectrum 
along the direct dimension, t2. A long delay lasting seconds (not shown) is required between successive 
executions of the sequence to allow full relaxation of the nuclei and equilibration of the NMR machine. 
 
When a ligand binds to a protein, the magnetic field strength around the binding atoms in the 
protein changes. This causes some peaks on the HSQC spectrum to move, potentially 
facilitating identification of the binding site. When a ligand is titrated in to a solution of a 
protein that it binds, the peaks on the HSQC spectrum of the protein can move smoothly from 
their initial position to their final position or, alternatively, to disappear from their original 
position and appear at their new position. Which of these two phenomena is observed depends 
on the rate of exchange between the bound and unbound states
112
. Very fast rates of association 
and dissociation lead to the atoms producing each peak experiencing a time-averaged magnetic 
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field and the production of an intermediate peak position. In contrast, slow on and off-rates 
result in two distinct populations of the protein molecule, bound and unbound. As the 
concentration of compound is increased and the relative proportions of the two spectra change, 
one spectrum fades and the other increases in intensity. What is termed intermediate exchange is 
possible at the boundary between these two extremes, where the first order rate constants of 
binding and release are comparable to the difference in the atoms’ Larmor frequencies (angular 
frequencies of precession). 
1.3.2.3.3. NOESY-HSQC and TOCSY-HSQC Experiments 
In this project Mdm2 L33E was used. Assignments for wild type Mdm2 had already been 
published but there was some variation between these and HSQC results obtained with the 
L33E mutant, necessitating the collection of additional spectra for assignment of the L33E 
peaks. Often assignment requires the production of 3D spectra, the product of triple resonance 
methods such as the HNCA
109(p482)
 and HNcoCA
109(p491)
 experiments. For these experiments, 
protein samples containing labelled carbon (
13
C) are required, which are expensive to produce. 
In this project, the wild type assignments meant that 
1
H-
15
N NOESY-HSQC and 
1
H-
15
N 
TOCSY-HSQC 3D-spectra, which do not require the carbon to be labelled, were sufficient. 
In a NOESY (nuclear Overhauser effect spectroscopy) pulse sequence, magnetisation is 
transferred through space between nearby nuclei (typically protons). The return of the 
magnetisation vector to the z-axis parallel to the external field following sample excitation is 
known as relaxation. The magnetisation vectors of nuclei with different chemical shifts precess 
at different angular velocities and usually relax at different rates. In NOESY, the rapid transfer 
of magnetisation between nearby hydrogen nuclei results in simultaneous relaxation, known as 
cross-relaxation, of the nuclei concerned. This results in spectrum cross-peaks. 
In a TOCSY (total correlation spectroscopy) 2D spectrum, magnetisation is transferred between 
nuclei through bonds, as opposed to through space, by a mechanism known as scalar coupling, 
which is discussed further in Appendix B (p301). The transfer occurs during a delay referred to 
as the mixing time. Using multiple pulses in the mixing period prevents the precession of 
nuclear spins (chemical shift refocussing). This allows magnetisation to be transferred multiple 
times along the residue side chain as opposed to through a single bond as in an HSQC 
experiment. 
Due to the large number of hydrogen atoms in a protein, both 
1
H-
1
H NOESY and 
1
H-
1
H 
TOCSY spectra have many peaks, which makes it difficult to distinguished each one. 
The NOESY-HSQC and TOCSY-HSQC spectra (where the HSQC sequence is preceded by the 
NOESY and TOCSY sequence respectively, which acts as a filter) are edited versions of the 2D 
NOESY and TOCSY spectra, only showing peaks where there is a corresponding peak on the 
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HSQC spectrum. The NOESY-HSQC and TOCSY-HSQC spectra are 3D because the 
1
H 
dimension of the NOESY or TOCSY and the 
1
H dimension of the HSQC are traversed 
separately and plotted on two different axes
109(p289)
. 
A pulse sequence for the NOESY-HSQC experiment is shown in Figure 1.11 and the TOCSY-
HSQC pulse sequence is shown in Figure 1.12. The effect of each pulse and delay on the sample 
is shown in Table 6.3 and Table 6.4 of Appendix B. 
 
 
Figure 1.11: A NOESY- HSQC pulse sequence
107(p242). τm is the mixing time, the period allowed for the 
transfer of magnetisation between the hydrogen nuclei by the nuclear Overhauser effect. The bars, gaps 
and other labels have the same meaning as in Figure 1.10 and described in its caption. 
 
 
 
Figure 1.12: A TOCSY-HSQC pulse sequence. “CPD” indicates where composite pulse decoupling 
was applied. The bars, gaps and other labels have the same meaning as in Figure 1.10 and described in its 
caption. 
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Both the NOESY-HSQC and TOCSY-HSQC spectra of a protein comprise a region containing 
amide and aromatic hydrogen peaks in the 6 < σH < 10 ppm part of the spectrum and a region 
containing peaks produced by the aliphatic hydrogen atom nuclei of the side chains in the 0 < σH 
< 6 ppm part. Details of how these spectra were used to identify the HSQC peaks of Mdm2 in 
this project are given in the NMR results chapter (p252). 
1.3.2.3.4. Expression and purification of proteins for NMR 
The study of proteins often requires that they be produced in high concentrations. For example, 
in competition assays to test potential inhibitors of an interaction, the concentration of at least 
one of the two interacting molecules must exceed the dissociation constant of the complex for 
there to be a significant concentration of the complex to be dissociated. In NMR, signals are 
weak due to the small differences in nuclear energy being observed so concentrated samples are 
required for NMR too. 
Gräslund et al.
113
 review protein expression and purification. High concentrations are achieved 
by producing a large amount of the protein, purifying it efficiently and then reducing the 
volume of the pure solution. Usually, transgenic bacteria are transformed with DNA coding for 
the protein of interest as part of a plasmid vector and are then grown in a nutrient-rich medium. 
An antibiotic resistance marker gene in the vector enables the selection of transformed cells by 
addition of the corresponding antibiotic to the medium. 
Cells producing large amounts of a foreign protein typically divide less frequently. 
Consequently, expression of the protein is usually controlled by the use of an inducible 
promoter, such as that of the lac operon, to allow expression to be delayed until the lag phase of 
population growth has been completed. 
Within the plasmid, the protein of interest is typically expressed with one or more concatenated 
tags to facilitate purification. Protease sites to facilitate removal of the tags are sometimes 
included, especially if the tags are large protein molecules. There are several commonly used 
affinity purification tags
113
. His-tags, oligo-histidine sections, adhere to ions such as nickel or 
cobalt in a resin column. The protein tags maltose binding protein and glutathione-S-transferase 
bind to resin columns containing maltose and glutathione respectively. 
Proteins can also be purified by methods that separate according to size (for example, size 
exclusion chromatography), charge (such as ion exchange chromatography) or hydrophobicity 
(hydrophobic interaction chromatography for instance). Size exclusion chromatography uses 
inert beads with holes of a particular size. Smaller proteins take a more convoluted route 
through the column so have a larger elution volume. To prevent the formation of disulphide 
bridges between protein molecules, a reducing agent such as dithiothreitol (DTT, 
SH(CH2)CH(OH)CH(OH)CH2SH) can be added to the buffer. After nickel affinity 
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chromatography, the protein will precipitate if ethylenediaminetetraacetic acid (EDTA) is not 
added to chelate any nickel prior to the addition of DTT
113
. 
Concentration is carried out using a membrane with pores large enough to let water and other 
molecules with a mass below the molecular weight cut-off (MWCO) pass through but small 
enough for the protein of interest to be retained. Centrifugation is used to accelerate filtration
113
. 
Separation of the proteins in samples by sodium dodecyl sulphate (Na
+
 CH3(CH2)11OSO3
-
) 
polyacrylamide gel electrophoresis (SDS-PAGE) enables the purification process to be 
monitored. The dodecyl sulphate ion is a detergent which denatures proteins and coats them 
such that the rate of electrophoretic separation depends on their mass alone. 
In this project, the Mdm2 protein used in NMR experiments was 
15
N-labelled. To produce 
labelled proteins, bacteria are grown in minimal media in which their only source of a particular 
element is a compound containing the heavy isotope
114
. Typically, 
15
NH4Cl is the source of 
15
N 
and 
13
C-glucose provides 
13
C.  If there is little bacterial growth, a solution containing vitamins 
and minerals such as Basal Medium of Eagle (BME) can be added to augment the minimal 
medium. A small amount of unlabelled rich medium can also be used to provide a trace amount 
of any essential compound missing from the minimal media. If growth is still inadequate, 
expensive, labelled rich media can be used. 
Some of the isotopes used for NMR, for instance 
1
H, 
19
F and 
31
P, are the natural, ubiquitous 
isotopes of the elements in question; however, others, most notably 
2
H, 
13
C and 
15
N, are isotopes 
that are stable but only present in low concentrations in the natural environment. To produce 
labelled compounds for media containing these isotopes, isotopic enrichment is necessary.  
Enrichment of deuterium oxide in water can be performed via the Girdler sulphide process, 
which relies on the kinetic isotope effect
115
. Isotopic enrichment of 
15
N is possible by 
equilibrium fractionation using the NITROX method, which exploits the greater stability of 
14
NO and H
15
NO3 as opposed to 
15
NO and H
14
NO3 at low temperatures
116
. 
1.3.3. INVESTIGATION OF THE P53-MDM2 INTERACTION USING NMR 
There has been extensive investigation of the p53-Mdm2 interaction by NMR. In this project, 
oligoamide trimers with oxygen-linked side chains were titrated into a solution of 
15
N-labelled 
Mdm2 L33E and their effect on the Mdm2 HSQC spectrum was observed. Most NMR work 
with aromatic oligoamides has concerned the investigation of oligomeric foldamers in 
isolation
55,117
; however, Lu et al.
118
 have carried out a similar experiment previously. They 
titrated an oligobenzamide dimer with carbon-linked side chains into a solution of wild type 
Mdm2 (p268). 
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Other p53-Mdm2 PPI inhibitors have been more extensively researched using NMR. Wang et 
al.,
119
 describe the use of HSQC experiments to measure the affinity of compounds based on an 
oxodihydrobenzoimidazolylacetamide scaffold for Mdm2. Isolindolinone inhibitors
120
, 
chalcones
121
 and isoquinolin-1-ones
122
 have also been studied. 
The adaptability of the Mdm2 binding site to different ligands was revealed by Schon et al.
123
 
who studied how the Mdm2 HSQC spectrum changed upon the binding of p53-like peptides. 
The dynamics of the N-terminal part of Mdm2, which is thought to occlude the p53 binding site 
when no ligand is present, has also been investigated
124,125
. The binding of p53-derived peptides 
to wild type Mdm2 is known to cause the movement of HSQC peaks created by residues some 
distance from the p53 binding site
126
, highlighting the potential benefit of using the stable L33E 
mutant tested in this project in future binding studies. 
The binding of Mdm2-derived peptides to p53 has also been investigated using NMR
127
. The 
DNA binding domain of p53 (p29) was seen to bind weakly to the acidic domain of Mdm2, a 
finding which is consistent with the opposing charges of these two regions. 
Attempts to obtain a 1D proton NMR spectrum of oligobenzamides in this project were 
informative in that they suggested the aggregation of some oligobenzamides despite their being 
soluble. Czarna et al.
128
 describe the use of HSQC peak movement to test multiple fragment-like 
inhibitors of the p53-Mdm2 interaction as part of a combined high-throughput computational 
and laboratory-based screening process and they highlight how NMR results can reveal 
essential properties of a compound such as its potensity to precipitate. 
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1.4. Computational Methods Used in This Project 
 
This section introduces docking, molecular dynamics simulations and methods of estimating the 
free energy of binding. While the protein-protein interaction context of this project is novel, the 
assessment of potential inhibitors can be likened to any investigation of a set of small molecules 
binding to a protein of interest. Guvench and MacKerell
129
 discuss the trade-off encountered by 
any researcher wishing to use computational methods to predict the relative binding affinity of a 
set of compounds, that of speed versus accuracy. They highlight the two ends of the spectrum: 
at one end, fast docking and scoring where the protein is considered static and the solvent is 
treated as a continuum: at the other end, accurate calculation of free energies based on the 
comparison of all atom molecule dynamics simulations generated in steps along a bound to 
unbound reaction coordinate, as exemplified by the method of thermodynamic integration. In 
this project, both docking and thermodynamic integration were carried out. Guvench and 
MacKerell
129
 observe that some methods such as the implicit solvent MM-PBSA (molecular 
mechanics Poisson-Boltzmann surface area) method provide a useful compromise between 
speed and accuracy and, as discussed in the results, MM-PBSA proved to be most useful in this 
project. 
1.4.1. SCREENING AND DOCKING 
1.4.1.1. High-Throughput Screening 
In virtual screening, a very large number of compounds are investigated with the aim of 
generating a rough ranking, from which can be drawn a smaller, refined set of compounds for 
testing by more accurate methods
130
. There are two options: ligand-based screening and 
structure-based screening. Shangary and Wang
44
 discuss the roles that cheaper, computational 
methods, such as in silico screening and de novo compound design, have played in the 
development of p53-Mdm2 inhibitors. 
Ligand-based screening seeks to predict new inhibitors through comparison with existing 
ligands or, in the case of enzymes, the substrate and or predicted transition state which must be 
stabilised. One piece of software facilitating such screening is ROCS (OpenEye)
131
. Ligand-
based design is relevant to the current project in that oligobenzamides have been chosen for use 
as scaffolds based on their ability to place side chains in a similar relative location to those of 
residues in the p53 helix. However, ligand-based screening is of little relevance to the testing of 
potential inhibitors in this project. It is biased towards ligands which are similar to existing 
molecules, preventing their fair comparison. Furthermore, this bias means that ligand-based 
screening is not a source of interesting new chemistry. 
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In contrast, structure-based drug design makes direct use of the target protein’s structure rather 
than relying on the properties of the target protein being encapsulated in those of the known 
binding molecules. The success of structure-based methods depends on the availability of 
accurate structural information, which can be difficult to obtain. Many proteins, particularly 
membrane proteins, are not amenable to crystallisation or NMR and a suitable structure is not 
available. Fortunately, there are many X-ray crystal and NMR structures of Mdm2, the focus of 
this project. 
Structure-based screening typically involves docking, the computational fitting of compounds 
into the surface of a protein to predict where they will bind most strongly. In virtual screening, 
the docking must be rapid so the structures of the protein and ligands are often static. In such 
cases, a number of different conformations of the ligand are generated and docked to account 
for the ligand flexibility
132
. If the ligand conformation is changed during docking, this 
movement may be limited to a small number of degrees of freedom. For example, in ReCore 
(BioSolveIT)
133
, the problem of finding a side chain that fits is simplified to a search for groups 
with the correct vectors, the vectors being the direction of the leaving bond (the bond 
connecting the fragment to a larger molecule) and the directionality of a pharmacophore feature 
such as a hydrogen bond donor. Possible side chains are rotated relative to the core structure but 
there is no rotation about any of the bonds within the core or the side chain. Possible side chains 
are ranked based on the relative geometry of the query vectors and the corresponding vectors in 
the side chain
133
. According to the ReCore manual, the closer the vectors and the more similar 
their directionality, the greater the score. 
In high-throughput screening, compounds pass or fail based on whether they satisfy certain 
criteria, for example, based on the existence of hydrogen bond acceptors or aromatic rings in 
specific positions. When searching for drug-like compounds these criteria are pharmacophore 
constraints. Galatin and Abraham
134
 used quantitative structure-activity relationships (QSAR) 
derived using a structure of Mdm2 bound to the p53 transactivation domain peptide to predict 
successfully the effect on binding affinity of small changes to the peptide sequence. 
Lu et al.
118
 used the program CAVEAT
135
 to filter compounds to ensure that they all had side 
chains which could mimic those of Phe19, Trp23 and Leu26 in the human p53 transactivation 
domain, three residues identified as key "hot spots" by Böttger et al.
26
 using phage display. 
Criteria for screening can be generated using the binding positions of small, fragment-like 
molecules. The docking of small fragments is unreliable
136
 but fragment binding sites can be 
determined by X-ray crystallography or NMR
137
. Fragment positions can be used to generate 
possible binding molecules as well as screen a database for them; positioned fragments can be 
grown
138
 or joined
139
. The smaller chemical space of fragments as compared to that of larger 
61
  
 
 
 
6
2
 
compounds has made predicting compounds by ligand-based drug design an increasingly 
popular alternative to high-throughput synthesis and screening
140
. 
1.4.1.2. Docking 
In more rigorous docking, the ligand is considered flexible during the docking process; 
however, this comes at the expense of using more computational power. The protein is still 
often kept rigid in the docking process but some software can also move flexible parts of the 
protein. Autodock, one of the programs used in this project, can do this; although, this feature 
was not used in this project. If the protein has a flexible binding site but software does not 
permit movement of protein atoms then it is possible to dock into an ensemble of X-ray 
structures
141
 or conformations generated by computational means. Computational methods of 
generating an ensemble include taking snapshots from a molecular dynamics simulation
142
, 
using normal mode analysis
143
 and docking a few compounds with a method that does allows 
for protein movement
144
. 
There are disadvantages to using multiple structures. As well as slowing down the docking 
process overall, using different conformations can introduce error if the conformations used do 
not accurately represent the possible conformations of the protein
145
. This can occur even if the 
ensemble members are different crystal structures
141
. 
When docking a molecule, a scoring method is needed to predict the relative stability of binding 
poses both during the docking process and to rank the resulting compound poses. Huang et al.
146
 
describe four types of scoring function: force-field based functions, empirical functions, 
knowledge-based methods and consensus methods which involve a combination of these.  
Examples of force-field-based scoring functions are DOCK and AutoDock
146
. Force fields are 
discussed in detail in the context of molecular dynamics simulations on p67. 
Empirical scoring functions are simpler, typically using an equation like the following. 
∆𝐺 = ∑ 𝑊𝑖𝑉𝑖𝑖   1.14 
The score, ∆𝐺, is the weighted sum of a number of chosen variables, V. These may include the 
numbers of electrostatic interactions, hydrogen bonds and van der Waals interactions, the 
number of rotatable bonds and the hydrophobic surface area at the ligand-protein interface. 
The weights, W, are empirically derived using the structures of known complexes
146
. 
Examples of empirical scoring functions are ChemScore
147
, X-Score
148
 and FlexX
149
. 
Knowledge-based scoring functions are methods which use the experimentally determined 
structures of protein-ligand complexes, specifically, the frequency with which certain pairwise 
interactions are found in those structures. 
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In general, 
∆𝐺 = −𝑘𝑇 ln (∏
𝜌𝑖(𝑟𝑖)
𝜌𝑖
∗(𝑟𝑖)
𝑖 )  1.15 
Where ρi is the probability density of finding a distance of ri between the interacting pair of 
atoms, i, at the binding surface. ρ*i is the probability density which would be observed in a 
theoretical reference state in which there is no interaction
146
. k is the Boltzmann constant and T 
is the temperature in kelvins. Potentials of mean force are calculated using a formula of this 
type150. 
In this project, three docking programs were used: FlexX (BioSolveIT)
149
, Autodock 4 (version 
4.2)
151
 and Autodock Vina
152
. In FlexX, docking is a sequential process comprising the 
placement of a core fragment and then incremental addition of atoms to this core until the fully 
docked compound has been produced. Each step is repeated hundreds of times and the highest-
scoring poses (evaluated using the FlexX statistical potential scoring function
153
) are selected 
for the next stage
153
. Other popular docking programs utilising this incremental approach are 
DOCK, Glide and Hammerhead
154
. 
In contrast to the docking methods above, Autodock
151
 uses a genetic algorithm, meaning that 
the state of the ligand is treated like genetic material. In the case of Autodock, the information 
comprises the location (three coordinates), orientation (four rotation quaternions) and 
conformation (one variable for each torsion angle) of the molecule
155
. A set of random poses are 
generated, the best poses are selected and then a new set of poses are generated based on the 
selected poses by combining and then mutating their information
155
. The process of pose 
selection, genetic recombination and pose production is repeated thousands of times to produce 
a population of high-scoring poses. In the event of there being many very similar poses, they are 
clustered by RMSD (p78) to produce distinct poses. The docking program GOLD also uses a 
genetic algorithm. Autodock uses a Lamarckian genetic algorithm, meaning that some fitting of 
each pose is performed before its genetic material (updated to take into account the effects of 
this local fitting) is processed to generate the next pose set
156
. 
In terms of the computational time required for docking, Autodock Vina is much more efficient 
than Autodock 4. It uses a third search algorithm for global search based on the Iterated Local 
Search method devised by Baxter
157
. It is a Markov chain Monte Carlo iterative method, 
meaning that each iteration consists of the production of a possible pose based on the current 
one and the acceptance or rejection of this pose based on its probability relative to the current 
pose. In the case of Autodock Vina, the production of the possible pose involves a mutation 
followed by application of the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method
152
. This 
method uses both the value and gradient of the scoring function in the optimisation 
process
158(p194)
. 
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At the beginning of this project, rapid docking and scoring were used to predict the relative 
binding affinity of oligobenzamides for Mdm2; however, the synthetic inaccessibility of the 
compounds meant that validation was not possible. Schneider
159
 highlights the relatively few 
examples of drug discovery projects using virtual screening, citing the poor accuracy of these 
methods but also the need to identify synthetically accessible compounds, with docking ideally 
forming part of a cycle of computational and synthetic work. 
Docking predicts binding poses successfully
160
, but docking scores are typically poor estimates 
of the true binding affinity of compounds
161,162
. Oligobenzamides are large molecules and 
therefore have the potential to make numerous interactions when they bind. The more 
interactions a set of compounds can make with a binding site, the harder it is to determine their 
relative affinities correctly
163
. Docking aims to find the most stable pose of a compound and 
docking scores are based on this pose. The true affinity of a compound, in contrast, depends on 
all of the system’s possible states, and the relative frequencies at which those states (each 
comprising a set of atom positions and momenta) occur as the compound and protein move 
around. Therefore, for accurate binding energy predictions, this phase space must be fully 
sampled, for example, by carrying out molecular dynamics simulations
161,162
. 
1.4.2. MOLECULAR DYNAMICS SIMULATIONS 
A molecular dynamics simulation is a computer simulation of molecules within a virtual box. In 
this project, simulations of ligands bound to the protein Mdm2 were performed. Simulations 
require much more computation time than even flexible docking. 
An X-ray crystal or NMR structure is usually chosen as the initial structure of a protein at the 
start of a simulation. The initial ligand atom positions may be from the crystal structure or be 
the result of docking. The water atoms usually come from a box of pure solvent which has 
previously been simulated to the point of equilibration. Ions are also added as necessary so the 
system has an overall neutral charge, as required by the Particle Mesh Ewald method
164
 (p76). 
Initially, each atom in the system is assigned a random velocity based on the system 
temperature. Repeatedly, the position the atoms will be in after a small time step has elapsed is 
calculated based on the forces acting on them. The resulting set of frames is known as a 
trajectory. 
1.4.2.1. Necessary Assumptions 
Before molecular dynamics simulations are discussed in detail, it is worth considering a couple 
of the many assumptions made when a molecular dynamics simulation is performed. The 
validity of the results depends on the validity of these. 
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1.4.2.1.1. Ergodicity 
The probability distribution of the possible states of a system is known as its ensemble. 
In a simulation, the system is usually heated up to the desired temperature using a constant 
volume simulation. Once equilibrated at the correct temperature, more natural, constant pressure 
simulation begins. (The volume of the system is allowed to vary (p82).) In the constant volume 
simulation, the NVT (constant particle number, volume and temperature) or canonical ensemble 
is being sampled. In the constant pressure simulation, the NPT (constant particle number, 
pressure and temperature) or isothermal–isobaric ensemble is being sampled. 
The ensemble average of a property is the value of the property in each possible microstate of 
the system, weighted by the probability of the system being in that microstate. 
〈𝐴〉 = 𝐴𝑖𝑃𝑖 1.16 
Where 〈𝐴〉 is the ensemble average, A is the property, P is the probability and i is the 
microstate. The probability of a compound being found in each microstate depends on the 
energy of that microstate and the temperature (p91). 
In molecular dynamics simulations, systems are modelled over time and the averages obtained 
from them are time-averages.; they are only estimates of the true ensemble averages
165(p17)
. 
In the context of molecular dynamics simulations, the ergodic hypothesis states that, given 
sufficient time, a simulation will sample all of the possible states of the system and therefore 
that averages over the frames in a simulation reflect the ensemble average
166(p307)
. 
In practice, the ergodic assumption is seldom completely fulfilled
165(p17) 
because the transitions 
between some stable states have a low probability due to the high energy of the intervening 
microstates. As a result, sampling may be incomplete, causing time-averages to be weighted 
towards the initial state of the system. 
1.4.2.1.2. The Born-Oppenheimer Approximation 
The mass of an atomic nucleus is thousands of times greater than the mass of each of its 
electrons. Consequently, when the velocity of the nucleus changes, there is a large change in 
momentum. This causes the nucleus to exert a large force on its surrounding electrons. Because 
these electrons have a small mass, the consequent change in their momentum corresponds to a 
large change in their velocity, so they adjust rapidly to the change in nuclear position. The 
Born-Oppenheimer approximation states that electrons have no momentum and adjust 
instantaneously to any change in nuclear position. Thus, when the movement of nuclei is 
considered, the electrons can be assumed to be stationary relative to the nuclei with which they 
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are associated. Likewise, the nucleus can be assumed to be stationary relative to electron 
movement, because the nucleus moves much more slowly
166(p35)
. 
Further consideration of this approximation depends upon an understanding of the Hamiltonian 
operator and the Schrödinger equation. 
A fundamental particle can be treated like a spherical standing wave with a single peak at the 
particle’s position. The function which describes this wave is the particle’s wavefunction. The 
concept of a wavefunction can be extended to a system where the wavefunction, Ψ, describes 
the state of the system. 
In physics and chemistry, an operator is an operation which, when applied to the state of a 
system, generates a value. When the Hamiltonian operator, ℋ, is applied to the wavefunction of 
a system, it returns the rate of change of the wavefunction, phase shifted by 90° (multiplied by i, 
the square root of -1). The shift puts it in phase with the original wavefunction. 
ℋ Ψ(𝐫, t) =
𝑖ℎ
2𝜋
𝜕
𝜕𝑡
Ψ(𝐫, t) 1.17 
Where h is Planck’s constant, r is the state of the system and t is time166(p27).  
The Planck-Einstein equation, stated in terms of angular frequency, reveals how the rate of 
change of a wave is also its energy. 
E = ℎ𝜈 =
ℎ
2𝜋
𝜔 =
ℎ
2𝜋
𝑑𝜃
𝑑𝑡
𝜃(𝑡) 1.18 
Where E is the energy, ν is the frequency (s-1), ω is the angular frequency (rad s-1) and θ is the 
angular displacement (rad). Consequently, Equation 1.17, the time-dependent Schrödinger 
equation can be re-written in a time-independent form
166(p27)
: 
ℋ Ψ(𝐫) = 𝐸Ψ(𝐫) 1.19 
The result of applying the Hamiltonian operator to a system is therefore the total energy of the 
system and this operator is often equated to the summation of the different energies that 
contribute to the total energy of the system. 
Let the nuclear coordinates be expressed by the vector R and the state of the electrons embodied 
in vector r. If the Born-Oppenheimer approximation is made, the total wavefunction, Ψ(R, r), 
can be modelled as the product of two separate nuclear and electronic wavefunctions (Χ and Ψe 
respectively), calculable using modified Hamiltonian operators, ℋe and ℋn respectively
166(p35)
. 
Ψ(𝐫, 𝐑) = 𝒳(𝐑)Ψ𝑒(𝐫, 𝐑) 1.20 
Schrödinger equations can be formulated for both the electronic (Equation 1.21) and nuclear 
(Equation 1.22) components
166(p27)
. 
66
  
 
 
 
6
7
 
ℋ𝑒 Ψ𝑒(𝐫) = 𝐸𝑛(𝐑)Ψ𝑒(𝐫) 1.21 
ℋ𝑛 𝒳(𝐑) = 𝐸𝒳(𝐑)𝒳(𝐑) 1.22 
As shown, the coefficients En and EΧ vary with the nuclear positions, R. 
ℋ𝑛 = −
ℏ
2𝑚
∑∇2𝑖
𝑁𝑛
𝑖=1
+ 𝒱 1.23 
Where ħ is Planck’s constant, h, divided by 2π, µ is the mass of each atom (assumed to be 
identical in this example), 𝒱 is the interatomic potential, otherwise known as the vibronic 
energy and  is the del-squared operator or Laplacian, which is here applied to the nuclear 
wavefunction
167(p12)
. 
In Euclidean (x, y, z) space, 
∇2≡
𝜕2
𝜕𝑥2
+
𝜕2
𝜕𝑦2
+
𝜕2
𝜕𝑧2
 1.24 
 
𝒱 = E𝑛 −∑∑
𝑍𝑎𝑒
𝑟𝑖𝑎
𝑁𝑛
𝑎=1
𝑁𝑒
𝑖=1
. 1.25 
Where Ne is the total number of electrons (over all atoms), Nn is the number of nuclei, Za is the 
charge of nucleus a, e is the elementary charge (the charge of a proton) and ria is the distance 
between nucleus a and electron i. En is the electronic energy as shown in Equation 1.21 and 
which may be calculated using ℋe. 
ℋ𝑒 = −
ℏ
2𝜇
∑∇2𝑖(R)
𝑁𝑒
𝑖=1
+∑∑
𝑒2
𝑟𝑖𝑗
𝑖
𝑗=1
𝑁𝑒
𝑖−1
−∑∑
𝑍𝑎𝑒
2
𝑟𝑖𝑎
𝑁𝑛
𝑎=1
𝑁𝑒
𝑖=1
+∑∑
𝑍𝑎𝑍𝑏𝑒
2
𝑟𝑎𝑏
𝑎
𝑏=1
𝑁𝑛
𝑎=1
 1.26 
 
Where μ is the mass of an electron (the reduced mass with respect to the nucleus), rij is the 
distance between electrons i and j and rab is the distance between nuclei a and b
167(p11)
. Note that 
the del-squared operator is applied to the electronic wavefunction in this equation, not the 
nuclear positions R; the value just depends upon R. 
 In a quantum mechanics simulation, 𝒱 is estimated using the positions of the nuclei and then 
equation 1.22 is solved, yielding Ex(R) which can be used to work out how the nuclei will move 
and therefore what 𝒱 will be after a small amount of time has elapsed, the time step. 
1.4.2.2. The Force Field 
Quantum mechanical calculations have limited scalability. A time complexity of O(N
3
) where N 
is the number of orbitals is typical
168
 due to the need to perform matrix multiplication. 
Consequently, it would be too computationally challenging to perform macromolecular 
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molecular dynamics simulations in which all of the electronic orbitals were explicitly modelled. 
Quantum mechanical models are generally only used for the simulation of small molecules or a 
small part of a larger system (in a QM/MM simulation)
169
. Consequently, the vibronic potential 
energy of the system, 𝒱 (discussed above), is usually estimated in a molecular dynamics 
simulation of a macromolecule using an equation containing parameters for different atoms, 
bonds, torsion angles and through-space interactions. This equation is known as a force field. A 
key assumption with most force fields is that different factors make independent contributions 
to the binding energy. In practice the polarisation of atoms by those in their vicinity and the 
limited occupancy of molecular orbitals (exchange effects) mean that forces are not entirely 
additive
167(p141)
. 
Most force fields are derived from the following standard formula for the AMBER (Assisted 
Model Building with Energy Refinement) force field
170
: 
𝒱(R) = ∑ 𝑘𝑏(𝑏 − 𝑏0)
2
𝑏𝑜𝑛𝑑𝑠
+ ∑ 𝑘𝜃(𝜃 − 𝜃0)
2
𝑎𝑛𝑔𝑙𝑒𝑠
 
                     + ∑ 𝑘𝜙 cos[(𝑛𝜙 − 𝛿)
2 + 1]
𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠
+ ∑ [
𝑞𝑖𝑞𝑗
𝑟𝑖𝑗
+
4𝜀𝜎𝑖𝑗
12
𝑟𝑖𝑗
12 −
4𝜀𝜎𝑖𝑗
6
𝑟𝑖𝑗
6 ]
𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 𝑝𝑎𝑖𝑟𝑠
 
1.27 
Where 𝒱(R) is the total potential energy associated with the bonded and non-bonded 
interactions between all of the particles in a simulated system where the particles are at 
positions described by the vector R. The bonded interactions are modelled by the first three of 
the four terms, which relate to bond stretching, bond bending and bond torsion respectively. The 
non-bonded interactions (electrostatic interactions and van der Waals forces) are modelled by 
fourth term. 
b is the length of a bond being evaluated and b0 and kb are constants describing the equilibrium 
length and stiffness of bonds of that type
170. Similarly, θ is the angle between two bonds under 
consideration and kθ indicates the amount of energy stored when the angle is bent away from its 
equilibrium angle, θ0. In the third term, the summed expression describes a component of the 
torsional energy profile for rotation about a particular bond. ϕ is the torsion angle, kϕ relates to 
the amplitude of the energy barrier, n is the number of peaks (and troughs) in the energy per 
360° rotation and δ is the phase (peak position). Multiple sets of parameters for this third term 
allow a complex torsional energy profile to be modelled as the sum of a series of cosine waves. 
The last, non-bonding interaction term accounts for electrostatic interactions and the Leonard 
Jones potential for each pair of non-bonded atoms (i and j), the latter comprising a highly 
distance-dependent, repulsive exchange force and an attractive dispersion force
170
. qi and qj are 
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the charges of the atoms. rij is the distance between them. ε is the permittivity of the 
environment between the nuclei and σ is the distance at which the Leonard-Jones potential is 0. 
Some force fields related to the AMBER  force field are the CHARMM (Chemistry at HARvard 
Macromolecular Mechanics) force fields and the OPLS (Optimized Potentials for Liquid 
Simulations) force fields but there are many others
170
. Parameters can be derived using 
experimental data or generated by applying ab initio quantum mechanics methods to small 
molecules
170
. 
1.4.2.2.1. Torsion Parameters for Oligobenzamides 
Figure 1.6 (p36) shows the scaffolds at the core of the oligobenzamides investigated in this 
project. The blue R groups are the side chains intended to bind to Mdm2 and mimic the residue 
side chains of the p53 transactivation domain helix. There are five different scaffolds. In the N1 
scaffold, the side chains are attached through nitrogen, in the O1 and O2 scaffolds the 
attachment is through oxygen and in the S1 and S2 scaffolds the attachment is through sulphur.  
Vemparala et al.
171
 discuss how the GAFF (General Amber Force Field) force field has 
inappropriate torsion parameters for the modelling of oligobenzamides. They calculated and 
validated torsion parameters for the ortho-substituted oligobenzamide bonds shown in Figure 
1.5. 
 
 
Figure 1.13: Torsion angles for which Vemparala et al.
171
 determined parameters prior to this 
project. Three torsion angles within two different ortho-substituted oligobenzamide molecules are shown 
using arced arrows. The three bonds associated with each torsion angle are highlighted in red. 
 
In my work, only Vemparala’s amide bond parameter (torsion 3 in Figure 1.5), which is similar 
to the GAFF parameter, was used. However, Fuller et al.
172
 used the aromatic carbon (Ca)-N 
torsion parameter calculated using the SCH3 substituent for modelling of the O1 scaffold even 
though this parameter is for attachment using sulphur instead of oxygen. Fuller argues that the 
difference in the strength of the O-H and S-H hydrogen bonds is unimportant, a claim supported 
by the recent work of Liu et al.
173
 who generated and validated torsional parameters for the Ca-
peptide carbon and Ca-N bonds in both ortho and meta substituted oligobenzamides for OCH3 
and SCH3 substituents and found them to be similar. In this current project, Liu’s validated 
parameters were used for these torsion parameters affected by intramolecular hydrogen bonding. 
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Liu et al. note that even though ortho substituents appear to have similar effects, regardless of 
whether the attachment heteroatom is oxygen or sulphur (as assumed by Fuller et al.), where 
substitution is at the meta position, the choice of oxygen or sulphur does make a difference. In 
the meta case, sulphur significantly reduces the strength of the intramolecular hydrogen bond 
because steric effects are more likely to push the sulphur atom away from the hydrogen with 
which it is hydrogen bonded. A similar effect was observed earlier by Galan et al.
174
 who 
investigated fluoro- and chloro-ortho-substituted N-methylbenzamides. As a result of their 
electronegativity, hydrogen bonds involving each of these halogen substituents are stronger than 
those involving oxygen or sulphur. However, whereas the most electronegative substituent, the 
fluorine, increases rigidity, the chloro group does not appear to, an observation which the 
authors attribute to steric effects commensurate with its greater size. 
In the N1 scaffold, although there is no intramolecular hydrogen bonding, the torsion 
parameters could differ both for every compound tested and between the subunits within each 
compound. This is because, in these molecules, the substituents are on the amide nitrogen atom, 
in the vicinity of the rotating bonds, as opposed to some distance away, attached to the aromatic 
rings. This project involved both inductively electron donating and inductively electron 
withdrawing side chains. Consequently, the decision was made to base parameters on the 
torsional barrier height of the un-substituted oligobenzamide when molecules based on the N1 
scaffold were simulated. The results of Liu et al.
173
 indicated that GAFF parameters would not 
be appropriate but AMBER torsion parameters had not been calculated for un-substituted 
oligobenzamides. DFT (density functional theory) calculations had been performed on 4-(4-
aminobenzamide)benzoic acid to find the torsional potential energy profiles for the Ca-Cp and 
Ca-N bonds
175
 so the barrier heights from these profiles were used for modelling. To facilitate 
the fair comparison of results for different scaffolds, these N1 scaffold parameters were also 
used for Ca-N and Cp-Ca bonds not constrained by hydrogen bonding in the O1, S1, O2 and S2 
scaffolds (for the bond on the opposite side of the ring to the substituent). 
1.4.2.2.2. Calculation of Partial Charges 
Gasteiger charges can be used for docking. These are estimates of the charges based solely on 
the connectivity of the atoms
176
. However, accurate partial charges are required for molecular 
dynamics simulations and unlike many molecular parameters, atomic partial charges must 
generally be calculated for each specific molecule because they depend on the structure of the 
compound beyond their immediate vicinity.  
In this project, HF (Hartree-Fock) RESP partial charges were calculated using RESP ESP 
Charge Derive
177
. These are derived using a Hartree-Fock molecular electrostatic potential grid 
calculated for the molecule, a three-dimensional array of point charges approximating the 
continuous Hartree-Fock approximation of the Schrodinger equation. The Hartree-Fock 
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approximation is based on the assumption that the wavefunction can be described as the sum of 
a set of functions, basis functions, which each describe an orbital of the system, and which are 
collectively known as a basis set. 
Ψ =∑𝜒𝑖
𝑁
𝑖=1
=∑𝑠𝑖𝜑𝑖
𝑁
𝑖=1
=∑(𝑠𝑖 ∑𝑐𝜇𝑖𝜙𝜇
𝐾
𝜇=1
)
𝑁
𝑖=1
 1.28 
Where Ψ is the molecular wave function, which is the sum of N molecular spin orbital 
functions, χ, which are each the product of a spin, s, and a molecular, spatial orbital ψ created by 
the summation of K atomic orbitals, φ166(p35,p41). cμi is the molecular orbital coefficient indicating 
the contribution of atomic orbital μ to molecular orbital i. 
The orbitals of atoms can be modelled using basis functions, sums of Gaussian functions, 
individually known as primitive Gaussian functions
166(p65,p67)
. This makes it easy to combine the 
orbital wavefunctions. 
𝑔(𝑥, 𝑦, 𝑧) = 𝑥𝑎𝑦𝑏𝑧𝑐𝑁𝑎,𝑏,𝑐 ∑ 𝑑𝑖𝑒
−𝛼𝑖(𝑥
2+𝑦2+𝑧2)
𝑎+𝑏+𝑐
𝑖=1
 1.29 
Where g is the function of a Gaussian orbital in dimensions x, y and z. a, b and c are coefficients 
describing the shape and orientation of the orbital. For example, a, b and c must sum to 0 for an 
s orbital, 1 for p orbitals and 2 for d orbitals. For each primitive function comprising the orbital, 
α controls the size of the Gaussian and d controls its contribution to the overall function. N is a 
normalisation factor. 
In the 6-31G basis set there are 6 Gaussians used to represent the core orbitals of each atom and 
then 4 used to represent the valence orbitals, 3 smaller ones (referred to as contracted) and a 
larger one (referred to as a diffuse orbital)
166(p70)
. In this project, the 6-31G* basis set was used. 
The additional asterisk here signifies the use of Gaussian functions usually used to model d-
orbitals when modelling heavy atoms (which do not have occupied d orbitals) to account for the 
polarisation of the occupied orbitals by the surrounding atoms
178(p189)
. 
After a molecule has been minimised, partial charges are fitted to each atom in the molecule, so 
that the electrostatic potential energy around the molecule is reproduced as accurately as 
possible. 
Specifically, at each of a three-dimensional array of points around the molecule, the difference 
between the predicted potential derived from the partial charges using Coulomb’s law and the 
potential estimated from the wavefunction is minimised. (The electrostatic potential energy is 
here defined as the amount of energy required to move a point charge with the charge of a 
proton from an infinitely distant point to the point in question.) 
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𝑅 = ∑ 𝑤𝑖 (𝜙𝑖
Ψ − 𝜙𝑖
pred
)
2
𝑁𝑝𝑜𝑖𝑛𝑡𝑠
𝑖=1
 1.30 
R in Equation 1.30 is minimised where, for each grid point, i, of which there are Ngrid, w is a 
weighting factor, φΨ is the charge derived from the wavefunction and φpred is the potential 
derived from the partial charges being fitted
(166, p190)
. 
𝜙𝑖
Ψ(𝐫) = ∑
𝑍𝑗
|𝐫 − 𝐫𝑗|
− ∫
𝜌(𝐫)
|𝐫𝜌 − 𝐫|
𝑑𝐫𝜌
𝑁𝑛𝑢𝑐𝑙𝑒𝑖
𝑗=1
 
 
1.31 
The potential at position r is the sum of the potential due to the nuclear charge (the first term in 
Equation 1.31) and the potential due to the electron density (the second term), which is 
subtracted because the electrons are negatively charged
166(p189)
. (Note that r is a Cartesian space 
position vector here as opposed to the positions of the electrons as in section 1.4.2.1.2.) 
𝜙𝑖
pred(𝐫) = ∑
𝑞𝐫
4𝜋𝜖0𝑟𝑖𝑗
𝑁𝑎𝑡𝑜𝑚𝑠
𝑗=1
 1.32 
Where Natoms is the number of atoms, qj is the charge of atom j and rij is the distance between 
grid point i and atom j
166(p190)
.  (ε0 is the permittivity of free space, 8.854 × 10
-12
 F m
-1
.) Charges 
are fitted such that the sum of the partial charges is equal to the total charge of the molecule. 
The grid points used for fitting are outside the molecule so buried atoms are a long distance 
from any of the points, having little bearing on R in Equation 1.30. Consequently, these buried 
atoms can be assigned extreme charges during fitting if the size of these charges is not 
restrained. Charges produced using restraints are usually referred to as restrained electrostatic 
potential (RESP) charges
177,179
. 
The software used in this project to calculate partial charges (RESP ESP Charge Derive
177
) uses 
a hyperbolic penalty to penalise extreme values when R is calculated during the fitting process. 
1.4.2.2.3. Minimisation Using the AM1 Method 
Prior to the calculation of partial charges, oligobenzamides were minimised using the AM1 
method. This means that the atoms in the molecule, with their orbitals, were moved and rotated 
so as to minimise the total energy of the molecule. 
To determine the energy of a molecule, the Schrödinger equation or an approximation of it must 
be solved (p66). If the Hartree-Fock approximation is made, the total energy can be determined 
by solving the equation for each orbital separately. 
ℱ𝜒𝑖 = 𝐸𝑖𝜒𝑖 1.33 
Where Ei is the energy of molecular spin orbital χi. 
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ℱ indicates application of the Fock operator, which is similar to the Hamiltonian operator 
except that the energy is not the true energy, but a value which takes into account the Coulomb 
and exchange interactions between electrons such that the sum of the resulting eigenvalues 
(energies) of the molecular spin orbitals accurately reflects the energy of the whole 
molecule
166(p57)
. 
The Fock operator can be applied to the known molecular orbital wavefunctions of a molecule 
to calculate an energy contribution for each pair of electrons. These values can be placed in a 
matrix, the Fock matrix, F. 
𝐅 = 2𝐇𝟏𝟏,𝐍 + 2𝐉 − 𝐊  1.34 
Where N orbitals in a molecule, 11,N is the row vector of ones of length N, H is a column vector 
containing the energy obtained by application of the Hamiltonian operator to each core orbital, J 
is an N x N matrix containing the energy of the Coulomb interaction between each orbital and K 
is a matrix similar to J which accounts for the exchange interaction
166(p61)
. 
In the AM1 method, three empirical functions are used to calculate the Fock matrix elements, 
one for the diagonal elements and two for the off-diagonal elements, one for orbitals on the 
same atom and one for orbitals on different atoms. 
The Roothan-Hall matrix equations allow the energy of the molecule to be found from the Fock 
matrix. These can be expressed as a matrix equation: 
𝐅𝐂 = 𝐒𝐂𝐄 1.35 
Where F is the Fock matrix, C is the matrix of molecular orbital coefficients (containing the cμi 
values in Equation 1.28 (p71)), S is an overlap matrix to account for the deviation from 
orthonormality of the molecular orbitals and E a diagonal matrix of the orbital energies
166(p59)
. F 
and S are known: C and E are found by solving the equation
166(p61)
. 
In the AM1 method, as in many termed semi-empirical methods, the orbitals are assumed to be 
non-overlapping (orthonormal) making S of Equation 1.35 an identity matrix. 
Consequently
166(p60)
, 
𝐅𝐂 = 𝐂𝐄. 1.36 
This greatly simplifies calculation of E from the Fock matrix F. 
The diagonal elements of E, ε, include the Coulomb and exchange interaction energies twice, 
once for each electron involved in each interaction so when the total potential energy of the 
electrons (Eelec) is calculated from matrix E, the Coulomb and exchange interactions must be 
subtracted, as shown in the equation below
166(p62)
. 
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E𝐸𝑙𝑒𝑐 =∑[𝜀𝑖 −∑(2𝐽𝑖𝑗 − 𝐾𝑖𝑗)
𝑁
𝑗=1
]
𝑁
𝑖=1
 1.37 
 
The total energy is the sum of the electronic energy (EElec, calculated using matrix E) and the 
nuclear repulsion, EAB, for each pair of atoms (A and B)
166(p85)
. 
𝐸𝑇𝑜𝑡𝑎𝑙 = 𝐸𝑒𝑙𝑒𝑐 +∑ ∑ 𝐸𝐴𝐵
𝑀
𝐵=𝐴+1
𝑀
𝐴=1
 1.38 
In the AM1 method, for most bonds (all except for the OH and NH bonds), the following 
formula is used. 
𝐸𝐴𝐵 = 𝑍𝐴𝑍𝐵(𝑠𝐴𝑠𝐴|𝑠𝐵𝑠𝐵)[1 + 𝑒
−𝛼𝐴𝑅𝐴𝐵 + 𝑒−𝛼𝐵𝑅𝐴𝐵]
+
𝑍𝐴𝑍𝐵
𝑅𝐴𝐵
[∑𝐾𝐴𝑖𝑒
−𝐿𝐴𝑖(𝑅𝐴𝐵−𝑀𝐴𝑖)
2
𝑖
+∑𝐾𝐵𝑗𝑒
−𝐿𝐵𝑗(𝑅𝐴𝐵−𝑀𝐵𝑗)
2
𝑗
] 
1.39 
Where the A and B subscripts denote the nuclei either side of a bond. RAB is the distance 
between the nuclei, ZA and ZB are the nuclear charges, K, L and M are fitted constants 
controlling the shape of the Gaussian functions, i for atom A and j for atom B. α is also a fitted 
parameter. (sAsA|sBsB) denotes the overlap integral of the core orbitals of atom A with the core 
orbitals of atom B, written assuming each atom only has an s orbital in its core so this integral is 
the integral for the product of the functions for the two electrons in the s orbital of atom A 
(sAsA) overlapping the product of the functions of the two electrons in the s orbital of atom B 
(sBsB)
166(p97)
. 
At the limit of RAB=0, the energy EAB is proportional to the inverse of RAB, consistent with 
Coulomb’s law (which states that the force is proportional to the inverse of RAB squared). At the 
limit of infinite distance, EAB is constant. 
1.4.2.2.4. Ewald Summation 
When partial charges have been calculated for all of the atoms in a system, the electrostatic 
interaction between atoms can be quickly estimated during a molecular dynamics simulation 
using a force field like the one shown in Equation 1.27. However, calculation of the electrostatic 
interactions in a simulation is still the most time-consuming part of the process. 
The amount of time required to calculate the through-space interactions in the manner suggested 
by Equation 1.27, scales with the number of atoms squared because every atom can potentially 
interact with every other atom. The size of the dispersion force attracting two atoms is inversely 
proportional to the 6
th
 power of their distance apart so, for determination of the Leonard-Jones 
potential, a distance cut-off can be applied to reduce the number of atom pairs which need be 
evaluated. In contrast, electrostatic interactions are long range so a small cut-off cannot be used 
without introducing a considerable degree of inaccuracy into the simulation
180
. 
74
  
 
 
 
7
5
 
Simulations are usually performed with what are termed periodic boundary conditions where 
particles leaving on one side of the simulation appear on the opposite side, as if they had entered 
a translated copy of the simulation box flush with the original. This maintains the total number 
of particles and reduces the number of particles which must be simulated for a system in bulk 
solvent. Atoms must be simulated as if they interact with the atoms in every image of the 
infinitely tessellated periodic box so there are potentially an infinite number of interactions to 
sum to calculate the total electrostatic potential energy. 
𝒱 = ∑ ∑ ∑ ′
 
𝑞𝑖𝑞𝑗
4𝜋𝜀0|r𝑖𝑗 + n||n|=0
𝑁
𝑗=𝑖+1
𝑁−1
𝑖=1
 1.40 
Where 𝒱 here is the potential energy of the electrostatic interactions between N atoms in a 
periodic box and between those atoms and every atom in the images of the periodic box which 
would be produced by its infinite tessellation in all directions. qi and qj are the charges of atoms 
i and j respectively. rij is the vector from i and j. The third sum is over all n except for the 
|n| = 0 case when i = j (because an atom does not interact with itself). 
In Equation 1.40, 𝒱 converges slowly as interactions with images of increasing distance from 
the origin are added. Ewald summation solves the problem of this slow convergence. It involves 
splitting the series in to four series which each converge quickly. 
Equation 1.40 can be rewritten so every interaction is counted twice and the total is halved: 
 
1.41 
This can be further rewritten to include any function f(i, j) if this is both added and subtracted so 
that it does not affect the final result. 
 
1.42 
 
The periodic boundary conditions make it possible to calculate part of the electrostatic energy in 
reciprocal space using a Fourier-transformed version of the real-space formula. 
Let 
 
1.43 
Where L is the side length of the period box (assumed to be cubic in this example), α is an 
arbitrarily chosen constant (often set to 5/L) and k is the equivalent of n in reciprocal 
space
166(p337)
. 
𝒱 =
1
8𝜋𝜀0
∑∑ ∑ ′
 
𝑞𝑖𝑞𝑗
|r𝑖𝑗 + n||n|=0
𝑁
𝑗=1
𝑁
𝑖=1
 
𝒱 =
1
8𝜋𝜀0
∑∑  ∑ ′
 
𝑞𝑖𝑞𝑗
|r𝑖𝑗 + n||n|=0
− 𝑓(𝑖, 𝑗) + [𝑓(𝑖, 𝑗)] 
𝑁
𝑗=1
𝑁
𝑖=1
 
𝑓(𝑖, 𝑗) = ∑
4𝑞𝑖𝑞𝑗𝜋
𝐿3|k|2
exp −
|k|2
4𝛼2
 cos(k ∙ r𝑖𝑗 )
|k|≠0
+
2𝜋
3𝐿2
∑𝑞𝑘 |𝑟𝑘 |
k
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K =
2𝜋
𝐿
n 1.44 
Substitution of f(i, j) into equation 1.42 yields 
 
1.45 
Where erfc(x) is the error function of x
166(p338)
. 
 
 1.46 
Equation 1.45 shows the four rapidly converging series used in Ewald summation, two indicated 
in each of the sets of square brackets. The first term of the first bracket is a summation over real 
space. Although it is not clear from Equation 1.45, this first term alone is the sum of 3 
components, the electrostatic energies of interest (component A) minus the same energies 
convoluted by a Gaussian function (component B) plus a third component, the interaction 
between each i, j interaction and its Gaussian convolution (component C). In order to obtain the 
energies of interest (component A) it is necessary to remove components B and C. The second 
term of the first square bracket, a summation in reciprocal space, cancels out component C. The 
first term of the second square bracket is also a summation in reciprocal space and it almost 
cancels out component B. It is not quite equal to component B because the situation where 
|n|=|k|=0 does not exist in the reciprocal space. This missing component is added by the fourth 
and final term (square bracket two, term two), completing the cancelation of component B and 
leaving component A, the electrostatic energy of the interactions. 
The Ewald summation method has time complexity O(N
3/2
). A faster variant of the Ewald 
summation method is the Particle Mesh Ewald (PME) method which has time complexity 
O(NlogN). In the PME method, charges are assigned to the points of a 3D grid prior to Ewald 
summation. The grid is treated as an array of particles and the resulting forces on each charge 
are then mapped back onto the actual particles
165(p312)
. Because the particles are regularly 
spaced, alternative expressions for the reciprocal space components can be used which allow 
them to be calculated faster
165(p310)
. 
1.4.2.3. The Time Step 
The time step is the interval in a simulation trajectory between successive force recalculations. 
The amount of time required to carry out a simulation is proportional to the number of steps in 
the trajectory so it is desirable to increase the length of the time steps to reduce their total 
number. However, if the time steps are too long, the movement of molecules, which is 
continuous in reality, is not reproduced accurately in a simulation.  
𝒱 =
1
8𝜋𝜀0
∑∑  ∑′
 
𝑞𝑖𝑞𝑗 erfc(𝛼|𝒓𝑖𝑗 + 𝒏|)
4𝜋𝜀0|𝒓𝑖𝑗 + 𝒏||n|
−
𝛼
 𝜋
∑𝑞𝑘
2
k
 
𝑁
𝑗=1
𝑁
𝑖=1
+  ∑
4𝑞𝑖𝑞𝑗𝜋
𝐿3|k|2
exp −
|k|2
4𝛼2
 cos(k ∙ r𝑖𝑗 )
|k|≠0
+
2𝜋
3𝐿2
∑𝑞𝑘 |r𝑘 |
k
   
erfc(𝑥) =
2
 𝜋
∫ 𝑒−𝑡
2
dt
∞
𝑥
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1.4.2.3.1. The Size of the Time Step 
A time step must be chosen which is long enough for the highest frequency oscillation in the 
system to be modelled. The frequency at which a bond vibrates depends on the stiffness of the 
bond and the mass of the linked atoms, with smaller atoms resulting in higher frequencies. The 
fastest motion in a real system is the vibration of the bonds between heavy atoms and hydrogen 
due to the small mass of the hydrogen atom. 
𝜐 =
1
2𝜋
√
𝑘
𝜇
               where        𝜇 =
𝑚1𝑚2
(𝑚1 +𝑚2)
 1.47 
Where ν is the frequency at which a bond oscillates with atoms of mass m1 and m2 at either end 
if it has a stiffness of k. μ is the reduced mass of the lighter atom with respect to the heavier one. 
ν can also be determined experimentally. For example, at 298 K, compounds typically have an 
infra-red spectrum line at 3000 cm
-1
 which is caused by the C-H bond absorbing the light and 
stretching
181(p423)
. Multiplying by the speed of light gives the oscillation frequency for this bond 
as 9  1013 Hz, making the period of oscillation 11 fs. 
In a simulation, a method known as SHAKE
182
 can be used to constrain all bonds to hydrogen. 
If SHAKE is not used then the time step must be small enough for this fast vibration to be 
modelled correctly. Using time steps of 1 fs results in 11 steps per C-H bond oscillation, which 
is usually sufficient for a simulation to be stable. If the size of the time step is increased to, for 
example, 2 fs, this can lead to extreme bond lengths occurring, the relaxation of which can 
destabilise the system. When the SHAKE method is used, a constraining force is applied to all 
bonds to hydrogen prevent these high energy states occurring so a time step of up to 2 fs can be 
used. SHAKE not only increases simulation stability but it also improves accuracy when 
comparing simulations because high energy states occur rarely so might be sampled in one 
simulation but not another. 
The potential energy associated with different intra- and inter-molecular interactions can vary at 
different rates. Slow energy changes can therefore be evaluated at alternate steps, or less 
frequently still. The force due to these interactions can be assumed to be unchanged in the 
intervening steps or, alternatively, extrapolated
166(p363)
 based on the rate of change of the force 
(dF/dt) and d
2
F/dt
2
. 
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1.4.2.3.2. The Verlet Algorithm 
Once the net force on a particle is known, its acceleration can be calculated by dividing the 
force by the mass of the particle. 
v(𝑡 + 𝛿𝑡) = v(𝑡) + a𝛿𝑡 1.48 
Where v and a are vectors containing, respectively, the velocities and accelerations of atoms 
(assumed to have constant acceleration) in a system before (t) and after (t + δt) a time step of 
length δt166(p355). 
Where the vector r describes the position of the atoms, 
r(𝑡 + 𝛿𝑡)   = r(𝑡) + ∫ v(𝑡)
𝑡+𝛿𝑡
𝑡
d𝑡 
 
 
= r(𝑡) + [𝑡v(𝑡) +
1
2
𝑡2a]
𝑡
𝑡+𝛿𝑡
 
 
 
= r(𝑡) + (𝑡 + 𝛿𝑡)v(𝑡 + 𝛿𝑡) +
1
2
(𝑡 + 𝛿𝑡)2a − 𝑡v(𝑡) −
1
2
𝑡2a. 1.49 
lim
𝛿𝑡→0
r(𝑡 + 𝛿𝑡)  = r(𝑡) + 𝛿𝑡v(𝑡) +
1
2
𝛿𝑡2a 1.50 
 
The Verlet algorithm (Equation 1.52) describes how the atomic positions after the next time step 
can be calculated from the coordinates in the current time step, r(t), the coordinates for the 
previous time step, r(t – δt), and the acceleration of the atoms, a166(p356). 
lim
𝛿𝑡→0
[𝒓(𝑡 + 𝛿𝑡) + 𝒓(𝑡 − 𝛿𝑡)]  = 2r(𝑡) + 𝛿𝑡2a 1.51 
lim
𝛿𝑡→0
[𝒓(𝑡 + 𝛿𝑡)]  = 2r(𝑡) − r(𝑡 − 𝛿𝑡) + 𝛿𝑡2a 1.52 
1.4.2.3.3. Equilibration and Sampling 
The root mean square deviation (RMSD) can be used to quantify the difference between two 
sets of paired values. If each set is considered to be a point in N-dimensional space, the RMSD 
is the distance between the two points.  
The two sets of values can be the Cartesian coordinates (x, y, z) of the atoms in two structures. 
In this case 
RMSD = √ ∑ [(𝑥𝑖 − 𝑥𝑗)
2
+ (𝑦𝑖 − 𝑦𝑗)
2
+ (𝑧𝑖 − 𝑧𝑗)
2
]
𝑎𝑡𝑜𝑚𝑠
. 
1.53 
Using the RMSD assumes that the scales of the x, y and z axes are the same. When comparing, 
for example, the deviations of points on a 
15
N-HSQC spectrum, the axes need to be scaled for 
the distance to still be meaningful. 
One of the uses of RMSDs is to assess the equilibration of a molecular dynamics simulation, the 
extent to which the system has converged on a steady state where the final, fixed phase space is 
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being sampled and the system is thus capable of producing statistically independent as opposed 
to trending observations. 
The RMSD can be used in a variety of ways, the simplest method being to plot the RMSD of 
each of the frames in a molecular dynamics simulation trajectory relative to the first frame and 
see when the RMSD plateaus. This was the method used in this project due to its simplicity. 
However, an all-to-all RMSD analysis can also be performed in which every frame is compared 
to every other. This reveals the extent to which populations are revisited. 
Grossfield and Zuckerman
183
 identify some limitations of the RMSD. The RMSD, for example, 
is a single variable so cannot encapsulate the entire state of the system. It could theoretically 
level off before the system has equilibrated if the remaining equilibration will not affect the 
RMSD
183
. 
If a simulation is performed to monitor a particular variable such as a binding affinity, then this 
can be monitored instead of the RMSD. While the variable might not be a good indicator of 
equilibration, levelling off of a particular observation suggests that any remaining equilibration 
will not affect its value. In the thermodynamic integration (p83) investigations performed in this 
project, equilibration of the derivative of the vibronic potential energy with respect to the 
reaction coordinate, d𝒱/dλ, was checked for. 
Principal component analysis can be used to identify variables which better encapsulate the 
major dynamic modes of the system. Like the RMSD, these can be plotted against time, 
individually or together to see when the values of the components settle on particular set of 
values or appear to be moving between a limited number of sets of values, each reflecting a 
local minimum in the energy landscape
183
. Rather than attempt to map the phase space of a 
simulation on to scalar variables and then identify such low energy states, clusters of 
conformations can be identified by cluster analysis of the trajectory frames. A histogram can 
then be produced which reflects the number of trajectory frames mapping to each cluster 
identified. Histograms produced at intervals along a simulation trajectory can be tested to 
determine when they become samples of the same population, indicating that equilibration has 
occurred
184
. 
Once equilibration has occurred, it is useful to identify the length of time needed between 
samples for them to be independent, the correlation time. In order to calculate the error on 
estimated parameters, it is useful to make independent observations. 
The central limit theorem describes how the variance of the means of samples from a population 
depends on the sample size. 
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𝑉𝑎𝑟(?̅?) =
𝑉𝑎𝑟(𝑋)
𝑛
 1.54 
Where n is the number of values per sample and ?̅? is the sample mean of the random variable 
X. 
If contiguous sample windows containing a certain number of frames are taken from different 
parts of a trajectory, each used to calculate a mean value and the variance of these means is 
compared to that of the global population, the number of statistically independent samples per 
window can be found. Alternatively, windows regularly spaced along a trajectory can be 
analysed and the interval between the windows increased until the variance of the windows and 
variance over the entire trajectory are consistent with independent sampling
183
. 
The most straightforward and rigorous method of producing independent observations of a 
variable is to carry out multiple simulations and see when the results converge. All confidence 
limits on simulation derived variables in this thesis are based on separate repeats. This method 
allows random error in docking due to insufficient sampling to be considered by starting each 
simulation from a separate docking run. Implicit solvent results in this project were started from 
the results of separate docking runs. 
1.4.2.4. Maintaining the Simulated Temperature and Pressure 
1.4.2.4.1. Constant Temperature 
In the real world, a system exchanges energy with its surroundings. Consequently, the 
temperature of a real system typically equilibrates to the temperature of its surroundings. To 
reproduce this effect in simulations, a method is required to maintain the system temperature. 
The temperature of a simulation is a function of the translational kinetic energy of the 
particles
165(p140)
. 
𝑇 = 𝑘∑
〈|𝐯𝑖|
2〉
𝑚𝑖
𝑖
 1.55 
Where T is the temperature, k is the Boltzmann constant. v is the velocity of particle i and mi is 
its mass. 
In the Berendsen thermostatic method, the velocities are scaled at  intervals
166(p383)
. 
𝐯𝑎𝑑𝑗 = 𝐯𝑖𝑛𝑖𝑡√1+
𝛿𝑡
𝜏
(
𝑇𝑏𝑎𝑡ℎ
𝑇
+ 1) 1.56 
Where vinit and vadj are velocities before and after scaling in a system at a current temperature of 
T coupled to a heat bath of temperature Tbath where the time step is δt and τ is what is termed the 
coupling parameter. The Berendsen method ensures that the rate of change of the temperature is 
directly proportional to the difference between the temperature of the water bath and the 
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temperature of the system. The rate is also proportional to the time step and the coupling 
parameter. 
The Berendsen thermostat is useful for controlling the temperature in a potentially unstable 
system as it is equilibrates. In this project, simulations were carried out with a large number of 
compounds and it was desirable for as many simulations as possible to be stable both to 
simplify production and statistical analysis. Furthermore, in the stable simulations, rapid 
equilibration was essential because it was not possible to manually inspect every trajectory to 
ensure that it had equilibrated; only a selection of trajectories could be examined. Consequently, 
the Berendsen thermostat was used for all simulations in this project with the exception of 
thermodynamic integration runs. 
A disadvantage of the Berendsen thermostat is that it does not ensure the correct distribution of 
potential or total energy throughout the system; it merely ensures that the total energy is 
correct
185
. All of the simulations carried out in this project had explicit solvent molecules which 
will have assisted with the partitioning of energy between the parts of the system 
(thermalisation). However, in thermodynamic integration runs where the reaction coordinate λ 
is close to 0 or 1, the weak coupling of some atoms to the simulation can mean that there is 
insufficient exchange of energy with other atoms for thermalisation to occur
186(p118)
. 
Many thermostatic methods lead to correct sampling, including the Andersen thermostat
187
, the 
Nosé-Hoover thermostat
188
 and Langevin dynamics
189
. In the Nosé-Hoover thermostat 
method
166(p384),188
, the system temperature is maintained by extension of the system to contain an 
additional component which has momentum and so can act as a store of kinetic energy. This 
component, the position of which is described by the single coordinate s, disconnects the kinetic 
energy of the un-extended (real) system from the total kinetic energy of the system, allowing it 
to be changed such that the real system has the desired temperature. The effect of the additional 
component in its one-dimensional extension of the system is to apply a varying but 
deterministic mass-dependent force to the particles similar to a friction force, which controls the 
momentum and speed of the particles in the real system and therefore the temperature of the real 
part of the extended system. 
𝑑p𝑖
𝑑𝑡
= −
𝜕𝑈
𝜕r𝑖
−
𝑑 ln 𝑠
𝑑𝑡
p𝑖 1.57 
Where p is the momentum of a particle with position r in a system where the real part has a 
total internal energy of U and s is the position of the additional component at time t
165(p152)
. 
In this project, Langevin dynamics was used to maintain the temperature of thermodynamic 
integration runs. In this method a constant friction force is applied and there is a random 
perturbation. 
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𝑑p𝐢
𝑑𝑡
= −
𝜕𝑈
𝜕r𝒊
− 𝛾p𝑖 + 𝑋𝑖 1.58 
Where γ is a coefficient of friction and Xi is a random variable distributed normally with mean 0 
and variance equal to twice the product of the friction coefficient, the mass of the atom, mi, the 
Boltzmann constant, k, and the temperature, T. 
𝑋𝑖 ∼ 𝑁(0, 2𝛾𝑚𝑖𝑘𝑇) 1.59 
1.4.2.4.2. Constant Pressure 
The pressure in a system is described by the virial equation: 
𝑃 =
𝑅𝑇
𝑉
+
1
3𝑉
⟨∑(ri ∙ Fi)
𝒊
⟩ 1.60 
Where P is the pressure, R is the universal gas constant, T is the temperature in kelvins, V is the 
volume and the particles, i, have position ri and a force on them of Fi
190
. The angle brackets 
indicate the pressure is the Boltzmann average over all possible microstates of the system. 
For a single simulation trajectory frame: 
P =
𝑅𝑇
𝑉
+
1
3𝑉
∑(r𝑖 ∙ F𝑖)
𝒊
 1.61 
The part of molecular dynamics simulations in which data is collected is typically performed at 
constant pressure because, in the real world, pressure is exerted on systems by their 
surroundings causing them to equilibrate at atmospheric pressure. In a simulation, the volume of 
the periodic box occupied by the particles is changed to maintain the pressure. 
Berendsen
166(p386),191
 describes a simple system of pressure control involving a pressure bath 
where coordinates are adjusted to effect the necessary change in volume when the pressure 
changes and the AMBER software used in this project uses such a method
186(p25)
. 
r𝑎𝑑𝑗 =  1 −
𝜅𝛿𝑡
𝜏𝑝
(𝑃 − 𝑃𝑏𝑎𝑡ℎ) 
1
3⁄
r𝑖𝑛𝑖𝑡 1.62 
The rate of change of the volume is proportional to the difference between the pressure of the 
system, P, and the “pressure bath” pressure, Pbath.  δt is the time step, κ is the isothermal 
compressibility of the system and τp is a constant describing the degree of coupling between the 
system and the bath. The rate of change of the volume is proportional to the difference between 
the current system pressure and the target pressure. 
As with the Berendsen thermostat, use of the Berendsen barostat does not ensure correct 
sampling of the isothermal–isobaric ensemble in NPT simulations and other, better methods of 
pressure control exist. For example, as with the Nose-Hoover thermostat, the system can be 
extended to contain an additional moving component. The moving component occupies a 
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volume (due to its velocity) and consequently it occupies part of the extended system, pushing 
the real part of the system into the correct volume for the desired pressure
166(p387)
. 
A system is usually equilibrated under NVT conditions before a constant pressure run is started 
to ensure that the initial scaling when the barostat is enabled is not very large, destabilising the 
system
186
. 
1.4.3. THEORETICAL ESTIMATION OF BINDING AFFINITIES 
In this project, binding affinities were initially estimated using thermodynamic integration and 
then later using the implicit solvent MM-PBSA and MM-GBSA methods. Gilson and Zhou
192
 
and Foloppe and Hubbard
193
 review some methods by which the relative binding energy of 
ligands can be estimated including these methods. 
Comparing simulations of two systems, each with a large phase space is inaccurate as their 
phases spaces might have been sampled differently in each simulation. High energy states are 
particularly problematic because they occur rarely but can make a significant contribution to the 
potential energy of a system
166(p314),183
. Furthermore, the high potential energy states of a 
protein-ligand complex include states in which the ligand is far from the protein surface. In such 
states it is debatable whether the ligand is still bound and therefore whether the state should be 
considered when calculating the energy of the protein-ligand complex
192
. Thermodynamic 
integration and implicit solvent techniques are methods that enable a fairer comparison of 
simulations involving different ligands. 
In the MM-GBSA and MM-PBSA implicit solvent methods, the solvent molecules are not 
modelled explicitly (individually). Instead, the solvent is treated as a continuum
166(p592)
. This 
decreases the number of particles, significantly reducing the size of the space to be sampled. As 
a result, comparing simulations of different ligands is fairer because the results are less likely to 
differ due to differences in the configuration of the solvent. 
In the thermodynamic integration method, the number of particles is not reduced; rather, 
particles are shared between the systems being compared to ensure that they take similar paths 
through the phase space. 
1.4.3.1. Thermodynamic Integration 
∆∆𝐺 = ∆𝐺𝑙𝑖𝑔𝑎𝑛𝑑𝐵 − ∆𝐺𝑙𝑖𝑔𝑎𝑛𝑑𝐴 = (𝐺𝐵𝑏𝑜𝑢𝑛𝑑 − 𝐺𝐵𝑓𝑟𝑒𝑒) − (𝐺𝐴𝑏𝑜𝑢𝑛𝑑 − 𝐺𝐴𝑓𝑟𝑒𝑒) 1.63 
Where ΔΔG is the difference in the free energy of binding of two ligands, A and B, with free 
energies of binding ΔGligandA and ΔGligandB respectively. ΔΔG is equal to the free energy of their 
bound state (GAbound and GBbound respectively) minus the free energy of the unbound molecules 
(GAfree and GBfree). 
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As shown in Figure 1.14 and Equation 1.64, the difference in binding energy is equal to the 
change in free energy if ligand A were to be transformed in the binding site into ligand B 
(ΔGAtoBbound) minus the change in free energy if the same transformation were to be performed 
with the ligand unbound, free in solution (ΔGAtoBfree). 
∆∆𝐺 = (𝐺𝐵𝑏𝑜𝑢𝑛𝑑 − 𝐺𝐴𝑏𝑜𝑢𝑛𝑑) − (𝐺𝐵𝑓𝑟𝑒𝑒 − 𝐺𝐴𝑓𝑟𝑒𝑒) = ∆𝐺𝐴𝑡𝑜𝐵𝑏𝑜𝑢𝑛𝑑 − ∆𝐺𝐴𝑡𝑜𝐵𝑓𝑟𝑒𝑒 1.64 
 
 
 
Figure 1.14: A Bordwell thermodynamic cycle to show how thermodynamic integration allows a 
free energy of binding to be estimated using thermodynamic integration. Two ligands are shown, A 
and B, both free in solution (Afree and Bfree) and bound to the protein (Abound and Bbound). The difference 
between the free energy change when ligand B is transformed into ligand A while bound to the protein 
and the free energy change when ligand B is similarly converted to ligand A when free in solution is 
equal to the difference in binding energy between the compounds. 
 
In reality, there may be no mechanism by which ligand A could be transformed into ligand B, 
but such modifications can be studied in silico. In thermodynamic integration, simulations are 
performed at various points along the reaction coordinate, λ, of the alchemical transformation 
both for the bound ligand and the free ligand. In each of the simulation, the first derivative of 
the vibronic potential energy with respect to the reaction coordinate, d𝒱/dλ, is calculated192. 
Numerical integration of d𝒱/dλ between λ=0 (the starting system containing molecule A) and 
λ=1 (the final system containing molecule B) yields an estimate of the overall change in free 
energy, ΔG (ΔGAtoBbound or ΔGAtoBfree)
192
. 
∆𝐺 = 𝐺1 − 𝐺0 = ∫ (
𝜕𝐺
𝜕𝜆
)
𝑁,𝑉,𝑇
 ∂𝜆
1
0
. 1.65 
The pressure and volume are assumed to be constant so the change in vibronic potential energy 
(which is a change in Helmholtz free energy) is equal to the change in Gibbs free energy (p90).  
The (arithmetic) mean derivative of the potential energy from the trajectory frames analysed is 
assumed, making the ergodic assumption, to be an estimate of the Boltzmann average of the 
derivative. 
A
bound
 
A
free
 
GligandA
B
bound
 
 
GligandB
GAtoBbound
GAtoBfree
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∆𝐺 = ∫ ⟨d𝒱 d𝜆⁄ ⟩  d𝜆
1
0
= ∫
(
 
 ∑ [𝑒
−(
𝒱𝑖
𝑘𝑇)
d𝒱𝑖
d𝜆 ]𝑖
∑ [𝑒
−(
𝒱𝑗
𝑘𝑇)]𝑗
)
 
 
d𝜆
1
0
  1.66 
Where k is the Boltzmann constant and T is the temperature. 
Across the simulations, atoms which exist in compound A but not in compound B have to 
disappear as λ is increased and, similarly, atoms which exist in compound B only must appear. 
In practice, three separate TI steps are often used. Firstly, charges are removed from the 
disappearing atoms. Secondly, atoms appear and disappear as necessary. Thirdly, in the final 
step, the charges are put on to the new atoms. 
The use of these three steps means that simulations are not carried out with charged atoms that 
are almost decoupled from the system (atoms disappearing when λ=1 or appearing when λ=0). 
These can potentially collide when attracted to an oppositely charged atom due to there being 
insufficient Pauli repulsion after the Leonard-Jones potential has been scaled by λ. 
The Leonard-Jones potential (p68), is an AMBER force field component which is attractive at 
long distances but repulsive when atoms are close together, preventing their collision. 
𝒱(R)LJ, unchanged 
= ∑ [
𝐴𝑖𝑗
𝑟𝑖𝑗
12 −
𝐶𝑖𝑗
𝑟𝑖𝑗
6 ]
𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 𝑝𝑎𝑖𝑟𝑠
 
 
 = 4𝜀 ∑
[
 
 
 
1
((
𝑟𝑖𝑗
𝜎𝑖𝑗
)
6
)
2 −
1
(
𝑟𝑖𝑗
𝜎𝑖𝑗
)
6
]
 
 
 
𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 𝑝𝑎𝑖𝑟𝑠
 1.67 
Rij is the distance between atoms i and j, ε is the permittivity of the environment the atoms are in 
and σij is the distance at which the potential is 0. If atoms become close together, then the 
Leonard-Jones potential can suddenly become very large causing the simulation to destabilise. 
Even without charges, atoms may, by chance, become close in the course of their movement. In 
addition to performing the transformation in three stages as described, the Leonard-Jones 
potentials are usually replaced by what are called soft core potentials. These are Leonard-Jones 
potentials with an additional term, α, to ensure that the denominator of the attractive and 
repulsive terms is always of some magnitude
166(p579),186(p118)
. 
The Leonard-Jones potentials for the disappearing and appearing atoms are as follows. The total 
Leonard-Jones potential energy is the sum of that of the disappearing atoms, the appearing 
atoms and that of the unchanged atoms (calculated as normal). 
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𝒱(R)LJ, disappearing = 4𝜀(1 − 𝜆) ∑
[
 
 
 
1
(𝛼𝜆 + (
𝑟𝑖𝑗
𝜎𝑖𝑗
)
6
)
2 −
1
𝛼𝜆 + (
𝑟𝑖𝑗
𝜎𝑖𝑗
)
6
]
 
 
 
𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 𝑝𝑎𝑖𝑟𝑠
 1.68 
𝒱(R)LJ, appearing = 4𝜀𝜆 ∑
[
 
 
 
1
(𝛼(1 − 𝜆) + (
𝑟𝑖𝑗
𝜎𝑖𝑗
)
6
)
2 −
1
𝛼(1 − 𝜆) + (
𝑟𝑖𝑗
𝜎𝑖𝑗
)
6
]
 
 
 
𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 𝑝𝑎𝑖𝑟𝑠
 1.69 
 
1.4.3.2. Implicit Solvent Methods 
Water molecules were included in every simulation performed in the course of this project. 
However, later in the project, two implicit solvent methods, where the solvent is modelled as a 
continuum
166(p592)
, were used to estimate binding affinities. The explicit water was removed from 
the recorded trajectories prior to analysis. 
1.4.3.2.1.  The MM-PBSA Method 
In the molecular mechanics-Poission-Boltzmann surface area (MM-PBSA) implicit solvent 
method (figure 3)
194
, a thermodynamic cycle is employed; the free energy of solvation for the 
ligand, protein and complex are used to convert a binding energy predicted in vacuo to one for 
in solution. 
 
 
Figure 1.15: The Bordwell thermodynamic cycle used in the MM-PBSA method. The free energy of 
binding in solution (∆𝑮𝒃𝒊𝒏𝒅
𝒂𝒒
) is determined from more easily calculable energies, namely, the free energy 
of binding in the gas phase (∆𝑯𝒃𝒊𝒏𝒅
𝒈𝒂𝒔
− 𝑻∆𝑺𝒃𝒊𝒏𝒅
𝒈𝒂𝒔
), and the free energies of solvation of the ligand, the 
receptor and the complex, ∆𝑮𝒔𝒐𝒍𝒗
𝑳𝒊𝒈𝒂𝒏𝒅
,, ∆𝑮𝒔𝒐𝒍𝒗
𝑷𝒓𝒐𝒕𝒆𝒊𝒏, and ∆𝑮𝒔𝒐𝒍𝒗
𝒄𝒑𝒙
, respectively. This diagram has been adapted 
from a published figure
195
. 
 
The total free energy change of solvation can be modelled as the sum of two components, an 
electrostatic component, ΔGelec, and a non-polar component, ΔGnonpolar. 
∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐺𝑒𝑙𝑒𝑐 + ∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 1.70 
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When a species becomes solvated, the dielectric permittivity of the region surrounding the 
atoms changes. In the MM-PBSA method, the Poisson-Boltzmann equation is used to calculate 
the resulting change in electrostatic potential around the species. This is then used to determine 
the change in electrostatic energy, ΔGelec. 
∆𝐺𝑒𝑙𝑒𝑐 =
1
2
∑𝑞𝑖(r𝑖)∆𝜙(r𝑖)
 
r
 1.71 
Where qi is the charge of atom i at position ri experiencing a change in electrostatic potential of 
Δφ(ri)
165(p292,p607)
. Calculation of the change in electrostatic potential is discussed in more detail 
below. 
The solvent accessible surface area of the species is used to estimate the non-polar component 
of solvation, ΔGnonpolar. 
∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 = 𝛾𝐴 + 𝑏 1.72 
Where A is the solvent accessible surface area and γ and b are empirically derived constants 
(which can be used with any molecule). 
The solvent accessible surface area indicates the size of this non-polar component because it is 
roughly proportional to the number of water molecules in the first solvation shell around the 
species
166(p609)
. Two factors contribute to the non-polar component of the free energy of 
solvation, an energetically unfavourable cavitation component, ΔGcav and an energetically 
favourable, van der Waals component, ΔGvdW
196
, both of which are proportional to the size of 
this first solvation shell. 
∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 = ∆𝐺𝑐𝑎𝑣 + ∆𝐺𝑣𝑑𝑊 1.73 
ΔGcav accounts for the decrease in entropy of solvent molecules as they are forced out of the 
volume to be occupied by the solute and into a more dense and regular arrangement in solvent 
shells around the solute
197
. The volume of a complex is roughly equal to the sum of the unbound 
protein and unbound ligand volumes so any dependence of ΔGnonpolar on species volume should 
be largely cancelled out when ΔGnonpolar is used to calculate the binding energy of a ligand for a 
protein. 
ΔGvdW is the free energy change due to van der Waals forces (instantaneous dipole-induced 
dipole attractions and Pauli exclusion principle-related repulsions) the form between the surface 
of the solute and the first solvation shell of solvent molecules. 
Returning to the electrostatic component from Equation 1.70, ΔGelec, calculation of the 
electrostatic potential, φ(ri), requires a partial differential equation to be solved. If the dielectric 
constant of the medium were the same throughout the system (independent of r), then the 
following form of the Poisson differential equation
166(p603)
 could be used. 
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∇2𝜙(r) ≡ ∇ ∙ ∇𝜙(r) = −
4𝜋𝜌(r)
𝜀
, 1.74 
Where ρ(r) is the charge density and ε is the permittivity. 2 indicates application of the del-
squared operator (Equation 1.24) which is equivalent to finding the gradient in the x, y and z 
directions ( operator) and then finding the gradient of each of these gradients and adding these 
second derivative results (·). 
It is assumed when using Equation 1.74 that the change in dielectric constant across the system 
is uniform when solvation occurs. In practice, the dielectric constant is position dependent due 
to the motion of mobile charges down the electrostatic potential gradient when the permittivity 
changes. A term based on the Boltzmann distribution must be introduced to account for this 
effect. 
∇ ∙ ε(r)∇𝜙(r) −  𝜀𝜅 sinh𝜙(r) = −4𝜋𝜌(r), 1.75 
where κ is known as the Debye-Hückel inverse length166(p604). 
𝜅 = √ 
𝜋𝑁𝐴𝑒2
125𝑘
 
𝐼
𝑇
 1.76 
Where I is the ionic strength, T is the temperature and e is a constant, the charge of a proton. 
Equation 1.75 can be simplified further, when the electrostatic potentials are very small 
(𝑒|𝜙(r)| ≪ 𝑘𝑇) because 
sinh 𝑥 =
1
2
(𝑒𝑥 − 𝑒−𝑥) = ∑
𝑥2𝑛+1
(2𝑛 + 1)!
∞
𝑛=0
= [𝑥 +
𝑥3
6
+
𝑥5
120
+
𝑥7
5040
+⋯] ≈ 𝑥 1.77 
Where e is the base of natural logarithms. 
The result is the linearized Poisson-Boltzmann equation. 
∇ ∙ ε(r)∇𝜙(r) −  𝜀𝜅𝜙(r) = −4𝜋𝜌(r) 1.78 
This linearized equation often gives good results even when 𝑒|𝜙(r)| is of a similar size to 𝑘𝑇198 
and it is the form of the Poisson-Boltzmann equation used to predict MM-PBSA binding 
energies by the mmpbsa.py program of the Amber suite, which was used in this project. 
1.4.3.2.2. The MM-GBSA Method 
The Molecular Mechanics-Generalised Born Surface Area (MM-GBSA) method of predicting 
the free energy of binding in a solvent is similar to that of the MM-PBSA method with the 
difference that the free energy of solvation is calculated using the Generalised Born equation 
rather than the Poisson-Boltzmann equation. 
In Born’s model of solvation199, charges are treated as ions surrounded by a spherical solvent 
cavity of equal and opposite charge. 
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For a single ion, 
𝐺𝑒𝑙𝑒𝑐 = −
𝑞2
2𝜀𝑅
 1.79 
Where Gelec  is its electronic free energy, q is the charge of the atom, ε is the relative permittivity 
of its environment and R is the radius of the cavity in the model, which corresponds to the van 
der Waals radius of the charged particle
166(p594)
. 
For a system containing many particles (represented using i and j below), the electrostatic 
energy comprises this Born solvation component (from Equation 1.79) plus the energy of the 
Coulomb interaction between the particles. 
𝐺𝑒𝑙𝑒𝑐 =
1
𝜀
∑ ∑
𝑞𝑖𝑞𝑗
𝑟𝑖𝑗
𝑁
𝑗=𝑖+1
𝑁
𝑖=1
−
1
2𝜀
∑
𝑞𝑖
2
𝑅𝑖
𝑁
𝑖=1
 1.80 
Where rij is the distance between particles i and j and Ri is the effective Born radius of the 
particle. 
In the model, solvation of an ion is likened to bringing the particle from a vacuum (ε=1) into the 
solvent sphere, which has relative dielectric ε. 
∆𝐺𝑒𝑙𝑒𝑐 = −
𝑞2
2𝑅
(1 −
1
𝜀
) 1.81 
 
When multiple particles are considered
166(p598)
, 
∆𝐺𝑒𝑙𝑒𝑐 = −(1 −
1
𝜀
)(∑ ∑
𝑞𝑖𝑞𝑗
𝑟𝑖𝑗
𝑁
𝑗=𝑖+1
𝑁
𝑖=1
+
1
2
∑
𝑞𝑖
2
𝑅𝑖
𝑁
𝑖=1
). 1.82 
The Born radius must be continually recalculated for particles in close proximity to others. 
1
𝑅𝑖
≈
1
𝑎𝑖
− 𝐼 1.83 
Where I is estimated using the function 
𝐼 =
1
4𝜋
∫
1
|r|4
𝑑r
∞
|𝑟|=𝑎𝑖
. 1.84 
Where the integral is limited to the solute-occupied volume and the atom i is at position 
 |𝒓| = 0200. 
Equation 1.83 leads to underestimation of the Born radii of atoms buried in a macromolecule. 
To account for this, other functions have been proposed. In this project the following function of 
Onufriev et al.
200
 was tested (p169) to see if it improved results. 
𝐼 =
1
𝑎𝑖
tanh(𝛼Ψ − 𝛽Ψ2 + 𝛾Ψ3) 1.85 
Where α, β and γ are empirically derived constants and 
Ψ = 𝐼(𝑎 − 0.09) 
1.86 
The 0.09 was empirically derived by Onufriev et al.. 
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1.4.3.3. Entropy and Normal Mode Analysis 
The change in the internal entropy of the ligand and protein upon binding is not normally 
included in an MM-PBSA or MM-GBSA calculation. However, this entropy change can be 
estimated using Normal mode analysis and then multiplied by the temperature to determine its 
effect on the free energy of binding. Consequently, Normal mode analysis will now be 
introduced, starting with an explanation of the partition function. 
 
The entropy of a system, S, is, by definition, the logarithm of the number of ways (Ω) in which 
the elements of the system can potentially be arranged
165(p11)
. 
𝑆 = 𝑘 lnΩ ≡ logexp (1 𝑘⁄ )Ω 1.87 
Where k is the Boltzmann constant. 
By definition, 
𝐻 = 𝐺 + 𝑇𝑆 = 𝑝𝑉 + 𝐹 + 𝑇𝑆 = 𝑝𝑉 + 𝑈 1.88 
where H is the enthalpy of a system, G is the Gibbs free energy, T is the temperature, S is the 
entropy, p is the pressure, V is the volume, F is the Helmholtz free energy and U is the internal 
energy
165(p168)
. 
The entropy of the Universe as a whole, a closed system, is always increasing. Over time, the 
free energy (energy which can do work), G is converted to thermal energy which cannot do 
work, TS in formula 1.88. 
𝑈  = 𝑇𝑆 + 𝐹  
 = 𝑇(𝑘 lnΩ) + (−𝑘𝑇 lnQ)  
 = 𝑘𝑇 ln
Ω
𝑄
 1.89 
Where Q is what is termed the canonical partition function
165(p169)
. It is evident from Equation 
1.89 that, for a system of constant pressure and volume, the partition function (Q) is the 
reciprocal of the factor by which Ω would be increased if all of the free energy of the system 
were to be used to do work (so F became 0 and Q became 1). 
 
The canonical partition function, Q, can also be described as the sum of the Boltzmann factor 
for all of the microstates, i, of the system (the different quanta of Helmholtz free energy, εi, the 
system can have)
165(p12)
: 
𝑄 =∑𝑒−(
𝜀𝑖
𝑘𝑇)
𝑖
 1.90 
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𝑃𝑖 =
𝑒−(
𝜀𝑖
𝑘𝑇)
∑ [𝑒
−(
𝜀𝑗
𝑘𝑇)]𝑗
=
𝑒−(
𝜀𝑖
𝑘𝑇)
𝑄
 1.91 
Where Pi is the probability of the system being in microstate i (and have Helmholtz free energy 
εi)
165(p12)
. 
In quantum mechanics, some states have a limited occupancy. For example, the electron orbitals 
of an atom cannot contain more than two electrons. This restriction affects the distribution of 
particles between the possible energy states of the system and its inclusion in the partition 
function Qquantum below, is achieved using an additional variable, the degeneracy (maximum 
occupancy) of microstate i, gi. 
𝑄𝑞𝑢𝑎𝑛𝑡𝑢𝑚 =∑𝑔𝑖𝑒
−(
𝜀𝑖
𝑘𝑇)
𝑖
 1.92 
To understand how the entropy of a system can be estimated by Normal mode analysis, it is 
useful to express the total entropy of the system (S) in terms of the molecular partition function, 
hereinafter denoted by Z. This is the partition function for one of the molecules in the system 
(as opposed to the system as a whole). (The molecules are assumed to all be identical in this 
example.) 
From Equation 1.89, 
𝑆 =
𝑈
𝑇
+ 𝑘ln𝑄 1.93 
 
For a system where the particles are distinguishable, 
𝑆𝑑𝑖𝑠𝑡 =
𝑈
𝑇
+ 𝑘ln𝑍𝑁 1.94 
Where Sdist is the entropy and N is the number of molecules
201(p53)
. 
In reality, identical molecules are indistinguishable so the number of unique ways they can be 
rearranged is reduced by a factor of N!
201(p53)
. 
𝑆  =
𝑈
𝑇
+ 𝑘ln
𝑍𝑁
𝑁!
  
 =
𝑈
𝑇
+ 𝑁𝑘ln𝑍 − 𝑘ln(𝑁!) 1.95 
lim
𝑁→∞
𝑆  =
𝑈
𝑇
+ 𝑁𝑘ln𝑍 − 𝑁𝑘ln𝑁 + 𝑘𝑁  
 =
𝑈
𝑇
+ 𝑁𝑘 (ln
𝑍
𝑁
+ 1) 1.96 
The total internal energy of a system, U, can be expressed in terms of the molecular partition 
function. To do this it is necessary to express the partial derivative of the molecular partition 
function at constant volume in terms of the energy of each microstate (i), εi, and the microstate 
degeneracy, gi. 
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From Equation 1.90
201(p184)
, 
𝑍  =∑𝑔𝑖𝑒
−𝜀𝑖 𝑘𝑇⁄
𝑖
. 
1.97 
(
𝜕𝑍
𝜕𝑇
)
𝑉
 =
1
𝑘𝑇2
∑𝑔𝑖𝜀𝑖𝑒
−𝜀𝑖 𝑘𝑇⁄
𝑖
 1.98 
 
𝑈  = 𝑁∑𝜀𝑖
𝑖
 
 
 =
𝑁
𝑍
∑𝑍𝜀𝑖
𝑖
  
 =
𝑁
𝑍
∑𝑔𝑖𝜀𝑖𝑒
−𝜀𝑖 𝑘𝑇⁄
𝑖
  
 =
𝑁𝑘𝑇2
𝑍
(
𝜕𝑍
𝜕𝑇
)
𝑉
  
 = 𝑁𝑘𝑇2 (
𝜕 ln 𝑍
𝜕𝑇
)
𝑉
 1.99 
Using equation 1.99
201(p52)
 to substitute U in Equation 1.96 yields
201(p52) 
𝑆 = 𝑁𝑘𝑇 (
𝜕 ln 𝑍
𝜕𝑇
)
𝑉
+ 𝑘𝑁 (𝑙𝑛
𝑍
𝑁
+ 1)  
 = 𝑁𝑘 [𝑇 (
𝜕 ln𝑍
𝜕𝑇
)
𝑉
+ ln𝑍 − ln𝑁 + 1]. 1.100 
In this project, Normal mode analysis was used to estimate the relative vibrational and 
translational entropy of the ligand and protein when free and when bound together. Normal 
mode analysis is the identification of the harmonic modes that a molecule can have, concerted 
atomic motions in which all of the nuclei are moving in phase
201(p196)
. Only these oscillations are 
stable. There is only one harmonic mode that corresponds to translation, the mode in which all 
of the nuclei are moving in the same direction. The others are internal vibrations, vibrational 
modes. 
Where Svib is the entropy due to the vibrational modes, 
𝑆𝑣𝑖𝑏 = 𝑁𝑘 [𝑇 (
𝜕 ln𝑍𝑣𝑖𝑏
𝜕𝑇
)
𝑉
+ ln𝑍𝑣𝑖𝑏] 1.101 
Where Zvib is the vibrational molecular partition function. The entropy can now be expressed in 
terms of the partition function, Zi, of each vibrational mode, i, 
166(p162)
. 
𝑍𝑣𝑖𝑏 =∏𝑍𝑖
𝑖
 1.102 
𝑆𝑣𝑖𝑏 = 𝑁𝑘∑[𝑇 (
𝜕 ln 𝑍𝑖
𝜕𝑇
)
𝑉
+ ln𝑍𝑖]
𝑖
 1.103 
92
  
 
 
 
9
3
 
Analysis of a structure such as a molecular dynamics simulation snapshot allows the frequencies 
at which a molecule will vibrate in each of its harmonic modes to be determined. This allows Zi 
to be calculated for each mode and thus enables calculation of the entropy. 
In this project, Nmode in the AMBER package used to perform the Normal mode analysis. It 
first uses the Cerjan–Miller algorithm202 to identify the second derivative of the potential energy 
(with respect to position), for each of the atoms in terms of the positions of all of the other 
atoms. The result of this calculation is a 3N×3N matrix (where N is the number of nuclei), 𝒱’’, 
where each matrix element is the force an atom exerts on another multiplied by the geometric 
mean of the masses of the two atoms
166(p275)
. 
To find the Normal modes, an equation is defined which enforces harmonic motion
166(pp274-275)
. 
M-1 2⁄ 𝓥′′M-1 2⁄ x = λx. 1.104 
Where M is a diagonal matrix containing the masses of the atoms (so 𝑴−𝟏 𝟐⁄ 𝓥′′𝑴−𝟏 𝟐⁄  is a 
matrix containing the forces each atom exerts on each other), λ is a column matrix containing 
the energy associated with each normal mode, εi, (the eigenvalues) and x is a matrix (the 
eigenvectors) which attributes each force component to one or more of the normal modes. 
The energies associated with each harmonic of a mode, εi, are multiples of the energy associated 
with the fundamental frequency of that mode, εif, (if the vibrational zero point energy is 
regarded as 0)
166(p275),201(p107,p184)
 and Zi, can be calculated from εi
201(p185)
. 
𝑍𝑖   = ∑𝑒
−𝜀𝑖𝑓𝑛 𝑘𝑇⁄
∞
𝑛=0
  
 =
1
1 − 𝑒−𝜀𝑖 𝑘𝑇⁄
 1.105 
 
Equation 1.105 can be used to substitute for Zi in Equation 1.103
201(p197,p198)
. 
𝑆𝑣𝑖𝑏  = 𝑁𝑘∑[𝑇(
𝜕 ln
1
1 − 𝑒−𝜀𝑖 𝑘𝑇⁄
𝜕𝑇
)
𝑉
+ ln
1
1 − 𝑒−𝜀𝑖 𝑘𝑇⁄
]
𝑖
  
 = 𝑁𝑘∑[
𝜀𝑖 𝑘𝑇⁄
𝑒𝜀𝑖 𝑘𝑇⁄ − 1
− ln(1 − 𝑒−𝜀𝑖 𝑘𝑇⁄ )]
𝑖
 1.106 
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1.5. Molecular Dynamics Simulations and The p53-Mdm2 Interaction 
1.5.1. SIMULATIONS WITH OLIGOBENZAMIDES 
Performing what appear to have been the first binding affinity predictions for Mdm2 made 
using all-atom, explicit solvent molecular dynamics simulations, Fuller et al.
203
 demonstrated 
the successful application of thermodynamic integration (TI) to oligobenzamide inhibitors of the 
p53-Mdm2 interaction. Their study focussed on six molecules with side chains linked through 
oxygen. This project builds on their work, testing a much greater number of compounds to 
determine if such simulations are of practical use with the larger chemical space now 
synthetically accessible to our collaborating chemists. Included are 31 already synthesised and 
tested molecules where side chains are attached via the amide group nitrogen. 
Fuller et al.
172,203
 report how an oligobenzamide appears to be stable when bound to Mdm2 in an 
antiparallel orientation in addition to when parallel to the alignment of the bound p53-helix. 
Their results are based on simulations starting from docking poses generated using Autodock 
where a small docking grid was used, forcing compounds to bind close to the binding site. In 
my work, the greater speed of Autodock Vina permitted a far greater number of compounds to 
be investigated and for them to be docked quickly without restriction of the searched volume to 
the binding site. This enabled key assumptions to be tested, such as the hypothesis that 
oligobenzamides bind in the p53 binding site and the assumption that, if and when they do, they 
bind with each side chain positioned so as to mimic a p53 residue. Fuller’s suggestion that the 
specific combination of side chains could dictate whether parallel or antiparallel binding is most 
efficient, is also investigated.  
Fuller et al. used torsion parameters intended for use with sulphur to model the intramolecular 
hydrogen bonding between the side chain-linking oxygen and amide group hydrogen (p69). In 
this project, more recently published parameters for use with oxygen were tested to see if they 
also yielded stable simulations. 
The results of Fuller et al. suggested that the effect of multiple side chain modifications could 
be predicted in a single TI analysis in which all of the side chains were simultaneously 
transformed
203
. However, predicting the relative affinity of a large number of molecules by TI is 
still impractical. The paradigmatic model of an oligobenzamide inhibitor in which each side 
chain mimics a single amino acid suggests that side chains could make independent 
contributions to the binding energy which could be summed to predict the relative binding 
energy of a compound with any side chain combination. In this project, I investigate if this 
independence is observed or whether the concerted transformation of all side chains is essential 
if accurate affinities are to be obtained. 
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1.5.2. OTHER SIMULATIONS OF THE P53-MDM2 INTERACTION 
Molecular dynamics simulations have been used extensively to study the p53-Mdm2 
interaction. 
The p53 residues Phe19, Trp23 and Leu26 are known to contribute significantly to the binding 
energy of the p53-Mdm2 interaction
26
. Espinoza-Fonseca et al.
204
 studied the duration of 
interactions between aromatic residues of p53 and Mdm2 and concluded that interactions 
between Phe19 and Trp23 of p53 and Tyr51 and Tyr63 of Mdm2 played a key role in 
recognition. Verma et al.
205
 have investigated how the polyphenols quercetin and taxifolin bind 
to Mdm2 and how they might displace p53 from the binding site by disrupting its interaction 
with the side chain of Tyr51. 
Alanine scanning has been performed on p53 in silico using the MM-PBSA method to estimate 
the affinity of mutated peptides
195
. In such experiments, a simulation of the protein is performed 
for each residue with the residue side chain replaced by a methyl group. Applied to p53 in the 
human p53-Mdm2 interface, the method correctly identifies Phe19, Trp23 and Leu26 as 
residues critical for binding
195
. Zhong and Carlson
206
 performed alanine scanning on Mdm2 and 
identified Leu54, Ile61, Met62, Tyr67, Glu72, Val93, His96 and Tyr100 as important for p53 
binding. 
Ding et al.
207
  used quantum mechanical simulations to study the key interacting residues of 
p53-Mdm2. They identified p53 residue Leu22 as also important; although, they concluded that 
overall the p53-Mdm2 interaction was driven by van der Waals forces rather than specific 
residue-residue interactions. 
Espinoza-Fonseca et al.
208
 used molecular dynamics to compare the dynamics of Mdm2 with 
and without bound p53. Their simulations reveal that p53 stabilises the flexible p53 binding site 
of Mdm2 when it binds. Joseph et al.
43
 investigated how the Mdm2 binding site is more flexible 
than the Mdm4 binding site, a feature which appears to allow Nutlin-3 to bind much more 
strongly to the former than the latter.  
Shan et al.
209
 used simulations, as well as NMR, to investigate whether the second of the two 
p53 transactivation domain subdomains interacts with Mdm2 (in addition to the first subdomain, 
which contains Phe19, Trp23 and Leu26). They found that it did, but did not undergo binding-
induced folding like the first subdomain does. 
Dastidar et al.
210
 have discovered that the N-terminal part of Mdm2 can influence p53 binding 
through its effect on the conformation of Tyr100. Dastidar et al.
211
 have also used simulations to 
study the dynamics of the first 24 residues and how these dynamics are influenced by Ser17 
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phosphorylation and mutation of Ser17 to aspartate. Because this N-terminal region can block 
access to the p53-binding site it is absent from the constructs used in this project (p32). 
Using Brownian dynamics
212
, ElSawy et al.
213
 have investigated the binding of p53 and a Nutlin 
to both Mdm2 and Mdm4 over a longer timescale than can typically be studied in a molecular 
dynamics simulation. Specifically, they studied the transient interactions which p53 forms with 
each protein prior to formation of the stable bound state. p53 appears to interact with the N and 
C termini of Mdm2 before it reaches its binding site. 
In this project, implicit solvent methods including the MM-GBSA method (p88) were used to 
predict the relative affinities of oligobenzamides for Mdm2. Chen et al.
214
 describe their use of 
the MM-GBSA method to predict the relative binding energies of four small molecules (a 
benzodiazepinedione, a chromenotriazolopyrimidine, a Nutlin and an imidazolylmethylindole 
derivative) for Mdm2. The results correlated well with previously published, experimentally 
determined binding affinities. 
 
The aim of this chapter has been to introduce the motivations for, background of and theory 
behind this project, in preparation for the subsequent results chapters. This chapter does not 
introduce the statistical methods employed in the project; these can be found in Appendix A 
(p290). 
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2. In Silico Predictions Suggest Oligobenzamide Side Chains Do 
Not Make Independent Contributions to the Binding Energy 
 
 
 
2.1. Summary 
 
This chapter concerns the docking of oligobenzamides into the crystal structure of Mdm2, the 
simulation of these oligobenzamides bound to Mdm2 and analysis of the results to discern the 
complex relationship between the choice of scaffold and side chains and the binding pose and 
predicted affinity of an oligobenzamide. 
The paradigmatic model of oligobenzamide binding places the chains of the peptidomimetic in 
separate binding pockets, those usually occupied by the side chains of p53 residues Phe19, 
Trp23 and Leu26. Initially, such an arrangement was assumed and the properties of a side chain 
within each binding pocket likely to increase the affinity of a bound oligobenzamide were 
identified. Specifically, the ZINC database, a database of commercially available small 
molecules, was used to generate side chains which could potentially be added to an 
oligobenzamide scaffold and then, in silico, these side chains were systematically attached to a 
docked oligobenzamide and docking scores were obtained. The docking scores of 
oligobenzamides which differed in their side chain at a single side chain attachment position 
were then compared to attribute the differences in score to side chain properties. 
It was not possible to test the predictions made using the ZINC database due to the large number 
and synthetic intractability of the compounds. Consequently, subsequent work focussed on the 
analysis of a smaller number of molecules and the production of more accurate binding affinity 
predictions using molecular dynamics simulations. 
All-atom molecular dynamics simulations of oligobenzamides demonstrated that stable 
stimulations could be started from the poses generated by docking oligobenzamides into Mdm2 
from PDB (www.rcsb.org
36
) structure 1T4F. Thermodynamic integration (TI) was used to 
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modify the side chains of an N-alkylated oligobenzamide
98
 (the N1 scaffold molecule shown in 
Figure 2.1, p102) and the results were used to produce a set of predicted affinities for 31 
compounds which had previously been synthesised and for which laboratory data was available. 
TI was also used to investigate the effect of attachment atom modification in the O1 and S1 
scaffolds (Figure 1.6, p36) and to investigate the importance of certain scaffold torsion 
parameters for the accurate prediction of binding affinity. 
The correlation between experimental and predicted results for the 31 small molecules based on 
the N1 scaffold was statistically significant but small. Subsequent analysis of more extensive 
docking results by logistic regression suggested that side chain changes permit a wide variety of 
different binding poses, a possibility alluded to by Fuller
172
. The results implied that, for 
oligobenzamides, binding energy was a property of the combination of side chains rather than 
being the sum of independent contributions attributable to each side chain. This finding 
advocated a new approach whereby side chain combinations as opposed to individual side 
chains were tested. 
The large number of possible side chain combinations meant that, to investigate each one, a 
method which enabled a binding affinity to be derived from a single simulation was required. 
The Molecular Mechanics-Poisson Boltzmann Surface Area (MM-PBSA) and Molecular 
Mechanics Generalised Born Surface Area (MM-GBSA) implicit solvent methods allow this. 
Predicted binding energies generated using these methods were more closely correlated with 
experimental results. However, the correlation was only moderate. Future work would ideally 
use long simulations but the necessity to carry out simulations for every combinatorial library 
member in different binding poses could make this impractical. A possible compromise would 
be to treat each combination individually when docking and then, once the likely binding site of 
each possible ligand had been identified, investigate each side chain individually within each 
binding site. To investigate the interaction of factors which could affect affinity and test whether 
side chains made independent contributions to the binding energy both overall and within a 
particular binding pose (as assumed in the aforementioned proposition), predictions were made 
for a large number of compounds based on different scaffolds and analysis of variance 
(ANOVA)
215
 was performed. 
ANOVA tests are more reliable with complete data (when side chain interactions are being 
investigated, results for every possible side chain combination); however, the production of 
poses within a specific site for every member of a combinatorial library is a challenge. Initial 
testing with O-alkylated oligobenzamides used docking pose optimisation (Autodock “local” 
docking) to ensure that a pose was generated for every library member close to the paradigmatic 
binding pose. However, trajectory analysis with the MM-PBSA method yielded positive free 
energies of binding, which suggests that the results were unreliable. Consequently, subsequent 
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work used standard docking results from which poses within four specific and common binding 
poses were identified and the problem of missing data (having no binding pose for some 
molecules) was solved using impution. 
The ANOVA results suggest that there is a statistical interaction between the side chain choices 
when treated as ANOVA factors. If binding poses are segregated by binding position prior to 
analysis, a small interaction is still observed, indicating that the aforementioned interaction 
between side chains is not solely due to the influence of side chains on where binding occurs. 
However, the extent of the interaction is much reduced. 
At the end of this chapter, which describes the entirety of the computational work performed in 
this project, it is hypothesised that the lack of a high correlation between computational and 
experimental results could be partly attributable to error in the laboratory assay used for 
prediction validation. The need for an orthogonal method to assess binding affinity is 
highlighted. The development of such an assay is the subject of Chapter 3. The validation of 
predicted binding poses is also proposed due to the variety of poses predicted by docking. Small 
molecule binding positions can be probed using NMR and this is the subject of Chapter 4. 
Key research outcomes described in this chapter: 
 Identification using FlexX of the properties of side chains in the Phe19, Trp23 and 
Leu26 binding sites associated with increased binding affinity, most notably the need 
for a large side chain in the Trp23 site and a flexible one in the Leu26 site. 
 Discovery that oligobenzamides can bind to Mdm2 in many different places depending 
on the choice of side chains. 
 Discovery of a robust, moderate correlation between the predicted and experimentally 
determined oligobenzamide binding affinities for Mdm2 when using implicit solvent 
methods. 
 Discovery that there is a statistical interaction between the effects of side chains at 
different positions on the affinity of an oligobenzamide within a particular binding site 
but that this interaction is relatively small in magnitude. 
 Identification of oligobenzamides where side chains are attached through sulphur at the 
ortho ring position as warranting further investigation due to the availability of 
parameters for this scaffold and the stronger binding of this scaffold relative to the 
corresponding one with oxygen-linked side chains suggested by thermodynamic 
integration results. 
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2.2. Methods 
2.2.1. PDB STRUCTURE PREPARATION 
Compounds were docked into a static structure derived from PDB (www.rcsb.org
36
) structure 
1T4F
37
. Structure 1T4F features Mdm2 bound to a peptide with a sequence resembling that of 
the p53 transactivation domain. The p53 peptide was removed by manual editing and the 
remaining structure was protonated using the H++ server (http://biophysics.cs.vt.edu/) as 
appropriate for pH 7. The server was also used to predict the orientation of side chain amide 
groups and the imidazolyl group orientation and δ/ε tautomerisation of each histidine. pKa 
values were calculated using the default internal and external dielectric constants of 6 and 80 
respectively and the salinity was also left at its default value, 150 mM. 
2.2.2. COMPOUND 3D STRUCTURE PRODUCTION 
2.2.2.1. The scaffolds and side chains 
All of the compounds investigated in this project have a core structure corresponding to one of 
five scaffolds, the N1 scaffold, the O1 scaffold, the S2 scaffold, the O2 scaffold or the S2 
scaffold. These are shown in Figure 1.6 (p36). 
The compounds shown in Figure 2.1 (p102), hereinafter referred to as the “starting molecules”, 
are based on these scaffolds. All of them have the side chains benzyl, napthylmethyl and 
isobutyl. These correspond to the side chains of the amino acids Phe19, Trp23 (actually 3-
indolylmethyl in tryptophan) and Leu26 of p53 so these molecules might be expected to bind 
tightly to Mdm2. 
Rough 3D structures of these molecules (input as Daylight SMILES
216
) were generated using 
Obgen, a program of the Open Babel open source suite of tools (suite version 2.2.3)
217
. The 
stereochemistry of the molecules was checked where applicable. Then, these were minimised 
using the Obminimize program of the same suite. The mmff94s force field
218
 was used. Up to 
10,000,000 steps of conjugate gradient minimisation were performed with Obminimize. The 
required convergence for termination prior to the maximum number of cycles being reached 
was set to 110-8 kcal mol-1 Å-1. The number of steps and convergence were increased from 
their default values of 2500 and 110-6 kcal mol-1 Å-1 because it was thought that further 
minimisation of the small number of side chains might reduce the amount of time required to 
minimise each member of the large combinatorial library subsequently produced by the 
attachment of these side chains to a scaffold. 
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 N1 O1 (X=O) and S1 (X = S) O2 (X=O) and S2 (X = S) 
 
  
 
Figure 2.1: Model compounds for each oligoamide scaffold, which were used as the starting point 
for further modification to produce all of the compounds tested. Five compounds are indicated, the 
N1 starting molecule, the O1 starting molecule, the S1 starting molecule, the O2 starting molecule and the 
S2 starting molecule. The bonds shown in red were the bonds cut to modify the side chains unless 
otherwise stated. Dashed lines show the location of the intramolecular hydrogen bonds present in the 
scaffolds with O-linked and S-linked side chains. 
 
The five molecules shown in Figure 2.1 were used as the starting point for generating all of the 
oligobenzamide structures discussed in this project. In initial work using the ZINC 
database
219,220
, chains were modified using the high-throughput screening software ReCore and 
the docking software FlexX (BioSolveIT)
149
. (See p106 for details.) However, in subsequent 
work, which will now be described, molecules containing the side chains to replace those on the 
five starting molecule structures (Figure 2.1) were generated using Obgen and Obminimize (as 
described above) and then the side chains were spliced on to one of the five starting molecules 
using custom software (Side Chain Splicer, p105). The side chains are shown in Figure 2.2. 
They were selected on the basis of the compounds the collaborating chemistry group had made 
or planned to synthesise. Minimisation with Obminimize was repeated after splicing using up to 
10,000 steps of conjugate gradient minimisation with a required convergence of 110-7 kcal 
mol
-1
 Å
-1
. 
The 3D structure of each side chain was generated attached to one of the units shown in Figure 
2.3 (p105) before it was spliced onto one of the scaffold structures. These units were used to 
promote establishment of an extended side chain conformations which would not sterically 
clash after subsequent attachment to the scaffold. 
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Continued on the next page… 
Figure 2.2: The side chains used in this project. Different investigations used different sets of side 
chains. The set used in each investigation are given in the results section. The R group is inductively 
electron withdrawing because the atom attaching the side chain to the scaffold is nitrogen, oxygen or 
sulphur. Consequently, for example, the imidazole isomer shown in 13 is the most stable protonation state 
in an oligobenzamide, unlike in histidine where the side chain is attached through carbon so is subject to 
inductive electron donation. 
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Figure 2.2 continued from the previous page. 
 
At times in this project it was necessary to choose which side chains to investigate at each side 
chain attachment position. The number of side chains used for a particular investigation was 
decided with the total required computation time in mind. With regard to each attachment 
position, some consideration was given to the size of the Phe19, Trp23 and Leu26 side chains 
which the oligobenzamide side chains are intended to mimic. Specifically, side chains with two 
or more aromatic rings were only tested at the middle side chain position and there was bias 
towards the testing of aromatic side chains at the N-terminal position and aliphatic side chains at 
the C-terminal attachment position. However, there was also a desire to test a large chemical 
space, especially where it included structures which might soon be made in the collaborating 
chemistry group. 
Throughout this project, conversions between Structure Data File (SDF) files (Molecular 
Design), Mol2 (Tripos) and PDB formats were performed using the Babel program of Open 
Babel
217
. This program was also used to protonate of molecules unless otherwise stated. 
The Filter program from the Open Babel suite was used for the calculation of molecular 
properties. These properties included the topological polar surface area (PSA) and XlogP. The 
PSA of a species is the exposed van der Waals surface of the polar atoms in the molecule and 
their attached protons. The topological PSA is an accurate estimate of the true PSA calculated 
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by summing pre-calculated fragment contributions
221
. As indicated in Equation 2.1, the partition 
coefficient of a species is the ratio of the concentrations of its unionized form in each layer of a 
mixture of water and octan-1-ol, two immiscible solvents. 
𝑃𝑋 =
[𝑋]octan-1-ol
unionised
[𝑋]water
unionised
 2.1 
In similarity to the topological PSA, the XlogP
222
 is an estimate of the logP determined by the 
summation of predetermined logP contributions for the different parts (in this case atoms) of the 
molecule. 
 
a   For attachment to the N1 scaffold 
 
b   For attachment to the other scaffolds 
     O (X=O) and S (X = S) 
   
Figure 2.3: The units holding the side chain, taking the place of the scaffold, when 3D structures of 
each side chain were generated. Three molecules are indicated, one to generate side chains for 
attachment to the N-linked scaffold (a), one for attachment to the O1 and O2 scaffolds (b, X=O) and one 
for attachment to the S1 and S2 scaffolds (b, X=S). 
t
Bu signifies a tert-butyl group (-C(CH3)3). These 
molecules were used to encourage the production of extended side chain conformations which would not 
sterically clash with the scaffold when attached. 
 
3D depictions of ligands and proteins herein were, unless otherwise stated, produced using the 
UCSF Chimera package
223
, which is developed by the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco, and supported by 
grant NIGMS P41-GM103311. 
2.2.2.2. Custom Splicing Software: Side Chain Splicer 
Custom software, Side Chain Splicer, was used for splicing. Written in Perl, it uses 
trigonometric functions to calculate how atoms must be moved and then to apply these 
transformations to the atoms concerned. 
The software accepts as input the structures of the two molecules to be joined (in Mol2 format) 
and the numbers of 6 atoms: 
 Those either side of the bond to be cut in the first molecule. 
 Those either side of the bond to be cut in the second. 
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 A third atom in each molecule which, together with the atoms either side of the bond, 
defines a plane through each molecule. These two planes (one through each molecule) 
are lined up following splicing by rotation of the component from the second molecule 
(the side chain) around the axis defined by the bond created. 
Further details: 
 The first molecule is not translated or rotated so it can be in a docked pose. 
 The length of the bond created is the mean length of the bonds cut. Wherever possible, 
identical bonds were cut so the resulting bond was the correct length. (In other cases, 
minimisation with Amber
224–226
 was applied following splicing, which will have 
regularised the molecular geometry.) 
 In the output file, the atoms of the final molecule comprise the atoms from the first 
followed by the atoms from the second. The order of the atoms in each molecule is 
unchanged. In this project, the scaffold atoms in the starting molecules (p101) preceded 
those of the side chains. This enabled the production of combinatorial libraries in which 
the core oligoamide backbone atoms had identical numbering. 
All of the custom software used in this project is of my own creation. 
2.2.2.3. Preliminary work using the ZINC database and ReCore 
As described in the results section (p128), oligobenzamides with a diverse range of side chains 
were docked using FlexX. The aim was to identify the side chain properties likely to increase 
the affinity of an oligobenzamide acting as a peptidomimetic with its side chains in the sites 
usually occupied by p53 residues Phe19, Trp23 and Leu26. 
1171 side chains were tested attached to the O1 scaffold using the ReCore high-throughput 
screening and FlexX docking software, two parts of the LeadIT package (BioSolveIT) (version 
1.0.2)
133
. The software enables a set of molecules to be cleaved to produce fragments. ReCore 
allows these fragments to be screened using a pharmacophore model and FlexX facilitates the 
subsequent combinatorial docking of a scaffold to which these side chains have been attached. 
The filtering, screening and docking will now be described in more detail. 
ZINC is a database of commercially available compounds (http://ZINC.docking.org/)
219,220
. The 
unprocessed source molecule dataset (9,959,338 molecules at the time) was downloaded from 
the ZINC database in Daylight SMILES
216
 format. These input molecules were filtered to 
identify molecules which could be used in oligobenzamide synthesis to attach a side chain. In 
tribenzamide synthesis, each of the three monomers is synthesised separately, a process which 
includes attaching the side chain. Then, these three monomers are joined together to produce the 
tribenzamide. In the first of these two steps, side chain attachment can be through an SN2 
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substitution, using a primary or secondary hydroxyl group or halide on the side chain donor 
molecule as a leaving group
49
. There must be only one leaving group of the same or higher 
leaving group ability for the correct reaction to occur. Alternatively, a BAc2 reaction can be 
carried out using an acyl chloride. This creates an ester link between the aminobenzoic acid unit 
and the new side chain. If an acyl chloride group is used, there can be no group of equivalent or 
greater reactivity in the molecule donating the side chain.  
When the aminobenzoic acid monomers are joined together to generate the oligobenzamide, the 
amino group of each monomer must act as a nucleophile and react with the preceding activated 
monomer
49
. There must be no better nucleophile present in any of the side chains (for example, 
a sulphydryl group) because this would react in preference to the amino group. In addition, no 
group must be more reactive than the nucleophilic group on the oligobenzamide which the 
amino group must attack. The nature of this group is dependent on the coupling agent used. 
While it may be difficult to assess every side chain individually for inductive and mesomeric 
effects, which will subtly affect the reactivity of functional groups, molecules with groups 
which are commonly very reactive, such as those with an acyl chloride group, can be excluded 
as necessary.  
Filtering was carried out with the aid of Filter (OpenEye Scientific Software) (version 2.0.2). 
Molecules with a primary or secondary halogen atom, a primary or secondary hydroxyl group or 
an acyl chloride group were identified. Further filters were used to ensure synthetic 
accessibility. Firstly, molecules were filtered to ensure that they did not have one of a number of 
reactive groups for which filter information was supplied with the ReCore software
227
. 
Secondly, molecules were only used if they would produce a small side chain (Mr ≤ 500). 
Otherwise, the side chain added would be of an unsuitable size and the compound might be 
difficult to make or expensive to purchase. Thirdly, only molecules yielding a side chain with 
40 or fewer rotatable bonds were used because compounds with small side chains are easier to 
dock and have a smaller conformational space to sample in any subsequent molecular dynamics 
simulations. Finally, only molecules containing just the atoms hydrogen, carbon, nitrogen, 
oxygen, sulphur, phosphorus, fluorine, chlorine, bromine and iodine were used, to remove 
exotic molecules which might have unusual chemistry. 1171 suitable molecules, which could be 
used to attach a particular side chain, were identified. 
Open Babel
217
 was used to generate all of the ionisation states of these molecules which would 
predominate at pHs between pH 5.0 and pH 9.5 (as SMILES). 
The reactive hydroxyl, halogen or acyl chloride group, was removed and replaced with the 
group shown in Figure 2.4. The SMILES were modified using a custom Python program 
utilising the OEChem Python wrapper from the OEChem Toolkit (OpenEye Scientific 
Software) (version 1.4.2). This process created the bond shown in blue in Figure 2.4. 
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Figure 2.4: The structure joined to ZINC source molecules prior to ReCore cleavage. Attachment 
created the blue bond. The red bond was then cleaved by ReCore, so that every side chain had an oxygen 
atom which could be used later to orientate it in high-throughput screening. 
 
3D structures were generated from the resulting SMILES using Omega (version 2.3.2) 
(OpenEye Scientific Software). The aromatic unit attached was intended to mimic the scaffold 
during structure generation and encourage the formation of an elongated side chain structure, in 
the same way as the units shown in Figure 2.3 (used in subsequent work). The default force 
field was used (a variant of the MMFF94s field
218
 which lacks the electrostatic interaction 
terms). Up to 400 conformers with a strain energy within 10 kcal mol
-1
 of the minimum were 
produced per molecule, subject to a maximum run time limit of 2 minutes for each molecule. 
Any non-planar nitrogen atoms were inverted and where side chains contained aliphatic rings, 
different ring conformations were generated. 
The 3D structures were cleaved using ReCore to produce fragments. The bond cleaved is shown 
in red in Figure 2.4. Ultra-high throughput screening of the possible side chain fragments was 
then carried out using ReCore. In ReCore, the problem of finding a side chain that fits between 
a scaffold and a protein binding pocket is simplified to a search for groups with a particular 
pharmacophore feature (for example, a hydrogen bond donor) in the correct orientation relative 
to the leaving bond vector (the direction of the bond which would connect the fragment to the 
rest of the molecule). In this screening, the oxygen introduced above using the OEChem Toolkit 
was specified as a hydrogen bond donor pharmacophore feature. 
Screening with ReCore is fast because although the possible side chains are rotated relative to 
the core structure, there is no rotation about any of the bonds within the core or the side chain. 
FlexX was used to dock oligobenzamides with side chains that passed the ReCore screening 
process, as described in the next section. 
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2.2.3. DOCKING 
2.2.3.1. FlexX 
In initial work, fragments derived from ZINC database molecules were generated using 
software from BioSolveIT, ReCore
133
 and FlexX
149
 (version 1.0.2). In FlexX docking, a core 
fragment is first positioned and then this core is incrementally appended with side chains until 
the fully docked compound has been produced. Each addition is repeated and the highest-
scoring poses are selected for the next stage. FlexX
c
, an extension of FlexX was used to dock a 
library of compounds in the form of a core structure and possible side chains (generated using 
ReCore). FlexX uses an empirical scoring function
228
. FlexX scores mentioned herein are given 
in units of kJ mol
-1
. 
Initially, the three side chain positions were considered separately (one after the other). When 
each side chain was tested, the core docked by the software comprised the scaffold and the other 
two side chains. FlexX rotates this invariant, core component by a few degrees to generate an 
ensemble of structures on to which potential side chains can be joined. After each possible side 
chain has been attached to one of the core poses, the resulting structure is optimised to generate 
the final docking pose. 
Poses were filtered using the software; only solutions where the root mean square deviation 
(RMSD) (p78) of the core and unmodified side chain atoms from their starting position was less 
than 2 Å were considered. 
2.2.3.2. Autodock 4.2 
Although FlexX was used initially, there is a deficiency in the FlexX scoring function, namely, 
its lack of terms to explicitly account for ligand and protein desolvation upon binding
229
 (p130). 
Consequently, subsequent docking was performed using Autodock 4.2151 and then, later, with 
Autodock Vina
152
. The top pose generated by Autodock 4 using the O1 scaffold starting 
compound (Figure 2.1) has all three side chains in precisely the positions of the Phe19, Trp23 
and Leu26 side chains of p53, suggesting Autodock 4 docking is accurate (Figure 2.8, p129) 
and Autodock 4 does have terms to account for desolvation. 
Autodock has no feature corresponding to the combinatorial docking of FlexX, which allows 
side chains to be attached to a core. Consequently, when using Autodock 4, side chains were 
attached using custom software (Side Chain Splicer, p105). The scaffold starting molecule 
(p101) was docked using standard docking (hereinafter referred to as “global docking”), the 
pose was exported, the side chains were swapped using Side Chain Splicer and then the binding 
position was optimised using Autodock (a process hereinafter referred to as “local docking”). 
The default pseudo-Solis and Wets local search method
156,230
 was used  for this optimisation. 
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Autodock 4 requires that a 3D search space be defined. Docking of the O1 starting compound 
using a box size greater than the size of the protein, allowing any possible binding position, did 
not yield poses around the p53 binding site. PDB structure 1T4F, from which the Mdm2 
structure used for docking was extracted, comprises p53 bound to Mdm2. Using the cubic 
volume shown in Figure 2.5, which has sides of length 38.4 Å and is centred on the alpha 
carbon of Phe19 in the p53, did generate the expected binding pose of this molecule (Figure 2.8, 
p129). 128 grid points, 0.3 Å apart were used in each dimension. This is a bigger box than was 
used in earlier work by Fuller et al.
203
 (22 x 22 x 18 Å). 
 
 
Figure 2.5: The volume of the Mdm2 structure from PDB 1T4F which was used for initial docking 
with Autodock 4. The cubic space shown has sides of length 38.4 Å and is centred on the alpha carbon of 
Trp23 in the p53 helix in structure 1T4F (not thrown). 
2.2.3.3. Autodock Vina 
Docking the O1 scaffold starting molecule (Figure 2.1) with Autodock Vina yielded the 
expected pose along with other plausible arrangements of the ligand. 
25,000 compounds with different side chains were docked using Autodock Vina to investigate 
the effect of side chain properties on binding pose. Whereas it is impractical to dock a large 
number of compounds in this way using Autodock 4.2, necessitating docking of the scaffold, 
attachment of the side chains and then optimisation of the docking pose, the search algorithm of 
Autodock Vina is much faster (p63). 
The results of the global docking revealed that oligobenzamides could theoretically bind to the 
Mdm2 structure in many different places. Consequently, because it enabled a wider search for 
possible binding positions, docking prior to simulations was, unless otherwise stated, performed 
using Autodock Vina. 
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Autodock Vina adjusts the amount of time spent searching for the best pose according to the 
number of atoms and number of degrees of freedom of the molecule being docked; however, it 
has a setting, the exhaustiveness, which can be used to change the balance between speed and 
search comprehensiveness if necessary. The makers of Autodock Vina do not reveal how this 
arbitrary setting is used by the program, only that the amount of time spent searching for the 
highest-scoring pose varies approximately linearly with the value set
231
. In this project, 
Autodock Vina was run with the exhaustiveness set to the default value of 8 unless otherwise 
stated. The appropriateness of this setting was evaluated as discussed in the results section 
(p186). 
A search volume does not have to be defined with Autodock Vina and the program clusters 
poses by RMSD prior to output in an automated manner transparent to the end user
152
. (An 
RMSD cut-off does not have to be specified and no details of the structures prior to clustering 
are printed.) 
2.2.3.4. Re-protonation of docking poses 
To accelerate the docking process, Autodock 4 and Autodock Vina merge all non-polar 
hydrogen atoms (hydrogen atoms bonded to carbon) with their carbon atom, and treat each 
hydrocarbon unit (CH, CH2 or CH3) as a single, united atom. In the docking output, the united 
atom positions were treated as the positions of the carbon atoms and the non-polar hydrogens 
were added to these using Open Babel
217
. To add these protons, all hydrogen atoms were 
removed from the poses and then complete protonation was performed. With the exception of 
some renumbering of chemically identical hydrogen atoms on the same carbon, this method 
ensured consistent hydrogen atom numbering. This made it easier to transfer RESP charges to 
the resulting poses for molecular dynamics simulations as discussed in the next section. 
2.2.3.5. Pose recognition 
Autodock Vina automatically clusters poses prior to their output
152
. In this project, large 
numbers of compounds with different structures were tested, necessitating further sorting of all 
the docking results. Oligobenzamides were found to be able to bind in a disparate assortment of 
conformations so further clustering was not appropriate (p153). Instead, poses were 
computationally categorised based on the position of the side chains and rings of the scaffold in 
each molecule relative to the binding sites of p53 residues Phe19, Met20, Tyr22, Trp23 and 
Leu26 in the 1T4F crystal structure, the structure from which the Mdm2 structure used for 
docking had been extracted. Side chains were considered to be within a pocket if the centre of 
mass of the heavy atoms comprising the side chain (everything except for the hydrogen atoms) 
was within either 3 or 4 Å of the centre of mass of the heavy atoms of the p53 residue in 
question. (The cut-off was set on a case by case basis, as indicated in the results section.) 
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Hydrogen atoms were not used because 1T4F is a crystal structure so does not contain hydrogen 
atoms due to their small cross section. 
Large cut-offs were used to reduce the chance of false negatives. In a small number of cases, a 
side chain centre of mass had a position such that it fell within the cut-offs of both of two 
adjacent binding sites. Poses for which this occurred were discarded prior to further analysis. 
2.2.4. PARAMETERS 
2.2.4.1. Parameters used for FlexX docking 
FlexX docking was only performed with compounds based on the O1 scaffold (shown in Figure 
1.6, p36). Rotation about the amide carbon to aromatic carbon bonds of the scaffold is possible 
because steric hindrance prevents the amide and aromatic ring atoms from lying in the same 
plane. Consequently, the amide and aromatic ring atoms do not form a large rigid conjugated 
system as is the case in benzamide
171
. In contrast, intramolecular hydrogen bonding means that 
rotation about the aromatic carbon to amide nitrogen bonds on the other side of the amino 
groups is discouraged. The FlexX torsion angle energies were modified so that they more 
accurately reflected these two effects (Table 2.1). No data were available for systems with an 
oxygen atom ortho to the amide group. Consequently, published parameters for the 
corresponding bond in thiomethyl acetaniline
171
 (where sulphur replaces the oxygen) were used. 
Fuller et al.
172
, who performed molecular dynamics simulations with these parameters, claim 
that this approximation is reasonable, citing the more recent work of Liu et al., who have 
derived torsion parameters with both oxygen and sulphur and shown them to be similar. 
Table 2.1: The AMBER force field torsion potential parameters for docking in FlexX  
 
Torsion PK /kcal mol-1 Phase /° N 
ca-ca-n-c 2.617 0 3 
0.115 0 2 
4.507 0 1 
n-c-ca-ca 2.075 0 2 
These parameters are not entered into FlexX; they were used to calculate the torsion-associated potential 
energies at 10° intervals which were then used to modify the FlexX torsion_fine.dat file. In the AMBER 
force field, the torsion energies are modelled using cosine waves, each with a height (PK), phase and 
periodicity (N). The first bond (the green torsion in Figure 2.6A) is best described using three of these 
components. The second (the red torsion in Figure 2.6A) requires only one. IDIVF=1. In subsequent 
simulation work, both torsions were modelled using a single trigonometric term. 
 
The new parameters generated by Liu et al.
173
 were used for molecular dynamics simulations in 
this project, making the simulations here described the first O-ortho and O-meta-substituted 
trimeric oligobenzamide simulations to be performed with the correct torsion parameters for the 
bonds about which rotation is restricted due to intramolecular hydrogen bonding. 
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2.2.4.2. Parameters used for Autodock docking 
Although torsion parameters were modified for FlexX docking and for molecular dynamics 
simulations, the Autodock 4.2 and Autodock Vina scoring parameters were not modified for the 
following reasons: 
1. The parameters of Liu et al.173 mentioned in the previous section had not been published 
at the time docking began. 
2. Whereas FlexX was only used with O1 scaffold compounds, Autodock was used with 
all five scaffolds. Use of modified parameters for some scaffolds but not others could 
have introduced bias preventing the fair comparison of results. 
3. The parameters supplied with the Autodock software had been rigorously validated for 
use with the Autodock software, unlike any parameters they would be replaced with. 
4. Docking of the O1 scaffold starting molecule with Autodock 4.2 appeared to place it in 
a plausible pose with each side chain appearing to mimic the side chain of a p53 residue 
(Figure 2.8, p129). 
5. Searching is faster in Autodock 4.2 if the torsion angles in the backbone are held rigid. 
6. The end user is not expected to modify the parameter files of Autodock Vina. 
 
The torsion angles were fixed when docking with Autodock 4 (but not Vina) in the cis 
conformation so the side chains were on all on one side of the molecule. This is the same 
procedure which was used by Fuller et al.
203
. 
2.2.4.3. Parameters used for molecular dynamics 
Difficulties with synthesis of the target molecules meant that only a few compounds were 
available for the validation of computational results. Consequently, as the project progressed, 
the focus shifted from the generation a large number of estimated binding affinities to the 
production of a smaller number of more accurate predictions, necessitating the simulation of 
oligobenzamides (discussed in the next section). 
Parameters for simulations came from the General AMBER Force Field (GAFF) (version 1.4)
226
 
with the exception of some torsion parameters. The torsion parameters for the bonds connecting 
the aromatic rings in the scaffold (three: ca-n, n-c and c-ca where ca represents aromatic carbon 
and c and n represent the sp
2
-hybridised carbon and nitrogen atoms of the amide group 
respectively) were set to previously published AMBER force field parameters (in the case of the 
amide bond
171
 and torsions affected by intramolecular hydrogen bonding
173
) or (in the case of 
the ca-n and c-ca torsions in the absence of intramolecular hydrogen bonding) were calculated 
from previously published torsional barrier heights
175
. The parameters for the latter barrier 
heights were calculated by subtraction of the total increase in AMBER 1-4 electrostatic and 1-4 
van der Waals energies associated with going from the bottom of the barrier to the top of the 
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barrier from the torsional barrier height. The three torsion angles are highlighted on an 
oligobenzamide in Figure 2.6A. The barrier heights were for 4-(4-aminobenzamide)benzoic acid 
(Figure 2.6B). The 1-4 interaction energy (the sum of the electrostatic and van der Waals 
components between atoms at either end of the torsion angle) needs to be subtracted because it 
will be calculated and added on to the torsional energy calculated from the torsion parameters in 
Amber when the simulation is run, and the final barrier height in the simulation needs to equal 
the published barrier height. 
 A 
    
B 
    
Figure 2.6: Structures relevant to the calculation of the oligobenzamide scaffold torsion parameters 
used in this project. A) An oligobenzamide with the bonds for which the torsion energies were modified 
indicated with coloured arrows. The colours correspond to those shown in the header row of Table 2.2. B) 
4-(4-aminobenzamide)benzoic acid, the compound used as a model for bonds not affected by 
intramolecular hydrogen bonding when calculating parameters. 
 
The 1-4 interaction energies for 4-(4-aminobenzamide)benzoic acid were calculated at 10° 
intervals (Figure 6.4, p310) using Amber. At each 10° point, the bond being rotated was fixed 
and the rest of the structure was minimised by steepest descent minimisation. Every point from 
0° to 350° was actually tested for both of the ca-n and c-ca bonds because, despite the apparent 
partial symmetry of the molecule (Figure 2.6B), which suggests that the interaction energy 
should only need to be measured for torsion angles from 0° to 90°, in practice some variation 
was observed for the n-ca bond energy across the whole torsional space. The carboxylic acid 
group on the end of the molecule was left protonated, making the compound asymmetrical, and 
the use of steepest descent minimisation meant that the 180° flip of this terminal carboxylic acid 
necessary to completely minimise the energy in some cases was not possible. Where the 
energies for two torsion angles differed even though the symmetry of the molecule suggested 
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that they should be identical, the minimum energy of the two was taken, as would have been 
obtained using conjugate gradient minimisation (which would have found the global as opposed 
to the local minimum). 
Table 2.2: The oligobenzamide torsional barrier heights used for molecular dynamics (in kJ mol
-1
) 
Scaffold 
Torsional barrier height /kJ mol-1 
ca-ca-c-n ca-c-n-ca c-n-ca-ca 
N1 29.2
a
 70.8
b
 26.0
a
 
O1 29.2
a
 70.8
b
 36.0
c
 
S1 29.2
a
 70.8
b
 42.7
c
 
O2 36.0
c
 70.8
b
 26.0
a
 
S2 21.8
c
 70.8
b
 26.0
a
 
GAFF 121.3 83.7 15.1 
 
The barriers are shown for three key bonds found in the scaffold. The torsions are described using GAFF 
atom types. “ca” represents aromatic carbon and “c” and “n” represent sp2-hybridised carbon and nitrogen 
respectively. These torsion angles are indicated by coloured arrows on the oligobenzamide in Figure 2.6A 
above, where the colour of the arrows corresponds to those used in the header of this table. Five different 
oligobenzamide scaffolds were tested, the N1, O1, S1, O2 and S2 scaffolds.  (See Figure 1.6 (p36) for 
their structures.) The torsion energy parameter entered into Amber (PK), which was specified for the 
whole bond (IDIVF=1), is half the barrier height. There are two peaks per 360° rotation (N=2) and 0° is a 
minimum so the phase is 0. The 29.2 and 26.0 kJ mol
-1
 values are the result of subtraction of the 1-4 
interaction energy from published barrier heights. For details of these calculations see Table 6.5 (p310). 
The bottom row of the table, labelled “GAFF” indicates the parameters for the bonds in the GAFF force 
field (version 1.4)
226
. Most notable is the difference between the ca-ca-c-n barrier height for 
oligobenzamides and the 121 kJ mol
-1
 GAFF barrier height for this bond, which is the result of steric 
hindrance in oligobenzamides rotating the amide carbonyl group out of the plane of the adjacent benzene 
ring
173
. References: a
175
 b
171
 c
173
. 
 
Table 2.2 shows the final barrier heights used. Parameters labelled with superscript “a” were 
produced by subtraction of the 1,4-interaction energy and the calculation is shown in Table 6.5 
(p311). The PK torsion parameters (which determine the height) are half the barrier heights 
shown in Table 2.2 (but in kcal mol
-1
, as required by Amber).  For these torsions, there are two 
peaks per 360° so N is 2. As the minima are at 0° and 180°, the phase parameter is 0. 
Figure 1.6 in the introduction (p36) shows the structures of the five oligobenzamide scaffolds 
investigated in this project. Synthesis was considerably more successful with scaffold N1 than 
scaffold O1.  Consequently, it was important to perform molecular dynamics simulations using 
the N1 scaffold. In the N1 scaffold, the side chains are attached directly to the nitrogen in the 
core of the molecule. Consequently, N1 scaffold oligobenzamides with different side chains 
could potentially have different backbone torsion parameters. As discussed in the introduction 
(p70), because the side chains to be tested comprised both inductively electron withdrawing and 
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inductively electron donating side chains, it was assumed that they did not affect the backbone 
torsion parameters of this scaffold. 
While the previously published AMBER parameters and the aforementioned barrier heights 
(used as a necessity due to the absence of published parameters) were originally validated with 
experimental data, rigorous validation of the parameters used in combination, which was 
considered beyond the scope of this PhD, would ideally be performed prior to their extensive 
use in future work. The results generated using these parameters in this project were consistent 
with experimental results determined by fluorescence polarisation (supplied by Kerya Long, 
University of Leeds) as discussed in the results section (Figure 2.22). 
With regard to the side chains, the Amber
224–226
 parmchk program was used to generate any 
undefined side chain torsion parameters not explicitly given in the GAFF force field. It does this 
automatically either by identifying analogous parameters from the GAFF force field and 
copying them or, in some cases, by empirical estimation. The results of the program were 
checked to verify that all of the necessary parameters had been located or calculated for every 
molecule. 
Protein parameters came from the ff03 force field
232
. The protein was used with Gasteiger 
partial charges
176
. 
2.2.4.4. Calculation of small molecule RESP charges 
RESP partial charges (p70) were calculated for oligobenzamides (as a whole molecule) using 
RESP ESP Charge Derive (RED) (Version II.3 or III.3)
177
. Structures were minimised using 
Gaussian 03 (release D.02)
233
 or Gaussian 09 (release D.01)
234
 using the AM1 method prior to 
calculation of the charges. The charges of the Hartree-Fock molecular electrostatic potential 
grid points were determined using the 6-31G* basis set. 
RESP was used to determine atom-centric charges using the Connolly surface algorithm
235
 with 
restraint weights of 0.0005 and 0.001. The partial charge calculation was performed such that 
chemically identical atoms were assigned equal charges. Identical atoms were identified using 
custom software. (This software uses Babel (OpenBabel) to produce canonical Daylight 
SMILES
216
 for molecules, strings describing the connectivity of molecules, which are 
independent of the atom order in the starting structure and which can therefore be used to 
identify identical molecules.) 
When side chains were swapped using Side Chain Splicer (p105), it was necessary to calculate 
partial charges for the new molecule. It was often desirable to retain the coordinates of the 
atoms but minimisation was required for charge generation. To solve this problem, a custom 
script was used to transfer charges from the minimised molecule, with charges assigned by 
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RED, to the same molecule with different coordinates, for example, the original, posed 
molecule prior to minimisation. 
2.2.5. MOLECULAR DYNAMICS 
2.2.5.1. Creation of molecular dynamics parameter files 
Before molecular dynamics simulations can be carried out in Amber, a coordinate file and a 
parameter file have to be created for the complete system. The coordinate file contains the 
starting coordinates of the atoms. The parameter file contains molecule-specific parameters 
based on the atom types present in the molecule and their connectivity. The coordinate and 
parameter files were generated using the tleap program of the Amber suite. 
The protocol used for production of parameter files using tleap: 
1. The ff03 and GAFF force field parameters were loaded along with any additional 
parameters for the ligand generated by the Amber parmchk program. 
2. The modified torsion parameters (discussed above) were loaded, overriding those 
previously set. 
3. The protein was added to the system followed by the docked ligand. 
4. Cubic periodic boundary conditions were defined and the resulting cube was filled with 
TIP3P water
236,237
. The sides of the cube were orthogonal to those of the x, y and z axes 
and 10 Å from the nearest atom. In the TIP3P water model, the hydrogen-oxygen bond 
lengths are fixed at 0.9572 Å and the bond angle is fixed at 104.52°
236
. 
5. If the system was negatively charged, Na+ ions were added until it was neutral. If the 
system was positively charged, Cl
-
 ions were added until it was neutral. (The addions2 
function was used, which causes the water added in the previous step to be considered 
when the lowest energy positions for the ions are calculated.) 
6. The coordinate and parameter files were saved. 
If parameters were required for the system lacking water and ions or for just the protein or 
ligand in isolation (for MM-PBSA or MM-GBSA calculations) then the above procedure was 
performed with the relevant steps omitted. 
2.2.5.2. Parameter files for thermodynamic integration 
The creation of parameter files for TI calculations is complicated by the requirement that all 
atoms except those differing between the two systems being compared have identical 
coordinates. As outlined in Figure 2.7 below, tleap was run 3 times per pair of compounds being 
compared. The initial run created a PDB file containing water and ions with atoms positioned 
such that they did not clash with the atoms of either of the two posed ligands. Two subsequent 
tleap runs were then performed as outlined by the numbered points above but with the solvent 
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addition step replaced by loading of the solvent and ion-containing PDB followed by manual 
setting of the periodic box dimensions. 
All simulations were performed in Amber 10
224–226
 using TIP3P explicit solvent. Solvent 
molecules were removed prior to MM-PBSA and MM-GBSA calculations using the Amber 
ptraj program. This program was also used to translate atoms into the instance of the periodic 
box centred on the origin. 
2.2.5.3. Initial simulations 
Initial simulations of a couple of oligobenzamides (the N1 and O1 starting compounds shown in 
Figure 2.1, p102) were carried out to see simulations started from docking poses of molecules 
were stable. These were carried out using the PMEMD program of Amber 10 as follows. Up to 
2500 cycles of minimisation were performed, of which the first 1500 were steepest descent, the 
rest being conjugate gradient. The system was then heated from 100 K to 300 K over 50 ns of 
constant volume simulation. Then, a 5 ns constant temperature and constant pressure simulation 
was performed. The Berendsen weak thermostat
166(p383)
 was used throughout. For details of this 
thermostat and the reasons it was used in all work except for thermodynamic integration see 
p81.  A time step of 2 fs was used to speed up the simulation process. SHAKE
182
 (p77) was used 
to control all bonds involving hydrogen. Slowly varying terms were calculated every two steps 
during all constant volume equilibration simulations in this project (by setting the Amber nrespa 
setting to 2), but on every step in constant pressure runs for more accurate simulation unless 
otherwise stated. 
2.2.5.4. Simulations for MM-PBSA and MM-GBSA calculations 
2500 cycles of minimisation were performed in Amber 10 (particle mesh Ewald version): 1500 
of steepest descent followed by 1000 of conjugate gradient minimisation. Over 10 ps of constant 
volume simulation, the system was heated from 100 to 300 K before constant pressure 
simulation began at 300 K. 250 ps was allowed for equilibration of compounds as discussed in 
the results section (p165). When investigating changing all three side chains on the O-linked 
scaffold, data collection was carried out over just 250 ps following equilibration. However, 6 
repeats were carried out per compound so each MM-PBSA result was based on snapshots over 
1.5 ns of simulation. All other simulations analysed using implicit solvent methods were run for 
500 ps following the first 250 ps of constant pressure equilibration. SHAKE
182
 was used with a 
time step of 2 fs to control all bonds involving hydrogen. 
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Figure 2.7: Preparation of coordinate and parameter files for TI simulations in Amber with two 
molecules of different structure. Two systems are required differing by only a few atoms. The original 
ligand (molecule 1, in its docking pose) is modified to molecule 2 by way of the side chain which differs 
between the molecules being swapped using the Side Chain Splicer software (p105). Charges (originally 
calculated with the unbound, minimised molecule) are then copied from the minimised instance of 
molecule 2 to the splicing-derived molecule 2 which has the scaffold in the same pose as in molecule 1. 
Three separate runs of the Amber tleap program are carried out (indicated by the grey regions). So that 
equilibration is fast, solvent and ions (K
+
 and Cl
-
) for neutralisation are placed in positions where they 
will not clash with either the original or modified ligand. A PDB file is produced containing the solvent 
and aforementioned ions which is then added to the protein and desired ligand when LEaP is run to 
generate the parameter and coordinate files. 
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2.2.5.5. Thermodynamic integration simulations 
Thermodynamic integration (TI) was used to estimate differences in binding affinity between 
molecules with small differences in structure. O1 and S1 scaffold oligobenzamides with the 
same side chains were compared, as were O2 and S2 scaffold molecules. Compounds with the 
same scaffold but different side chains (for example due to the presence of an additional methyl 
group, halogen atom or alcohol group in one in one of the pair) were also compared. Exact 
details of the oligobenzamides compared can be found in the results section. 
Up to 15,000 cycles of minimisation were carried out prior to TI simulations. These cycles were 
steepest descent, the only form of minimisation supported by Amber when TI calculations are 
carried out. The maximum number of minimisation cycles permitted was increased from its 
default value (to 15,000) because a large number of simulations were performed, increasing the 
chance of any one simulation failing and increased minimisation ensured that every subsequent 
simulation was stable. In practice, the maximum number of cycles was often not performed 
because (as in all Amber minimisation carried out in this project) a gradient convergence cut-off 
of 50 cal mol
-1
 Å
-1
 was used, which is significantly less strict than the default convergence of 
0.1 cal mol
-1
 Å
-1
. Raising this cut-off did not appear to affect the ability to start stable 
simulations. The distance cut-off for direct space calculations of through-space forces between 
non-bonded atoms was increased from the default value of 8 Å to 12 Å during minimisation 
(but not in the subsequent simulations). 
TI was carried out using the sander program of Amber10 as opposed to the pmemd program, 
which uses the Particle Mesh Ewald method of charge calculation. (pmemd does not support TI 
in Amber 10.) A total of 50 ps of constant volume simulation was used to heat the system from 
100 K to 300 K and then 150 ps of constant pressure simulation was allowed for equilibration 
prior to data collection. d𝒱/dλ was then recorded after every 500 steps. Langevin dynamics 
(p81) with a collision frequency of 5 (ps)
-1
 was used to maintain the temperature.  
Transformations were performed in three steps as described below (p121). For the removal and 
addition of charges (steps 1 and 3), a time step of 2 fs was used with SHAKE
182
 to control all 
bonds involving hydrogen atoms. In the main transformation step (step 2), SHAKE was turned 
off and a time step of 1 fs was used. Soft core potentials (p85) were used in this middle step to 
increase simulation stability
238
. 
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2.2.6. THERMODYNAMIC INTEGRATION CALCULATIONS 
2.2.6.1. Integration 
TI allows the difference in binding free energy between two compounds to be predicted. 
As discussed in the introductory chapter (p83), this is the difference in energy between the 
bound systems, where the compounds are on the protein surface, minus the difference in energy 
between the unbound systems where the compounds are free in the solution (Equation 1.64, 
p84). 
It is assumed that the difference in binding free energy, ΔΔG, is equal to the difference in 
vibronic potential energy, 𝒱. Calculation of the difference in potential energy, Δ𝒱, between the 
systems containing each compound (either free or bound to the protein) involves the 
determination of 𝑑𝒱 𝑑𝜆⁄  at points along an alchemical reaction coordinate from 0 (the starting 
compound) to 1 (the product). Integration under the 𝑑𝒱 𝑑𝜆⁄  curve from 0 to 1 yields the total 
change in potential energy (p83). 
In this project, Gauss-Legendre integration was used to calculate the area under the d𝒱 d𝜆⁄  
curve as it is more accurate than using the trapezium rule
239
. This method requires the use of 
irregularly spaced lambda points (points corresponding to the Gauss-Legendre abscissas). 
Gauss-Legendre integration is performed using points between x=-1 and x=1 but lambda values 
range from 0 to 1 so 
∫
d𝒱
d𝜆
1
0
d𝜆 =
1
2
∑ 𝑤𝑖 (
𝑑𝒱
𝑑𝜆
)
𝜆𝑖
 
∞
𝑖=1
 
2.2 
Where 
𝜆𝑖 =
𝑥𝑖 + 1
2
. 2.3 
wi is the weight associated with Gauss-Legendre abscissa xi. (The number of lambda points used 
is discussed at the bottom of the next section.) 
2.2.6.2. Transformation steps 
For each O-linked and S-linked scaffolds (scaffolds O1, O2, S1 and S2), the torsional energy 
parameters for the dihedral about which rotation was restricted due to intramolecular hydrogen 
bonding were changed in TI runs from 0.5 kcal below their normal position to 0.5 kcal above. 
This enabled assessment of the importance of dihedral parameter accuracy in predicting the 
binding energy of oligobenzamides. This transformation required a single step. 
TI was also used to alchemically change each sulphur atom in S-linked compounds to a 
methanediyil (-CH2-) group and to do the same in O-linked compounds. These transformations 
were carried out in three steps. In the first, partial charges were removed from the disappearing 
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atoms (most notably the oxygen and sulphur). In the second step, the disappearing atoms were 
decoupled from the system and the new atoms (most notably those of the methanediyl group) 
were introduced and in the final step, partial charges were put on the new atoms. The atom type 
of some hydrogen atoms close to the oxygen or sulphur in the starting compound changed when 
the transformation to a methanediyil group was performed. The parameters of these atoms were 
changed by removal and replacement of these atoms along with the oxygen or sulphur in the 
aforementioned steps. 
The effect of side chain modification was also assessed using TI investigations. Three steps 
were used unless no atoms were being added, in which case, no charge addition step was 
needed. When the side chain attachment atom or torsional barrier height was changed, 11 
lambda points were used for removal and re-addition of charges and 21 lambda points were 
used for step 2, the main transformation step. When the side chains were modified, 8 lambda 
points were used for every step. 
Where 21 lambda points were used, the Gauss-Legendre abscissas for n=10 and n=11 were used 
(with the weights halved) as opposed to the abscissas for n=21 so that the reaction coordinate 
(λ) was always between 0.01 and 0.99, as is necessary when soft core potentials are used in 
Amber
238
. 
2.2.6.3. Bias due to one-way conversion 
When side chains were modified using TI, many conversions were only performed in one 
direction. 
Given the large number of conversions which it was desirable to investigate and the large 
number of simulations which are required for each conversion (repeats for each lambda point 
both for the free ligand and the complex for each of the three steps outlined above), it was 
necessary for simulations to be run which equilibrated rapidly. This was achieved by ensuring 
there were no steric clashes at the start of any simulation. 
Firstly, care was taken to ensure that water molecules were positioned such that they were clear 
of the ligand in both the original system and the modified system. (For further details see p117.) 
Secondly, the size of the ligand was never increased by the addition of heteroatoms because this 
could create ligand atoms in space already occupied by the atoms of the protein. Although 
hydrogen atoms were added, compounds were usually modified to a side chain of a similar size 
(for example by converting one halogen atom to another) or modified by removal of atoms, a 
reduction in side chain size. This meant that where the molecules being compared were different 
sizes, the conversion was performed in one direction only. This introduces an intrinsic bias into 
the assessment of which compound is the more stable of two because the compound used to 
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generate the binding pose for both compounds (as described above) will be in its strongest 
binding pose, unlike the compound produced by modification. As a consequence of this bias, 
the side chain conversion TI results in this chapter should ideally be used for the comparison of 
similarly sized ligands with a common core. For example, the results for removal of a methyl 
group from the ortho position of a benzene ring could be compared to those of a methyl group 
being removed from the para position, but each individual result might not provide an accurate 
indication of whether the methyl group in each case improves the affinity or not; the original 
molecule (with the methyl group) is likely to be favoured in both cases, because this was used 
for the docking. Fortunately, there was no obvious evidence of this bias, which would have led 
to underestimation of the affinity of compounds with smaller side chains relative to those with 
larger side chains, in the final predictions when compared to fluorescence anisotropy results 
(p152). 
2.2.7. MM-GBSA AND MM-PBSA 
MM-GBSA and MM-PBSA predictions were made using from Amber 10 trajectories using 
Amber 11 because MM-PBSA processing in Amber 10 is limited to the single trajectory 
approach described below. Trajectory frames at intervals of 10 ps were extracted for analysis. 
2.2.7.1. Single, double and triple trajectory methods for calculation of binding free 
energies 
To predict the free energy of binding for a ligand, it is necessary to compare the energy of the 
free protein and ligand with the energy of their bound state. While simulations of the free 
ligand, free protein and complex can each be performed (a multi-trajectory approach), more 
accurate results can often be obtained using a single-trajectory approach, where the trajectories 
of the free protein and free ligand are extracted from the trajectory of the complex
240–243
. If the 
ligand and protein explore the same conformational space when free as when bound together 
then this method reduces noise because it ensures that the ligand does explore the same phase 
space in both the free and bound states. 
The suitability of the single-trajectory method depends on the extent to which the ligand and 
protein have similar conformations when free and when bound. The p53 binding site of Mdm2 
is very flexible and changes conformation upon binding. Furthermore, some oligobenzamides 
might assume a cis conformation (across the amide groups) when bound to Mdm2 so that all of 
the side chains are in contact with the protein but a trans arrangement  when they are free in 
solution to spread out the side chains
244
. However, in the O1, S1, O2 and S2 scaffolds there is 
intramolecular hydrogen bonding which will help maintain the cis conformation in the free 
ligand and compounds based on the N1 scaffold can be, for steric reasons, more stable in the cis 
than the trans arrangement when unbound
245–247
. The uncertainty regarding the best procedure 
warranted testing of a variety of methods to test the robustness of the predictions. 
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In this project, single (Equation 2.4), double (2.5) and triple (2.6) trajectory methods were 
tested, as indicated in the results section. In the double trajectory method, a separate simulation 
of the ligand in isolation is performed, but the trajectory of the free protein comes from that of 
the complex. In the triple trajectory method, the free protein energies from the double trajectory 
method results were averaged over all of the ligands and the result was used as the energy of the 
free protein for every ligand. To reiterate, the same free-protein energy was used for every 
ligand so it had no bearing on the ranking of the compounds, as would have been the case had a 
protein-only trajectory been performed. 
∆𝐺𝑆𝑇 = ∆𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − ∆𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑡𝑟𝑎𝑗𝑒𝑐𝑡𝑜𝑟𝑦) − ∆𝐺𝑙𝑖𝑔𝑎𝑛𝑑 (𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑡𝑟𝑎𝑗𝑒𝑐𝑡𝑜𝑟𝑦) 2.4 
∆𝐺𝐷𝑇 = ∆𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − ∆𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑡𝑟𝑎𝑗𝑒𝑐𝑡𝑜𝑟𝑦) − ∆𝐺𝑙𝑖𝑔𝑎𝑛𝑑 (𝑙𝑖𝑔𝑎𝑛𝑑 𝑡𝑟𝑎𝑗𝑒𝑐𝑡𝑜𝑟𝑦) 2.5 
∆𝐺𝑇𝑇 = ∆𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − ∆𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑡𝑟𝑎𝑗𝑒𝑐𝑡𝑜𝑟𝑦)̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ − ∆𝐺𝑙𝑖𝑔𝑎𝑛𝑑 (𝑙𝑖𝑔𝑎𝑛𝑑 𝑡𝑟𝑎𝑗𝑒𝑐𝑡𝑜𝑟𝑦) 2.6 
2.2.7.2. Parameters 
MM-PBSA and MM-GBSA calculations were carried out using the mmpbsa.py program of 
Amber 11 (AmberTools 1.5)
224–226
. However, parameter files for the complex, ligand and 
protein in the absence of solvent and ions (necessary for the MM-PBSA and MM-GBSA 
analysis) were generated using Amber 10 (AmberTools 1.4). (AmberTools 1.4 can only make 
predictions using the single trajectory approach. AmberTools 1.4 was used to generate the 
parameter files to ensure that the parameters used for implicit solvent calculations were identical 
to those used in the simulations (performed before AmberTools 1.5 had been installed).) 
Parameter files were generated using tleap (Amber 10). Prior to loading trajectories into 
mmpbsa.py, solvent and ions were removed from the trajectory of the complex and atom 
positions were moved into the periodic box centred on the origin using the Amber 10 ptraj 
program. 
Unless otherwise stated, default parameters were used for MM-PBSA and MM-GBSA analysis. 
One setting altered in MM-PBSA analyses was the required convergence of the energy gradient 
in minimisation (the drms setting) which was reduced from 0.001 to 0.0001 kcal mol
-1
 Å
-1
 
because sufficient computational power was available. 
2.2.7.3. Buried atom radii 
One of the MM-GBSA settings experimented with was the igb setting. This controls the 
Generalised Born model used. When set to 1, the original model described by equations 1.82 to 
1.84 in the introductory chapter (p89) is used. When set to 5, a modified model is used in which 
the Born radii of the atoms is increased for buried atoms to account for their radius usually 
being underestimated within macromolecules
200
. This is described by equations 1.85 and 1.86 
(p89) where the coefficients α, β and γ are 1, 0.8 and 4.85 respectively186(p49),200. For method 1, 
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the atomic radii of Tsui and Case
248
 were used (PBRadii=mbondi) and for method 5, the radii of 
Onufriev et al.
200
 were used (PBRadii=mbondi2). 
2.2.7.4. Normal mode analysis 
Normal mode analysis was used in some cases to estimate the change in entropy of the protein 
and an oligobenzamide ligand upon binding. Normal mode analysis involves prediction of the 
possible ways in which the ligand, protein and complex can resonate (p90). It was performed 
using the nmode program of Amber 10, which is called by mmpbsa.py when normal mode 
analysis is turned on. When enabled, Normal mode analysis was performed on every third frame 
processed in MM-PBSA and MM-GBSA analysis. Often the entropy change of the protein and 
compound upon binding is ignored because normal mode analysis is computationally expensive 
and its inclusion can introduce significant error because the calculated entropy often varies 
considerably between frames
249
. 
2.2.8. STATISTICAL METHODS 
Extensive use of statistical methods was made to analyse docking and simulation results in this 
project. Pearson’s correlation coefficient250 and Spearman’s rank correlation coefficient251 were 
used to investigate the correlation between predicted binding energies and experimental results; 
some docking results were analysed using logistic regression
252
 as detailed in the results section, 
and binding energies predicted using implicit solvent methods were analysed using analysis of 
variance (ANOVA)
215
.  For full details of the statistical methods used in this project, see 
Appendix A (p290). 
2.2.9. APPLICATION OF THE METHODS TO THE DATA 
The methods sections above describe: 
1. Preparation of the structure of Mdm2 from PDB structure 1T4F. 
2. Production of oligobenzamides with different side chains. 
3. Calculation of the properties of library members and their side chains. 
4. Docking of oligobenzamides into Mdm2. 
5. Modification of the side chains on docked poses in situ followed by re-docking 
(optimisation of the pose) of the new molecule. 
6. Analysis of how the docking poses of library members depend on the properties of the 
molecules in question (regression). 
7. Calculation of the atomic partial charges on selected library members. 
8. Simulation of these library members bound to Mdm2. 
9. Prediction of binding affinities using TI and the implicit solvent methods, MM-PBSA 
and MM-GBSA. 
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10. Comparison of TI and implicit solvent results with affinities measured in the laboratory 
using a fluorescence anisotropy assay. 
11. Analysis of the implicit solvent results using analysis of variance (ANOVA). 
Figure 6.2 (p306) shows in more detail how these methods were combined to generate the 
results discussed in the subsequent results section. The results section describes specifically 
what data sets the methods were applied to. This is also depicted in Figure 6.3 (p308) and can 
be summarised as follows. 
Result processing in this project entailed: 
1. Filtration of compounds from the ZINC database and their cleavage to produce side 
chains. 
2. Attachment of these side chains to the O1 scaffold starting molecule (Figure 2.1, p102) 
(previously docked with Autodock) using ReCore and docking of the resulting molecule 
in each case using FlexX. 
3. Analysis of the resulting docking scores, using Spearman’s rank correlation coefficients 
to investigate how side chain properties affected FlexX docking scores. 
4. Simulation of a few oligobenzamides based on the O1 and N1 scaffolds to see if the 
simulations were stable. 
5. Generation of 3D structures for side chains suggested by the collaborating chemistry 
group (supplied as formulae) and the splicing of the minimised side chains on to the 
posed scaffolds of previously docked starting molecules (Figure 2.1, p102). 
6. Global docking of 25,000 compounds with Autodock Vina and analysis of how their 
properties affected their predicted binding poses using logistic regression. 
7. From the poses of these 25,000 compounds, extraction of 
a. The top poses of selected compounds for thermodynamic integration and their 
modification to produce the second of the pair of molecules to be interconverted 
in the TI investigation. 
b. Poses for 31 previously synthesised compounds based on the N1 scaffold for 
binding affinity prediction using the MM-PBSA and MM-GBSA implicit 
solvent methods. 
c. Poses for two libraries of molecules, one with 285 (15 × 19) combinations of 
side chains at positions 1 and 2 and one with 285 combinations of side chain at 
positions 2 and 3, for analysis using the MM-PBSA method. 
8. Local docking (optimisation) of each of a combinatorial library of compounds based on 
the O1 scaffold comprising compounds with 12 different side chains in every 
combination at the three side chain positions. (These compounds are already in a 
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conformation close to the correct pose because they were produced by modification of 
the side chains on a previously docked starting molecule.) 
9. Calculation of RESP charges for selected library members following minimisation and 
the transfer of these charges onto docked poses of the compounds ready for molecular 
dynamics simulations. 
10. TI calculations to investigate the effect on binding affinity of changing the side chain 
attachment atoms and varying the backbone torsion parameters. 
11. TI calculations for compounds based on the N1 scaffold and their use to predict the 
relative binding affinities of the 31 compounds synthesised and tested in the laboratory. 
12. Prediction of binding affinities using the MM-PBSA and MM-GBSA methods for these 
31 compounds, either using a trajectory of the complex (the single trajectory approach), 
a trajectory of the complex and a trajectory of the free ligand (the double trajectory 
approach) or a triple trajectory approach (p124). 
13. Comparison of the predicted binding energies for these 31 compounds with 
experimental results from a fluorescence anisotropy assay. 
14. Prediction of the binding energies of each member of the library of O1 compounds 
mentioned in point 8 above using the MM-PBSA method and analysis of the results 
using analysis of variance (ANOVA) using the side chains at each of the three side 
chain positions as factors. 
15. Prediction of affinities for the library of compounds mentioned in point 7c above using 
the MM-PBSA method and analysis of the results using three separate sets of ANOVA 
investigations. As described in the results section, only poses corresponding to one of 
four binding positions (shown in Figure 2.23, p187) were selected. Each analysis 
involved three fixed factors: the choice of side chain at the middle position, the choice 
of side chain at either the first or last position and, as the third factor, either the scaffold 
choice or the binding position. 
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2.3. Results and Analysis 
2.3.1. DOCKING OF SIDE CHAINS DERIVED FROM MOLECULES OF THE 
ZINC DATABASE ALLOWED FAVOURABLE TRAITS IN THE PHE19, TRP23 
AND LEU26 BINDING POCKETS TO BE IDENTIFIED 
This section describes the docking of oligobenzamides with a diverse range of side chains using 
FlexX and the subsequent analysis of side chain properties and docking scores. The aim was to 
identify the side chain properties likely to increase the affinity of an oligobenzamide binding 
with its side chains in the sites usually occupied by p53 residues Phe19, Trp23 and Leu26 in the 
p53-Mdm2 interaction. 
An initial oligobenzamide binding position was required for high-throughput screening to 
identify potential side chains. The O1 scaffold starting compound (Figure 2.1, p102) was 
docked into Mdm2 from PDB structure 1T4F
37
 using AutoDock 4.2 as detailed in the methods 
section (p109). The side chains of the compound resemble the side chains of Phe19, Trp23 and 
Leu26 from the p53 helix. Comparison of the highest scoring pose obtained (Figure 2.8B) with 
the position of the p53 helix bound to Mdm2 in structure 1T4F (Figure 2.8A), which played no 
part in the docking, shows that the side chains have been positioned close to their expected 
positions (Figure 2.8C). The heavy atom RMSDs for the first side chain, second side chain 
terminal benzene ring and third side chain relative to the p53 residue side chains are 2.09 Å, 
1.24 Å and 1.66 Å respectively. 
Molecules from the ZINC source database were cut using ReCore (BioSolveIT) as described in 
the methods section (p106). These were spliced on to the docked O1 starting molecule (Figure 
2.8B) and screened using ReCore. 536, 505 and 508 possible side chains were identified by this 
high-throughput screening for the first, second and third side chain positions on the scaffold 
respectively. FlexX
c
 (part of FlexX (BioSolveIT)) was then used to carry out combinatorial 
docking. This software docks the scaffold and then attaches and tests each member of a library 
of possible side chains. The side chains are attached in situ and the resulting pose is minimised 
to complete the docking process. 
The side chain attachment positions were treated separately; each of the possible side chains 
was tested at each attachment position while the other two side chains were left unchanged from 
those of the initial structure. (For further details see p109.) Poses with an RMSD of greater than 
2 Å relative to the high-throughput screening pose generated by ReCore, in which the scaffold 
position is unchanged from in the Autodock pose, were discarded. Consequently all of the poses 
resemble that shown in Figure 2.8B where the N-terminal, central and C-terminal side chains 
are in the pockets usually occupied by p53 residues Phe19, Trp23 and Leu26.  
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B 
 
C 
  
Figure 2.8: The best pose resulting from the docking of an oligobenzamide into Mdm2 from PDB 
structure 1T4F superimposed on the structure of p53 from the PDB structure. A) Structure 1T4F 
showing a modified p53 peptide (green) in the p53 binding site of Mdm2 (grey). B) The highest scoring 
pose generated by docking the oligobenzamide shown in Figure 2.6A (p114) (blue) into the structure of 
Mdm2 from 1T4F. C) The result of removal of the protein and superimposition of the original p53 
structure (as in A) on the docked oligobenzamide structure (as in B). There is excellent agreement 
between the structures despite the p53 peptide playing no part in the oligobenzamide docking. 
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The properties of each side chain were calculated and Spearman’s Rank correlation coefficients 
(rs) were determined for each property to investigate whether its value correlated with the FlexX 
docking score of the resulting oligobenzamide. Positive Spearman’s rank values indicate that 
the higher the value of the property is, the greater the docking score; however, the scores are 
predicted ΔG values so higher scores correspond to weaker binding. Table 2.3 (p131) shows the 
results. Caution is necessary when interpreting these results for several reasons. Firstly, multiple 
hypotheses were tested. Secondly, it was assumed that all side chains bound in the expected 
docking pose (side chain 1 in or near the p53 Phe19 pocket, side chain 2 in or near the Trp23 
pocket and side chain 3 in or near the Leu26 pocket) and this assumption might be incorrect. 
Finally, docking scores are often poor measures of binding affinity
161,162
. 
As shown in Table 2.3, at the middle side chain position, larger side chains lead to better scores. 
(For the total number of atoms, number of carbons and number of heteroatoms, rs<-0.03, rs<-
0.14 and  rs<-0.10 respectively based on the 95% confidence limits shown in the table.) 
However, at the side chain position nearest to the amino terminus, small, low molecular weight 
groups appear to be favoured (because larger side chains result in larger scores and higher 
scores signify weaker binding). According to the 95% confidence limits, for the number of 
atoms in, number of carbons in and molecular weight of side chain 1, rs>0.05, rs>0.04 and 
rs>0.08 respectively. At the carboxyl terminus, the side chain has little room to manoeuvre so 
escape from the expected binding pocket requires side chain flexibility. This could explain why 
rigid conjugated systems are unfavourable at this position. (For the number of rotatable bonds, 
rs>0.25 and for the number of rigid bonds, rs <-0.29 based on the 95% confidence limits.) 
At all three side chain positions, fragments that lead to a molecule with a high polar surface area 
(PSA) have good scores (rs<-0.27, rs<-0.30 and rs<-0.47 for side chains 1, 2 and 3 respectively). 
More polar molecules have lower logP values and, consistent with this, side chains with a lower 
XlogP (increased water solubility relative to their solubility in octanol) also score favourably 
(rs>0.33, rs>0.24 and rs<0.29 for side chains 1, 2 and 3 respectively). The presence of hydrogen 
bond donors (rs<-0.02, rs<-0.11 and rs<-0.13) and acceptors (rs<-0.15, rs<-0.15 and rs<-0.28) 
appears to increase affinity and in the central and C-terminal side chain position, side chains 
with a positive charge have good scores (rs<-0.07 and rs<-0.10 respectively). 
It is difficult to reconcile the PSA, XlogP and hydrogen bonding  results with the overall 
hydrophobic nature of the p53 binding site of Mdm2
253
 and the known importance of side chain 
hydrophobicity for strong binding
31
. Park and Jeon
229
, point out that the FlexX force field lacks 
terms to directly account for ligand and binding site desolvation. These unexpected correlations 
could be the result of this bias inherent in the FlexX scoring function. Shoichet et al.
254
 discuss 
how virtual screening without considering differences in solvation energy between compounds 
has a tendency to return molecules that are too large or too highly charged. 
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Table 2.3: How the properties of side chains at the three side chain positions in the molecules docked with FlexX correlated with the docking scores of the compounds. 
 
Property 
Side chain 1 Side chain 2 Side chain 3 
n 
Med. 
value 
Spearman’s Rank 
n 
Med. 
value 
Spearman’s Rank 
n 
Med. 
value 
Spearman’s Rank 
Low 
limit  
High 
limit 
Low 
limit 
 
High 
limit 
Low 
limit 
 
High 
limit 
Number of atoms 365 13 0.05 0.12 0.20 348 13 -0.17 -0.10 -0.03 359 13 -0.13 -0.06 0.01 
Number of carbons 365 9 0.04 0.12 0.19 348 9 -0.21 -0.14 -0.08 359 9 -0.12 -0.05 0.02 
Number of heteroatoms 365 3 -0.18 -0.11 -0.04 348 3 -0.17 -0.10 -0.03 359 3 -0.29 -0.23 -0.17 
Hydrogen bond acceptors 365 1 -0.28 -0.22 -0.15 348 1 -0.28 -0.22 -0.15 359 1 -0.38 -0.33 -0.28 
Hydrogen bond donors 365 1 -0.15 -0.08 -0.02 348 1 -0.24 -0.17 -0.11 359 1 -0.25 -0.19 -0.13 
Molecular weight 365 190 0.08 0.16 0.23 348 186 -0.10 -0.03 0.04 359 186 -0.07 0.00 0.07 
Number of formal charges 365 0 -0.10 -0.03 0.04 348 0 -0.21 -0.14 -0.07 359 0 -0.23 -0.17 -0.10 
Sum of formal charges 365 0 -0.06 0.01 0.09 348 0 -0.19 -0.12 -0.05 359 0 -0.19 -0.12 -0.05 
Rotatable bonds 365 3 0.10 0.18 0.26 348 3 -0.03 0.05 0.13 359 3 0.25 0.33 0.40 
Rigid bonds 365 10 -0.07 0.00 0.07 348 10 0.02 0.10 0.18 359 9 -0.39 -0.34 -0.29 
Predicted compound XlogP 278 1.8 0.33 0.42 0.50 262 1.7 0.24 0.33 0.41 273 1.8 0.29 0.38 0.46 
Compound 2D PSA* 278 -0.72 -0.39 -0.33 -0.27 262 -0.65 -0.42 -0.36 -0.30 273 -0.67 -0.56 -0.52 -0.47 
Each side chain position was investigated separately. For each side chain position, a library of compounds which differed in terms of the side chain at the position in question was 
docked. The side chains used for this analysis were those obtained by cleavage of molecules from the ZINC source database, filtered such that all of the oligobenzamides generated 
were theoretically synthetically accessible. For further details see p106. The column labelled “n” indicates the number of side chains used and therefore also the number of data 
points used in the subsequent regression analysis. The “Med. value” column shows the median value of the side chain property for all of the compounds in the library used to 
investigate the side chain position in question. Spearman’s rank correlation coefficients were calculated to look for any correlation between the properties of side chains and the 
relative binding affinities of oligobenzamides containing them. 95% confidence limits (“high limit” and “low limit”) on the values of each Spearman’s rank are shown in the table on 
either side of the ranks themselves. For details of how these confidence limits were calculated, see p291. All of the properties shown were calculated using the Open Babel
217
 Filter 
program. *Topological polar surface area. (See p104.) Calculation of the topological PSA and logP estimate (XlogP
222
) of a molecule requires data for the functional groups within it. 
The functional group composition of some side chains meant that their predicted logP and polar surface area could not be calculated, so fewer side chains were investigated when 
analysing the effect of these two properties on docking score. 
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2.3.2. LONG SIMULATIONS OF OLIGOBENZAMIDES BASED ON THE N1 
AND O1 SCAFFOLDS ARE STABLE 
The estimation of accurate binding affinities for ranking requires that ensembles of 
conformations be generated for each compound. These can be produced by running molecular 
dynamics simulations. This section describes some initial testing of oligobenzamides bound to 
Mdm2 to check that the protein and ligands were behaving as expected with the parameters 
used. 
Docking of the N1 and O1 scaffold starting molecules (p102) using Autodock Vina generated a 
small number of poses of which a few (for each molecule) were consistent with binding in the 
p53 binding groove with the side chains occupying the pockets usually occupied by p53 side 
chains. 5 such poses were selected for the N-linked scaffold compound and 3 were selected for 
the O-linked compound (manually by visual inspection). These comprised poses both parallel 
and antiparallel to the p53 helix. Using the bound poses as initial structures, explicit solvent 
simulations were run of the complex using the new parameters (p115). These simulations were 
stable and the ligands remained bound to the protein. The atomic coordinate root mean square 
deviations (RMSDs) at the start of the trajectories are shown in Figure 2.9. See Equation 1.53 
(p78) for the definition of an RMSD and a discussion of its usage in the assessment of 
simulation equilibration. 
To investigate the rigidity of the O-linked scaffold, RMSDs for substructures of the scaffold 
were calculated from a 5 ns trajectory (Figure 2.10). The RMSD lines shown in red are for the 
12 carbon atoms of the N-terminal and middle benzene rings of the oligobenzamide scaffold 
(not the atoms in the side chains).  The blue lines are, similarly, for the 12 carbon atoms of the 
middle and C-terminal rings of the scaffold. RMSDs were calculated relative to the starting pose 
after alignment of the 12 atoms with those of the starting structure. Movement of the lines 
therefore indicates rotation of the rings relative to each other (provided that the amide bond 
remains in its trans arrangement). Migration of the N-terminal side chain out of the binding 
pocket is indicated by movement of the red line. Migration of the C-terminal side chain from its 
pocket is indicated by movement of the blue line and movement of the central side chain is 
indicated by simultaneous movement of both the red and blue lines. 
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 N-linked (ligand part only)
 
N-linked (ligand-protein complex)
 
O-linked (ligand part only) 
 
O-linked (ligand-protein complex) 
 
 
Figure 2.9: RMSDs of the ligand and ligand-protein complex in simulations of the N1 and O1 
starting molecules  bound to Mdm2. The compound structures are shown in Figure 2.1 (p102). These 
results are for the constant pressure run following a constant volume simulation and the RMSDs are 
relative to the structure at the start of the constant pressure part. The different lines of each graph show 
the results of different simulations started from different docking poses. The docking poses were 
manually selected prior to simulation but no selection has been applied to the trajectories shown. 
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 A (Parallel) 
 
B (Parallel) 
 
C (Antiparallel)
 
Figure 2.10: RMSD moving averages showing the relative orientation of the first and second 
oligobenzamide rings and the second and third oligobenzamide rings (red and blue respectively) of 
the O1 scaffold starting molecule starting from three different poses. The structure of the molecule is 
shown in Figure 2.1 (p102). The RMSDs are for the 12 carbon atoms of the two rings in question and are 
calculated following alignment of the atoms with those of the starting structure. A high RMSD indicates 
that one of the rings has rotated relative to the other so one of the side chains is projecting away from the 
protein (based on the assumption of that the amide bond remains trans). Simulations were started with 
poses parallel to the p53 in structure 1T4F and antiparallel as indicated. The RMSD moving averages 
shown are the mean of 21 RMSDs calculated at 500 fs intervals from 5 ps before the time point to 5 ps 
afterwards inclusive. Plotting an average enabled all of the data (collected at 500 fs intervals) to be used, 
the aim being to reduce the degree of random noise. 
 
The results indicate some flexibility of the scaffold, despite its intramolecular hydrogen 
bonding; however, inspection of the trajectories (using VMD (University of Illinois)
255
) reveals 
that the side chains do not venture far from their binding pockets. This is evident from Figure 
2.10. Using trigonometry it can be shown that rotation of both aromatic rings by 90° in opposite 
directions (holding the link rigid) would result in an RMSD of 1.3 Å (based on the assumption 
0.0
0.2
0.4
0.6
0.8
1.0
0 1000 2000 3000 4000 5000
R
M
SD
 /
Å
 
Time /ps 
0.0
0.2
0.4
0.6
0.8
1.0
0 1000 2000 3000 4000 5000
R
M
SD
 /
Å
 
Time /ps 
0.0
0.2
0.4
0.6
0.8
1.0
0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000
R
M
SD
 /
Å
 
Time /ps 
134
  
 
 
 
that the ring carbon atoms are 1.4 Å apart). Consequently, the deviations shown in Figure 2.10, 
which are fractions of an Angstrom, even though they are affected by other factors such as 
bending of the scaffold, reflect only small rotations of the rings relative to each other. Most 
deviations are brief (for tens of picoseconds) and, where there is a longer departure (as at 1.5 ns 
in Figure 2.10A), the side chains do eventually return. 
 A (Parallel) 
 
B (Antiparallel) 
 
C (Antiparallel) 
 
Figure 2.11: RMSD moving averages (over 21 RMSDs at 500 fs intervals) for the N1 scaffold 
starting  molecule indicating the deviation of the side chains from their starting position relative to 
the centre of the scaffold. Each RMSD was generated using the carbon atoms of the central ring of the 
scaffold and the second carbon of the side chain. High RMSDs indicate that the side chain has moved 
relative to the scaffold. The green, orange and purple lines are for side chains 1, 2 and 3 respectively (the 
N-terminal, central and C-terminal side chains). 
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Figure 2.11 shows the movement of the three side chains of the N-linked scaffold relative to the 
central ring of the scaffold. The RMSDs are each based on 7 atoms, the 6 carbon atoms of the 
central scaffold ring and the first carbon of the side chain in question (the atom bonded to the 
nitrogen). Some movement of the side chains is visible; however, overall the side chains stay in 
their initial position. Figure 2.12 below shows structures from the trajectory used to produce 
Figure 2.11C above. The apparent deviations of side chain 1 (at the N-terminal end of the 
oligobenzamide) visible in Figure 2.11C (shown in green) were not caused by movement of the 
side chain away from its binding site but by shifting of the scaffold. This figure is discussed 
further on p184 because it illustrates how the motion of side chain 1 at the left-hand end of the 
ligand (Figure 2.12B) might, through pushing on the scaffold, cause the conformation of side 
chain 3 at the other end of the molecule to change (Figure 2.12C). 
 A (0 ps) 
 
 
B (2000 ps) 
 
C (2500 ps) 
 
D (5000 ps) 
 
Figure 2.12: Structures from the 5 ns simulation of the N1 scaffold molecule (Figure 2.1, p102) used 
to produce Figure 2.11C. The oligobenzamide is shown in teal and the surface of Mdm2 is shown in 
grey. The time points shown have been selected such that they aid interpretation of Figure 2.11C. At the 
beginning (top left) and end (bottom right) of the simulation, the three side chains are in the expected 
binding position. At the 2000 and 2500 ps points, the scaffold is to the left of its initial position and the 
N-terminal side chain of the oligobenzamide (on the right in these images) has shifted relative to the 
scaffold to stay in its binding site. By the 2500 ps point, the C-terminal side chain has also shifted to point 
down, away from the scaffold. Changes in the conformation of the ligand appear to be accompanied by 
significant movement of the protein. Water and ions were removed from the trajectory using the ptraj 
program from the Amber 10 suite
224–226
. The frames of interest were extracted as PDB files using VMD 
1.9.1
255
. They were aligned (to the 0 ps positions using both ligand and protein atoms) with the Protein 
Structure Comparison Tool V 3.0.8 (RCSB)
256,257
 using the jCE algorithm (version 1.1)
258
 with default 
parameters. The images were rendered in Chimera (UCSF). 
 
The mobility of Mdm2 and oligobenzamides highlights the need to run simulations in order to 
sample different molecular conformations because the dynamics could have a significant impact 
upon affinity. 
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A single simulation would need to be of a substantial length of time to capture all of the binding 
states, given that the transient states visible in these simulations appear to persist for hundreds 
of picoseconds. Consequently, running multiple simulations from different docking poses, 
where possible, is appropriate. 
2.3.3. THERMODYNAMIC INTEGRATION 
2.3.3.1. Modification of the side chain attachment atoms revealed that sulphur in the S1 
scaffold might contribute more to binding than oxygen in the O1 scaffold 
Synthetic work in the collaborating Chemistry group had focussed on oligobenzamides with N-
linked and O-linked side chains, yet side chains can also be attached through sulphur. Initial 
testing using thermodynamic integration sought to compare the O1 and S1 scaffolds and 
compare the O2 and S2 scaffolds. Oligobenzamide inhibitors are proposed to bind with each 
side chain mimicking a particular residue side chain of the p53 transactivation domain. In this 
model, the role of the scaffold is solely to prearrange the side chains, not contribute directly to 
binding through interaction with the protein.  Thermodynamic integration was used to test this 
hypothesis through investigation of the effect of side chain attachment atom substitution on 
binding affinity. The results suggest that the S1 scaffold warrants further attention. 
Scaffolds O1 and S1 and scaffolds O2 and S2 (Figure 1.6, p36) differ only in the atoms used to 
attach the side chains to the scaffold; however, they could have significantly different degrees of 
flexibility. The intramolecular hydrogen bonding in the scaffolds with O-linked side chains is 
potentially stronger because oxygen is more electronegative than sulphur. Furthermore, as 
discussed in chapter 1 (p70),  steric effects caused by the large sulphur atom in the S2 scaffold 
prevent planarity of the aromatic ring and nearby amide group, reducing the potential for p-
orbital alignment and conjugation
173
. 
The effect of scaffold flexibility on binding affinity is hard to predict. A more rigid scaffold 
could potentially pre-organise an oligobenzamide, ensuring that, when it is bound, weakly 
binding side chains do not migrate away from the protein surface but instead remain and 
contribute to binding. The movement of residues in an alpha-helix is constrained by the 
secondary structure
259
 so an effective mimic of the p53 transactivation domain helix might be 
expected to have a scaffold which holds the side chains firmly in place. However, 
oligobenzamide scaffolds may not intrinsically place side chains in the optimal position. Some 
natural amino acids cannot be used because they are not compatible with the oligobenzamide 
synthetic process. These must be mimicked using different, less reactive, non-natural side 
chains (for example, a napthyl group in the case of phenylalanine). Consequently, some 
oligobenzamide flexibility might be required to allow side chains to sit where they will most 
effectively mimic the p53 residues. 
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Initially, attempts were made to perform a simple swap of oxygen in molecules based on the O1 
scaffold for sulphur and vice versa in a set of thermodynamic integration experiments. 
However, it proved impossible to start stable simulations of an oxygen-linked compound 
produced by taking the starting pose of a sulphur-linked compound and replacing the sulphur 
atoms with oxygen. (In this context, an unstable simulation is one in which a very large force is 
created that cannot be accurately modelled so causes uncontrolled atomic motion and simulation 
failure.) Initial simulation at 100 K was tried and initial restraints were also tested, applied to 
ligand atoms on the protein side of the converted atoms; however, these did not solve the 
problem. TI simulations using free compounds as opposed to bound molecules were, in contrast, 
successful. Although simulations for conversion in the other direction from the O1 to the S1 
scaffold were stable, transformation in both directions is typical to eliminate bias towards the 
compound used for docking and to look for hysteresis
166( p577)
. 
TI calculations for the modification of an oxygen or sulphur link to CH2 were stable. Therefore, 
to compare oxygen and sulphur-containing structures, a TI run in which the oxygen or sulphur 
attachment atoms were converted to CH2 was performed for each of a set of 12 
oligobenzamides. In TI simulations, equilibration of d𝒱/dλ appeared to occur in under 50 ps. 
However, due to the time required for equilibration of the RMSDs in earlier work, the initial 
150 ps of each trajectory was not used for analysis. 
Predicted changes in the free energy of binding upon these transformations are shown in Figure 
2.13 below. Three different sizes of side chain were tested at the middle position: a small one 
(tertbutyl, side chain 19 in Figure 2.2 (pages 103 and 104)), a medium-sized group, 
(fluorobenzene, side chain 25) and a large one (methylnapthyl, side chain 3). 
At each step, four repeats were performed and the confidence limits in Figure 2.13 are based on 
the standard errors of these results. The errors associated with the results are quite large relative 
to the size of the calculated changes. They suggest that the phase space was insufficiently 
sampled for good convergence of the results from different repeats. A disadvantage of 
thermodynamic integration is that many simulations have to be performed for every conversion. 
This reduces the amount of time for which each simulation can be performed. 
Inspection of the results reveals a smaller drop in the free energy of binding in the case of ortho-
attached side chains (top half of Figure 2.12) compared to with meta-attached side chains 
(bottom half of Figure 2.12). This is as expected, given the shorter and thus stronger hydrogen 
bonds in the latter case. 
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Figure 2.13: Predicted changes to the free energy of binding of 12 compounds upon transformation 
of the side chain attachment atoms from oxygen or sulphur to CH2. Energies are in kJ mol
-1
. The 
compounds were based on the O1 (top left), S1 (top right), O2 (bottom left) or S2 scaffold (bottom right) 
as indicated by the structure of the scaffold part shown, which is the central unit holding the middle side 
chain. Three different middle side chains were tested as indicated. Apart from being modified at the 
central side chain position, the compounds are otherwise identical to the starting molecules shown in 
Figure 2.1 (p102).  
 
  
8.2 ± 7.3 25.7 ± 5.7 
13.8 ± 9.2 14.5 ± 4.3 
1.5 ± 5.6 11.4 ± 6.3 
15.9 ± 10.0 9.7 ± 9.2 
19.7 ± 6.5 23.1 ± 7.5 
42.1 ± 9.5 35.9 ± 5.6 
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In Table 2.4, the predicted binding energy changes for the side chain-holding heteroatom 
conversions to CH2 are compared to investigate if the oxygen atoms in O1 scaffold 
oligobenzamides or the sulphur atoms in the S1 oligobenzamides contribute more to the binding 
of the ligand. A t-test was used to test the significance of each difference. 
The results suggest that in terms of the O1 and S1 scaffolds, the choice of attachment atom does 
have an impact on affinity, with sulphur leading to stronger binding. (For side chain 19, ΔΔΔG = 
9.93 kJ mol-1, p < 0.013 and for side chain 3, ΔΔΔG = 17.50 kJ mol-1, p = 0.018.) Hydrogen 
bonds involving sulphur are weaker than the equivalent bonds involving oxygen; however, 
sulphur-hydrogen bond strength is more direction-dependent
260
 and the increased rigidity of the 
S1 scaffold relative to the O1 scaffold which results from the maintenance of this bond is 
incorporated into the torsion parameters for this scaffold
173
 (Table 2.2, p115). Prearrangement of 
S1 scaffold side chains could make binding more entropically favourable and also keep side 
chains on the surface of protein where they can contribute to the binding affinity. 
No statistically significant difference in affinity was observed between O2 and S2 scaffold 
compounds. This could be because the S2 scaffold is more flexible than the O2 scaffold due to 
steric hindrance between the large sulphur atoms and the hydrogen atom with which they 
bond
173
. 
Table 2.4: Use of Student’s t-test to determine if there are significant differences between the 
changes in free energy when oxygen is replaced with CH2 and when sulphur is replaced with CH2 
Scaffolds 
Middle 
side chain 
Difference 
/kJ mol-1 
Standard 
deviation of 
the difference 
/kJ mol-1 
t 
Degrees of 
freedom 
P 
O1/S1 19 9.94 2.64 -3.8 5.93 0.013 
O2/S2 19 -6.29 3.48 1.8 4.88 0.145 
O1/S1 25 0.63 3.18 -0.2 4.25 0.852 
O2/S2 25 3.36 3.12 -1.1 5.88 0.331 
O1/S1 3 17.50 2.92 -6.0 5.64 0.002 
O2/S2 3 -6.15 4.26 1.4 5.96 0.208 
 
In the column labelled “t” are the test statistics evaluated using student’s t-distribution. In the rightmost 
column are the probabilities of a difference as large as the one observed occurring due to chance. Only the 
O1/S1 results for side chains 3 and 19 are significant at the 5% significance level. The number of degrees 
of freedom at which to evaluate the t-distribution was calculated using the Welch–Satterthwaite 
equation
261
 so the assumption of equal sample variances was unnecessary. In practice, use of these 
degrees of freedom as opposed to the usual 2n-2 degrees of freedom (6 in this case) makes little 
difference to the critical values. (With 6 degrees of freedom, the 95% significance critical value of t is 
2.447.) 
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2.3.3.2. Thermodynamic integration results suggest that predicted binding free energies 
are robust to small changes in the scaffold backbone torsion parameters 
Different torsion parameters are used for scaffolds with oxygen-linked side chains compared to 
scaffolds with sulphur-linked ones as detailed in the methods section (p113). To investigate the 
importance of the torsional barriers used and the significance that modification of the torsional 
barrier height might have had in the link atom modification TI investigation above, a second TI 
investigation with the same 12 oligobenzamides was performed.  In this, the torsion angle 
barrier height of the bond about which rotation is restricted due to hydrogen bonding was 
changed from 1 kcal mol
-1
 below to 1 kcal mol
-1
 above its normal barrier height. The results are 
shown in Table 2.5. A single step is required for this conversion. 
Table 2.5: For oligobenzamides based on each scaffold, the TI-predicted change in binding energy 
associated with modification of the torsion parameter for the bond about which rotation is 
restricted due to intramolecular hydrogen bonding such that the barrier height goes from 1 kcal 
mol
-1
 below to 1 kcal mol
-1
 above the normal barrier height 
A
tt
ac
h
m
en
t 
p
o
si
ti
o
n
 
Middle 
side chain 
Change in potential energy predicted by the AMBER force field when 
increasing the torsional barrier height by 2 kcal mol-1 /kJ mol-1 
Attachment through oxygen Attachment through sulphur 
Free Bound Free – Bound Free Bound Free - Bound 
Ortho 19 (Small) -0.576 -0.835 -0.259 ± 0.100 -0.383 -0.438 -0.055 ± 0.053 
25 (Med.) -0.544 -0.565 -0.021 ± 0.082 -0.394 -0.411 -0.017 ± 0.039 
3 (Large) -0.546 -1.161 -0.614 ± 0.148 -0.390 -0.454 -0.064 ± 0.072 
Meta 19 (Small) -1.127 -1.065 0.062 ± 0.132 -3.850 -3.467 0.383 ± 0.111 
25 (Med.) -1.237 -1.210 0.027 ± 0.261 -3.781 -3.911 -0.131 ± 0.177 
3 (Large) -1.182 -1.304 -0.122 ± 0.126 -3.787 -3.653 0.135 ± 0.078 
 
For each scaffold, (O1 (top left), S1 (top right), O2 (bottom left) and S2 (bottom right)) scaffolds with 
three differently-sized side chains were tested in the middle side chain position (making 12 molecules in 
total). Negative values indicate where increasing the torsion energy is energetically favourable. 
Simulations were each performed four times. The unbiased sample variances of the free and bound values 
were summed to get, in the case of each molecule, the variance of the difference. 95% confidence limits 
based on these variances are shown in the “Free - Bound” column. 
 
The large changes in potential energy in the bottom rows of Table 2.5 (typically -1.2 kJ mol
-1
 
for the O2 scaffold and -3.7 kJ mol
-1
for the S2 scaffold) could reflect the change in electrostatic 
energy when the atoms involved in intramolecular hydrogen bonding are brought into closer 
proximity by the increase in the torsional barrier height of the amide carbon-aromatic carbon 
bond. This stabilisation is not observed with the O1 and S1 scaffolds to the same extent, perhaps 
because their intramolecular hydrogen bonds are longer. This effect could be particularly large 
for the S2 scaffold because the torsion parameter for this bond is particularly low in order to 
reflect the effect of steric hindrance between the nearby sulphur atom and its hydrogen-bonded 
hydrogen on the extent to which the p-orbitals of the aromatic ring and amide overlap
173
. 
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With regard to the “Free - Bound” columns of Table 2.5, the change in the free energy of 
binding is predicted to be negative when the torsional barrier height is increased in the O1 and 
S1 compounds. This implies that a reduction in scaffold flexibility increases binding affinity. 
However, the comparatively small changes in binding energy observed when the torsion 
parameters were changed by over 8 kJ mol
-1
, most of which are not statistically significant, 
suggest that the difference in torsion parameters between the O1 and S1 scaffolds might not be 
the main cause of the any difference in the affinity of these scaffolds, as was suggested in the 
previous section. 
S1 scaffold compounds might bind stronger than O1 scaffold compounds due to the greater size 
and polarisability of sulphur relative to oxygen
262(p1252)
, which could potentially lead to stronger 
van der Waals forces between these side chain attachment atoms and the protein if they were to 
interact. Future work could investigate the presence of interactions between these link atoms 
and the protein in long simulations of O1 and S1 scaffold compounds. 
In Leeds, most synthetic work has focussed on compounds with N-linked and O-linked side 
chains. The predicted stronger binding of some compounds based on the S1 scaffold compared 
to their corresponding O-linked counterparts (in the previous section) together with  the 
predicted increase in ortho-substituted oligobenzamide affinity when the torsional barrier height 
is raised (discussed in this section) advocate further investigation of the S1 scaffold. 
The remainder of this chapter concerns the effect side chain choice, as opposed to scaffold 
choice, has on predicted affinity. 
2.3.3.3. Comparison of the side chains by TI allowed predictions for 31 compounds based 
on the N1 scaffold to be made but there was a poor correlation between these predictions 
and experimental results 
The central aim of this project was to investigate whether relative oligobenzamide binding 
affinities could be predicted successfully by computational means. This section describes the 
ranking of 31 compounds based on the N-linked scaffold (Figure 1.6, p36) using 
thermodynamic integration (TI) and the comparison of the predicted ranking with single point 
fluorescence anisotropy measurements of their relative affinities. A poor correlation was 
observed and the conclusion at the end of this section is that TI is not a method by which the 
relative affinities of oligobenzamides for Mdm2 can be predicted accurately. TI is a method best 
suited to the comparison of very similar ligands with similar binding poses. The 31 compounds 
investigated, selected on the basis of their ease of synthesis rather than their suitability for 
computational comparison, had significant differences and subsequent docking discussed later 
in this chapter (p153) revealed that oligobenzamides can bind to Mdm2 in many different 
places. Compound synthesis and fluorescence anisotropy measurements were performed by 
Kerya Long (University of Leeds).
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Figure 2.14: The TI transitions performed to modify the central side chain of oligobenzamides based on the N1 scaffold together with their associated calculated 
differences in binding energy. The numbers of the compounds correspond to the numbers shown in Table 2.6 and Figure 6.1. The calculated energies are in kJ mol
-1
 and 95% 
confidence limits are shown.  143
  
 
 
 
Figure 2.14 shows predicted ΔΔG values for conversion of the central side chain of the N1 
scaffold (Figure 2.1, p102) between various possible structures. To simplify side chain 
comparison, it was assumed that changes were additive, so, for example, the binding ΔΔG for 
conversion of a chloronapthyl group to a benzyl group was the sum of the ΔΔG for conversion 
of a chloronapthyl group to a napthyl group and the ΔΔG for converting a napthyl group to a 
benzyl group. 
When equilibrating simulations for TI, d𝒱/dλ (defined on p84) equilibrated rapidly. Curves of 
d𝒱/dλ against λ were typically smooth, especially for the removal of charges and addition of 
charges respectively, the first and last steps of the alchemical conversion. For example, see 
Figure 2.15 and Figure 2.16 below. 
The most significant change in binding free energy shown in Figure 2.14  is that for removal of 
the ammoniumyl (NH3
+
) group from side chain 22, -23.5 kJ mol
-1
. Removal of this charged 
group is predicted to be very favourable and much of the favourable ΔΔG (-15.4 kJ mol-1) is 
accounted for by step 1 of the TI conversion, removal of the positive charge. Of the 31 N-linked 
compounds synthesised and tested, the weakest binding was found to be the one with this side 
chain (which was at the middle side chain position), suggesting that this side chain is genuinely 
very unfavourable for binding. The p53 binding site of Mdm2 is hydrophobic; p53-Mdm2 
binding is driven by van der Waals forces
207
. Consequently, hydrogen bonds that the positive 
ammoniumyl group can make in the solvent are likely to be lost when the small molecule binds, 
making binding enthalpically unfavourable. Binding will also not be accompanied by the 
favourable entropy change which occurs when a hydrophobic group is buried and the water 
molecules around it are released from their regular arrangement
57
. A possible explanation 
considered was interaction of the charged side chain with the terminal, negatively charged 
carboxylate group in the free but not the bound ligand; however, simulations of the free ligand 
reveal that the side chain and C-terminal are too far apart and the oligobenzamide is 
insufficiently flexible to bring them together. 
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 Step 1 
 
Step 2 
 
Step 3 
 
 
Figure 2.15: Example TI d𝒱/dλ graphs: The modification of side chain 26 to side chain 27 at the 
middle position of the N1 scaffold (Figure 1.6, p36). The terminal side chains were as shown in Figure 
2.1 (p102). Results for the bound ligand are shown in red. Results for the free ligand are shown in blue. 
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Step 2 
 
Step 3 
 
 
Figure 2.16: Example TI d𝒱/dλ graphs: The modification of side chain 1 to side chain 11 at the 
middle position of the N1 scaffold (Figure 1.6, p36). The terminal side chains were as shown in Figure 
2.1 (p102). Results for the bound ligand are shown in red. Results for the free ligand are shown in blue. 
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Table 2.6 shows in more detail the results summarised in Figure 2.14, TI results for 
modification of the side chain at the central attachment position of the N1 oligobenzamide 
scaffold. The result for step 3 for the conversion of side chain 21 to side chain 17 (-376 kJ 
mol
-1
) appears to be unusually large in magnitude given that side chain 17 is an ethyl group. 
This energy change for the addition of charge to the system is due to charging of a Cl
-
 counter 
ion, which is present in the systems as a result of side chain 21 being negatively charged and the 
method of adding ions when simulations were set up (described on p117 and illustrated 
graphically in Figure 2.7 on p119). Charging of a counter ion (in this case K
+
) is also 
responsible for the large change observed in step 3 for the conversion of side chain 22 to side 
chain 15 (-370 kJ mol
-1
). 
Validation of computational results would have been most straightforward using a systematic 
set of compounds, for example, molecules differing in their side chain at a single attachment 
position. However, in the event, difficulties with chemical synthesis meant that the molecules 
available for comparison differed in their side chains at all three side chain attachment positions, 
as shown in Table 2.7. To facilitate the comparison of predicted and experimental results, the 
side chains at each position were assumed to make independent contributions to the binding 
energy, such that the ΔΔG for any two compounds differing at all three side chain positions was 
the sum of three energy changes, one for the modification at each side chain attachment 
position. TI simulations for modification at the first and last side chain positions (full results not 
shown) were performed in a similar manner to those for the middle position. This enabled 
binding energies to be predicted for all 31 compounds synthesised by the collaborating 
chemistry group (Table 2.7, p150). 
Table 2.7 shows, for each compound, the relative predicted free energies of binding and, for 
comparison, the fluorescence polarisation single point competition assay results obtained in the 
laboratory and supplied by Kerya Long (University of Leeds). The side chain numbers refer to 
the side chain structures shown in Figure 2.14 and also Figure 2.2 above (p103). The relative 
predicted free energies of binding (ΔΔG) are relative to the scaffold with side chain 17 (an ethyl 
group) at every side chain position. The values for side chain 2, the middle side chain, 
correspond to the changes shown in Figure 2.14. For example, where side chain 11 is shown 
present at the middle position in Table 2.7, the predicted binding energy contribution of side 
chain 2 is -4.4 kJ mol
-1
, consistent with the 4.4 kJ mol
-1
 ΔΔG for the conversion of side chain 11 
to side chain 17 in Figure 2.14. Other values in this column can be calculated by summing the 
transitions shown in Figure 2.14. For example, in the first row of data in Table 2.7, the -9.93 kJ 
mol
-1
 binding free energy contribution for side chain 2 corresponds to the sum of 5.53 kJ mol
-1
 
for the conversion of side chain 1 to side chain 11 in Figure 2.14 and the aforementioned 4.4 kJ 
mol
-1
 for the conversion of side chain 11 to side chain 17. 
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Table 2.6: Thermodynamic integration results for transformation of the middle side chain of the N1 scaffold starting molecule 
Modification Repeats Step 1 ΔG /kJ mol—1 Step 2 ΔG /kJ mol--1 Step 3 ΔG /kJ mol—1 Overall ΔΔG 
From To Bound Free Bound Free Bound Free 
1 11 6 11.92 ± 0.21 13.12 ± 0.22 -77.79 ± 1.15 -91.12 ± 0.58 60.84 ± 0.72 67.44 ± 0.18 5.53 ± 1.59  
2 11 6 -8.34 ± 0.95 -5.88 ± 0.29 -73.95 ± 0.96 -81.79 ± 0.99 43.02 ± 0.90 46.04 ± 0.15 2.37 ± 2.02  
3 2 3 3.38 ± 0.03 3.58 ± 0.00 21.15 ± 0.68 18.18 ± 0.18 28.53 ± 0.24 28.87 ± 0.27 2.44 ± 1.97  
4 11 3 -31.01 ± 0.17 -31.12 ± 0.13 -38.83 ± 4.02 -41.38 ± 0.18 29.26 ± 0.63 31.63 ± 0.17 0.29 ± 10.14 ? 
5 11 3 -68.94 ± 0.26 -70.01 ± 0.08 -62.11 ± 2.33 -68.50 ± 0.23 34.78 ± 0.41 35.00 ± 0.05 7.24 ± 5.93  
6 12 6 22.74 ± 0.60 24.20 ± 0.20 -136.31 ± 1.65 -163.13 ± 0.17 109.72 ± 0.87 118.50 ± 0.07 16.58 ± 2.07  
21 17 3 154.70 ± 2.67 155.05 ± 0.57 163.10 ± 1.02 178.94 ± 0.72 -370.59 ± 0.67 -376.29 ± 0.06 -10.48 ± 7.65  
12 17 3 13.56 ± 3.13 14.64 ± 0.10 -35.37 ± 2.84 -39.06 ± 0.04 0.18 ± 0.01 0.07 ± 0.00 2.73 ± 10.51 ? 
11 17 6 0.74 ± 0.76 4.47 ± 0.14 15.96 ± 1.04 7.95 ± 0.31 0.19 ± 0.00 0.07 ± 0.00 4.40 ± 1.40  
15 17 3 6.66 ± 0.03 5.59 ± 0.01 17.12 ± 0.44 15.90 ± 0.44 0.06 ± 0.00 0.02 ± 0.00 2.32 ± 1.54  
4 24 3 8.35 ± 4.59 -13.74 ± 0.32 -51.38 ± 3.44 -27.62 ± 0.24 0.00 ± 0.00 0.00 ± 0.00 -1.67 ± 14.27 ? 
24 11 3 33.49 ± 0.36 30.40 ± 0.03 -52.41 ± 0.93 -51.20 ± 0.12 29.18 ± 0.43 31.52 ± 0.16 -0.47 ± 2.75  
28 26 6 -18.91 ± 0.20 -16.04 ± 0.03 52.65 ± 1.09 52.66 ± 0.12 0.00 ± 0.00 0.00 ± 0.00 -2.88 ± 1.17  
27 26 3 133.22 ± 2.40 140.98 ± 0.27 -44.90 ± 0.93 -38.62 ± 0.08 -20.32 ± 0.12 -18.15 ± 0.02 -16.21 ± 6.44  
Continued on the next page… 
Step 1 was the removal of charges from the atoms to be removed. Step 2 was the decoupling of the atoms being removed and introduction of any new atoms. Step 3 was the addition 
of charge to any new atoms (and this step was only necessary where atoms were being added). The first two columns show the initial and final side chains. For the structures of these 
side chains see Figure 2.14 (p143) or Figure 2.2 (p103). 95% confidence limits are shown on values. The symbols on the right of the table show whether the new compound binds 
more strongly (red) or less strongly (blue) than the original. Grey question marks and green dashes indicate where the error indicated by the 95% confidence limits is greater than the 
overall change, with the dash being where the error is under 3 kJ mol
-1
 and the failure to see a significant change could be because the real affinities of the original and modified side 
chain are very similar. Initially, the TI conversions of each step were performed three times. The results for each step were then used to calculate the 95% confidence limits on the 
ΔΔG for that step. The variances of the three steps were summed to obtain the variance of the overall ΔΔG. If the error on the final ΔΔG was larger than the ΔΔG itself, meaning that 
the overall ΔΔG was not significantly different from 0 at the 5% significance level, then a further 3 repeats were performed in an effort to reduce the error. 
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Table 2.6 continued: Thermodynamic integration results for transformation of the middle side chain of the N1 scaffold starting molecule 
Modification Repeats Step 1 ΔG /kJ mol—1 Step 2 ΔG /kJ mol--1 Step 3 ΔG /kJ mol—1 Overall ΔΔG 
From To Bound Free Bound Free Bound Free 
26 27 3 20.05 ± 0.19 18.13 ± 0.02 45.50 ± 0.62 38.63 ± 0.07 -130.46 ± 0.37 -141.11 ± 0.18 19.44 ± 1.92  
26 25 3 20.43 ± 0.28 18.20 ± 0.09 -33.92 ± 0.63 -41.90 ± 0.28 -45.69 ± 0.14 -39.38 ± 0.21 3.92 ± 1.95  
25 26 3 45.20 ± 0.56 39.30 ± 0.11 34.31 ± 0.67 41.89 ± 0.00 -20.16 ± 0.04 -18.24 ± 0.03 -3.59 ± 2.18  
28 11 3 26.99 ± 0.19 28.79 ± 0.03 -22.36 ± 0.58 -29.82 ± 0.18 34.70 ± 0.46 34.96 ± 0.08 5.41 ± 1.97  
27 11 3 130.70 ± 0.80 141.13 ± 0.26 -96.11 ± 0.26 -95.20 ± 0.20 34.36 ± 0.10 34.97 ± 0.04 -11.96 ± 2.26  
26 11 3 20.18 ± 0.11 18.17 ± 0.05 -50.44 ± 0.44 -56.19 ± 0.34 34.72 ± 0.45 34.98 ± 0.10 7.50 ± 1.83  
25 11 6 45.89 ± 0.41 39.37 ± 0.06 -17.93 ± 0.52 -14.53 ± 0.17 34.48 ± 0.42 34.96 ± 0.10 2.64 ± 0.85  
29 15 6 -3.96 ± 0.49 0.71 ± 0.72 -6.84 ± 1.08 -17.12 ± 0.34 2.32 ± 0.09 1.69 ± 0.02 6.25 ± 1.50  
22 15 3 69.15 ± 0.95 84.54 ± 1.03 12.81 ± 1.31 17.26 ± 0.37 -369.58 ± 0.21 -365.93 ± 0.11 -23.49 ± 4.89  
19 15 3 47.02 ± 0.20 44.42 ± 0.08 -20.30 ± 1.79 -16.94 ± 0.39 -2.40 ± 0.04 -1.90 ± 0.02 -1.26 ± 4.60 ? 
20 19 3 -2.18 ± 0.06 -2.77 ± 0.01 -32.88 ± 0.68 -38.66 ± 0.17 -4.53 ± 0.40 -5.97 ± 0.02 7.82 ± 2.00  
18 15 3 -58.24 ± 0.93 -57.06 ± 0.17 -23.57 ± 0.59 -24.27 ± 0.41 -1.46 ± 0.13 -1.73 ± 0.03 -0.21 ± 2.96  
18 19 6 20.49 ± 0.07 18.06 ± 0.03 -73.67 ± 0.26 -79.22 ± 0.27 -54.18 ± 0.15 -47.75 ± 0.05 1.55 ± 0.43  
19 18 6 53.50 ± 0.23 47.60 ± 0.07 73.61 ± 0.38 78.96 ± 0.23 -20.72 ± 0.16 -18.02 ± 0.04 -2.16 ± 0.56  
  
149
  
 
 
 
The laboratory results are in the form of a percentage inhibition relative to Nutlin-3. These 
values indicate the extent to which the compound inhibited the p53-Mdm2 interaction at the 
assay concentrations (10 µM ligand, 54.5 nM fluorescein-labelled p53 peptide and 41.5 nM 
Mdm2 L33E) relative to a racemic Nutlin-3 control. 
 
Table 2.7: Comparison of fluorescence anisotropy results for 31 compounds based on the N1 
scaffold with predictions of their relative binding affinity from thermodynamic integration 
Side chains at 
each side chain 
position 
Effect relative to 
Nutlin-3 in 
fluorescence 
anisotropy 
assay (%) M
ea
su
re
d
 
ra
n
k 
Predicted binding energy contribution 
relative to side chain 17 (ethyl) /kJ mol-1 
P
re
d
ic
te
d
 
ra
n
k 
1 2 3 
Side 
chain 1 
Side 
chain 2 
Side 
chain 3 
Total 
26 1 18 120 1 -8.18 -9.93 -3.89 -22.00 4 
11 4 15 119 2 -7.29 -3.49 -3.96 -14.73 27 
25 1 15 114 3 -7.48 -9.93 -3.96 -21.37 6 
4 4 11 112 4 -10.93 -3.49 -7.10 -21.52 5 
11 1 18 110 5 -7.29 -9.93 -3.89 -21.11 8 
26 4 18 108 6 -8.18 -3.49 -3.89 -15.55 25 
29 5 19 103 7 -3.28 -11.65 -5.76 -20.68 11 
11 7 19 99.6 8 -7.29 -24.74 -5.76 -37.79 1 
18 29 24 97.2 9 -2.21 -8.57 -6.67 -17.45 20 
11 2 19 94.7 10 -7.29 -6.77 -5.76 -19.82 13 
11 24 19 93.7 11 -7.29 -5.15 -5.76 -18.19 18 
11 29 15 92.4 12 -7.29 -8.57 -3.96 -19.82 14 
24 29 18 86.4 13 -8.88 -8.57 -3.89 -21.35 7 
11 3 19 85.8 14 -7.29 -9.21 -5.76 -22.26 3 
11 19 11 84.0 15 -7.29 -0.66 -7.10 -15.05 26 
29 26 19 77.8 16 -3.28 -11.90 -5.76 -20.93 9 
11 11 19 77.5 17 -7.29 -4.40 -5.76 -17.45 21 
26 4 19 77.3 18 -8.18 -3.49 -5.76 -17.42 22 
25 4 19 75.0 19 -7.48 -3.49 -5.76 -16.72 23 
24 4 19 74.2 20 -8.88 -3.49 -5.76 -18.13 19 
25 20 15 73.0 21 -7.48 -7.77 -3.96 -19.21 15 
19 5 19 72.1 22 -1.65 -11.65 -5.76 -19.05 16 
11 25 15 71.3 23 -7.29 -7.05 -3.96 -18.29 17 
19 24 19 70.8 24 -1.65 -5.15 -5.76 -12.55 28 
11 25 19 65.7 25 -7.29 -7.05 -5.76 -20.09 12 
11 21 19 49.8 26 -7.29 10.48 -5.76 -2.57 30 
11 20 19 44.9 27 -7.29 -7.77 -5.76 -20.82 10 
11 18 19 38.7 28 -7.29 -2.51 -5.76 -15.56 24 
11 28 19 33.4 29 -7.29 -9.41 -5.76 -22.46 2 
11 27 19 31.6 30 -7.29 7.56 -5.76 -5.49 29 
11 22 19 5.98 31 -7.29 21.16 -5.76 8.12 31 
 
Fluorescence anisotropy results were supplied by Kerya long, University of Leeds. The overall change in 
binding energy for modification of all three the side chains was assumed to be equal to the sum of the 
changes associated with modification of each side chain individually. Both the practical and predicted 
rankings are from the strongest binding compound (1) to the most weakly binding (31). 
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In Figure 2.17 (p152) the predictions and experimental results are graphically compared. A high 
magnitude Pearson’s rank correlation coefficient of -0.58 was observed. However, the results 
are not normally distributed which makes it more appropriate to consider the Spearman’s Rank, 
which is only 0.40. 
 
The observed correlation is small in magnitude. At the 5% significance level, the two-tailed 
critical value for Spearman’s Rank with 30 degrees of freedom (n=31) is 0.35. Consequently, 
this rank of 0.40 would normally be considered a significant result. However, the results are not 
independent because of the way that they have been calculated. (As described above, the 
predicted relative binding energy of each oligobenzamide was calculated by way of a series of 
summations, specifically, addition of the ΔΔG values associated with small modifications to 
generate ΔΔG contributions for each side chain, followed by addition of these three side chain 
contributions to generate a total ΔΔG for each molecule.) Consequently, the Spearman’s Rank 
might be less statistically significant than it appears. In conclusion, the results suggest that TI is 
not a useful method of ranking oligobenzamides with N-linked side chains. 
 
There is a moderate correlation between the molecular weight of the 31 ligands and their 
affinity for Mdm2 as indicated by the fluorescence anisotropy assay. Spearman’s rank is 0.61, 
suggesting that molecular weight is a much better predictor of affinity than the TI method. The 
same magnitude of correlation is observed using predicted logP. The lowest molecular weight 
compounds are, in order of increasing size, compounds 28, 26, 31 and 24. The compounds with 
the lowest predicted logP are, in order, 26 (negatively charged), 31 (positively charged), 28, 24 
and 30. These weakly binding compounds can be found in the top left of Figure 2.17A, the top 
right of Figure 2.17B and, later in the chapter where use of the MM-PBSA method is described, 
the top left of Figure 2.22 (p174). 
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A 
 
B 
 
Figure 2.17: A comparison of predictions and experimental results for the 31 N-linked compounds 
ranked using thermodynamic integration. Each cross represents one of the 31 compounds tested. The 
numbers indicate the measured ranking of the compounds from 1 (the highest affinity) to 31 (the lowest). 
A) Comparison of the actual values. (A negative correlation is expected.) B) The same data but with the 
ranks plotted. It is more appropriate to consider Spearman’s Rank because the data are not normally 
distributed. Here a positive correlation is expected because both sets of results were ranked from the most 
strongly binding (1) to the weakest binding (31). 
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2.3.4. DOCKING POSES OF 25,000 COMPOUNDS REVEAL THAT 
OLIGOBENZAMIDES CAN BIND IN MANY DIFFERENT POSES 
2.3.4.1. Different oligobenzamides bind in different places 
This section concerns the docking of oligobenzamides to investigate whether they all bind in the 
same, expected position, an assumption which the analysis until this point has relied upon. This 
assumption is necessary when using thermodynamic integration and, if invalid, could explain 
the poor correlation between predicted and experimental results observed above. 
Gonzalez-Lopez de Turiso et al.
263
 discuss crystal structures of two similar morpholinone 
inhibitors of the p53-Mdm2 interaction which feature the two compounds in significantly 
different binding poses. (Essentially, the groups in the Phe19 and Leu26 pockets are swapped 
over.) Small changes in the structure of an oligobenzamide could similarly lead to very different 
binding poses. Fuller et al.
172
 reports the stable binding of an oligobenzamide based on the O1 
scaffold both parallel and antiparallel to the p53-helix orientation.  
To investigate where oligobenzamides with different combinations of side chains and different 
scaffolds bind, 25,000 compounds, roughly 5,000 for each of the N1, O1, O2, S1 and S2 
scaffolds (N1: 5047, O1:4933, S1:5042, O2:5043, S2:4935), were docked with Autodock Vina 
and the pose positions were analysed. Table 2.8 shows the side chains used. The numbers 
correspond to the side chains shown in Figure 2.2 (p103). 
Table 2.8: Side chains tested at each side chain position when docking 25,000 oligobenzamides to 
determine the effect of side chain selection on binding pose 
Side chain position Side chains tested at position Number of side chains 
1 4, 11, 13-15, 17-19, 21-30, 33, 36-40, 44 25 
2 1-32, 34-46 45 
3 11, 14, 15, 17-24, 30-32, 35-38, 40-43 22 
 
See Figure 2.2 (p103) for the side chain structures. The side chains tested were selected manually on the 
basis of their size and similarity to the Phe19, Trp23 and Leu26 p53 side chains as described on p104. 
 
Initially, the possibility of clustering all of the poses obtained was considered. The effect of 
different factors such as scaffold and side chain choice on the presence of poses in each cluster 
could then have been investigated. However, it was not immediately obvious how the differing 
connectivity of molecules should be treated in the clustering process. Furthermore, preliminary 
investigation revealed that the poses for different oligobenzamides, when combined, produced a 
broad and quite homogenous distribution of poses with little discernible clustering; while poses 
were focussed around the pockets of the p53 binding site and tended to be parallel or antiparallel 
to the p53 binding groove, they did not conform to one of a small number of clusters. Although 
poses of each oligobenzamide could be clustered in isolation, this did not simplify interpretation 
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of the disparate assortment of configurations obtained when the data for different compounds 
were consolidated. 
To enable interpretation, the centre of mass of each side chain in each docked pose was used to 
evaluate the position of the side chain with regard to each of the Mdm2 binding pockets. 
Specifically, the distance between the side chain centre and the centre of mass of each p53 
residue side chain in PDB crystal structure 1T4F (Mdm217-125 bound to a modified p53 
peptide
37
) was calculated. If this distance was within a cut-off (3 or 4 Å as indicated next to each 
set of results below) then the side chain was considered to be in the pocket usually occupied by 
that residue in p53. (Only heavy atoms were used to calculate the centres of mass because 
hydrogen atoms are not present in X-ray crystal structures.) For further details see p111. 
Table 2.9 below shows the most frequently occurring single side chain-pocket matches revealed 
by the pose analysis. For example, for the N1 scaffold, the most commonly occurring match is 
to find side chain 3 (the C-terminal side chain) in the pocket usually occupied by Phe19 of p53. 
For 99% of compounds, at least one of the poses had side chain 3 in this position and 54.5% of 
the time, the top pose for a compound satisfied the condition. 
The results suggest that different scaffolds favour different binding poses. For example, while 
the side chain 3-Phe19 pocket pairing is the most common with the N1 scaffold, the side chain 
2-Phe23 pairing is most common for the O1 and S1 scaffolds and for the O2 and S2 scaffolds 
the most common pairings are side chain 1 in the Trp23 pocket and side chain 2 in the Phe19 
pocket respectively. 
It appears that pockets 19 and 23 are usually occupied but it is difficult to interpret the single 
side chain-pocket match results below because they give little information about the pose. Table 
2.10 below indicates the most commonly occurring pairs of matches. For example, it shows that 
88.9% of scaffold N1 compounds have a pose with both side chain 2 in the Trp23 pocket and 
side chain 3 in the Phe19 pocket. 
As shown, for all of the scaffolds, the most common pair of matches involves the Phe19 and 
Trp23 sites, a finding that suggests that these pockets are particularly important for binding, as 
would be expected, given their size. For all of the scaffolds, side chain 2 is one of the side 
chains in this top match. The second most common pair of matches always appears to involve 
the Leu26 pocket, consistent with the widely held view that the Phe19, Trp23 and Leu26 
residues being those most important for p53 binding
26
. Adjacent side chains, particularly the 
middle and C-terminal side chains are seen to be able to occupy the Phe19 and Leu26 binding 
sites simultaneously to an extent sufficient to satisfy the 3 Å distance cut-offs. 
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Table 2.9: The most frequently occurring side chain to binding pocket matches for each scaffold 
Scaffold Rank Matching One 
pose 
(%) 
Best 
pose 
(%) 
 Scaffold Rank Matchi
ng 
One 
pose 
(%) 
Best 
pose 
(%) 
N1 1 SC3-19 99.0 54.5  S1 1 SC2-23 99.1 55.3 
2 SC2-23 98.5 57.7  2 SC2-26 91.0 19.8 
3 SC2-19 86.8 8.3  3 SC1-19 89.7 23.8 
4 SC2-26 83.6 10.6  4 SC1-23 84.0 14.3 
5 SC3-23 79.1 11.3  5 SC3-23 82.1 15.3 
6 SC3-26 73.4 4.2  6 SC2-19 79.4 5.7 
7 SC1-19 63.0 15.6  7 SC3-26 76.3 22.3 
8 SC1-22 60.2 0.3  8 SC3-19 72.5 16.7 
9 SC3-22 58.4 0.3  9 SC1-26 67.1 5.8 
10 SC2-20 38.0 2.2  10 SC3-22 58.6 1.8 
O1 1 SC2-23 99.1 55.6  S2 1 SC2-19 95.6 29.8 
2 SC2-26 90.4 22.3  2 SC1-23 93.5 45.1 
3 SC1-19 90.2 26.6  3 SC2-26 91.6 35.5 
4 SC1-23 86.0 19.1  4 SC2-23 88.5 16.9 
5 SC2-19 84.6 8.1  5 SC3-23 88.2 22.2 
6 SC3-23 80.2 14.1  6 SC1-19 79.2 13.3 
7 SC3-19 76.4 14.7  7 SC3-19 79.0 5.7 
8 SC1-26 67.7 12.3  8 SC3-26 77.2 15.2 
9 SC3-26 65.4 7.9  9 SC1-26 73.3 11.3 
10 SC3-22 65.2 6.9  10 SC1-22 60.8 5.5 
O2 1 SC1-23 94.7 42.6 
2 SC3-23 92.7 32.6 
3 SC2-26 92.4 38.0 
4 SC2-19 91.8 16.1 
5 SC3-19 83.0 9.9 
6 SC2-23 81.3 15.1 
7 SC3-26 71.4 5.2 
8 SC1-26 68.8 15.2 
9 SC1-19 64.8 2.9 
10 SC1-22 49.9 2.1 
 
“SC1”, “SC2” and “SC3” denote the 3 side chains of the ligand. The pockets in which they reside are 
indicated by the numbers “19”, “22”, “23” and “26”, which refer to the residues of p53 Phe19, Leu22, 
Trp23 and Leu26 which, through their position in the PDB structure from which Mdm2 was extracted for 
docking, define Mdm2 binding pockets. For more details see p111. A cut-off of 3 Å was used for 
matching. The “one pose” column shows the percentage of compounds for which there was one pose with 
its side chains in the position shown and the “best pose” column shows the percentage of compounds for 
which the top pose satisfied the condition. For example, 99% of the compounds based on the N-linked 
scaffold, yielded, when docked, at least one pose in which the third (C-terminal) side chain occupied the 
Mdm2 binding pocket normally occupied by p53 residue Phe19. The structures of the five scaffolds (N1, 
O1, O2, S1 and S2) are shown in Figure 2.1 (p102) and the side chains tested at each side chain position 
are shown in Table 2.8 above, where the numbers correspond to the structures in Figure 2.2 (starting on 
p103). 
 
  
155
  
 
 
 
Table 2.10: The most frequently occurring pairs of side chain to binding pocket matches for each 
scaffold 
Sc
af
fo
ld
 
R
an
k Matching 
One 
pose 
(%) 
Best 
pose 
(%) 
 
Sc
af
fo
ld
 
R
an
k Matching 
One 
pose 
(%) 
Best 
pose 
(%) 
N1 1 SC2-23   SC3-19 88.9 39.7  S1 1 SC1-19   SC2-23 74.0 20.0 
2 SC2-26   SC3-19 62.5 6.8  2 SC2-23   SC2-26 65.4 6.7 
3 SC2-23   SC2-26 57.7 4.0  3 SC2-23   SC3-19 61.9 14.9 
4 SC2-19   SC3-23 56.4 6.5  4 SC2-23   SC3-26 48.8 15.1 
5 SC1-22   SC2-23 44.8 0.2  5 SC1-19   SC2-26 42.9 2.3 
6 SC1-19   SC2-23 43.5 6.0  6 SC1-19   SC3-26 41.9 11.9 
7 SC2-23   SC3-22 38.0 0.3  7 SC1-26   SC3-22 40.7 1.1 
8 SC2-19   SC3-26 35.0 2.5  8 SC1-23   SC2-19 39.2 1.0 
9 SC3-23   SC3-26 28.1 1.5  9 SC1-26   SC2-19 36.6 0.7 
10 SC2-26   SC3-23 25.5 1.2  10 SC2-26   SC3-23 36.5 5.8 
O1 1 SC1-19   SC2-23 73.7 22.2  S2 1 SC2-19   SC3-23 71.7 13.3 
2 SC2-23   SC2-26 67.7 11.9  2 SC2-23   SC2-26 64.9 8.2 
3 SC2-23   SC3-19 64.8 11.7  3 SC2-19   SC3-26 64.6 10.1 
4 SC1-19   SC2-26 49.4 8.5  4 SC1-26   SC2-19 62.7 10.6 
5 SC1-26   SC2-23 47.6 9.5  5 SC2-23   SC3-19 61.4 3.4 
6 SC1-26   SC3-22 44.5 5.3  6 SC1-19   SC2-23 61.3 7.7 
7 SC1-22   SC2-23 43.8 2.5  7 SC3-23   SC3-26 61.0 10.1 
8 SC2-23   SC3-22 43.0 4.7  8 SC1-23   SC2-19 60.1 11.7 
9 SC1-23   SC2-19 42.9 2.8  9 SC2-26   SC3-19 57.6 3.1 
10 SC2-19   SC3-23 38.4 3.0  10 SC1-23   SC2-26 55.8 18.5 
O2 1 SC2-19   SC3-23 69.2 4.1 
2 SC2-26   SC3-19 67.3 7.5 
3 SC2-23   SC2-26 59.8 6.6 
4 SC1-26   SC2-19 59.7 9.2 
5 SC2-23   SC3-19 57.7 6.9 
6 SC1-23   SC2-26 57.4 15.8 
7 SC2-19   SC3-26 54.1 1.7 
8 SC1-23   SC2-19 53.5 7.6 
9 SC1-19   SC2-23 47.5 2.4 
10 SC1-23   SC1-26 46.8 9.6 
 
“SC1”, “SC2” and “SC3” denote the 3 side chains of the ligand. The pockets in which they reside are 
indicated by the numbers “19”, “22”, “23” and “26”, which refer to the residues of p53 Phe19, Leu22, 
Trp23 and Leu26 which, through their position in the PDB structure from which Mdm2 was extracted for 
docking, define Mdm2 binding pockets. For more details see “Pose recognition” on p111. A cut-off of 3 Å 
was used for identification of the side chains in each pocket. The “one pose” column shows the percentage 
of compounds for which there is one pose with its side chains in the positions indicated and the “best 
pose” column shows the percentage of compounds for which the top pose satisfies the condition. For 
example, 88.9% of the compounds based on the N-linked scaffold, yielded, when docked, at least one 
pose in which the second (middle) side chain occupied the Mdm2 binding pocket normally occupied by 
p53 residue Trp23 and the third (C-terminal) side chain occupied the Mdm2 binding pocket normally 
occupied by p53 residue Phe19. 
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Table 2.11: The most frequently occurring sets of three side chain to three binding pocket matches 
for each scaffold 
Sc
af
fo
ld
 
R
an
k 
Side chains 
One 
pose 
(%) 
Best 
pose 
(%) 
 
Sc
af
fo
ld
 
R
an
k 
Side chains 
One 
pose 
(%) 
Best 
pose 
(%) 1 2 3  1 2 3 
N 1 26 19 22 16.5 0.00  S1 1 26 19 22 45.6 1.35 
2 23 19 22 14.6 0.00  2 19 23 26 44.1 11.66 
3 22 19 26 13.8 0.50  3 23 19 22 42.6 0.99 
4 19 23 26 13.5 0.22  4 26 23 22 35.2 1.63 
5 22 19 23 11.4 0.38  5 26 23 19 30.1 5.63 
6 19 20 26 10.4 0.42  6 22 23 26 25.9 3.27 
7 26 23 22 9.4 0.00  7 23 23 22 19.2 0.56 
8 22 23 26 7.7 0.26  8 22 19 26 17.7 1.07 
9 22 23 20 7.3 0.00  9 22 19 23 13.0 0.58 
10 23 23 22 6.9 0.00  10 26 20 22 10.7 0.00 
O1 1 26 23 22 44.8 6.49  S2 1 22 19 26 58.8 6.42 
2 26 19 22 41.8 3.14  2 22 19 23 58.2 6.14 
3 23 19 22 39.9 2.39  3 26 19 22 47.1 1.54 
4 19 23 26 22.5 2.49  4 23 19 22 39.3 1.46 
5 26 23 19 22.3 3.24  5 26 23 22 16.9 0.04 
6 23 23 22 18.1 1.70  6 22 23 26 8.8 0.67 
7 22 23 26 16.1 0.53  7 23 23 22 7.2 0.04 
8 22 19 26 12.9 0.79  8 22 20 23 7.1 0.04 
9 26 20 22 11.3 0.02  9 22 20 26 6.8 0.04 
10 23 20 22 9.6 0.02  10 22 23 23 4.5 0.18 
O2 1 22 19 23 55.2 0.87         
2 22 19 26 54.8 1.03         
3 26 19 22 49.2 3.03         
4 23 19 22 37.9 1.57         
5 26 23 22 19.8 1.03         
6 22 23 26 16.8 0.65         
7 22 23 23 12.2 0.30         
8 23 23 22 8.9 0.18         
9 22 20 23 3.6 0.04         
10 22 20 26 3.5 0.04         
 
“SC1”, “SC2” and “SC3” denote the 3 side chains of the ligand. The pockets in which they reside are 
indicated by the numbers “19”, “22”, “23” and “26”, which refer to the residues of p53 Phe19, Leu22, 
Trp23 and Leu26 which, through their position in the PDB structure from which Mdm2 was extracted for 
docking, define Mdm2 binding pockets. A cut-off of 4 Å was used for identification of the side chains in 
each pocket. For more details see p111. The “one pose” column shows the percentage of compounds for 
which there is one pose with its side chains in the arrangement described. For example, 16.5% of the 
compounds based on the N-linked scaffold, yielded, when docked, at least one pose in which the first side 
chain was in the pocket usually occupied by p53 residue Leu26, the second was in the pocket usually 
occupied by Phe19 and the third was in the pocket usually occupied by p53 residue Leu22. The “best 
pose” column shows the percentage of compounds for which the top pose satisfied the condition.. For 
further details see Table 2.9 (p155). 
 
Table 2.11 above shows the three side chain-three pocket matches observed. While the Phe19, 
Trp23 and Leu26 pockets feature prominently in the side chain-pocket pairings above, the 
results in this last table indicate that compounds often do not occupy all three of these sites in a 
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particular pose. They suggest that a pose such as that shown in Figure 2.8 (p129), where the 
three side chains of an oligobenzamide occupy the Phe19, Trp23 and Leu26 binding sites, might 
be a rare, idealised conformation that reflects the similarity of the benzyl, napthyl and isopropyl 
side chains of the oligobenzamide shown to the phenylalanine, tryptophan and leucine p53 side 
chains being mimicked. 
The 22
nd
 residue of p53 is leucine. The Leu22 pocket appears frequently in Table 2.11 above; 
however, this might reflect its proximity to the centre of the binding site as opposed to any 
significant involvement in ligand binding. 
2.3.4.2. Logistic regression reveals that the relationship between side chain properties and 
binding pose is not straightforward 
The results above indicate that the choice of scaffold influences the binding pose and that 
oligobenzamides can potentially bind to Mdm2 in many different ways. This section describes 
the application of logistic regression
252
 (p292) to the docking results introduced above to 
investigate the effect of side chain choice on binding pose. 
Five Boolean questions were formulated which could be asked of a particular compound (Figure 
2.18). The first, for example, was whether there was a pose where the middle side chain was in 
the Trp23 binding pocket of Mdm2. This question was proposed because, of the 25000 
compounds tested, 52% (13090 compounds) did have such a pose and 48% (11910) did not, 
similar numbers, indicating that both scenarios are common, the outcome dependent on the 
choice of scaffold and side chains. The subsequent questions were similarly selected to provide 
large, roughly equal numbers of both positive and negative outcomes. While the first question, 
described above, was applicable to every compound, the others were not, instead being 
dependent on a particular orientation or conformation. However, these subsequent questions 
were selected to be applicable to a large proportion of the molecules. 
The five questions (illustrated graphically in Figure 2.18): 
1. Is there a pose where the middle side chain is in the Trp23 binding pocket of Mdm2? 
2. If there are one or more poses where the middle side chain is in the Trp23 binding 
pocket and another side chain is in the Phe19 pocket, is this other side chain side chain  
1 (the parallel conformation) or side chain 3 (the antiparallel conformation)? (Molecules 
with both a parallel and an antiparallel pose were excluded.) 
3. If there are one or more poses where binding is parallel and involves binding in the 
Phe19 and Trp23 pockets, do side chains 1 and 2 bind or side chains 2 and 3? (Cases 
where both poses occurred were ignored.) 
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4. If there are one or more poses where binding is antiparallel and involves binding in the 
Phe19 and Leu26 pockets with adjacent side chains (straddling the Trp23 pocket), do 
side chains 1 and 2 or side chains 2 and 3 bind? (Cases where both poses occurred were 
ignored.) 
5. Do any of the core parts of the compound occupy a binding site? The core was divided 
up into 3 sections with the amide bonds defining where each section ended and the next 
began. The heavy atoms were used to find the centre of mass of each section (near the 
middle of the benzene ring). As with the side chains, each of the core elements were 
assumed to be in a pocket if the distance of its centre of mass from the binding pocket 
centre was less than a 3 Å cut-off. 
 
 
Figure 2.18: A graphical summary of the 5 questions posed when investigating how side chains 
affect binding pose. For the purpose of logistic regression, the outcome on the left was treated as success 
and the outcome on the right was treated as failure. The blue numbers “19”, “23” and “26” indicate the 
pockets normally filled by p53 residues Phe19, Trp23 and Leu26 respectively. Q1) Is the Trp23 pocket 
occupied by the middle side chain? Q2) If the middle side chain is in the Trp23 binding pocket and 
another side chain is in the Phe19 pocket, is this other side chain side chain 1 (making the compound 
parallel to the p53 helix direction) or side chain 3 (antiparallel)? Q3) If binding is parallel and involves 
binding in the Phe19 and Trp23 pockets, do side chains 1 and 2 or side chains 2 and 3 occupy the 
pockets? Q4) If binding is antiparallel and involves binding in the Phe19 and Leu26 pockets with adjacent 
side chains (straddling the Trp23 pocket), do side chains 1 and 2 or side chains 2 and 3 bind? Q5) Is the 
scaffold bound in any of the binding pockets? 
 
For analysis, the molecular weight, logP, number of heteroatoms and number of aromatic rings 
were calculated for each side chain and the molecules as a whole, as described in the methods 
section (p104). Binary logistic regression was performed to generate, for each of the five 
questions above, for each scaffold, a model to predict, from the properties, the answer to the 
question. For example, a model was fitted for each scaffold to predict whether side chain 2 
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would be found in the Trp23 binding pocket, based on the molecular weight (MW), logP, 
number of heteroatoms (H) and the number of aromatic rings (R) in side chain 2. 
A binary logistic regression model predicts either “success” or “failure”. For question 1 above, 
the “yes” outcome was treated as success and the “no” outcome was treated as failure. For the 
other questions, the former outcome given above was treated as success and the latter as failure. 
Consequently, in Figure 2.18, the success outcomes are shown on the left and the failure 
outcomes are shown on the right. 
Table 2.12: Statistics for logistic regression models generated for each scaffold to predict whether 
the middle side chain bound in the Trp23 binding pocket 
Scaffold 
Property of side 
chain 2 
β SE Wald 
Significance 
P(H0) 
eβ 
N1 MW 0.010 0.002 31.237 <0.0005 1.010 
 logP 0.304 0.068 20.074 <0.0005 1.356 
 Heteroatoms 0.029 0.013 4.978 0.026 1.029 
 Rings 0.104 0.074 1.982 0.159 1.109 
O1 MW 0.006 0.002 13.068 <0.0005 1.006 
 logP 0.612 0.074 69.133 <0.0005 1.844 
 Heteroatoms 0.047 0.013 14.170 <0.0005 1.048 
 Rings -0.022 0.066 0.113 0.737 0.978 
S1 MW 0.004 0.002 5.609 0.018 1.004 
 logP 0.581 0.070 68.969 <0.0005 1.787 
 Heteroatoms 0.038 0.012 11.001 0.001 1.039 
 Rings 0.058 0.062 0.863 0.353 1.059 
O2 MW 0.016 0.002 60.346 <0.0005 1.017 
 logP 0.695 0.126 30.323 <0.0005 2.004 
 Heteroatoms 0.027 0.013 4.351 0.037 1.027 
 Rings -0.292 0.066 19.642 <0.0005 0.747 
S2 MW 0.016 0.002 94.326 <0.0005 1.016 
 logP 0.197 0.080 6.082 0.014 1.217 
 Heteroatoms 0.044 0.011 15.818 <0.0005 1.045 
 Rings -0.214 0.059 13.336 <0.0005 0.807 
 
β is the coefficient of the model for the property indicated in the second column from the left. The 
properties are as follows. “MW” is the molecular weight of the middle side chain. The “logP” was the 
XlogP (p104). “Heteroatoms” is the number of heteroatoms in this side chain. “Rings” is the number of 
aromatic rings. In the “SE” column are shown the standard errors on the β values. These standard errors 
are required for calculation of the Wald statistics shown in the “Wald” column. The “Significance” 
column gives the probability of a Wald statistic greater than the one obtained being generated due to 
chance if the null hypothesis (β=0) is true. eβ is the factor by which the odds ratio is increased when the 
value of the variable in question is increased by 1. For further details see p292. 
 
Table 2.12 shows details of the fitted models for question 1. In the β column of Table 2.12 are 
the β parameters for the five models (one for each scaffold). Each describes the effect of a factor 
(for example, molecular weight) on the probability of the success outcome. Values greater than 
0 indicate a higher value of the factor increases the probability of the success answer and values 
less than 0 indicate the opposite. Because each β value in the model has an exponential effect on 
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the predicted probability (as shown in Equation 6.9, p292) its effect can be more easily 
visualised by calculating e
β
, the multiplier effect which decreasing the factor (such as the 
molecular weight) by 1 has on the odds ratio of the success outcome (1/P-1 where P is the 
probability of success) (p292). 
It is necessary to test whether a β parameter is significantly different from 0. To check for 
statistical significance, the standard error on β can be calculated. A Wald statistic is similar to a 
t-value; it can be used to determine the statistical significance of an estimated β, given its 
standard error. The significance probability associated with each calculated Wald statistic is 
shown in the penultimate column of Table 2.12. Where the probability is less than 0.05, this 
indicates that, at the 5% significance level, the true β is not equal to 0 for that factor (the factor 
has an effect on the outcome). For full details of logistic regression and the Wald statistic see 
p292. 
Several trends can be seen in the logistic regression results above. For all five scaffolds, 
increasing the molecular weight and hydrophobicity of the middle side chain significantly 
increases the probability of binding in the middle position. (The e
β
 values for molecular weight 
(MW), logP and the number of heteroatoms are greater than 1 for every scaffold.) 
Models were also generated for questions 2 to 5. The e
β
 values are shown for each model in 
Table 2.13 below in the cases where the values were statistically significant at the 5% 
significance level. 
Question 1 concerned the middle side chain, side chain 2. Consequently, the factors for the 
question 1 models (one model for each scaffold) were the molecular weight, logP, number of 
heteroatoms in and number of rings of side chain 2. Because question 2 concerns which way 
around side chains 1 and 3 are (whether the oligobenzamide binds parallel or antiparallel to the 
p53 orientation) the factors used in the models were the difference in molecular weight, 
difference in logP, difference in the number of heteroatoms and difference between the number 
of rings in these side chains. For questions 3, 4 and 5 the properties of the whole molecule were 
used as factors. 
Question 2 asked whether binding was parallel or antiparallel to the p53 binding orientation. For 
this question, e
β
 is less than 1 in the molecular weight (MW) row for each scaffold. This 
indicates that a larger side chain at position 3 relative to that at position 1 favours binding in the 
antiparallel conformation. This conformation places the large side chain in the Phe19 binding 
site, which is deeper than the Leu26 site so could better accommodate a large side chain. e
β
 is 
significantly greater than 1 in the “rings” rows for the N1, O2 and S2 scaffolds, indicating that 
the more aromatic rings there are in side chain 3 relative to side chain 1, the more likely parallel 
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binding is (even though these increase the size of the side chain). The rigidity of aromatic side 
chains might prevent them from filling the Phe19 pocket in the antiparallel pose. 
Table 2.13: e
β
 values from all of the logistic regression analyses where the result is significant at the 
5% significance level (P(H0)<0.05) 
  eβ of property for each question 
 Question 1 2 3 4 5 
Property describes 
Side 
chain 2 
Difference 
SC3 –SC1 
Whole 
molecule 
Whole 
molecule 
Whole 
molecule 
 
Scaffold Property 
N1 MW  1.010  0.972  0.996   0.988 
 logP  1.356   0.868   
 Heteroatoms  1.029  1.088  1.207   
 Rings   1.227  1.341  1.285  0.539 
O1 MW  1.006  0.985    0.996 
 logP  1.844   0.753   0.866 
 Heteroatoms  1.048  1.074   1.129  0.915 
 Rings    0.745  1.381  0.783 
S1 MW  1.004  0.983   1.008  0.997 
 logP  1.787   0.689  0.823  0.878 
 Heteroatoms  1.039  1.074    
 Rings    0.793  1.364  0.748 
O2 MW  1.017   0.984   0.995 
 logP  2.004     
 Heteroatoms  1.027  0.868  1.207   
 Rings  0.747  1.618  0.659  1.241  0.823 
S2 MW  1.016  0.988  0.995   0.993 
 logP  1.217   0.751   1.147 
 Heteroatoms  1.045  0.821    
 Rings  0.807  2.112  0.679   0.895 
 
e
β
 values indicate the multiplier effect an increase of 1 in the value of the property has on the predicted 
probability of a positive prediction. Consequently, e
β
 values greater than one indicate a positive (but not a 
linear) correlation between the property and the probability and values less than 1 indicate a negative 
correlation. 
 
Question 3 concerned compounds binding parallel using the Phe19 and Trp23 pockets. It asked 
whether they bound in these pockets using side chains 1 and 2 or side chains 2 and 3. The 
overall properties of the molecule were used as factors. More hydrophobic molecules appear to 
be more likely to bind in the latter conformation because e
β
 is less than 1 in the logP row for 
every scaffold and for scaffolds N1 and O2, e
β
 is less than 1 in the heteroatom rows. (The 
presence of heteroatoms is indicative of more polar functional groups.) The Leu26 pocket is not 
deep. If the side chains are all hydrophobic, this pocket might not be used because it would not 
sufficiently bury the side chain in it, leading to entropically unfavourable ordering of the solvent 
molecules around the exposed part. 
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Larger molecules appear to be more likely to bind with side chains 1 and 2. (e
β
 is less than 1 in 
the MW row for scaffolds N1, O2 and S2 and e
β
 is less than 1 in the aromatic rings row for 
scaffolds O1 and S1.) Larger side chains were tested at side chain positions 1 and 2 than at 
position 3 due to the increased size of Phe19 and Trp23 compared to Leu26 in p53 (imitated by 
side chains 1, 2 and 3 respectively in the paradigmatic model of oligobenzamide 
peptidomimicry). Consequently, the results suggest that if large side chains are used at positions 
1 and 2, the oligobenzamide binds with these side chains in the Phe19 and Trp23 binding 
pockets to take advantage of the potential to fit closely into these large pockets, maximising the 
van der Waals forces between the protein and small molecule. 
As shown in Figure 2.18, question 4 was similar to question 3 but for parallel conformations 
straddling the central binding pocket. Here the effect is clear; the number of aromatic rings 
appears to be the only consistently important factor. The presence of rings favours binding with 
side chains 1 and 2 over binding with side chains 2 and 3. Aromatic side chains were primarily 
tested at positions 1 and 2 so these results suggest that if there are big, aromatic groups at these 
positions, then straddling of the Trp23 binding site is not possible, probably due to steric 
hindrance. Binding with side chains 2 and 3 would leave an aromatic residue at side chain 
position 1 free to interact with an aromatic residue of Mdm2 such as His96 or Tyr100, which 
would be nearby. 
The Nagelkerke R
2
 values
264
 for a fitted model indicate the degree to which it explains the 
variation in the observed results. They range from 0 (no explanation) to 1 (sufficient to fully 
describe the observed results). The Nagelkerke R
2
 values for question 4 (N1: 0.02, O1: 0.07, S1: 
0.11, O2: 0.01, S2: 0.01) indicate that the models do not explain the results well. They  suggest 
that other properties which were not considered are much more important for determining the 
pose. The two possible poses for this question shown in Figure 2.18 are very different so many 
factors could determine which one prevails. 
Finally, with regard to question 5, the core appears to be less likely to be involved in binding if 
the side chains are particularly bulky, particularly with the N1 scaffold, where the Nagelkerke 
R
2
 (0.298) suggests that the model explains 30% of the observed variation in the results. A 
possible explanation is that it is only energetically favourable for the side chains to bind instead 
of the core if they are large enough to fit closely into the binding pockets and not leave a void in 
which there are no ligand atoms to form van der Waals interactions with the protein. 
Figure 2.19 below summarises all of the logistic regression results.  
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Figure 2.19: The effect of different side chain properties on which of two possible conformations 
are taken up by an oligobenzamide. The black arrows indicate how the relative probability of the two 
poses changes. For example, with regard to pair of poses 1, a large middle side chain favours the left pose 
relative to the pose on the right. 
 
If oligobenzamides bind in many different ways to Mdm2, as suggested by the results of this 
analysis, this could be partly responsible for the poor correlation between thermodynamic 
integration predictions and experimental results (p151) because TI relies on the compounds 
being compared binding in similar positions. 
It has so far been assumed that side chains each make independent contributions to the binding 
energy but if the choice of side chains has a large impact on binding position then this would 
suggest that binding affinity is a complex function of the combination of side chains rather than 
the sum of independent factors. TI is not suitable where side chains do not act independently 
because it uses significant computing power and this makes it impractical to use it to assess 
every member of a large combinatorial library. 
TI is best suited to assessing the effect of a small change to a molecule as opposed to ranking a 
whole library. Furthermore, to assess the performance of a method, the results of all of the side 
chains should ideally be completely independent and this is difficult to achieve using TI. 
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2.3.5. MM-GBSA AND MM-PBSA RESULTS 
2.3.5.1. Binding energies predicted by implicit solvent methods correlate better with 
experimental results 
In this section, the challenge of predicting the relative affinities of the 31 N-linked compounds 
introduced on p142 is revisited. A moderate correlation (with a Spearman’s rank of 0.55 to 
0.60) is shown to exist between the measured ranking and the ranking predicted by both the 
MM-PBSA and MM-GBSA methods. The correlation is shown to be robust to changes in the 
number of docking poses used, the ionic strength, whether a separate trajectory is run of the free 
ligand and the set of Amber Born radii used (in the case of the MM-GBSA method). 
As described above (p151), thermodynamic integration results did not correlate well with 
measured affinities. The docking results above (p153) suggest that this could be because an 
assumption necessary for the TI approach to be used, specifically that oligobenzamides all bind 
in a similar place, is invalid. The MM-GBSA and MM-PBSA methods (introduced on p86) can 
be used to rank a series of compounds using as little as one trajectory per compound. 
Consequently, unless the trajectories are very long, a variety of different poses can be tested for 
every member of a large library. Because each side chain combination can be investigated, there 
is no need to assume that the oligobenzamides being compared all have a similar pose and study 
each side chain in isolation. 
Development of a fast method of testing a large number of compounds could be more useful 
than the development of a slower, more reliable method of affinity prediction because the 
affinity of a small number of compounds can be assessed accurately in the laboratory. Effort is 
underway to automate oligobenzamide production using microwave synthesis
245
. Furthermore, 
assay methods such as the fluorescence polarisation assay developed by the collaborating 
chemistry group
42
 and a FRET assay described in the next chapter can potentially be performed 
with large numbers of compounds on a microwell plate. These methods could soon allow large 
scale oligobenzamide production and testing in the laboratory, making a slow computational 
method obsolete. 
To assess the ability of the MM-GBSA and MM-PBSA methods to reproduce experimental 
results, they were used to predict the binding affinities of the 31 compounds for which 
fluorescence polarisation experimental data was available (introduced on p142). Simulations 
were started from the docking poses with the highest scores from each of three docking repeats. 
To investigate the rate at which simulations of oligobenzamides with N-linked side chains 
equilibrated, the RMSDs for the first part of 50 randomly selected trajectories were studied 
(Figure 2.20). By visual inspection of individual trajectories from this set in isolation, it was 
decided that, in the majority of cases, equilibration had occurred after 250 ps (that the RMSD 
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appeared to be fluctuating around a constant value) and this was the equilibration time used for 
subsequent work. Inspection of Figure 2.20 suggests that the RMSDs could still be increasing 
after 250 ps but this could be because viewing the trajectories overlayed  is similar to viewing 
an average RMSD. If the mean RMSD of multiple trajectories involving different ligands is 
plotted, equilibration appears to take longer than if individual trajectories from the same set are 
inspected. This is because the average RMSD keeps increasing until every single simulation in 
the set has equilibrated, which, given variation in the required  equilibration time for systems 
containing different compounds, could be significantly longer than most simulations require. 
 
 
Figure 2.20: Equilibration of compounds based on the N-linked scaffold: RMSDs of the protein and 
ligand atoms in a random selection of 50 trajectories of 573 different molecules bound to Mdm2. 
The RMSDs are relative to the structure prior to any simulation. Some equilibration occurred during 
constant volume simulation prior to t=0. Water and ions were removed prior to analysis. Snapshots were 
aligned prior to the RMSD calculation (but after removal of water and ions) to account for rotation of the 
entire system. The red line at 250 ps indicates the point after which snapshots were used for MM-PBSA 
and MM-GBSA calculations. 
 
After equilibration at constant volume, simulations were run for 750 ps at constant pressure. As 
discussed above, the first 250 ps were discarded leaving 500 ps, from which MM-PBSA and 
MM-GBSA results were derived. Longer simulations could have been carried out but the desire 
was to use the same simulation lengths as would be used to investigate large numbers of 
compounds later. 
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Table 2.14: The predicted free energies of binding for 31 compounds based on the N1 scaffold, 
generated using the MM-GBSA and MM-PBSA methods 
 GBSA predictions /kJ mol-1 PBSA predictions /kJ mol-1 
Trajectory 
Method 
Single Double Triple Single Single Single Double Triple Single Single 
IS 0 0 0 0.35 0 0 0 0 0.35 0 
Side 
chains 
 igb=1 igb=5 indi=1 indi=4 
4-4-11 -185.9 -172.3 -192.2 -182.9 -169.6 -151.7 -138.6 -160.5 -151.9 -500.1 
11-1-18 -188.1 -181.1 -181.9 -185.3 -173.3 -155.8 -149.0 -148.0 -156.1 -497.0 
11-2-19 -195.6 -189.4 -199.8 -192.5 -180.5 -158.6 -152.9 -162.4 -158.7 -551.6 
11-3-19 -187.4 -179.1 -209.6 -184.4 -172.5 -151.7 -143.2 -175.6 -151.9 -508.5 
11-4-15 -184.8 -168.1 -206.1 -181.9 -167.9 -148.1 -132.1 -169.9 -148.5 -543.3 
11-7-19 -184.9 -173.1 -175.6 -182.0 -171.3 -151.4 -139.9 -143.5 -151.7 -509.0 
11-11-19 -171.7 -163.5 -166.9 -168.7 -157.5 -138.6 -131.0 -122.5 -139.0 -502.4 
11-18-19 -168.8 -166.8 -191.6 -165.8 -153.7 -140.2 -138.3 -166.7 -140.3 -501.7 
11-19-11 -164.7 -166.2 -188.5 -161.6 -149.5 -134.2 -135.7 -152.8 -134.2 -535.5 
11-20-19 -177.7 -171.9 -169.8 -174.7 -165.2 -148.5 -143.2 -143.5 -149.0 -511.2 
11-21-19 -153.7 -150.2 -179.9 -147.4 -139.0 -123.3 -120.2 -146.2 -123.8 -769.2 
11-22-19 -158.3 -151.7 -176.7 -158.4 -137.4 -123.7 -117.8 -143.1 -123.7 -236.7 
11-24-19 -172.1 -161.5 -187.3 -169.2 -157.9 -139.5 -129.3 -150.3 -139.8 -500.4 
11-25-15 -172.7 -167.5 -197.3 -169.7 -157.4 -136.1 -131.6 -157.7 -136.1 -522.2 
11-25-19 -177.9 -169.5 -178.6 -174.9 -166.4 -142.5 -134.9 -140.9 -143.1 -511.3 
11-27-19 -171.8 -161.4 -183.2 -168.8 -162.2 -126.7 -116.9 -133.1 -126.7 -514.0 
11-28-19 -191.3 -183.7 -189.3 -188.4 -176.6 -156.6 -149.1 -149.7 -157.0 -506.9 
11-29-15 -173.4 -167.0 -172.7 -170.5 -157.4 -142.2 -135.7 -149.2 -142.4 -530.8 
18-29-24 -174.7 -169.6 -166.0 -171.8 -162.2 -142.5 -137.4 -137.2 -142.7 -492.8 
19-5-19 -175.7 -168.9 -175.1 -172.9 -162.4 -148.8 -142.3 -141.4 -149.2 -464.1 
19-24-19 -171.4 -161.4 -164.6 -168.4 -157.4 -141.4 -131.4 -133.7 -141.7 -501.2 
24-4-19 -196.4 -186.0 -198.7 -193.6 -180.5 -160.5 -150.9 -166.1 -160.8 -529.8 
24-29-18 -183.0 -182.3 -170.1 -179.9 -167.8 -147.3 -146.3 -132.1 -147.4 -559.7 
25-1-15 -190.5 -184.4 -194.2 -187.6 -176.6 -155.8 -150.5 -151.2 -156.1 -505.8 
25-4-19 -181.0 -168.9 -192.5 -178.2 -166.8 -146.6 -135.0 -157.4 -146.9 -484.2 
25-20-15 -173.3 -167.1 -154.2 -170.4 -162.6 -142.1 -135.9 -122.3 -142.4 -503.6 
26-1-18 -192.7 -188.8 -192.3 -189.8 -178.3 -158.7 -155.0 -159.4 -159.1 -516.7 
26-4-18 -195.1 -179.5 -193.7 -192.2 -178.3 -160.4 -145.9 -158.1 -160.8 -551.9 
26-4-19 -203.7 -185.2 -203.2 -200.8 -188.0 -167.3 -150.0 -170.5 -167.6 -546.0 
29-5-19 -190.4 -184.1 -196.4 -187.4 -176.0 -154.1 -148.1 -159.8 -154.5 -533.5 
29-26-19 -193.6 -188.9 -210.4 -190.5 -185.5 -162.7 -157.3 -180.8 -162.8 -564.8 
Median -181.0 -169.6 -188.5 -178.2 -166.8 -148.1 -138.6 -150.3 -148.5 -511.2 
IQR 18.1 16.1 20.0 18.1 18.6 15.0 15.1 17.9 15.1 33.1 
 
For both the MM-GBSA and MM-PBSA methods, 5 different sets of results are shown: results for the 
single, double and triple trajectory methods with default settings and then results calculated using the 
single trajectory method with either the ionic strength or another parameter as shown changed as 
indicated. In the single trajectory method, the energies of the protein and free ligand are calculated using 
the trajectory of the complex, ignoring the other component of the complex. In the double trajectory 
method, the energy of the free ligand is calculated using a second simulation of the complex in isolation. 
Finally, in the triple trajectory method, a separate simulation is usually run of the free protein in addition 
to simulations of the complex and free ligand. In this case, because the estimates were solely for the 
purpose of ranking, the mean protein ΔG from the single trajectory method was used as the free protein 
ΔG for all ligands when using the triple trajectory method. For further details see p123. The “igb” setting 
controls the Amber GB method used. When igb=1, the original method of calculating the Born radii is 
used (described by equations 1.82 to 1.84 in the introductory chapter (p89)). When igb=5, the Born radii 
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are scaled to account for the radii of buried atoms being underestimated by the original method
200
. For 
further details see p124. The “indi” parameter is the dielectric constant used for the volume inside 
macromolecules, expressed as a multiple of the permittivity of a vacuum (8.85 × 10
-12
 Fm
-1
). See p89 for 
more information on relative permittivity and its use in the MM-PBSA method. IS=Ionic strength. 
IQR=Interquartile range. 
 
Table 2.14 shows binding energies predicted by the MM-PBSA and MM-GBSA methods 
averaging over the top three poses from three docking repeats so each result is based on 9 
simulations, 4.5 ns of simulation time in total. 
The rationale behind this decision to average over the top three poses is worth discussion. 
Docking scores are typically poor measures of binding affinity
161,162
. This is to be expected, 
given the need for a scoring function to predict affinity from a single pose as opposed to an 
ensemble of the possible conformations which a compound can assume within a binding site. 
Because the docking poses generated by Autodock Vina might not be ranked correctly, it could 
be unreliable to base predicted affinities on simulations run from just the highest scoring poses 
of each compound. 
Rather than averaging over the top three poses, an alternative would have been to run 
simulations from multiple poses, calculate accurate affinity predictions from each trajectory and 
then select the best (most negative) predicted binding energy. However, the best affinity 
calculated might have been the best due to chance, not because the pose used to start that 
simulation corresponded to the correct binding site. Therefore, using this method could have led 
to the results being based on the wrong trajectories. Furthermore, there might not be one 
predominant binding site; the top poses found by docking could all indicate valid binding sites 
with similar affinities, the laboratory-measured binding constant being a function of the binding 
constant at each of these sites. 
Initially, trajectories from the three highest scoring binding poses for each compound were used 
because three is the lowest number of readings from which a mean with reasonably sized 
confidence limits can be calculated. 
The large number of results shown in Table 2.14 reflects the variety of different methods which 
can be used to estimate binding affinities. Presenting results for just those methods that lead to 
good correlations with the measured affinities would give an unrepresentative picture of the true 
accuracy of the methods. Results for different methods are also useful to assess the robustness 
of the predictions to changes in the settings used. 
One method choice, which is indicated in the third row of Table 2.14, is the number of 
trajectories to use to calculate each affinity. In the single trajectory method, the protein and 
ligand coordinates are extracted from the trajectory of the complex, assumed to be 
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representative of the unbound molecules and used to calculate the energy of the free protein and 
free ligand. In the double trajectory method, the energy of the free ligand is calculated using a 
second trajectory of the ligand in isolation. A triple trajectory method can also be performed in 
which a third simulation is run of the free protein. In this work, because the estimates were 
solely for the purpose of ranking, the “triple trajectory” results were generated by using the 
mean protein ΔG (from the single trajectory method results) as the free protein ΔG for every 
ligand. For further details see p123. 
Two of the Generalised Born methods available in AMBER (switched between using the igb 
setting) were tested (using an ionic strength of 0). These were the original model (igb=1) 
described by equations 1.82 to 1.84 in the introductory chapter (p89) and a modified model 
(igb=5), where a function with empirically derived parameters is used to rescale the Born radii 
of atoms based on the degree to which the atoms are buried and in so doing account for the 
underestimation of Born radii within macromolecules
200
. For further details see p124. The 
original model was also tested using an ionic strength of 0.35 M, which is close to the ionic 
strength of the buffer used in the laboratory assays. MM-PBSA results were also obtained using 
two different ionic strengths and two different values for the internal dielectric constant. 
Table 2.14 reveals how different results are obtained, depending on the trajectories used to 
estimate the solvation energy of the free ligand and free protein. The range of the results was 
higher when using the triple trajectory method as opposed to the single and double trajectory 
methods. This suggests that subtraction of the vacuum and solvation energies of the unbound 
protein calculated using the trajectory of the complex compensates for some of the variation in 
the potential energy of the complex. The results therefore advocate the use of a single or double 
trajectory approach. 
While the results of the different methods shown in Table 2.14 differ, they are largely similar 
with the exception of the MM-PBSA results obtained with a dielectric constant of 4 in the 
rightmost column.  The calculated binding energies are all large in magnitude (very negative) 
and these are especially so, with a predicted median free energy change of -512 kJ mol
-1
. The 
change in entropy of the protein and ligand is not intrinsically included when predicting binding 
affinities using the MM-PBSA and MM-GBSA methods. To investigate whether this missing 
entropic effect was responsible for the extreme values, normal mode analysis was performed on 
the trajectories. 
Normal mode analysis is computationally expensive and it has been found to introduce 
significant error because the results often vary significantly between snapshots. Consequently, it 
is often not performed when similar ligands binding to the same site are compared
249,265
. Similar 
entropy changes were calculated regardless of the trajectory method used and there was little 
variation between the results for the different compounds. For example, as shown in Table 2.15, 
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the interquartile range of the results for the different compounds using the single trajectory 
method was 21.6 J mol
-1
 K
-1
, which is just 5% of the median entropy change (approximately). 
The rightmost column of Table 2.15 shows the amount which must be added and subtracted 
from each value in the single trajectory entropy column to generate its upper and lower 95% 
confidence limits. (A mean entropy was calculated for each of the three repeats (using the top 
three poses in that repeat) and the confidence limits are based on these three means.) The 
median of the confidence limit values is 25.7 J mol
-1
 K
-1
 so the median distance between the 
upper and lower confidence limits of the entropy values (twice this, 51.5 J mol
-1
 K
-1
) is more 
than double the aforementioned interquartile range of the entropies themselves. Although 
increasing the number of repeats could increase the accuracy, the large error is consistent with 
the findings of the research cited above
249,265
, which found that including the effect of entropy as 
predicted by normal mode analysis often does not improve the  accuracy with which the relative 
affinities of ligands can be calculated. 
The binding energy of the effective p53-Mdm2 interaction inhibitor Nutlin-3 is -42.4 kJ mol
-1
 
based on its published Ki of 26 nM (assumed to have been measured at 298 K)
266
. While 
including the effect of the entropy might not improve the ranking, its inclusion shifts most of the 
binding energies predicted by the MM-PBSA and MM-GBSA methods from around -150 kJ 
mol
-1
 and -175 kJ mol
-1
 respectively to more reasonable values around -20 kJ mol
-1
 and -55 kJ 
mol
-1
. It does not shift the MM-PBSA results obtained with a dielectric constant of 4 in the 
rightmost column of Table 2.14 to reasonable values, suggesting that these results are 
anomalous. 
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Table 2.15: Normal mode analysis of simulations of the 31 N-linked compounds synthesised 
Side 
chains 
Entropies /kJ mol-1 K-1 Overall entropy for each 
trajectory method /J mol-1 K-1 
95% Limits 
For Single 
Trajectory 
Method (±) 
/J mol-1 K-1 
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Single Double Triple 
4-4-11 16.34 15.35 1.435 1.421 -444.3 -430.1 -442.3 7.1 
11-1-18 16.21 15.37 1.276 1.262 -435.8 -422.2 -409.5 30.4 
11-2-19 16.22 15.35 1.282 1.275 -418.1 -411.8 -420.0 18.6 
11-3-19 16.24 15.35 1.316 1.312 -426.4 -422.0 -430.0 34.4 
11-4-15 16.23 15.35 1.321 1.303 -435.2 -417.5 -432.9 24.2 
11-7-19 16.27 15.37 1.324 1.303 -423.2 -402.0 -394.7 18.4 
11-11-19 16.20 15.36 1.252 1.242 -407.9 -398.0 -401.2 38.6 
11-18-19 16.15 15.35 1.216 1.214 -416.9 -415.4 -425.6 29.6 
11-19-11 16.17 15.34 1.233 1.228 -412.4 -406.7 -424.4 11.7 
11-20-19 16.22 15.37 1.254 1.250 -406.1 -402.2 -390.4 27.8 
11-21-19 16.18 15.38 1.217 1.217 -415.7 -416.0 -401.1 25.7 
11-22-19 16.17 15.35 1.240 1.243 -425.0 -428.4 -436.2 46.4 
11-24-19 16.22 15.36 1.268 1.261 -415.3 -409.0 -407.4 19.4 
11-25-15 16.18 15.35 1.245 1.241 -409.0 -405.3 -421.2 29.4 
11-25-19 16.22 15.36 1.266 1.261 -405.5 -400.6 -403.4 11.0 
11-27-19 16.20 15.35 1.270 1.266 -419.2 -414.6 -429.4 35.7 
11-28-19 16.24 15.37 1.319 1.307 -441.2 -429.2 -424.4 19.9 
11-29-15 16.23 15.38 1.249 1.253 -397.8 -401.7 -380.5 10.7 
18-29-24 16.21 15.37 1.266 1.269 -433.0 -436.8 -425.3 20.3 
19-5-19 16.23 15.35 1.303 1.299 -419.6 -415.4 -430.9 17.5 
19-24-19 16.20 15.36 1.240 1.236 -407.1 -403.1 -400.4 35.6 
24-4-19 16.29 15.37 1.360 1.341 -446.7 -427.4 -417.5 10.7 
24-29-18 16.22 15.37 1.272 1.276 -425.4 -429.5 -422.6 18.8 
25-1-15 16.24 15.38 1.285 1.276 -431.5 -421.8 -401.9 26.8 
25-4-19 16.29 15.36 1.357 1.340 -431.2 -414.0 -413.9 42.4 
25-20-15 16.21 15.36 1.251 1.245 -401.0 -395.0 -398.4 61.6 
26-1-18 16.23 15.37 1.297 1.292 -435.6 -430.9 -420.2 18.4 
26-4-18 16.27 15.36 1.352 1.341 -440.1 -429.5 -434.4 21.8 
26-4-19 16.29 15.37 1.365 1.352 -449.8 -437.1 -424.3 47.4 
29-5-19 16.26 15.35 1.350 1.351 -442.0 -443.0 -455.2 39.5 
29-26-19 16.23 15.37 1.293 1.293 -434.2 -433.3 -429.7 34.9 
Median 16.22 15.36 1.276 1.275 -425.0 -416.0 -421.2 25.7 
IQR 0.04 0.02 0.068 0.057 21.6 23.4 26.9 N/A 
 
Entropies for the complex, free protein and free ligand were calculated from trajectories of each Mdm2-
compound complex using Amber nmode. Subsequently, another value for the entropy was calculated for 
each compound using simulations containing only the ligand. The overall entropy difference for single, 
double and triple trajectory approaches was then calculated. In the single trajectory method, the entropy 
change of binding was estimated using only the entropies calculated from the trajectory of the complex. 
In the double trajectory method, the entropy of the free ligand from the trajectory of the ligand in isolation 
was used. In the “triple trajectory” method, the mean protein entropy (the average of the values in the 
third column) was used as the free protein entropy for every ligand. (See p123.) The rightmost column 
indicates the error in the single trajectory method entropies. It shows the amount which must be added 
and subtracted from each entropy in the 6
th
 column to generate its 95% confidence limits. The error in 
normal mode analysis entropies means that the entropy change of the protein and ligand is often ignored 
when making MM-PBSA and MM-GBSA predictions
249
. IQR=Interquartile range. 
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The results shown above were generated using the top three poses produced in each docking 
repeat. To investigate whether this was the best number of poses to use, the correlation between 
the predicted relative affinities and affinities measured in the laboratory using fluorescence 
polarisation by Kerya Long (University of Leeds) was determined using different numbers of 
poses from each repeat (Figure 2.21). For this analysis, the binding energies predicted with the 
full MM-PBSA method and the single trajectory approach were used (for reduced noise). The 
relative internal dielectric for buried atoms and the ionic strength were left at their default 
values of 1 and 0 respectively. 
 
 
Figure 2.21: The effect of the number of docking poses of each molecule considered on the 
magnitude of the Spearman’s Rank coefficient for the correlation between fluorescence 
polarisation results and predicted MM-PBSA binding energies. The single trajectory method was 
used with the internal dielectric constant set to 1 and the ionic strength set to 0 (the default values). 
 
There is a drop in the correlation in going from using two poses to using three or four. 
Although, this result might be due to chance, it suggests that the top two poses are 
representative of where oligobenzamides actually bind but that the third and subsequent poses 
are less so. Consequently, the coefficients shown in Table 2.16 and Table 2.17 below were 
determined using the first two docked poses from each of the three docking runs. 
Table 2.16 and Table 2.17 shows the correlation between predicted and experimental results 
obtained using different methods. A moderate correlation was obtained for both the single and 
double trajectory methods using both MM-PBSA and MM-GBSA, using either Pearson’s 
product moment correlation coefficient or Spearman’s rank and using an ionic strength of 0 or 
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0.35 M. However, they are consistent with the results of the triple trajectory method being less 
reliable than those produced by the single and double trajectory approaches. 
 
Table 2.16: The effect of the number of trajectories used and including entropy on the correlation 
coefficient between predicted binding affinities and fluorescence polarisation single-point assay 
results 
Trajectory 
Method 
Method 
No entropy With entropy 
Pearson Spearman Pearson Spearman 
Single 
GB 0.563 0.551 0.580 0.573 
PB 0.613 0.556 0.614 0.498 
Double 
GB 0.564 0.569 0.567 0.481 
PB 0.587 0.523 0.566 0.394 
Triple 
GB 0.277 0.265 0.256 0.191 
PB 0.320 0.314 0.292 0.233 
 
There were 31 compounds in total. All of the correlations are statistically significant. MM-GBSA and 
MM-PBSA can be performed using a 1, 2 or 3 trajectory approach. These were implemented as discussed 
in the methods section. Correlations were calculated with and without normal mode analysis entropies 
included. The colour reflects the coefficients shown in each box; the strongest correlations are highlighted 
in blue and the weakest ones are indicated in red. 
 
Table 2.17: The effect of the GB method used, internal dielectric constant and ionic strength on the 
correlation coefficient between predicted binding affinities and fluorescence polarisation single-
point assay results 
Method 
Ionic strength 
/M 
No entropy With entropy 
Pearson Spearman Pearson Spearman 
GB igb=1 0 0.563 0.551 0.580 0.573 
GB igb=1 0.35 0.545 0.551 0.498 0.505 
GB igb=5 0 0.549 0.511 0.508 0.517 
PB indi=1 0 0.613 0.556 0.614 0.498 
PB indi=1 0.35 0.613 0.560 0.568 0.549 
PB indi=4 0 0.343 0.376 0.350 0.368 
 
There were 31 compounds in total. These results were calculated using the single trajectory method. The 
Generalised Born (GB) and Poisson Boltzmann (PB) methods were used to calculate the electrostatic 
component of the solvation energy as indicated. Two different GB models provided by Amber, switched 
between using the igb parameter, were used, the original model (igb=1) and a modified model (igb=5). In 
the latter, a function with empirically derived parameters is used to rescale the Born radii of atoms. For 
further details see p124. When using the PB method, two different relative dielectric constants were used 
for buried atoms, the default value of 1 and a higher value of 4, set using the indi parameter. For more 
information on relative permittivity and the MM-PBSA method, see p89. The colour reflects the 
coefficients shown in each box; the strongest correlations are highlighted in blue and the weakest ones are 
indicated in red. 
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Figure 2.22 shows graphically the correlation with the MM-PBSA method with an ionic 
strength of 0 and internal dielectric constant (relative permittivity) of 1. The correlation is 
negative because the more negative the free energy of binding for a compound, the more 
strongly it binds to Mdm2 and the greater the extent to which it is likely to displace the labelled 
p53 peptide in the competition assay which was used for laboratory testing. For more details of 
fluorescence anisotropy and the competition assay see p48. 
 
 
Figure 2.22: The correlation between MM-PBSA results and single point assay results. The single 
trajectory method was used with the internal dielectric constant set to 1 and the ionic strength set to 0 (the 
default values). The data are positively skewed on the binding energy axis and negatively skewed on the 
abscissa, supporting use of Spearman’s rank as opposed to Pearson’s product moment correlation 
coefficient. A negative correlation is apparent from this graph, as expected given that the more negative 
the free energy of binding, the greater the affinity of the compound for Mdm2 and thus the greater the 
expected inhibition at the concentrations tested in the competition assay (10 µM oligobenzamide, 54.5 
nM fluorescein-labelled p53 peptide and 41.5 nM Mdm2 L33E). Although the results suggest that there 
could be a linear correlation between the predicted free energies of binding and the percentage inhibition, 
the correlation would not be expected to be linear given the exponential relationship between binding 
energy and association constant. 
 
As shown in Table 2.16 and Table 2.17, there is not a clear improvement in the correlation 
coefficients observed when the entropy from normal mode analysis is added. This is interesting 
because, due to its lack of intramolecular hydrogen bonding, the N1 scaffold is the scaffold 
most likely to lose entropy upon binding. 
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In conclusion, the results in this section reveal a moderate correlation between predictions and 
experimental results for compounds based on the N1 scaffold. While there exist many ways in 
which MM-GBSA and MM-PBSA results can be calculated and predictions were made after the 
experimental data were made available, the results indicate that the observed correlation is 
visible using both these implicit solvent methods and using a variety of different settings. The 
best correlations were obtained with the MM-PBSA method using a single or double trajectory 
approach. 
Although a few compounds based on scaffold O1 were made, it was only possible to compare 
practical and computational results for 6 compounds and there was a high degree of error in the 
experimental results. A strong correlation was not observed and so the small number of readings 
meant that no conclusion could be drawn. 
2.3.5.2. ANOVA: side chains interact with each other but the interactions are small in 
magnitude 
Testing every member of a large combinatorial library in multiple binding positions is 
computationally demanding. Once every library member has been docked and the likely binding 
sites of ligands have been identified, side chains could be investigated individually within each 
binding site by a method such as thermodynamic integration. This might overcome the problem 
of ligands binding in different places but require fewer simulations. To predict whether such 
methods would work, a deeper understanding of the relationship between the choice of scaffold 
and side chains and binding pose and predicted binding affinity is necessary. This section 
describes the production of MM-PBSA predictions for every member of a large combinatorial 
library and analysis of the results using ANOVA (described on p294) to determine the 
complexity of model necessary for affinity prediction. 
To eliminate the effect that side chains have on each other’s binding through their effect on 
binding pose it is necessary to compare the affinities of oligobenzamides all bound in the same 
position. In this project, two separate approaches were used to generate docking poses at a 
particular site. 
The first method entailed taking the O1 scaffold starting compound pose (Figure 2.1, p102) with 
its side chains in the Phe19, Trp23 and Leu26 binding sites, modifying the side chains in situ 
and then optimising the pose using Autodock as described in more detail below. This method is 
useful in that it ensures that a pose is obtained for every combination of side chains. ANOVA 
analysis is more reliable when there are equal numbers of results for every cell (factor value 
combination) (p296)
267
. 
The second method involved docking poses as normal (using Autodock Vina) and then selecting 
poses which bound at a particular site (p186). This method results in missing data where 
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docking fails to generate a pose for a particular ligand within the site of interest and the results 
thus require more complex treatment (p296). 
The inherent problem of missing binding data where compounds in a library do not bind to a 
protein may be one of the key reasons why ANOVA has not previously been used to investigate 
the interaction of functional groups in ligand binding. 
2.3.5.2.1. Simulations started from poses derived by side chain replacement 
followed by pose optimisation within a particular binding site suggest a three-way 
interaction between the three side chains but the predicted binding energies are 
positive, which implies the docking poses are unnatural 
Simulations were run with every possible combination of 12 side chains at the three side chain 
attachment positions on scaffold O1 (1728 compounds in total). The side chains used were 
numbers 1, 2, 3, 4, 5, 6, 11, 19, 22, 26, 47 and 48. See Figure 2.2 (p103) for the structures. 
Simulations were started from the best pose obtained in each of six separate sets of Autodock 4 
local searches. As detailed in the methods (p109), a local search in Autodock involves 
optimising (minimising the potential energy of) a pose close to the binding pose. Here, the 
docked O1 scaffold starting molecule (Figure 2.1, p102) with side chains in the Phe19, Trp23 
and Leu26 binding sites (Figure 2.8, p129) was taken, the side chains were changed (using Side 
Chain Splicer, p105) and then the local search was used to position the compound as best 
possible. 
Six short simulations (500 ps) were performed for each compound. The second 250 ps of each 
trajectory was used for analysis so a total of 1.5 µs of simulation was used for calculation of 
each binding energy (because there were six repeats). 
Although this local optimisation method was convenient because it resulted in a set number of 
poses for every combination of side chains and the subsequent ANOVA was balanced, the free 
energies of binding subsequently predicted using the MM-PBSA method were positive. This is 
evident from the last line of Table 2.18, which shows various statistics for the variables 
calculated. While the MM-PBSA results exclude the effect of the entropy change of the ligand 
and receptor upon binding, this is typically negative (as shown in Table 2.15, p171) so increases 
the free energies when included, rather than reducing them. 
The almost universally positive binding energies predicted are not consistent with the known 
binding of many oligobenzamides to Mdm2 when present at concentrations far below 1 mol 
dm
-3
. Consequently, the docked poses used to start the simulations might not have been 
representative of where compounds actually bind. The local docking method finds the best 
binding pose for compounds assuming that they bind in the same position as the starting 
compound. This assumption might be incorrect. 
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Table 2.18: Statistics for the predicted binding energies of O1 scaffold oligobenzamides  
 
 
Median Range Interquartile range 
Gas phase ΔΔG 
/kJ mol-1 
Van der Waals 44.28 56.99 9.00 
Electrostatics 40.67 302.21 68.30 
Complex 7046.0 520.2 78.9 
Receptor 6695.5 305.5 56.7 
Ligand 277.0 151.0 26.8 
Overall 83.59 310.00 71.15 
Solvation ΔΔG 
/kJ mol-1 
Poisson Boltzmann -60.09 287.33 67.27 
Surface area -4.240 5.212 0.758 
Complex 1403.3 584.6 96.4 
Receptor 1331.7 267.5 48.9 
Ligand 121.2 207.8 27.6 
Overall -64.15 288.21 67.49 
 Total 19.37 41.53 6.06 
 
Predictions were made using the MM-PBSA method. The simulations were started from poses generated 
by in situ side chain substitution followed by local pose optimisation using Autodock. 
 
Despite their unusually high values, a full factorial ANOVA was performed on the MM-PBSA 
predicted binding energies. A full factorial ANOVA is one in which the fitted model contains 
all of the possible interaction terms. The model used in this case can be described using the 
following formula: 
𝑌𝑖𝑗𝑘𝑛 = 𝑚 + 𝑎𝑖 + 𝑏𝑗 + 𝑐𝑘 + (𝑎𝑏)𝑖𝑗 + (𝑎𝑐)𝑖𝑘 + (𝑏𝑐)𝑗𝑘 + (𝑎𝑏𝑐)𝑖𝑗𝑘 + 𝜖𝑖𝑗𝑘𝑛 2.7 
Where Yijk is the binding energy of a ligand (actually raised to the power 0.65 here to increase 
residual heteroscedasticity as discussed below) with side chains i, j and k, which it is assumed 
can be predicted by the summation of 7 coefficients, looked up using i, j and k. The first is a 
constant, m. This is 0.74 for the results in this section (Fm=3.2010
5
, P(m=0)<0.0005). The next 
three terms (ai, bj and ck) are main effects, variables which each depend on the value of a single 
factor, in this case, the side chain at one of the side chain attachment positions. The fitted model 
has one value of a for every side chain found at side chain position 1, one value of b for every 
side chain found at side chain position 2 and so on. The two way interaction terms follow. The 
fitted model has a two-dimensional array for each of these three terms, from which a value is 
selected when a prediction is made based on the two side chains in question (1 and 2, 1 and 3 
and 2 and 3 for (ab)ij, (ac)ik and (bc)jk respectively in Equation 2.7). Finally, (abc)ijk is the three-
way interaction. Fitting this model generates a three-dimensional array of values for this last 
term. 
The model states that prediction using the coefficients is imperfect; for every ligand binding 
energy prediction there is a residual error, εijkn where n is the repeat number. 
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Before inspection of the fitted model, it is necessary to consider the assumptions of ANOVA 
because if these are not met, the chance of a false positive result is increased (the probability of 
a null hypotheses being rejected increases above the chosen significance level). Firstly, the 
values analysed must be independent. Secondly, the residuals left at the end of fitting (the error 
values) should be homoscedastic, meaning that the variance of these residuals should be the 
same for every set of conditions (for every set of side chains in this case). Thirdly, the residuals 
should be normally distributed. 
The TI predictions generated earlier in this chapter were not independent due to their method of 
calculation whereby components for each side chain were added. In contrast, the MM-PBSA 
results are independent (the first assumption). 
To test for homogeneity of the variances of the residuals (the second ANOVA assumption), 
Levene’s test268,269 was performed in SPSS. (For this analysis, an ANOVA models were used 
with all of the full factorial interaction terms except for the three-way interaction, the inclusion 
of which would have reduced the number of energies in each cell too much.) Use of the raw, 
untransformed MM-PBSA binding energies for modelling yielded a Levene’s test F value of 
1.645, which is too great to have occurred due to chance alone (P(H0)<0.0005 based on 1727 
and 8640 degrees of freedom); there was not equality of variances. Plotting the residual standard 
deviations from each cell (side chain combination) against the mean predicted binding energy of 
that cell reveals that the data are heteroscedastic. The variance increases with the free energy of 
binding. In an effort to correct for the apparent trend, a transformation was applied; the square 
root of each of the values (ΔG0.5) was tested. However, this was too extreme a transformation. It 
did not just remove the positive correlation between binding energy and residual variance but 
went further, creating a negative correlation. Consequently, exponents between 0.5 (taking the 
square root) and 1 (applying no transformation) were tested and raising the energies to a power 
of 0.65 produced the most homoscedastic residuals. 
The Levene’s test F-value for the transformed data is 1.370, which is still statistically significant 
(P(H0) <0.0005, d1=1727, d2=8640); however, F is small in magnitude. Because tests for 
homogeneity of variance are sensitive and the ANOVA test is reasonably robust to homogeneity 
of variances when there is a large amount of data, the use of tests for homoscedasticity before 
ANOVA is controversial
270(p308)
. Consequently, the remaining heterogeneity of the variances 
following the aforementioned transformation was ignored. 
When an ANOVA is performed, it is assumed that the residuals follow a normal distribution. 
The residuals obtained using the untransformed data have a positive skew (g1=0.174). The 
distribution is also slightly leptokurtic (pointed) (g2=0.619). The positive skew is removed by 
the transformation (g1=-0.002, SEg1=0.024). The kurtosis is not but the degree of kurtosis is 
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small (g2=0.517 after transformation), so this was ignored. For a discussion of what constitutes a 
small kurtosis and the interpretation of Levene’s test results for large samples see p298. 
The results of the full factorial ANOVA (Table 2.19 below) reveal that there is a statistical 
interaction between every side chain (a three-way interaction) (F=1.151, P(H0)<0.0005). Instead 
of each side chain contributing independently to the binding energy, the affinity of each side 
chain depends to an extent on the side chains at each of the other positions, even where the side 
chains in question are at opposite ends of the scaffold. Because the simulations used to generate 
the predictions in this section were started from similar poses due to the docking method used, 
this result suggests a degree of mechanical coupling between the side chains of an 
oligobenzamide as it moves within a particular binding site. 
Table 2.19: The results of fitting an ANOVA model to investigate the effects of side chain choice on 
the predicted binding energy of O1 scaffold oligobenzamides 
Source of 
variation 
Sum of 
Squares 
/kJ2 mol-2 
Degrees of 
freedom 1 
Mean Sums 
of Squares 
/kJ2 mol-2 
F Significance 
SC1 6.87104 11 6246.757 510.664 <0.0005 
SC2 2.01104 11 1823.358 149.057 <0.0005 
SC3 2.27104 11 2065.213 168.828 <0.0005 
SC1*SC2 3982.857 121 32.916 2.691 <0.0005 
SC1*SC3 1.13104 121 92.996 7.602 <0.0005 
SC2*SC3 3234.467 121 26.731 2.185 <0.0005 
SC1*SC2*SC3 1.87104 1331 14.078 1.151 <0.0005 
Error 1.06105 8640 12.233  N/A  N/A 
 
Predictions were made using the MM-PBSA method. The simulations were started from poses generated 
by in situ side chain substitution followed by local pose optimisation using Autodock. SC1 is the side 
chain at position 1 (the amino end of the compound). SC2 is the side chain at position 2 and SC3 is the 
side chain at position 3.  For each source of variation, the first number of degrees of freedom for the F-
test to check its significance is shown. The second number of degrees of freedom for these tests was 
8640. For a definition of the mean sums of squares see p295. 
 
The significance of the three-way interaction (F=1.151, P(H0)<0.0005) reveals that the side 
chain at one position can not just influence the affinity of the other two side chains but also the 
way in which the other two side chains influence each other. The docking results on p153 
suggest that side chains could influence each other’s effect on binding through their impact on 
the binding pose. Because the ANOVA investigation described in this section focussed only on 
binding poses in the expected positon with side chains occupying the Phe19, Trp23 and Leu26 
binding sites, its results suggest that, in addition, side chains affect the binding of each other 
within a particular binding site. The interaction after binding pose has been accounted for is 
investigated further on p190, where more reliable, negative predicted binding energies are used. 
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Because this section describes a balanced ANOVA (equal numbers of results for every 
combination of side chains), the F-values for the two-way interactions (F = 2.691, 7.602, 2.185) 
and main effects (F = 510.7, 149.1, 168.8) indicate the extent to which the side chains affect the 
results after the three-way interaction has been accounted for. Specifically, that P<0.0005 for 
every term of the model indicates that, at the 0.5% significance level, every term is useful for 
explaining the results. The side chains have an effect which is independent of the other side 
chains in addition to the aforementioned interaction effects. 
The proportion of the variation in a set of data which is explained by a fitted ANOVA model is 
indicated by its R-squared and adjusted R-squared values. Both range from 0 (no predictive 
ability) to 1 (perfect prediction of the results by the model) (p297). For the ANOVA described 
above, SSError (p297) is 1.0610
5 
(kJ mol
-1
)
0.65×2
 and the total adjusted sums of squares (SSTotal), 
which is independent of the model, is 2.55105 (kJ mol-1)0.65×2, making R2 equal to 0.585. 
To investigate the magnitude of the interactions, three other models were tested and the 
(unadjusted) R-squared values were determined for each using the new SSError and the 
previously calculated SSTotal above. 
 The model with no three-way interaction (SSError = 1.25 (kJ mol
-1
)
0.65×2
): 
𝑌𝑖𝑗𝑘𝑛 = 𝑚 + 𝑎𝑖 + 𝑏𝑗 + 𝑐𝑘 + (𝑎𝑏)𝑖𝑗 + (𝑎𝑐)𝑖𝑘 + (𝑏𝑐)𝑗𝑘 + 𝜖𝑖𝑗𝑘𝑛 2.8 
 The model after the first and last side chain two-way interaction has been removed 
(SSError = 1.36 (kJ mol
-1
)
0.65×2
): 
𝑌𝑖𝑗𝑘𝑛 = 𝑚 + 𝑎𝑖 + 𝑏𝑗 + 𝑐𝑘 + (𝑎𝑏)𝑖𝑗 + (𝑏𝑐)𝑗𝑘 + 𝜖𝑖𝑗𝑘𝑛 2.9 
 The model with no two-way interactions (SSError = 1.44 (kJ mol
-1
)
0.65×2
): 
𝑌𝑖𝑗𝑘𝑛 = 𝑚 + 𝑎𝑖 + 𝑏𝑗 + 𝑐𝑘 + 𝜖𝑖𝑗𝑘𝑛 2.10 
As above, Yijkn is the (transformed) free energy of binding, ai, bj and ck are the main effect terms 
for the N-terminal, central and C-terminal side chain attachment positions respectively, (ab)ij, 
(ac)ik and (bc)jk are the two-way interaction terms for the side chain 1-side chain 2, side chain 1-
side chain 3 and side chain 2-side chain 3 interactions respectively and εijkn is the residual error 
where n is the repeat number. 
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Table 2.20: Incorporating different degrees of interaction between the side chains: R-squared and 
adjusted R-squared values for four ANOVA models to predict the relative affinities of O1 scaffold 
oligobenzamides 
Model Unadjusted R-squared Adjusted R-squared 
No interaction 0.438 0.436 
No interaction of side chains 1 and 3 0.467 0.452 
No three-way interaction 0.511 0.491 
Complete factorial design 0.585 0.501 
 
Unadjusted R-squared values (see p297) range from 0 to 1 and describe the fraction of the variation in the 
results explained by the model. Adjusted R-squared values (see p298) facilitate a fairer comparison of 
models with different numbers of factors. A complete factorial ANOVA design is a model where the 
equation describing it has a term for every possible interaction between the factors. Each increase in the 
adjusted R-squared value down the table is statistically significant according to the Wald statistic for the 
highest order interaction in the more complicated model. (P(H0)<0.0005 in every case.) 
 
Table 2.20 shows the R-squared values for the models. The complete factorial design (the 
model with all of the possible interaction terms) accounts for less than 60% of the variation in 
the results (R
2
=0.585). This highlights the significant error in all of the calculated binding 
energies. This error would be reduced by increasing the simulation time. (Because the fitted 
model has a three-way interaction term dependent on the choice of all three side chains and 
these were the only factors distinguishing one oligobenzamide from another in this controlled 
computational investigation, the residual error reflected by this R-squared is entirely due to 
variation between repeats due to sampling error.) 
A large drop in the unadjusted R
2
 value is observed in going from the complete factorial model 
with all of the interactions to the model with no interaction effects at all. An ANOVA model 
will usually fit a set of the results better if the number of terms is increased because the 
additional parameters can absorb some of the random variation in the data. Adjusted R
2
 values 
(Equation 6.24 (p298)) take this effect into account. They can provide a better indication of how 
well models with different numbers of fitted parameters perform relative to each other. 
The adjusted R-squared values (Table 2.20 above) suggest that the three-way interaction makes 
only a small improvement to the fit of the model. Consequently, while the interactions are 
statistically significant, the interactions appear to be quite small in magnitude and thus explain 
little of the variation in the results. 
The simple model with no interactions appears to be quite predictive relative to the other 
models. The small effect sizes of the interactions imply that processing time might be best spent 
creating an accurate model of the main effects as opposed to simulating large numbers of 
compounds in an effort to model the interaction terms. Linearly scaling the unadjusted R-
squared values so that the R-squared of the full factorial ANOVA was 1 (as if there were no 
sampling error) would bring the unadjusted R-squared value for the no-interaction-term model 
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up to 0.75. Consequently, if longer simulations were run or more repeats were performed to 
reduce sampling error, it might not be necessary to perform simulations with every member of a 
library; up to 75% of the variation in predicted affinity between oligobenzamides with different 
side chain combinations could be revealed through study of each side chain attachment position 
in isolation. 
2.3.5.2.2. The interaction of the side chains is evident in many components that 
contribute to the binding energy 
To determine whether a particular component of the binding energy was responsible for the 
observed interactions (for example, the change in the electrostatic energy or the surface area-
dependent component of the free energy of solvation), ANOVA was performed using some of 
these components as the dependent variable. 
Some of the results of this analysis are shown in Table 2.21. Data for these variables were not 
transformed prior to analysis because the results of Levene’s tests (column 2) revealed 
significant homoscedasticity, with the exception of those variables asterisked, for which the p-
value of the complete factorial design should be ignored. 
In Table 2.21, ∆𝐺𝑀𝑀−𝑃𝐵𝑆𝐴 is the MM-PBSA predicted binding energy, which is the sum of two 
components (Equation 2.11 and Equation 2.12). The first is the difference in energy of the 
complex and the unbound receptor and ligand in the gas phase, ΔHgas,complex – ΔHgas,receptor – 
ΔHgas,ligand, which can also be written ΔHvdW + ΔHElec, where ΔHvdW is the change in potential 
energy associated with the van der Waals forces and ΔHElec is the change in the electrical 
potential energy. Because the dissociated protein and ligand came from the trajectory of the 
complex, there is no predicted change in internal energy. The second is the difference in 
solvation energies of the complex and the free receptor and ligand, ΔGsolv,complex - ΔGsolv,receptor – 
ΔGsolv,ligand. This is calculated using the Poisson Boltzmann equation (ΔGPB) to account for 
changes in the electrostatic energy and an empirical surface-area based method to account for 
the non-polar element of the solvation (ΔGCavity). Consequently, it can also be written ΔGPB + 
ΔGCavity. 
∆𝐺𝑀𝑀−𝑃𝐵𝑆𝐴 = (∆𝐻𝑣𝑑𝑊 + ∆𝐻𝐸𝑙𝑒𝑐) + (∆𝐺𝑃𝐵 + ∆𝐺𝐶𝑎𝑣𝑖𝑡𝑦) 2.11 
 
= (∆𝐻𝑔𝑎𝑠,𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − ∆𝐻𝑔𝑎𝑠,𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 − ∆𝐻𝑔𝑎𝑠,𝑙𝑖𝑔𝑎𝑛𝑑)
+ (∆𝐺𝑠𝑜𝑙𝑣,𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − ∆𝐺𝑠𝑜𝑙𝑣,𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 − ∆𝐺𝑠𝑜𝑙𝑣,𝑙𝑖𝑔𝑎𝑛𝑑) 
2.12 
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Table 2.21: Statistics for the ANOVA models created to investigate interaction of the side chain factors in the determination of various components of the MM-PBSA-
predicted binding energies
 
Dependent 
Variable 
Levene’s Test p-values for 
complete 
factorial 
design 
Unadjusted R-squared values for model Adjusted R-squared values for model 
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F p 
ΔHvdW 1.367 <0.0005 0.038*0 0.447 0.356 0.296 0.264 0.337 0.330 0.277 0.261 
ΔHElec 1.411 <0.0005 0.044*0 0.911 0.896 0.893 0.884 0.893 0.892 0.890 0.884 
ΔGPB 1.391 <0.0005 0.080*0 0.915 0.901 0.898 0.889 0.898 0.897 0.895 0.889 
ΔGCavity 1.369 <0.0005 0.006*0 0.442 0.346 0.295 0.266 0.330 0.321 0.276 0.264 
ΔHgas,complex 1.063 0.049 0.445*0 0.544 0.474 0.462 0.439 0.453 0.453 0.447 0.438 
ΔHgas,ligand 2.667* <0.0005 <0.0005* 0.970 0.965 0.932 0.818 0.964 0.964 0.930 0.817 
ΔGsolv,complex 1.032 0.192 0.109*0 0.770 0.733 0.726 0.714 0.725 0.723 0.719 0.713 
ΔGsolv,ligand 4.024* <0.0005 <0.0005* 0.987 0.985 0.963 0.890 0.985 0.984 0.962 0.890 
ΔGMM-PBSA 1.367 <0.0005 <0.0005* 0.585 0.511 0.467 0.438 0.501 0.491 0.452 0.436 
The MM-PBSA predictions (ΔGMM-PBSA) can be divided into their constituent components in two different ways, by type or by species. In the top four data rows the separation is by 
type. ΔHvdW is the in vacuo change in van der Waals potential energy associated with binding and ΔHelec is the in vacuo change in electrical potential energy. ΔGPB is the difference in 
solvation free energy between the complex and free protein and ligand due electrostatics. The difference between the solvation energies due to the non-polar component of the 
solvation energy predicted using the solvent accessible surface area is ΔGCavity. In the lower four data rows, the MM-PBSA-predicted free energy of binding is split into components 
relating to the complex and components relating to the free ligand. ΔHgas,complex and ΔHgas,ligand are the in vacuo energies given by the AMBER force field of the complex and free 
ligand respectively. ΔGsolv,complex and ΔGsolv,ligand are the free energies of solvation of complex and ligand respectively. The values in the top four data rows are not independent to the 
results in the bottom four data rows as shown in Equation 2.11 and Equation 2.12 (p182). The p-values for the three-way interaction in the complete factorial design are shown. For 
all eight possible dependent variables indicated, the p-values for the highest order interaction in the three smaller designs lacking some interaction terms are all less than 0.0006, 
meaning that the differences are significant at the 0.1% significance level, with the exception of the ΔHgas,ligand and ΔGsolv,ligand results. *The gas phase binding energies and solvation 
energies for the ligand in isolation have a broad range of variances so the F-test results are unreliable. 
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Table 2.21 shows R-squared values for models with different numbers of factors. Unadjusted R-
squared values (p297) range from 0 to 1 and describe the fraction of the variation in the results 
explained by a model. Adjusted R-squared values are similar but account for the number of 
factors in a model (p298) so facilitate the fairer comparison of models with different numbers of 
factors. 
The unadjusted R-squared values for the full factorial models give an indication of the extent to 
which there was sufficient sampling of the phase space to determine accurately each component 
of the MM-PBSA predicted binding energy. For example, the unadjusted R-squared values for 
the gas-phase enthalpy of the ligand (ΔHgas,ligand) and the free energy of solvation of the ligand 
(ΔGsolv,ligand) have very high unadjusted R-squared values (0.970 and 0.987 respectively) because 
the phase space of the ligand is much smaller than that of the complex so is sampled more 
comprehensively within the simulation time used. 
The significances of the three-way interactions in each ANOVA analysis are shown in the table. 
The p-values in the fourth column indicate that the three-way interaction discussed earlier does 
not stem from a single component of the binding energy; an interaction is observed with many 
of its contributing parts. Where the existence of the three-way interaction is borderline for some 
components, there are significant pairwise interactions (not shown) between all of the factors. 
Data rows 1 to 4 of Table 2.21 show the results of ANOVA with the dependent variable (the 
variable which the model seeks to explain) changed to each of the different physical factors that 
contribute to the binding energy (shown in Equation 2.11) (ΔHvdW, ΔHElec, ΔGPB and ΔGCavity). 
Interactions effects appear to have the greatest impact on ΔHvdW and ΔGCavity because, with 
these, the adjusted R-squared values drop significantly upon removal of the interaction terms. 
ΔHvdW and ΔGCavity both depend on short range interactions. In the case of ΔHvdW, the attractive 
dispersion force between two atoms is proportional to the 6
th
 power of their distance apart. 
ΔGCavity is calculated using the change in solvent accessible surface area and this only changes 
when parts of the protein and ligand touch. Given the short range of these effects, it is 
noteworthy that the greatest drop in adjusted R-squared occurs upon removal of the two-way 
interaction between the terminal side chains. A possible explanation is that side chains influence 
the binding of each other through their effect on the position of the scaffold within the binding 
site. In order for certain side chains to be accommodated at the ends of the molecule, the 
scaffold might need to move and this could cause the nature of other side chains’ interaction 
with the protein to change. Figure 2.12 (p136) illustrates this activity. It shows structures from 
one of the 5 ns simulations of the N1 scaffold starting molecule (Figure 2.1, p102) performed to 
verify simulation stability. Concerted movement of side chain 1 (shown on the right-hand side 
of each image) and the scaffold core is evident upon comparison of Figure 2.12A with Figure 
2.12B. It is possible that side chain 1 pushes against the protein and moves the scaffold. Within 
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roughly 200 ns, side chain 3 adapts to the new scaffold position (Figure 2.11C (p135), Figure 
2.12C). Eventually the scaffold and both side chains return to a conformation similar to that of 
their initial pose (Figure 2.12D). 
Data rows 5 to 8 of Table 2.21 show the results of ANOVA with the dependent variable set to 
each of the ligand-dependent components shown in Equation 2.12, namely the force field-
derived energy changes for the gas phase complex and free ligand (ΔHgas,complex and ΔHgas,ligand) 
and the solvation free energies of the complex and ligand generated using the Poisson-
Boltzmann equation and solvent accessible surface areas (ΔGsolv,complex and ΔGsolv,ligand). As 
shown in the table, the three-way interaction is not statistically significant in terms of 
ΔHgas,complex and ΔGsolv,complex, the variables relating to the complex (P=0.445 and P=0.109 
respectively). These results imply that the interaction between side chains manifest in the total 
energy change ΔGMM-PBSA might stem from side chain interaction in the free ligands as opposed 
to their complexes. While the p-values for the three-way interaction significance in relation to 
the free ligand energies, ΔHgas,ligand  and ΔGsolv,ligand, must be treated with caution (due to 
heteroscedasticity), these results are consistent with this hypothesis. Furthermore, removal of all 
interaction terms from the ΔHgas,complex and ΔGsolv,complex models results in the adjusted R-squared 
values dropping by 0.015 and 0.012 respectively whereas removal of the interaction terms from 
the ΔHgas,ligand and ΔGsolv,ligand models results in the adjusted R-squared values dropping by 
considerably more, 0.147 and 0.095 respectively, consistent with side chain interactions 
occurring in the free ligand rather than in the ligand-protein complex. However, these results are 
misleading because they reflect the variation caused by interaction effects as a proportion of the 
total variation (in the affinity of different oligobenzamides) as opposed to in absolute terms. 
Between different ligands, ΔHgas,complex and ΔGsolv,complex vary more than ΔHgas,ligand  and 
ΔGsolv,ligand due to the presence of the protein in simulations of the complex, which can interact 
with the ligand in many ways and assume different conformations as it does so. Consequently, 
the interaction effects may just be a lower proportion of the total variation in the case of the 
complex because there is more variation in total. Furthermore, the statistical interactions 
apparent in the unbound ligand components of the binding energy could involve the protein 
because the trajectory of the free ligand used for this analysis was extracted from the trajectory 
of the complex. 
Although it is unlikely that statistical interactions between the side chain factors exist solely in 
the unbound ligand, the extent to which the pose of a ligand affects the interaction of the side 
chains is worth investigation because it could have an impact on the best approach for affinity 
prediction in future. In the next section, the effect of the pose on the side chain interaction 
effects is confirmed. 
The movement of the scaffold from side to side illustrated in Figure 2.11 and discussed in 
relation to the ΔHvdW and ΔGCavity components above suggests that side chains do not just 
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influence each other through their effect on binding position but also through scaffold-mediated 
mechanical coupling within a particular binding site. In the subsequent section (p191) this is 
tested for. 
2.3.5.2.3. The binding pose has a statistically significant effect on the 
interaction between the side chains 
The previous section described the use of ANOVA to analyse the MM-PBSA-predicted binding 
free energies of oligobenzamides based on the O1 scaffold. The O1 scaffold starting compound 
(Figure 2.1, p102) was docked using Autodock to generate an initial pose. Subsequently, for 
each side chain combination of interest, the side chains of the posed starting compound were 
modified in situ and then local optimisation was performed to generate a pose with which a 
simulation could be initialised. Most of the binding energies calculated from these simulations 
were positive, which suggests that oligobenzamides do not actually bind in the poses predicted 
by this method. The docking results on page 153 consistent with this hypothesis, suggesting that 
oligobenzamides often fail to bind with a side chain in each of the three p53 hotspot binding 
sites as assumed in the previous section. 
In subsequent results now described, standard, global docking as opposed to just a local search 
was performed for all compounds prior to simulations, with the aim of simulating compounds in 
their true binding position. 
Three docking runs were performed using Autodock Vina with the exhaustiveness setting 
(p111) set to the default value of 8. To verify that the docking process was sufficiently 
exhaustive to obtain the best binding poses, a fourth docking run was performed with the 
exhaustiveness set to 16 to see if this led to higher scoring docking poses in the results. 
(According to the documentation, the time required for docking is roughly proportional to the 
value of the exhaustiveness setting.) The mean top pose scores for the three original docking 
runs were -7.41, -7.40 and -7.40 and the mean top pose score in the fourth was -7.49 kcal mol
-1
. 
The higher docking score for the last run with the higher exhaustiveness is statistically 
significant. However, this difference is small compared to the range of docking scores obtained 
for the top poses. Consequently, an exhaustiveness of 8, the default recommended value for this 
setting, appears to be sufficient. Box and whisker plots for the docking scores of the top pose for 
each compound showing the range of top pose scores are shown in Figure 6.5 (p311). 
To generate starting poses for simulations, the results of the three main docking runs described 
above were searched to identify compounds in each of the four poses indicated in Figure 2.23. 
These unsystematic poses were chosen because the 25,000 compound docking analysis above 
(p153) revealed that they were poses in which oligobenzamides were very commonly found. 
Missing values (p296) are problematic in ANOVA analysis. The use of these common poses 
minimised the number of combinatorial library members which could not be obtained in any 
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one of the poses (resulting in a missing MM-PBSA prediction) and so increased the reliability 
of hypothesis testing. It also means that the results are more applicabile to oligobenzamide 
binding in general. If there was, in a particular repeat, more than one pose for a compound 
which satisfied one of the conditions (A, B, C or D) then only the pose with the highest docking 
score was used. A compound can satisfy the requirements of poses B and D at the same time; 
however, data for poses B and D were never analysed simultaneously. 
 
 
Figure 2.23: Four poses, A, B, C and D referred to in the ANOVA results. The scaffold is shown in 
red: Mdm2 is shown in blue. The labels 19, 23 and 26 indicate the pockets normally occupied by p53 
residues Phe19, Trp23 and Leu26. For further details of pose recognition see the section entitled “Pose 
recognition” starting on p111. 
 
Simulations were run starting from all of the selected poses. Figure 2.20 above shows RMSD 
values for 50 N1 compounds when simulations are started from global docking poses generated 
using Autodock Vina. A similar rapid rate of equilibration was observed with oligobenzamides 
based on the O1, S1, O2 and S2 scaffolds (results not shown). The first 250 ps of constant 
pressure simulation was removed from all trajectories prior to their analysis using the MM-
PBSA method. 
Initially, five ANOVA analyses were performed, one for each scaffold. The three factors in each 
model were the pose (A, B, C or D) and the side chains at the first (N-terminal) and second 
(middle) side chain positions. The aim was to investigate how the pose factor affected the 
interaction between the side chains when using different scaffolds. The sparsity of the results 
was too great to carry out an ANOVA with all three side chains as factors in addition to the 
pose. A large amount of impution (p296) would have been required, which could have biased 
the results. 
Table 2.22 shows the side chains used. Every combination of side chains was tested. The 
numbers refer to the side chain structures shown in Figure 2.2 (p103). 
Table 2.23 gives some summary information about the data. Preliminary analysis revealed that 
while docking of a compound derived from any of the five scaffolds commonly yielded a pose 
in position A, for some scaffolds there were few compounds with a pose satisfying conditions 
B, C or D.  
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Table 2.22: Side chains tested at each side chain position when using the side chains at positions 1 
and 2 as factors in ANOVA models 
Side chain 
position 
Side chains tested at position Number of 
side chains 
1 4, 11, 13, 15, 19, 21, 22, 24, 25, 27, 29, 33, 37, 39, 44 15 
2 1, 3, 5, 6, 9-13, 15, 21, 22, 25, 26, 30, 32, 37, 39, 44 19 
3 19 (N1 scaffold) / 37 (O1, S1, O2, S2 scaffolds) 1 
 
The side chain numbers refer to the side chain structures in Figure 2.2 (p103). 285 (15 × 19) side chain 
combinations were tested. In each ANOVA investigation two poses were investigated so there were 570 
cells (possible sets of conditions) in total. The side chains tested were selected manually on the basis of 
their size and similarity to the Phe19, Trp23 and Leu26 p53 side chains, as described on p104. 
 
Table 2.23: Summary statistics for the MM-PBSA data following separation by scaffold type and 
impution ready for ANOVA analysis 
Scaffold 
Poses 
Studied 
Number 
of Cells 
Number of 
Results 
ΔG Values /kJ 
mol-1 
Levene’s Test 
Total Imputed Median Q3 - Q1 F P 
N1 A,B 570 1308 74 -33.34 6.57 1.417 <0.0005 
O1 A,D 570 1255 98 -32.45 7.08 1.291 0.001 
O2 A,C 570 1126 134 -34.06 6.40 1.143 0.057 
S1 A,D 570 1205 136 -33.49 6.70 1.307 0.001 
S2 A,C 570 1349 50 -32.84 6.58 1.172 0.020 
 
The pose letters refer to the arrangements depicted in Figure 2.23 (p187). The number of cells is the 
number of possible combinations of factor conditions, in this case 2  15  19, the number of poses 
multiplied by the product of the numbers of side chains at each position. For details of the impution 
carried out see the “Missing values” section beginning on p296. Non-parametric statics for the calculated 
free energies of binding follow the impution statistics, including the interquartile range (Q3-Q1). Finally, 
on the far right are the results of Levene’s test for the homoscedasticity of the residuals. F is the test 
statistic. In the P column is the probability of a Levene’s test test statistic value equal to or greater than 
the one shown in the penultimate column being observed if the residuals are homoscedastic. 
 
Table 2.23 shows how, to further reduce the sparsity of the results for this first investigation, 
only poses which satisfied two of the four pose conditions were analysed in the ANOVA for 
each scaffold: pose A and another pose condition which was often fulfilled when using the 
scaffold in question.  The table indicates the number of poses investigated for each scaffold, the 
number of values imputed for each analysis, nonparametric statistics for the predicted ΔG 
values and the F and p values of Levene’s test for residual homoscedasticity. 
The ΔG predictions are negative (as shown in the median ΔG column of Table 2.23), in contrast 
to the results obtained after the local search docking above, which were positive (Table 2.17, 
p177). This is consistent with only the global docking finding the correct binding positions. 
The negative ΔG values are large in magnitude. The small size of the interquartile ranges (Q3-
Q1) in Table 2.23 relative to the median ΔG values suggests that there is a similarly sized 
component absent from each prediction. No normal mode analysis was carried out to account 
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for the decrease in entropy of the ligand and protein upon binding. When the size of this entropy 
change is determined for similar ligands, there is typically little variation in the size of the 
values obtained
249
 so the systematic error in the results could be this unaccounted for entropic 
component. 
The F values for Levene’s test (p298) are less than 1.5 so the heterogeneity of the residual 
variances is low in magnitude in all of the models, even though, in most cases (where the p-
values are less than 0.05 in the rightmost column of Table 2.23) the heterogeneity is 
significantly different from 0. For a discussion concerning the interpretation of Levene’s test 
results for large samples see p298. 
Table 2.24 gives the significance of each of each of the sources of variation when fitting the 
complete factorial design (Equation 2.7, p177) and the same model lacking the three-way 
interaction (Equation 2.8, p180). The p-value for the three-way interaction in the former model 
is less than 0.05 for every scaffold except the O1 scaffold, for which it is 0.16. The geometric 
mean of the three-way significances averaged over every scaffold is 0.018. This suggests that 
there is, in general, a significant three-way interaction. It confirms that the pose affects the 
affinity of the side chains and, furthermore, that it affects the nature of the statistical interaction 
between the side chains. This is consistent with one of the factors being the pose position 
because in different poses different parts of the protein will mediate the interaction of the side 
chains so their interaction could be different. 
Table 2.24: For five different scaffolds, the significance of the ANOVA sources of variation for 
models fitted to investigate the effect of pose, N-terminal side chain and middle side chain choice on 
the MM-PBSA-predicted free energy of binding 
Source of 
Variation 
Statistical significance of source of variation (Results significant where P<0.05) 
Full factorial model for each scaffold Model with no three-way interaction 
N O1 O2 S1 S2 N O1 O2 S1 S2 
P 0.000 0.012 0.000 0.000 0.008 0.000 0.005 0.000 0.000 0.003 
SC1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SC2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
P*SC1 0.000 0.000 0.000 0.012 0.000 0.000 0.000 0.000 0.003 0.000 
P*SC2 0.000 0.052 0.008 0.003 0.060 0.000 0.030 0.008 0.004 0.053 
SC1*SC2 0.020 0.003 0.081 0.005 0.021 0.690 0.006 0.210 0.010 0.179 
P*SC1*SC2 0.013 0.160 0.020 0.040 0.001 N/A N/A N/A N/A N/A 
 
The factors of pose, N-terminal side chain and middle side chain are denoted by P, SC1 and SC2 
respectively. Where the significance is shown as 0.000, this means that the probability is less than 0.0005.  
 
For each of the N1, O2 and S2 scaffolds, the model lacking the three-way interaction term has 
an insignificant p-value for the side chain 1-side chain 2 interaction (N1: 0.69, O2: 0.21, S2: 
0.18). This suggests that the side chain interaction is heavily pose-dependent because it 
indicates that if the pose is not considered, the ANOVA analysis detects no systematic pattern 
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attributable to side chain interaction; the pose information is needed to make sense of the 
interaction between the side chains. 
In the absence of the three-way interaction, a statistically significant interaction is still observed 
between the pose and each side chain, with the exception of the pose and side chain 2 
interaction for the S2 scaffold (p-value 0.053) which is almost significant and could be a false 
negative result (a type II error). 
 A 
 
B 
 
 
Figure 2.24: R-squared values for ANOVA models fitted to investigate the effects of pose, N-
terminal side chain and middle side chain choice on the MM-PBSA-predicted free energy of 
binding. As shown, oligobenzamides based on all five scaffolds were investigated. A) Raw R-squared 
values. B) Adjusted R-squared values. 
 
Figure 2.24 above gives R-squared and adjusted R-squared values for the full factorial models, 
models with no three-way interaction and models with no interaction terms (Equation 2.10, 
p180). The drop in the adjusted R-squared values upon removal of the (pose-side chain 1- side 
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chain 2) three-way interaction term (0.02 to 0.05 depending on the scaffold) is noticeable in 
Figure 2.24B. It is larger, for example, than the drop of just 0.01 in the adjusted R-squared value 
seen when removing the three-way (side chain 1-side chain 2- side chain 3) term from the O1 
scaffold model where the three side chains were factors (Table 2.20, p181). This further 
supports a role for the pose in determining the nature of the interaction between the side chains. 
2.3.5.2.4. After changes in binding pose have been accounted for, an interaction 
between the side chains still exists 
In the analysis described above, the first side chain choice, second side chain choice and pose 
were treated as fixed factors. The ANOVA analysis revealed that the pose affected how the side 
chains interacted. This section describes the results of the data being split again, this time by 
pose and treatment of the scaffold as a factor. 
Separate ANOVA analyses were performed for each pose with three factors: the scaffold and 
the side chain choice at each of the two attachment positions. First, the analysis was performed 
using the first, N-terminal side chain and the middle side chain. Then the analysis was repeated 
using the middle side chain and the last, C-terminal side chain. Table 2.22 (p188) shows the side 
chains used in the former case (with attachment positions 1 and 2) and Table 2.25 below shows 
the side chains used in the second case (with attachment positions 2 and 3). 
Table 2.25: Side chains tested at each side chain position when using the side chains at positions 2 
and 3 as factors in ANOVA models 
Side chain position Side chains tested at position 
Number of side 
chains 
1 11 1 
2 1, 3, 5, 6, 9-13, 15, 21, 22, 25, 26, 30, 32, 37, 39, 44 19 
3 11, 14, 15, 17-19, 21-23, 30, 32, 36-38, 40 15 
 
The numbers refer to the side chain structures in Figure 2.2 (p103). The side chains tested were selected 
manually on the basis of their size and similarity to the Phe19, Trp23 and Leu26 p53 side chains as 
described on p104. 
 
Table 2.26 shows summary statistics for the results and including the degree of impution 
required and the results of testing for residual homoscedasticity. Notice that a significant degree 
of impution was required, which increases the chance of a type II error (observing no interaction 
where there is one in reality). The F values for Levene’s test are low, as in Table 2.23, so 
conclusions can reliably be drawn from the results. 
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Table 2.26: Summary statistics for the MM-PBSA data following separation by pose and impution 
ready for ANOVA analysis 
Si
d
e 
C
h
ai
n
s 
P
o
se
 Scaffolds 
Considered 
Number 
of Cells 
Number of 
Results 
ΔG Values 
/kJ mol-1 
Levene’s test 
Total Imputed Q2 Q3 - Q1 F P 
1
 a
n
d
 2
 A N1,O1,O2,S1,S2 1425 2874 335 -32.90 7.01 0.928 0.928 
B N1,O1,O2,S2 1140 2126 324 -32.74 6.74 1.123 0.030 
C O2,S2 570 1417 30 -33.88 6.89 1.340 <0.0005 
D O1,S1 570 1133 136 -32.56 5.95 1.141 0.059 
2
 a
n
d
 3
 A N1,O1,O2,S1,S2 1425 3234 180 -34.50 7.07 1.118 0.013 
B N1,O1,S1 855 1908 144 -34.73 6.46 1.295 <0.0005 
C O2,S2 570 1622 6 -35.81 6.33 1.306 <0.0005 
D O1,S1 570 1387 68 -33.01 5.99 1.229 0.004 
 
The number of cells is the number of combinations of conditions. 1425, 1140 and 570 are the result of 
multiplying 285, the product of 15 and 19 (the numbers of side chains used at each side chain position) by 
the number of scaffolds investigated in each case. Q3-Q1 is the interquartile range; 50% of the values lie 
within this distance of each other. Non-parametric statistics (the median and interquartile range) are 
appropriate because the energies are not normally distributed. Levene’s test is a test for homoscedasticity 
of the residuals after fitting. F is the test statistic and P is the probability of an equal or greater test 
statistic being produced due to chance if the residuals are actually homoscedastic (the null hypothesis). 
 
Table 2.27: The statistical significance of sources of variation in eight ANOVA models fitted to 
investigate the influence of scaffold and side chain choice on affinity 
Side 
chains 
changed 
Pose Full factorial 
model 
three-way 
significance 
Significance of the two-way interactions for the model 
with no three-way interaction 
Sc*SA S*SB SA*SB 
1 and 2 A 0.082 <0.0005 <0.0005 0.018 
 
B 0.034 <0.0005 <0.0005 0.528 
 
C 0.064 0.028 0.581 0.007 
 
D 0.026 0.009 0.228 0.180 
2 and 3 A 0.084 <0.0005 0.001 0.505 
 
B 0.087 <0.0005 0.009 0.019 
 
C 0.515 0.002 0.009 0.019 
 
D 0.241 <0.0005 0.072 0.001 
 
The models are vary in terms of the pair of adjacent side chains used as factors (1 and 2 or 2 and 3) and 
the pose that the oligobenzamides are in (A, B, C or D). The factors Sc, SA and SB are the scaffold, the 
first side chain of the pair and the second side chain of the pair respectively. The significance of the three-
way interaction for the full factorial ANOVA is shown and then the significance of the two-way 
interactions in the model with no three-way component. Type III sums of squares were used throughout 
so the two-way significances refer to their respective two-way interaction after the other two-way 
interactions have been accounted for. (The significance of an interaction is the probability of the observed 
results occurring by chance if the interaction does not exist.) 
 
For each pose, Table 2.27 shows the significances of the three-way interaction in the full 
factorial model and of the two-way interactions in the model lacking the three-way term. When 
only compounds with similar poses are compared, an interaction between the side chains is still 
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observed. In every case except one, either the three-way interaction or the two-way side chain 
interaction in the model with no three-way interaction is significant at the 5% significance level. 
2.3.5.2.5. The choice of scaffold could affect not just the effect of each side chain 
on affinity but also the interaction between the side chains 
The oligobenzamide scaffolds have different degrees of flexibility. Figure 2.9 (p133) showed 
RMSD values for two different ligands, the N1 and O1 scaffold starting molecules (Figure 2.1, 
p102). After equilibration, the RMSDs of the two ligands’ atoms relative to their starting pose 
are different, over 2 Å for the N1 scaffold and under 2 Å in the case of the latter. The N1 
scaffold could be more flexible than the O1 scaffold because it lacks intramolecular hydrogen 
bonds. 
Interconversion of the O1 and S1 scaffolds by TI (p137) revealed that the side chain attachment 
atom in these scaffolds has an impact on affinity, an effect which could reflect differences in 
flexibility between these scaffolds as well, given the increased strength of hydrogen bonds 
involving oxygen relative to those involving sulphur and the increased directionality of the latter 
relative to the former. A steric effect unique to the S2 scaffold (the large size of the sulphur 
atom and its close proximity to the hydrogen atom with which it interacts) is thought to increase 
its flexibility
173
. 
The differences in flexibility between the scaffolds could result in differing degrees of 
mechanical coupling between the side chains. The results in Table 2.27 above support this 
hypothesis because they indicate that, at the 5% significance level, the interaction of side chains 
depends on the choice of scaffold. Specifically, the geometric mean of the three-way interaction 
significances when side chains 1 and 2 are modified (0.082, 0.034, 0.064 and 0.026) is 0.046, 
which is less than 0.05. For the modification of side chains 2 and 3 (0.084, 0.087, 0.515 and 
0.241) the geometric mean is 0.174, which is not significant. This latter result could differ 
because the poses A, C and D are defined using the positions of side chains 1 and 2 so poses 
within the A, C and D groups may have a variety of conformations around side chain 3, 
reducing the overall fit of the model, including the effect of the scaffold. Consistent with this, 
the adjusted R-squared values for the models involving modification of side chains 2 and 3 are 
generally lower than those involving modification of side chains 1 and 2 (Figure 2.25). 
There is typically a 10% difference between the adjusted R-squared values of the full factorial 
models (the models with the scaffold-side chain-side chain three-way interaction) and the 
corresponding models lacking no interaction terms (Figure 2.25) and much of the drop in R-
squared is realised when the three-way term is removed. Therefore, the effect of the scaffold on 
the interaction between the side chains could be of some magnitude and the effect of the 
scaffold on the communication of the side chains should be investigated further. 
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Azzarito et al.
51
 discuss how different scaffolds can adapt to arrange side chains in the same 
positions and thus have very similar affinities. The Mdm2 binding site is also flexible and has 
been shown to adapt to bind different peptides with similar affinity
79
. The results herein are not 
consistent with these ideas. Instead, they suggest a prominent role for the scaffold in not just 
determining the affinity of each side chain but also in affecting how those side chains 
communicate. 
The docking results discussed above (question 5, p164) indicate that the scaffold can often bind 
directly to the protein. Although the significance values of the main effects in the ANOVA here 
are biased due to the impution, they are consistent with this conclusion, in that they show a large 
scaffold main effect (p<0.05) in all cases except for modification of side chains 2 and 3 in pose 
D where the p value is 0.85. If the scaffold itself interacts with the Mdm2 protein and shifts the 
positon of the side chains so as to optimise its own binding, this could explain its influence on 
the side chain effects. 
  
194
  
 
 
 
A 
 
B 
 
 
Figure 2.25: Adjusted R-squared values for the eight ANOVA models referred to by Table 2.26 and 
Table 2.27. A) Using the N-terminal side chain and the middle side chain as factors. B) Using the middle 
and C-terminal side chains as factors. 
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2.4. Conclusions and Further Work 
 
The initial aim of this project was to demonstrate that the relative binding affinities of 
oligobenzamides can be predicted computationally. The prediction of accurate binding affinities 
requires that binding poses be generated for possible ligands, that molecular dynamics 
simulations be run from the docked poses and the trajectories then analysed to estimate the free 
energy of binding for each compound. 
One of the challenges of simulating oligobenzamides is correctly calculating the energy 
associated with the torsion angles of the backbone. Modification (using TI) of the barrier 
heights for the bonds about which rotation is restricted in the O and S-linked scaffolds had little 
effect on their binding energy so any effects side chains have on the scaffold torsion energies in 
these scaffolds is unlikely to prevent the accurate ranking of oligobenzamides. Because in the 
N1 scaffold the nitrogen atoms holding each side chain are within the backbone, the torsion 
parameters could vary depending on the choice of side chains, making this scaffold more 
challenging. 
In an attempt to predict the affinities of 31 compounds based on the N1 scaffold, two 
approaches were tried, namely, using TI and using implicit solvent methods. In the former, the 
effect of small changes to the side chain at each of the three side chain positions was evaluated 
and it was assumed that side chains made independent contributions to the binding energy. The 
correlation between the predicted free energies of binding and the experimentally determined 
affinity ranking of the compounds was found to be poor. Specifically, Spearman’s rank, the 
absolute value of which ranges from 0 for no correlation to 1 for a perfect correlation, was 
found to be just 0.4. In contrast, when the implicit solvent MM-PBSA and MM-GBSA methods 
were used to make predictions, a much greater correlation with experimental results was 
observed. While the exact correlation depended on the settings used, Spearman’s rank values of 
roughly 0.55 were typical, provided that the trajectory of the free protein was extracted from the 
trajectory of the complex and, when using the MM-PBSA method, the relative internal 
dielectric was not increased from its default value of 1. The greater correlation obtained with the 
implicit solvent methods could reflect the fact that it was unnecessary to assume compounds all 
bound in the same pose; all of the compounds could be docked and simulated. 
To investigate further the assumption that all oligobenzamides bind to Mdm2 in the 
paradigmatic pose of the O1 scaffold starting molecule (where the side chains occupy the 
binding sites of p53 residues Phe19, Trp23 and Leu26) regardless of their side chain structure, 
25,000 compounds were docked using Autodock Vina. Oligobenzamides were predicted to bind 
in many different poses, indicating that this prerequisite for TI may be violated. 
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To investigate the extent to which the side chains of an oligobenzamide influence the binding of 
each other, both through their effect on binding pose and within a particular binding pose, the 
MM-PBSA method was used to predict the affinities of a large combinatorial library of 
oligobenzamides in different poses and the affinities were studied using ANOVA. 
When the choice of side chain at each position was treated as a factor, a statistical interaction 
between the side chains was evident; however, inclusion of interaction terms in the models did 
not significantly increase their adjusted Nagelkerke R
2
 values, indicating that the interactions 
are small in magnitude. 
Because the ANOVA results show a statistical interaction between binding pose and the choice 
of side chains, grouping compounds based on their likely binding position (from docking) 
would be appropriate when predicting the effect different side chains have at each side chain 
position. However, due to the small magnitude of the interactions between side chains, after 
accounting for the effect of side chain choice on the binding position, it might not be 
appropriate to test large combinatorial libraries in each binding site.  
The models used do not explain a significant amount of variation in the results. This suggests 
that making predictions using longer simulations might be useful, something which would only 
be practical if independent contributions from each side chain were assumed, reducing the 
number of compounds that require testing. Within each possible oligobenzamide binding 
position, each side chain position could be investigated separately to determine the contribution 
different functional groups at that position are likely to make to the binding affinity. To predict 
the relative binding affinity for a new molecule, the compound could be docked to identify 
where it was likely to bind and this would indicate which set of side chain contribution 
predictions to sum to get the total predicted binding energy of the compound. 
To predict the side chain properties likely to increase affinity at a particular binding site, it is 
useful to generate oligobenzamide poses within that site. Local optimisation of a docked 
oligobenzamide following subsequent in situ modification of its side chains using Autodock led 
to MM-PBSA values which were positive. This suggests that the optimised poses were not 
realistic. 
FlexX is a docking program designed to place ligands in a pose close to a conformation 
previously generated by high throughput screening. A fragment library was docked using FlexX 
and the docking scores were analysed to identify the desirable properties of side chains when an 
oligobenzamide binds in the expected, idealised conformation occupying the Phe19, Trp23 and 
Leu26 binding sites. A smaller side chain is favourable at the first side chain attachment site, a 
larger side chain is favoured at the second position and aliphatic side chains as opposed to 
aromatic ones are favourable at the last side chain position. These findings are consistent with 
the properties of the p53 side chains mimicked in this binding pose. However, the results also 
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suggested that more hydrophilic side chains would bind more strongly, a finding which is not 
consistent with earlier work
31,253
 and could be explained by the lack of terms to account for 
ligand and protein desolvation in the FlexX scoring function
229,254
. These findings highlight the 
need to run simulations and use more accurate methods of affinity prediction than scoring. 
Sampling of all the possible torsion angles of oligobenzamides may require tens of nanoseconds 
worth of simulation time
172
. Fuller et al. demonstrates how Hamiltonian replica exchange can be 
used to increase the efficiency of sampling
203
. Simulations (replicas) are started at various 
lambda values and the lambda values are then swapped between the simulations at intervals 
(equivalent to the exchange of coordinates and momenta between simulations running at 
different lambda values). This reduces the chance of each simulation becoming stuck in an 
energy minimum and ceasing to explore the phase space
271
. Replica exchange could be used in 
future work to reduce sampling error. 
While the TI results presented in this chapter did not correlate strongly with experimental 
results this could reflect the way in which TI was applied; TI might be a useful method for 
comparing ligands which docking suggests have very similar binding poses. One of the 
problems with TI is the requirement to perform many simulations in order to determine the 
effect of the reaction coordinate (λ) on the potential energy of the system. In this respect, a 
method known as lambda dynamics
272
 could be a useful alternative. In this method, lambda is a 
variable which can change freely during the simulation so its effect on the potential can be 
ascertained in a single simulation. While a lambda dynamics simulation might have to be long, 
it would not necessary to simulate multiple systems to equilibration as when using the TI 
method. Multiple lambda variables can be used. This could allow multiple functional groups to 
be tested at a particular side chain position in a single simulation or even simultaneous 
modification at multiple side chain attachment positions. 
In order for methods such as TI and lambda dynamics to be effective, the poses of ligands must 
be determined accurately. When docking was performed in this project, the flexibility of the 
protein was neglected. In future work, flexible docking could be performed in which the entire 
protein or just the protein side chains can move
152
 or, alternatively, compounds could be docked 
into an ensemble of structures generated by a molecular dynamics simulation. Flexibility can 
lead to poorer docking because information in the in initial crystal structure is lost
145
. However, 
the Mdm2 binding site is flexible so conformational change might be essential to facilitate 
accurate determination of binding poses. (See Figure 1.3 on p32.) After fully flexible docking, it 
might be difficult to define where the p53 binding pockets are for the purpose of pose 
interpretation. If an ensemble of structures were produced by molecular dynamics simulations, 
the p53 peptide could be simulated in the binding site. This would not only allow the pocket 
positions to be tracked but also force them to stay open. 
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Synthetic work on oligobenzamides has focussed on compounds with N-linked
245
 and O-
linked
49
 side chains as opposed to ones where attachment is through sulphur. Modification of 
side chain attachment atoms using TI suggested that the sulphur atoms in oligobenzamides 
based on the S1 scaffold contribute more to binding energy than the corresponding oxygen 
atoms in the O1 structure. Consequently, some sulphur-linked oligobenzamides might bind 
more strongly than their equivalent oxygen-linked molecules and the sulphur linked scaffolds 
should be investigated further. 
It is necessary to demonstrate a high correlation between predicted and experimental results to 
show the practical use of implicit solvent methods in the prediction of the oligobenzamide 
affinities. While the computational methods used in this chapter could be developed further the 
experimental results used for their evaluation must be accurate too for a high correlation to be 
obtained. The experimental results used in this chapter were generated using a fluorescence 
polarisation competition assay. In this assay, an inhibitor binding to Mdm2 displaces a 
fluorescently-labelled p53 peptide. The release decreases the anisotropy of the label 
fluorescence and this is detected. Unfortunately, the collaborating chemistry group had found 
evidence of compounds binding directly to the fluorescently labelled peptide
42
. Furthermore, 
some variation in the ranking used in this chapter was observed when the assay was repeated. 
An orthogonal assay was thus needed to assist with validation of the computational findings. 
The next chapter details the development of a FRET-based assay which could be used instead of 
or in addition to the fluorescence polarisation assay in future. 
The importance of correct binding pose prediction on the accuracy of predicted affinities 
warrants validation of the oligobenzamide docking poses generated by Autodock Vina. This is 
challenging because there is no crystal structure of an oligobenzamide bound to Mdm2. Chapter 
4 describes the production of 
15
N-labelled Mdm2 L33E and its use in NMR studies to 
investigate the binding of small molecules to Mdm2. 
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3. Novel FRET Assays for Monitoring Inhibition of the p53-
Mdm2 Interaction 
 
 
 
3.1. Summary 
 
This chapter describes the development of FRET-based assays to determine the relative affinity 
of potential inhibitors for the p53 binding site of Mdm2. These assays all use GFP-labelled 
Mdm2 but the FRET acceptor fluorophore differs. Initial trials using Yellow fluorescent protein 
(YFP) were of limited success due to the significant overlap of the GFP and YFP emission 
spectra. Subsequent trials using eosin were much more successful and it was possible to develop 
both a cuvette-based assay and a plate reader-based assay. Each of these assays was validated 
with some inhibitors. The development of a plate reader assay is significant because it indicates 
the potential for robotic, high-throughput screening. 
Despite the success of this in vitro assay, it could not be developed for in vivo work because 
p53-labelled eosin cannot be expressed within a cell. Consequently, a second protein FRET 
acceptor was trialled, mCherry. Two p53-mCherry proteins were made, one using a wild-type 
peptide and the other using a mutated peptide known to bind more strongly than the wild-
type
273
. The FRET assay results reflected this difference of affinity. This observation, coupled 
with the fact that inhibitors known to bind to the p53 binding pocket of Mdm2 displace the p53-
eosin and p53-mCherry proteins in their respective assays, suggests that, despite the labelling, 
the p53 peptide in each case still binds in the expected position, validating the use of the FRET 
assays for inhibitor testing. 
In the context of FRET analysis, oligobenzamides exhibit some inconvenient features; they do 
not bind strongly to Mdm2, they are coloured, they bind to some aromatic small molecule 
fluorophores and they have a low solubility. The assays described in this chapter use various 
methods to overcome these significant problems. Firstly, the eosin and mCherry assays are 
performed with 10% dimethylsulphoxide (DMSO) to increase the solubility of a low-solubility 
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compound, such as an oligobenzamide. Secondly, when testing inhibitors, the drop in GFP-
Mdm2 fluorescence, rather than the fluorescence of the acceptor or the ratio of GFP to acceptor 
fluorescence, is used to monitor FRET, so any change in acceptor fluorophore emission due to 
oligobenzamide binding has no effect on the measurements. Finally, the high absorbance and 
low solubility of oligobenzamide compounds makes testing high inhibitor concentrations 
impossible, something which would normally make it impractical to find the affinity of weakly 
binding compounds. Thus, in the eosin assay here described, a no-eosin control is used to 
eliminate mathematically the compound absorbance and make the endpoint of the titration 
(equal fluorescence of the mix and the control) known. The latter makes it possible to fit a 
titration curve to the assay results and determine the IC50 of an inhibitor without having to add 
inhibitor until the level of FRET reaches a plateau. 
Key research outcomes described in this chapter: 
 Development of FRET-based assays for testing oligobenzamides and other inhibitors 
with low solubility, low affinity and significant absorbance. 
 Adaption of assays using p53-eosin for microwell plates in preparation for high-
throughput screening. 
 Testing of two p53-mCherry proteins which could in future be used in an in vivo assay. 
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3.2. Introduction 
 
The previous chapter describes the computational prediction of binding affinities, specifically, 
prediction of the affinities of a diverse library of oligobenzamides for Mdm2. The compounds 
investigated included 31 oligobenzamides based on the N-linked scaffold which had been 
synthesised and for which fluorescence anisotropy (FA) single-point assay data were available, 
allowing in silico and in vitro results to be compared. There was a moderately strong correlation 
between Molecular Mechanics-Poisson Boltzmann Surface Area (MM-PBSA) predictions and 
FA laboratory results. The differences between measured and predicted binding affinities could 
indicate that the computational predictions are not very accurate but will also reflect error in the 
laboratory measurements. 
In the FA assay used to generate this laboratory data, a compound is titrated into a solution of 
unlabelled Mdm2 and fluorescein-labelled p53. The p53-fluorescein is excited with polarised 
light and the polarisation of the light emitted by the fluorescein is monitored
42
. When an 
inhibitor of the p53-Mdm2 interaction is added, the p53-fluorescein which was bound to the 
Mdm2 is released. Free in solution, the peptide can rotate faster resulting in a decrease in the 
anisotropy of its fluorescence. This is a useful assay due to its high signal to noise ratio and the 
small amount of peptide required; however, there is some evidence that compounds bind to the 
fluorescein label
42
. If they do, the overall anisotropy is not directly indicative of the proportion 
of peptide which is bound, making any calculated Kd inaccurate. Consequently, there is a need 
for a method that directly measures the binding of Mdm2 to p53 peptide rather than the mobility 
of the p53 peptide. The results of such a method might correlate better with in silico predictions. 
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3.3. Methods 
3.3.1. FLUORESCENCE MEASUREMENTS 
3.3.1.1. Equipment 
All measurements were carried out in Dulbecco A phosphate buffered saline (PBS)  (Oxoid)  
(160 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1 mM KH2PO4) with 10% DMSO. 
Fluorescence was measured using either a quartz cuvette in an RF-5301PC (Shimadzu) 
spectrofluorimeter kept, unless otherwise stated, at 10°C using a refrigerated water bath or using 
microwell plates, at 30°C using a POLARstar Optima (BMG Labtech) plate reader. 
The cuvette volume was always between 500 and 700 µl of solution. The path lengths through 
the cuvette solution were 10 mm and 4 mm in the case of the excitation and emitted light 
respectively.  
In the plate reader, black 96 well plates (Falcon) were used with a well volume of 100 µl. 
Curves were fitted to results using the nls (non-linear least squares) function of the 
programming language R
274
. 
3.3.1.2. Materials 
FRET experiments were performed using GFP as the donor fluorophore and three different 
acceptor fluorophores: eosin and two proteins, YFP and mCherry. The concentration of the 
fluorescently labelled peptide and each protein was determined from their absorbance. The 
extinction coefficient was assumed to be unaffected by the labelled species. Absorbances were 
measured at 25°C using a Cary 300 Bio spectrophotometer (Varian). 
L33E GFP-Mdm217-126 was produced fully purified by Geoffrey Plante (University of Leeds) at 
a concentration of 225 µM in pH 7.3 buffer comprising 25 mM Tris, 150 mM NaCl, 5% 
glycerol, 1 mM EDTA and 1 mM DTT. Aliquots were stored at -80°C. It was made prior to the 
start of the FRET work and the amount was sufficient to cover all of the laboratory work 
undertaken. 
p53-YFP was supplied in pH 7.9 buffer comprising 20 mM Tris, 500 mM NaCl and 500 mM 
imidazole by Geoffrey Plante (University of Leeds). The protein was stored aliquoted at -80°C. 
An attempt was made to purify the p53-YFP by gel-filtration and remove the imidazole; 
however, the yield of gel filtration to remove the imidazole was prohibitively low. 
Consequently, the results shown in this thesis were produced with the imidazole-containing 
stock. The imidazole was significantly diluted in the experiments performed. 
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An oligopeptide comprising residues 13 to 33 of p53 (Sigma Aldrich) was supplied labelled 
with eosin at a concentration of 600 or 800 µM in DMSO by George Preston (University of 
Leeds). It was stored at -80°C. 
Two p53-mCherry proteins, the wild-type and a mutant, were expressed and purified (p210). 
Oligobenzamides PPY-2-75 and PPY-2-75 were supplied by Panchami Prabhakaran (University 
of Leeds) dissolved in DMSO at a concentration of 10 mM. They were stored at -20°C. 
The known inhibitors Nutlin-3
40
 (racemic mixture) and R5C3
275
 were obtained as freeze dried 
solids from Sigma Aldrich. They were dissolved in DMSO upon arrival and stored at 5°C. 
The peptide comprising residues 13 to 33 of p53 can be considered to be an inhibitor of the p53-
Mdm2 interaction. It was obtained unlabelled from Sigma Aldrich. 
Unlabelled Mdm2 was used in a fluorescence anisotropy experiment. It was supplied by Alice 
Bartlett (University of Leeds) in pH 7.3 buffer comprising 25 mM Tris, 150 mM NaCl, 5% 
glycerol, 1 mM EDTA and 1 mM DTT. 
3.3.1.3. FRET measurements 
This chapter describes the development of FRET-based assays in which the affinity of potential 
inhibitors for the p53 binding site of Mdm2 is assessed based on their ability to displace a 
labelled p53 peptide from GFP-labelled Mdm2. Three different FRET acceptors were tested. In 
each case, experiments were performed to validate the assay. Firstly, the effect of acceptor-
labelled p53 on the spectrum of GFP-Mdm2 was determined in the presence and absence of the 
known p53-Mdm2 interaction inhibitor Nutlin-3. Secondly, the labelled p53 was titrated into 
GFP-Mdm2 to determine the dissociation (Kd) of the interaction. The Kd can be compared to 
that of the unlabelled proteins and is necessary for the conversion of inhibitor IC50 values into Ki 
values as described below. Thirdly, compounds were titrated into a mixture of GFP-Mdm2 and 
the labelled p53 to see if the relative affinities of known inhibitors were consistent with 
previously published work and, where possible, whether oligobenzamides generated a titration 
curve. 
Experiments were performed in a spectrofluorimeter cuvette, with the exception of titrations 
involving the addition of compound to a mixture of GFP-Mdm2 and p53-eosin; these were 
carried out both into a cuvette and across a microwell plate, the latter in preparation for future 
high-throughput screening. 
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3.3.1.3.1. Titration of labelled p53 into GFP-Mdm2 
3.3.1.3.1.1. With p53-YFP as the FRET acceptor 
To determine the dissociation constant, a 500 μl solution was made up comprising 5 μM GFP-
Mdm2 and 10 μM p53-YFP in PBS with 10% DMSO. The GFP fluorescence was measured at 
505 nm, exciting at 470 nm. The sample was then serially diluted with a solution lacking the 
p53-YFP component but otherwise identical and the fluorescence measurement was repeated 
after each dilution. 
There is some excitation of YFP in 470 nm light and some emission by YFP at 505 nm. To 
determine how much direct excitation and fluorescence of the p53-YFP contributed to the 
measured fluorescence, the experiment was repeated without the GFP-Mdm2 component. (A 
solution of 10 μM p53-YFP was diluted with buffer.) The results of this control experiment 
were subtracted from the fluorescences of the main GFP-Mdm2-containing experiment to obtain 
the GFP fluorescence. 
Serial dilution entailed the removal of solution from the cuvette and then its subsequent 
replacement with diluent. The addition of cold solution was used to keep the cuvette cold. This 
dilution method allowed the starting main run and the control p53-YFP-only run solutions to be 
set up with identical p53-YFP concentrations, reducing the error when the direct YFP 
fluorescence was subtracted. (If the high p53-YFP concentration fluorescences had been 
measured at the end of a long titration involving many small additions, this error could have 
been large.) After each addition, the solution was mixed by pipetting. 
Equation 3.1 was fitted to the fluorescences (after subtraction of the direct p53-YFP 
fluorescence)
276
. It was assumed that the GFP-Mdm2 fluorescence was proportional to the 
Mdm2-p53 concentration. 
F = F0 −  A ([Mdm2] + [p53] + Kd
−√([Mdm2] + [p53] + Kd)2 − 4[Mdm2][p53]) 
3.1 
Where F is the fluorescence, F0 is the fluorescence in the absence of p53-YFP, Kd is the 
dissociation constant, [Mdm2] and [p53] are the concentrations of GFP-Mdm2 and p53-YFP 
respectively and A is another constant, specifically the change in fluorescence when 1 mol of 
Mdm2 binds to 1 mol of p53 in a volume of 1 litre. For each dissociation constant to be found, 
the mean logarithm of the Kd values from different repeats was determined and confidence 
limits on the Kd value were calculated using the standard error of the log Kd values
277
. 
𝑆𝐸10𝑥 = 𝑆𝐸𝑥
𝑑
𝑑𝑥
10𝑥 = (ln 10)10𝑥𝑆𝐸𝑥 3.2 
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3.3.1.3.1.2. With p53-eosin as the FRET acceptor 
500 μl of a solution of GFP-Mdm2 at a concentration of 1 μM in PBS with 10% DMSO was 
placed in a cuvette and p53-eosin was titrated in such that the p53-eosin concentration in the 
cuvette increased exponentially with successive additions. The solution added contained 1 μM 
GFP-Mdm2 and, like the analyte, had 10% DMSO to ensure that only the concentration of p53-
eosin (and the total volume) changed with each addition. To cover a large concentration range, 
two p53-eosin solutions were used, a 0.23 μM solution and a 30 μM solution. The GFP 
fluorescence at 505 nm was read during the titration, exciting at 450 nm. Excitation was also 
carried out at 450 nm when taking emission spectra. To mix the solution after each addition, a 
magnetic stir bar was moved up and down in the cuvette using magnets held outside the cuvette. 
The mean logarithm of the Kd and the standard error of this value were determined. These were 
used to calculate the Kd and its confidence limits. 
3.3.1.3.1.3. With p53-mCherry as the FRET acceptor 
The Kd was determined for each p53-Cherry protein by way of its titration into 1 μM GFP-
Mdm2 in PBS with 10% DMSO. Equation 3.1 was fitted to the results of each titration to 
determine a value for the p53-mCherry dissociation constant. p53-mCherry was added from 
solutions of two different concentrations, as with the titration of p53-eosin into GFP-Mdm2, in 
order to cover a wide concentration range. The volume of each addition was progressively 
increased such that the concentration of p53-mCherry in the cuvette increased exponentially by 
a factor of 2.4 until a limit (5 μM) was reached. The concentration was then increased in a linear 
manner so that many observations were made at the high concentration end of the titration 
curve. This greatly increased the accuracy with which the dissociation constant (Kd) values 
could be calculated because the Kd has a big impact on the gradient of the titration curve as it 
begins to plateau. 
3.3.1.3.2. Titration of compounds into mixtures of GFP-Mdm2 and labelled p53 
3.3.1.3.2.1. With p53-YFP as the FRET acceptor 
The known p53-Mdm2 interaction inhibitor Nutlin-3
40 was tested to see if the FRET assay 
enabled its Ki to be determined correctly. A solution of 5 μM Nutlin-3, 2 μM GFP-Mdm2 and 2 
μM p53-YFP in PBS with 10% DMSO was titrated into a solution lacking the Nutlin-3 but 
otherwise identical. A similar titrant but with 350 μM Nutlin-3 was then added to increase the 
concentration further. The initial volume in the cuvette was 500 μl. Excitation was at 450 nm 
and the ratio of YFP (530 nm) to GFP (495 nm) fluorescence was monitored. Mixing was 
carried out using a very small magnetic stir bar, which was moved vertically through the 
solution. To determine the IC50 value (the inhibitor concentration at which there was 50% 
inhibition), the ratios from each repeat were fitted to equation 3.3, which may be derived from 
the Hill equation
278
 by setting the Hill coefficient to 1. The mean of the log IC50 values was 
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calculated together with its standard error. The IC50 value and 95% confidence limits were 
found from these. 
𝑅 = 𝑅0 − 𝐴
[𝐼]
[𝐼] + 𝐼𝐶50
 3.3 
Where R is the ratio, R0 is the ratio in the absence of inhibitor, A is the range of the fluorescence 
change and [I] is the concentration of inhibitor. 
3.3.1.3.2.2. With p53-eosin as the FRET acceptor 
Titrations were carried out into a cuvette in the spectrofluorimeter or, alternatively, across a 
microwell plate, where the fluorescence was measured using a plate reader. In the 
spectrofluorimeter, excitation was at 450 nm and emission was measured at 495 nm. In the pate 
reader, a 450 nm filter was used for excitation and emission was detected using a 492 nm filter. 
The emission wavelengths, which are significantly lower than the maximum emission 
wavelength of GFP, were chosen to avoid the detection of p53-eosin, which emits very little 
light of wavelengths shorter than 495 nm. The filters used in the plate reader had a bandwidth of 
5 to 7 nm. 
Potential inhibitors were titrated into 1 μM GFP-Mdm2 and 2 μM p53-eosin in PBS with 10% 
DMSO. In the cuvette assay, the initial volume of the analyte was 300 μl. The inhibitor solution 
(titrant) was added so as to increase the concentration of inhibitor in the cuvette by a factor of 
1.5 with every addition. To enable a large range of concentrations to be covered, inhibitor 
solutions of two different concentrations, x and 38x were used consecutively in each titration. 
Depending on the inhibitor in use x equalled 1.8 or 2.7 µM. These titrant solutions also 
contained 1 μM GFP-Mdm2, 2 μM p53-eosin and 10% DMSO to ensure that only the 
concentration of inhibitor changed. The increasing volume of solution in the cuvette was 
factored in when calculating the size of each addition. Mixing was performed using a miniature 
magnetic stir bar as described above. Each main titration was followed by a second control 
titration, identical in every way except that the p53-eosin was replaced with buffer in both the 
titrant and the analyte. 
When the assay was performed using microwell plates, 16 exponentially increasing inhibitor 
concentrations from 0.11 to 230 µM were used for both the main and control titrations. 
The main and control titrations were repeated at least 3 times. For each repeat, the ratio of the 
GFP fluorescence with p53-eosin to that of the control was found at each inhibitor 
concentration. A curve based on Equation 3.4 was fitted to these ratios to determine an IC50 
value for each repeat. Calculation of the mean log IC50 value and its standard error enabled the 
IC50 value and its 95% confidence limits to be determined for each inhibitor. 
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𝑅 = 𝑅0 + (𝑅∞ − 𝑅0)
[𝐼]𝑛
[𝐼]𝑛 + 𝐼𝐶50
𝑛 
3.4 
Where R is the ratio of the GFP fluorescences, the no-p53-eosin GFP fluorescence divided by 
the with-p53-eosin GFP fluorescence. R0 is the ratio when there is no inhibitor, but with results 
from the cuvette experiments, the value of R0 was assumed to be equal to the ratio for the lowest 
concentration point used. In the plate reader, R0 was found to be 0.442 ± 0.014 for the majority 
of runs. Where this was not the case (for example, R0 was 0.55), a run was considered 
anomalous and was repeated. 
In Equation 3.4, n is the Hill coefficient. It was normally fixed at 1 but the plate reader results 
obtained with the oligobenzamide PPY-2-75 could not be fitted using a Hill coefficient of 1. 
They were consistent with a Hill coefficient of 2 so fitting was carried out with n fixed at 2 
instead. This decision is discussed further in the results section on p235. 
At high inhibitor concentrations there should theoretically be no FRET in either the main or 
control titrations. Their fluorescences should thus be identical, making R, the ratio of these two 
fluorescences (at a very high inhibitor concentration) equal to 1. Consequently this value (1) 
was used when fitting Equation 3.4 to the ratios determined in the plate reader. Contrastingly, in 
the spectrofluorimeter experiment, a maximum ratio of 0.946 ± 0.015 was observed with Nutlin-
3 and all of the results were fitted using this result.  It is possible that the DMSO denatured 
some GFP-Mdm2 and p53-eosin in the long p53-eosin-containing experiment in the 
spectrofluorimeter, causing some aggregation which no amount of inhibitor could dissociate. 
The efficacy of PPI inhibitors was quantified by determination of their dissociation constant 
(Ki). Where possible, the Ki was evaluated in preference to the IC50 value (the concentration at 
which the PPI disrupts 50% of the complexes) because it is not dependent on the concentrations 
of the proteins. 
In the absence of inhibitor: 
[Mdm2]0  =
1
2
([Mdm2]T − [p53]T − Kd
+√([p53]T − [Mdm2]T + Kd)2 + 4[Mdm2]TKd) 
3.5 
Where Kd is the p53-Mdm2 dissociation constant. [p53]T and [Mdm2]T are the total 
concentrations of p53 and Mdm2 respectively and [Mdm2]0 is what the concentration of free 
Mdm2 would be if there were no inhibitor present. 
[p53.Mdm2]
50
=
1
2
[p53.Mdm2]
0
=
1
2
([𝑝53]𝑇 − [Mdm2]0) = 
1
2
([p53]
T
− [p53]
0
) 3.6 
Where [p53.Mdm2]0 is the free p53-Mdm2 concentration when there is no inhibitor and 
[p53.Mdm2]50 is the same concentration but at the point of 50% inhibition. 
According to Nikolovska-Coleska et al.
276
, 
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𝐾𝑖 =
[𝐼]50
[𝑝53]50
𝐾𝑑
+
[Mdm2]0
𝐾𝑑
+ 1
 
3.7 
Where 
[I]
50
= IC50 − [Mdm2]T+[p53.Mdm2]50+
Kd[p53.Mdm2]50
[p53]
50
 3.8 
[p53]50 and [I]50 are the concentrations of free labelled p53 and inhibitor respectively at the 
point of 50% inhibition. 
3.3.1.3.2.3. With p53-mCherry as the FRET acceptor 
Inhibitors of the p53-Mdm2 interaction were titrated into 2 μM GFP-Mdm2 and 5 μM wild-type 
p53-mCherry in PBS with 10% DMSO up to a concentration of 60 μM. GFP was excited at 440 
nm and GFP fluorescence was measured at 505 nm. No no-p53-mCherry control was used; 
Equation 3.4 was fitted as before to find each IC50 value, except that in this case R represented 
the raw GFP fluorescence. The minimum fluorescence, maximum fluorescence and Hill 
coefficient were allowed to vary when fitting each curve. 
3.3.1.4. Additional experiments to investigate the GFP-Mdm2 and p53-eosin assay 
3.3.1.4.1. Titration of unlabelled Mdm2 into p53-eosin 
A high Kd was measured for the binding of GFP-Mdm2 to p53-Cherry. To investigate whether 
this was partly due to the presence of the GFP label, a titration was carried out without the GFP 
label to see if the Kd was lower. Unlabelled Mdm2 was titrated into 250 nM p53-eosin in a 
FluoroLog (Horiba) spectrofluorimeter. The titrant and analyte contained 10% DMSO. The 
eosin was excited with polarised light at 525 nm and its emission at 543 nm was measured using 
a second polarising filter. Both filters could be positioned horizontally (H) or vertically (V) and 
the anisotropy at each point was calculated using the fluorescence (F) obtained with each of all 
four possible filter orientations, HH, HV, VH and VV. 
𝐴 =
𝐹𝑉𝑉 − (
𝐹𝐻𝑉 × 𝐹𝑉𝐻
𝑉𝐻𝐻
)
𝐹𝑉𝑉 + 2 ∗ (
𝐹𝐻𝑉 × 𝐹𝑉𝐻
𝑉𝐻𝐻
)
 3.9 
 
3.3.1.4.2. Titration of an oligobenzamide into p53-eosin in the absence of GFP-
Mdm2 
Previously published fluorescence anisotropy results suggest that oligobenzamides bind to p53-
fluorescein
42
. Eosin is a similar compound to fluorescein so oligobenzamides might also bind to 
p53-eosin, an interaction which would complicate the analysis of GFP-Mdm2 and p53-eosin 
competition assays. 
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In a control experiment, the oligobenzamide PPY-2-75 was titrated into a solution of 1.6 µM 
p53-eosin in PBS with 10% DMSO across a microwell plate to investigate whether PPY-2-75 
has any effect on p53-eosin fluorescence in the absence of GFP. 492 nm and 590 nm filters 
were used for excitation and emission respectively. A dilution factor of 1.5 was used to create 
28 exponentially increasing concentrations from 0.9 nM to 50 µM. The plate was read at 30°C. 
3.3.1.4.3. Single point assays measuring FRET and fluorescence anisotropy 
To perform single point assays, compounds were added to a solution of 1 μM GFP-Mdm2 and 2 
μM p53-eosin in a cuvette in the FluoroLog (Horiba) spectrofluorimeter and the FRET and 
fluorescence anisotropy of the p53-eosin were measured in quick succession. The fluorescence 
anisotropy of the eosin can be measured in the presence of GFP-Mdm2 if it is excited at 535 nm 
because this wavelength is too high to excite the GFP-Mdm2. A circular dichroism cuvette was 
used to minimise the solution volume and therefore the amount of labelled peptide used. 
3.3.2. PRODUCTION OF P53-MCHERRY 
3.3.2.1. Site directed mutagenesis: Production of doubly His-tagged wild-type and singly 
His-tagged mutant p53-mCherry constructs 
A pET-28b-TEV plasmid encoding a 279 residue fusion protein comprising a p53-like peptide 
(Figure 3.1) and the fluorescent protein mCherry was produced by Jillian Augustine (University 
of Leeds). The encoded protein had oligo-histidine tags at both the N and C termini. The mutant 
peptide used had previously been shown to have increased affinity for Mdm2
279
 with a Kd of 5.6 
nM in 10% DMSO, considerably lower than the wild-type p53 transactivation domain peptide 
Kd of 0.9 μM
273
. It shares the key residues Phe19, Trp23 and Leu26 with the wild-type peptide. 
The crystal structure of the mutant with Mdm2 (PDB structure 3G03
280
) suggests that the L22Y 
mutation is at least partly responsible for the increased affinity; Tyr22 fills a hydrophobic space 
which is solvent-accessible when the wild-type binds (with Leu22)
273
. The mutant peptide also 
binds to Mdm4 more strongly than the wild-type peptide. In this case, the hydrophobic part of 
the Thr27 side chain is thought to contribute to the affinity through its interaction with Mdm4 
residue Met53. In the wild type peptide, the polar backbone carbonyl group of Pro27 takes its 
place close to Met53. 
I designed primers for site-directed mutagenesis to transform the construct above into, firstly, 
one with only one His tag (Figure 3.2) and, secondly, one encoding the wild-type p53 peptide 
(still with two His tags) (Figure 3.3). The site-directed mutagenesis was performed by Jillian 
Augustine who then supplied the resulting constructs.  
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 MGHHHHHHHHHHSSGHENLYFQGSQLTFEHYWAQLTSSKGEEDNMAIIKEFMRFKVHMEGSVNGH
EFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEG
FKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDG
ALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGR
HSTGGMDELYKLEHHHHHH 
  Blue – Oligo-histidine tag Green - p53-like sequence 
Yellow - TEV protease cut site Red - p53-mCherry 
 
Figure 3.1: The amino acid sequence of the double His-tagged mutant p53-mCherry protein 
(encoded by DNA initially produced by Jillian Augustine). Residues are coloured as shown in the key. 
 
 Before site-directed 
mutagenesis 
(No stop codon) 
GACGAGCTGTACAAG...CTCGAGCACCACCACCACCACCACTGA 
D  E  L  Y  K     L  E  H  H  H  H  H  H  X 
After site-directed mutagenesis 
Stop codon present 
GACGAGCTGTACAAGTAACTCGAGCACCACCACCACCACCACTGA 
   D  E  L  Y  K  X 
  
One of the two site-directed 
mutagenesis primers 
5’- gacgagctgtacaagtaactcgagcaccacca – 3’ 
 
Figure 3.2: Diagram to show how a new stop codon was introduced into the p53-mCherry 
construct. The capitalised DNA sequences show the end of the mCherry coding sequence in the 
construct. Underneath each is the encoded amino acid sequence. Two primers are used for mutagenesis, 
each the reverse complement of the other. 
  
 Mutant construct 
(unmodified) 
CAGCTGACCTTTGAACATTATTGGGCGCAGCTGACC   AGCAGC 
Q  L  T  F  E  H  Y  W  A  Q  L  T     S  S 
 
Corresponding part of 
wild-type mdm2 DNA 
CAGGAAACCTTTAGCGATCTGTGGAAACTGCTGCCGGAAAACAGC 
Q  E  T  F  S  D  L  W  K  L  L  P  E  N  S 
 
Corresponding part of 
forward primer 
CAGGAGACCTTTTCAGATTTATGGAAGCTGCTGCCCGAAAACAGC 
Q  E  T  F  S  D  L  W  K  L  L  P  E  N  S 
 
  
Forward primer 
(100 bp) 
5'- gcggccatgaaaacctgtacttccagggatcccaggagaccttttcagat 
    ttatggaagctgctgcccgaaaacagcaagggcgaggaggataacatggc -3' 
 
Figure 3.3: Diagram to show how the mutant p53 peptide was mutated to the wild-type peptide in a 
single site-directed mutagenesis experiment. Two primers are used for mutagenesis, each the reverse 
complement of the other. The top sequence shows the part of the mutant construct which was mutated. 
The two DNA sequences below show the corresponding part in the wild-type mdm2 gene and in the 
forward primer. The entire sequence of the forward primer is shown at the bottom. Where sequences 
differ from that of the mutant construct, this is indicated in red. 
 
  
211
  
 
3.3.2.2. Production of the singly His-tagged wild-type p53-mCherry construct 
To produce a wild-type construct with only one His-tag, the two constructs (the wild-type with 
two His-tags and the mutant with one His-tag) were cut with PstI and ClaI (New England 
Biolabs) and the larger fragment from the wild-type construct digest (with the N-terminal end of 
p53-Cherry containing the wild-type p53 peptide) was ligated into the smaller fragment from 
the mutant-construct digest (with the C-terminal end of p53-Cherry with no His-tag) (Figure 
3.12). ClaI was chosen because it cuts within the kan gene of the vector so kanamycin could be 
used to select for transformants containing both parts of the desired plasmid correctly 
orientated. 
100 ng µl-1 of plasmid DNA was incubated with both PstI and ClaI in the supplied NEBuffer 4 
with bovine serum albumin (BSA) at 37°C as directed by the manufacturer. After 2 hours’ 
incubation, solutions were run on a 1% agarose gel made with and run in tris-borate EDTA 
(TBE) buffer (20 mM Tris-acetate, 0.5 mM EDTA). A constant voltage of 60 V was applied. 
RedSafe (iNtRON Biotechnology) was added to the gel to stain bands, which were cut out on a 
SafeImager blue light transiluminator (Invitrogen). The desired pieces of DNA were purified 
from their excised gel bands using the QIAquick gel extraction kit (QIAGEN) as directed by the 
manufacturer. DNA was eluted in the supplied TE buffer (10 mM pH 8 Tris-Cl buffer with 1 
mM EDTA). 
Ligation was performed over 1 hour at 37°C using T4 DNA ligase (Invitrogen) with the 
supplied buffer. DNA concentrations were measured using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific) and a ratio of 3 large DNA fragments to every small 
fragment was used in the ligation. DH5α cells were transformed immediately as described 
below. 
3.3.2.3. Transformation of DH5α (cloning competent) cells 
100 µl of DH5α Escherichia coli cells (fhuA2 lac(del)U169 phoA glnV44 Φ80' lacZ(del)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17) in transformation buffer (10 mM PIPES, 15 mM 
CaCl2, 250 mM KCl, 55 mM MnCl2 (pH 6.4)) was thawed on ice. 9 µl of purified DNA in TE 
buffer (10 mM pH 8 Tris-Cl buffer with 1 mM EDTA) was added. The cells were left for 30 
minutes on ice, incubated at 42°C for precisely 30 seconds (heat shock) and then returned to the 
ice for 5 minutes. 
Standard practice is to incubate cells in 1 ml of 2xYT broth for 45 minutes at 37°C and then 
plate 40 µl or 400 µl of media on plates with antibiotic; however, attempts to transform with the 
single-His-tagged wild-type p53-mCherry construct and then plate repeatedly yielded no 
colonies suggesting inefficient ligation or transformation. Colonies were produced successfully 
by transfer of the transformed cells into 1 L of 2xYT media in a 2 L baffled flask (incubated at 
37°C with shaking). After 45 minutes, kanamycin was added to the flask and it was left 
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overnight at 37°C to give any correctly transformed cell a chance to multiply. A 1 million times 
serial dilution of the saturated solution which resulted was spread on kanamycin-containing 
plates the next day, which were then incubated at 37°C to obtain individual colonies. 
3.3.2.4. Identification of transformants with the correct construct 
Colony PCR suggested that all of the colonies obtained had the desired construct and this was 
confirmed for some colonies by sequencing. 
For colony PCR, cells from each selected colony were transferred to 30 μl of purified water. 
The water was boiled for 10 minutes. Then, 3 μl was used to complete a 30 μl PCR reaction 
mixture. Taq polymerase (New England Biolabs) was used with ThermoPol buffer (New 
England Biolabs) and custom primers for the N and C termini of the protein: 
5’-AAAGGATCCCAGGAAACCTTTAGCGATCTGTGGAAACTG-3’ (N) 
5’-AAACTCGAGTTACTTGTACAGCTCGTCC-3’   (C) 
 
The protein-coding region was cut in the middle during the splicing process so PCR between the 
ends of the protein was sufficient to confirm that both halves of the open reading frame were 
present in a construct. 
Details of the PCR program used for colony PCR are shown in Table 3.1. 
Table 3.1: The program used for colony PCR 
Stage Temperature /°C Time /s 
Initial denaturation 96 120 
Cycles (20) Denaturation 94 30 
Annealing 40 30 
Extension 72 90 
Final extension 72 240 
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3.3.2.5. Expression and purification of p53-mCherry 
Both of the p53-Cherry constructs were purified in the same manner. 
Novagen Rosetta 2 (Merck Biosciences) cells were transformed with the p53-mCherry construct 
as directed by the manufacturer. After inoculation, 6 litres of 2xYT broth (16 gl
-1
 tryptone soya 
broth (Oxoid), 10 gl
-1
 yeast extract (Oxoid) and 2.5 gl
-1
 sodium chloride) was incubated at 37°C 
until the optical density at 600 nm was 0.8. 1 mM IPTG was then added to induce expression 
and the cells were incubated at 18°C overnight. 
After 15 hours, the cells were pelleted using 15 minutes’ centrifugation at 6000 × g and then re-
suspended in 20 mM Tris buffer (pH 7.9) with 0.5 M sodium chloride and 20 mM imidazole. 
DNase was added. Suspensions were sonicated (5 s 20 times using a Soniprep 150 (MSE) with 
mixing halfway through) and then centrifuged at 15000 × g for 30 minutes. The supernatants 
were filtered using a Millex-GP 0.2 µm filter (Millipore). Next, metal affinity chromatography 
was carried out. A 5ml HisTrap HP Ni
2+
 column (GE Healthcare) was equilibrated with the 
resuspension buffer and then loaded with each lysate. After washing (with 100 ml of the 
resuspension buffer), fractions (30 ml) were eluted using the same buffer but with progressively 
increasing concentrations of imidazole (30 mM, 150 mM, 300 mM, 500 mM and 1M).  
The 300 mM imidazole fractions were concentrated using a Centricon YM-10 (10 kDa 
molecular weight cut-off) filter (Amicon) to 5 ml, passed through a Millex-GP 0.2 µm filter and 
then loaded on to a Superdex 75 Sephadex gel filtration column (GE Healthcare) which was 
equilibrated and then run with a pH 7.3 buffer comprising 25 mM Tris, 150 mM NaCl, 5% 
glycerol, 1 mM EDTA and 1 mM DTT. A single gel filtration column was used to process both 
proteins, the mutant first and then the wild-type. 
SDS-PAGE gels were run with samples from mCherry-coloured fractions as indicated in the 
results section. The stacking gel (pH 6.8) comprised 125 mM Tris buffer, 0.1% SDS, 0.1% 
APS, 50 mM 5% v/v acrylamide, 0.25% v/v TEMED. The resolving gel (pH 8.8) comprised 
375 mM Tris buffer, 0.1% SDS, 0.1% APS, 15% v/v acrylamide, 0.2% TEMED.  
Protein from all peaks was stored at -80°C. Selected samples were concentrated using a 
Centricon filter (10k MWCO) to concentrations of up to 194 µM (mutant) and 385 µM (wild-
type). The concentrations were determined using the mCherry absorbance, which was assumed 
to be unaffected by the preceding p53 peptide. 
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3.4. Results and Analysis 
3.4.1. INITIAL TESTING OF GFP-MDM2 
GFP-Mdm2 was expressed and purified by Jeff Plante (University of Leeds). He reported that 
the fluorescence of the GFP-Mdm2 appeared to decrease as a solution containing the protein 
was repeatedly pipetted. It is important for the fluorescence of the GFP to be constant for 
accurate FRET measurements to be made so this claim was investigated further. 
A drop in fluorescence was observed upon mixing by pipetting. To investigate the effect of 
more agitation of the solution, mixing was then performed magnetically, using a small magnetic 
follower placed at the bottom of the 3 ml cuvette. The shutter was left open and the GFP 
fluorescence of a stirred solution and an unstirred control were monitored over time (Figure 
3.4). As shown, the switch to magnetic mixing did not solve the problem of decreasing GFP 
fluorescence, suggesting that this mixing method was also too vigorous. Furthermore, it was 
deemed that regular use of the large amount of protein required for the 3 ml cuvette would be 
uneconomical so the cuvette size was reduced and this prevented conventional use of the stir 
bar. Therefore, to mix the solution in subsequent work, the magnetic follower was agitated 
vertically using two magnets (large stir bars) moved up and down manually either side of the 
cuvette. This appeared to solve the mixing problem because the GFP fluorescence no longer 
dropped upon mixing. 
 
 
Figure 3.4: The effect of mixing on the fluorescence of a 0.56 M GFP-Mdm2 solution. Red) With 
magnetic mixing. Blue) Without mixing. 
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3.4.2. EXPERIMENTS WITH P53-YFP  
3.4.2.1. Titration of p53-YFP into GFP-Mdm2 solution 
The GFP emission was reduced when p53-YFP was titrated into GFP-Mdm2 solution 
suggesting that FRET to the YFP was occurring (Figure 3.5). The dissociation constant (Kd) was 
found to be 1.3 ± 1.1 µM, which is consistent with the Kd of 0.9 μM found by Czarna et al.
273
 
for the binding to Mdm2 of an unlabelled peptide with a sequence corresponding to that of the 
p53 transactivation domain. The size of the 95% confidence limits on the calculated Kd reflects 
the difficulty of measuring a Kd accurately when using GFP and YFP. The emission spectra of 
these fluorophores overlap considerably so FRET has little effect on the combined spectrum. 
This is one of the reasons why GFP is rarely used with YFP; BFP (Blue Fluorescent Protein) 
with GFP and CFP (Cyan Fluorescent Protein) with YFP are more popular combinations
101
. 
3.4.2.2. Addition of Nutlin-3 to a solution containing p53-YFP and GFP-Mdm2 
Addition of the known p53-Mdm2 interaction inhibitor Nutlin-3 (Figure 3.6A) to the p53-YFP 
and GFP-Mdm2 solution caused the GFP fluorescence to be almost fully restored to its initial 
value. Nutlin-3 did not cause the expected decrease in fluorescence at the YFP-emission peak; 
however, the fluorescence at this wavelength includes emission from both fluorophores. Given 
that the GFP emission increased, the YFP-emission must have decreased, consistent with 
disruption of the p53-Mdm2 interaction by the inhibitor. 
Titration of Nutlin-3 into a solution of GFP-Mdm2 and p53-YFP yielded results to which a 
curve based on the Hill equation was fitted with the Hill coefficient fixed at 1 (Figure 3.6B). 
This gave a 50% inhibition midpoint (IC50) at 1.23 ± 0.16 µM. 
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  A 
 
 B   
 
 
Figure 3.5: Graphs to show the consequence of titrating p53-YFP into 5 μM GFP-Mdm2. A) How 
changes in the concentration of p53-YFP affect the fluorescence spectrum. The GFP fluorescence falls as 
the concentration of p53-YFP increases. B) How addition of p53-YFP affects the fluorescence at 505 nm. 
The highest concentration tested was 10 μM because the YFP absorbance would be significant at higher 
concentrations. Excitation was at 460 nm. 
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Figure 3.6: Titration of Nutlin-3 into a GFP-Mdm2 and p53-YFP solution. A) The spectra of three 
solutions: 2 μM GFP-Mdm2; 2 μM GFP-Mdm2 and 2 μM p53-YFP; 2 μM GFP-Mdm2, 2 μM p53-YFP 
and 50 μM Nutlin-3. B) The ratio of the fluorescence at 530 nm to the fluorescence at 495 nm of a 
solution containing 2 μM p53-YFP and 2 μM GFP-Mdm2 as Nutlin-3 was titrated in. 
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3.4.3. EXPERIMENTS WITH P53-EOSIN 
It might be possible to develop an in vivo assay involving co-expression of the GFP-Mdm2 and 
p53-YFP hybrid proteins in a cell. However, because these proteins have a low affinity for each 
other, large amounts of each protein would need to be expressed to achieve a significant 
concentration of the complex. Furthermore, the considerable overlap of the GFP and YFP 
emission spectra would mean that FRET had little effect on the emission spectrum. 
A possible strategy to deal with the overlap of FRET donor and acceptor emission spectra 
would be to record the fluorescence at multiple wavelengths and use mathematics to separate 
the fluorescence of donor and acceptor
281
. However, in the case of the oligobenzamides, the 
colour of the compounds themselves would make this approach challenging to implement. 
3.4.3.1. Titration of p53-eosin into GFP-Mdm2 solution 
Eosin was the third FRET acceptor to be tested. It was chosen for two reasons. Firstly, there is a 
significant distance between the peak in its emission spectrum (542 nm)
282
 and that of the GFP 
spectrum (509nm), so isolation of the GFP emission from a mixture is easier. Secondly, being a 
small molecule as opposed to a large protein, eosin is less likely to hinder binding of the 
labelled peptide to GFP-Mdm2. George Preston (University of Leeds) supplied p53 with an 
eosin label on the C-terminal cysteine (Figure 3.7). 
 
 
Figure 3.7: p53-eosin 
 
The addition of p53-eosin to GFP-Mdm2 causes a reduction in the GFP fluorescence (Figure 
3.9A). Then adding Nutlin-3 to a concentration of 50 μM reverses the drop in GFP fluorescence, 
to the extent that the intensity of the GFP emission peak is almost restored to its original level 
(Figure 3.9A). The remaining discrepancy could be explained by an inner filter effect: 
absorption of the GFP-emitted light by the eosin. 
219
  
 
Titration of p53-eosin into GFP-Mdm2 (Figure 3.9B) yielded a dissociation constant of 0.68 ± 
0.16 µM. This is close to the Kd of 0.89 μM measured by Czarna et al.
273
 for the binding of 
p5315-33 (residues 15 to 33 of human p53) to Mdm2 but is not consistent with the significantly 
lower Kd of 74 nM determined by Campbell et al.
98
 for the binding of p5315-31-fluorescein to 
Mdm2. It therefore suggests that steric hindrance by the GFP label might interfere with the 
binding of p53-eosin to the Mdm2. 
 
 
Figure 3.8: Inhibitors used to test the FRET assays. A) Nutlin-3
40
. The active isomer (Nutlin-3a) is 
shown. The racemic mixture was used in experiments. B) PPY-2-75. C) PPY-2-95. D) R5C3
275
.  
 
Adding oligobenzamide PPY-2-75 (Figure 3.8) to a GFP-Mdm2 and eosin-p53 solution reduces 
the eosin-p53 fluorescence and causes some recovery of the GFP-Mdm2 fluorescence (Figure 
3.9C), consistent with the compound being an inhibitor of the p53-eosin-GFP-Mdm2 interaction 
and the FRET reducing upon its addition. 
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Figure 3.9: Graphs to illustrate the effect of adding GFP-Mdm2 to p53-eosin. 450 nm light was used 
to excite the GFP. A) Emission spectra for 2 μM GFP-Mdm2 alone, in the presence of 2 μM p53-eosin 
and with both 2 μM p53-eosin and 2 μM Nutlin-3.  B) The effect of p53-eosin addition on the GFP 
fluorescence (at 505 nm). C) Emission spectra to show the effect of oligobenzamide addition on a 
solution of 1 μM GFP-Mdm2 and 6 μM p53-eosin. The final oligobenzamide concentrations are shown in 
the key. 
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3.4.3.2. Fluorescence anisotropy with p53-eosin 
To provide further validation of the GFP-Mdm2 and p53-eosin system, single point assays were 
performed. Several known inhibitors were added to a GFP-Mdm2 and p53-eosin mix and both 
the FRET (as indicated by the GFP fluorescence) and the p53-eosin anisotropy were measured. 
The fluorescence anisotropy of the eosin can be determined in the presence of GFP-Mdm2 
provided it is excited at a wavelength which is too high to excite the GFP-Mdm2. 535 nm was 
used in this case. The FRET and fluorescence anisotropy results showed the expected 
correlation (results not shown) supporting the hypothesis that the change in FRET is due to 
separation of the GFP-Mdm2 and p53-eosin. 
Although the single point assay results suggest that the amount of FRET is a measure of the 
amount of GFP-Mdm2-p53-eosin complex, if the bulky GFP label hinders compound binding, 
this could affect the relative affinities of compounds and thus make the assay unsuitable for 
ranking compounds in terms of their affinity for unlabelled Mdm2. 
 
 
Figure 3.10: Titration of unlabelled Mdm2 into 250 µM p53-eosin 
 
To test whether the high Kd obtained with GFP-Mdm2 and p53-eosin was due to the GFP label, 
unlabelled Mdm2 was titrated into 250 µM p53-eosin and the fluorescence anisotropy of the 
eosin was monitored (Figure 3.10). This yielded a much lower Kd of 38 ± 16 nM for the p5315-
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nM observed by Lai et al.
283
 using Oregon green-labelled p5317-26 and close to the Kd of 74 ± 4 
nM observed by Campbell et al.
98
 using p5315-31-fluorescein. This result suggested that although 
the GFP does not prevent binding of p53-eosin to GFP-Mdm2, it does weaken the interaction. 
In the complex, the part of p53-eosin closest to the GFP should be the eosin label. 
Consequently, rather than restricting access to the p53 binding site, the GFP might prevent 
interactions which unlabelled Mdm2 can make with the eosin. If true, this would probably not 
affect the ranking of different oligobenzamides. 
3.4.3.3. Titration of compounds into a p53-eosin and GFP-Mdm2 solution 
To investigate whether the GFP-Mdm2 and p53-eosin FRET assay could be used to determine 
successfully the affinity of some known inhibitors of the interaction, they were each titrated into 
a mixture of p53-eosin and GFP-Mdm2. 
The concentration at which an inhibitor causes 50% of the maximal possible inhibition of a 
biological system is known as the IC50 value. A lower IC50 value indicates stronger binding of 
the inhibitor to its target protein. 
IC50 values were determined for Nutlin-3 and unlabelled p53 peptide by carrying out, for each, 
two titrations. Firstly, the inhibitor was added to a solution of GFP-Mdm2 and eosin-p53, in 
which FRET can occur (the main titration). Secondly, the inhibitor was titrated into a solution 
with an identical concentration of GFP-Mdm2 but no eosin-p53 and, consequently, no FRET. 
Excitation was at 450 nm and emission was measured at 495 nm so that no direct eosin 
fluorescence (eosin fluorescence not due to FRET) was detected; only GFP fluorescence was 
observed. The ratio of fluorescence with eosin-p53 to that without was calculated and then 
plotted against inhibitor concentration. The resulting curve should, in theory, plateau at a ratio 
of 1 because at high inhibitor concentrations there is no FRET in either solution and, therefore, 
the GFP fluorescence should be the same in both. In practice, in the cuvette titration, the results 
were not consistent with complete convergence of the main and control fluorescences at high 
inhibitor concentration (Figure 3.11A). This could be attributable to irreversible aggregation of 
some GFP-Mdm2 and p53-eosin over the course of the experiment which no amount of 
inhibitor could disrupt. 
The IC50 for Nutlin-3 was 2.4 ± 1.2 μM when the compound was titrated into 1 μM GFP-Mdm2 
and 2 μM p53-eosin in the spectrofluorimeter. This corresponds to a Ki of 470 ± 330 nM. The 
published Ki for Nutlin-3 is 36 nM for the active Nultin-3 enantiomer
266
 so a Ki of twice this, 72 
nM, would be expected for the racemic Nutlin-3 mixture tested. The observed affinity of Nutlin-
3 for the p53 binding site of Mdm2 was evidently much lower than expected. Possible 
explanations include the presence of the GFP label or partial denaturation of the Mdm2 by the 
DMSO present. 
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The IC50 for unlabelled p53 peptide was found to be 13 ± 11 µM, which corresponds to a Ki of 
3.1 ± 2.9 µM. In this case, the peptide’s low binding affinity and high cost made it impossible to 
achieve the high inhibitor concentrations essential for the accurate determination of the IC50 
value. Only the first part of the titration curve could be obtained, accounting for the large error 
in the IC50 value. 
To decrease the amounts of unlabelled p53 peptide required to achieve high concentrations, the 
FRET assay was adapted for a microwell plate, with each titration corresponding to the use of a 
set of wells of increasing inhibitor concentration across the plate. Because the assay volume is 
smaller, higher concentrations can be achieved using less peptide. 
Nutlin-3, the oligobenzamide PPY-2-75 and another inhibitor, R5C3 (molecule d in Figure 
3.8)
275
, were tested successfully using this plate assay (Figure 3.11B). However, preliminary 
results with unlabelled p53 peptide (not shown) suggested that the peptide was affecting the 
meniscus shape and that the size of the effect was different in the main and control titrations. 
In contrast to the outcome of the cuvette assays, in the plate reader set-up, the results were 
consistent with convergence of the main and control GFP fluorescences at high inhibitor 
concentrations. The initial fluorescence ratio was also higher than observed in the 
spectrofluorimeter, as shown in Figure 3.11. Possible explanations for both of these 
observations are, firstly, that the shorter duration of the plate reader experiment allowed less 
time for denaturation and non-specific aggregation and, secondly, that the shorter light path 
through the solution reduced the eosin internal filter effect. Plates were read at 30°C, a 
significantly higher temperature than that used for cuvette measurements (10°C). This probably 
had an effect on the concentration of p53-Mdm2 before inhibitor was added so could also have 
contributed to the high fluorescence ratio at the start of the experiment. 
The plate reader assay has notable advantages, namely the smaller amount of compound 
required to achieve high concentrations and the greater amenability of the plates to high-
throughput testing. 
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                 Key            Nutlin-3      Unlabelled p53      Oligobenzamide      R5C3 
B 
  
Figure 3.11: Graphs to show the effect on FRET ratios of titrating known and potential inhibitors 
into a solution of 1 μM GFP-Mdm2 and 2 μM p53-eosin. GFP fluorescence was measured at 492 nm. 
A) Spectrofluorimeter results.  B) Plate reader results. Dotted lines show the maximum and minimum 
ratios obtainable in each experiment. Dashed lines show the fluorescence ratio at which there was 50% 
inhibition. 
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For Nutlin-3, the IC50 was found to be 3.9 μM ± 0.9 μM, which is similar to that obtained from 
the cuvette assay.  For R5C3, an IC50 value of 25 ± 4 μM was observed, a higher value than 
obtained with Nutlin-3. This is consistent with the relative Ki values of these two compounds, 
72 nM for Nutlin-3 and a higher value, 100 nM for R5C3
275
.  The oligobenzamide PPY-2-75 
appeared to bind to GFP-Mdm2 even more weakly than R5C3, which is consistent with 
previously published fluorescence anisotropy results which suggest that its Ki is micromolar. 
3.4.4. PRODUCTION OF P53-MCHERRY 
Although eosin is a better FRET acceptor than YFP because its emission peak is further away 
from the emission peak of GFP, it is harder to synthesise and purify p53-eosin than it is to 
express and purify p53-YFP. Furthermore, it would be difficult to introduce p53-eosin into a 
cell to carry out an in vivo assay. Consequently, an effort was made to produce another labelled 
peptide with a protein fluorophore, p53-mCherry. mCherry has an emission peak at 610 nm
284
, 
much higher than that of GFP (509nm
282
). The excitation maximum of mCherry is at 587 nm
284
. 
Preliminary work was performed by Jill Augustine (University of Leeds). She produced a 
construct coding for p53-mCherry based on the pET28bTEV vector, where the encoded p53 
peptide was of a mutated version which had previously been found to have a much higher 
affinity than the wild-type
279
. In the event, the mutant p53-mCherry DNA supplied was flanked 
by not one, but two histidine-tag-encoding regions, one at either end. Site-directed mutagenesis 
primers designed by me for this project (see methods section) allowed Jill Augustine to supply 
two further constructs: wild-type-p53-mCherry with two histidine tags and mutant-p53-mCherry 
with one histidine tag. 
To produce a wild-type-p53-mCherry construct with one histidine tag, both of the new 
constructs were cut with PstI, which cuts in the mCherry open reading frame, and ClaI, which 
cuts in the middle of the kan antibiotic resistance gene (Figure 3.12). The p53-mCherry front 
end of the wild-type construct was ligated to the no-histidine-tag C-terminal end from the 
mutant vector and DH5α cells were transformed with the reaction mixture. Those transformed 
with correctly re-ligated vector were selected using media containing the antibiotic kanamycin. 
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Figure 3.12: Diagram to illustrate the production of a wild-type-p53-mCherry construct with one 
oligo-histidine tag from the double His-tagged wild-type construct and one from the single His-
tagged mutant construct. Note that in the final construct, the C-terminal-tag is not actually absent but is 
preceded by a STOP codon. 
 
Figure 3.13 below shows agarose gels made during production of the wild-type construct with 
only one His-tag. Part A shows the gel used for purification following cutting of the two starting 
constructs. Part B shows the colony PCR results after re-ligation. All of the colonies tested had 
the correct construct, as predicted given that the PstI cut site is in the selectable marker. 
Both wild-type p53-mCherry and mutant p53-mCherry (Figure 3.14) were expressed, purified 
and then tested in the spectrofluorimeter. The results of purification by metal affinity 
chromatography are shown in Figure 3.15. The red mCherry label made it easy to identify 
which elution fractions contained labelled protein.  
  
Wild-type, 2 tags Mutant, 1 tag 
Wild-type, 1 tag 
PstI cuts in the 
mCherry ORF 
ClaI cuts in vector 
(in the kan gene) 
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 A                   B 
 
Figure 3.13: Agarose gels from the production of the single-His-tag wild-type p53-mCherry-
encoding construct. A) The results of cleavage of the wild-type double His-tagged construct (left) and 
the mutant construct with a STOP codon at the end (right). The apparent fragment sizes are consistent 
with the predicted sizes of 4.28 kb and at 1.77 kb. The bands were cut out after taking this image B) 
Results for colony PCR of the p53-cherry open reading frame in the course of checking for correctly 
ligated constructs. 
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Figure 3.14: The final sequences of the expressed mutant (A) and wild-type (B) p53-mCherry 
proteins 
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 A              B 
 
Figure 3.15: Metal ion affinity chromatography for separation of His-tagged p53-mCherry from 
the remainder of the cell lysate. A) Wild type. B) Mutant. 
 
The 300 mM imidazole samples were further purified by gel-filtration (Figure 3.16). Two peaks 
were apparent in the results for each protein, the first implying the presence of aggregated 
protein and the second, the presence of a smaller species than expected. Polyacrylamide gel 
electrophoresis (Figure 3.17) revealed that the protein producing the second peak was, in the 
case of both the mutant and wild-type titrations, the intact, 31 kDa monomer, consistent with the 
red colour of the solutions. 
 
 
Figure 3.16: Trace showing the UV absorbance during gel filtration of His-tagged p53-mCherry 
protein following metal ion affinity chromatography. The mutant protein sample (blue) was run first. 
Purification of the wild-type (red) was carried out immediately after all of the wild-type protein had 
cleared the column. There is a linear relationship between the logarithm of the molecular weight and the 
elution volume so this graph resembles a trace of absorbance against elution volume. The absorbance is in 
milli-absorbance units. 
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Figure 3.17: Polyacrylamide gels with fractions from purification of both the wild-type (A) and 
mutant (B) p53-mCherry proteins revealing that all samples contain an intact, 31 kDa p53-
mCherry protein. Samples were taken at the start (S), middle (M) and end (E) of each of the peaks 
shown in Figure 3.16 above. 
 
3.4.5. FRET EXPERIMENTS WITH P53-MCHERRY 
3.4.5.1. Titration of p53-mCherry into a GFP-Mdm2 solution 
The mutant peptide was found to bind more strongly to GFP-Mdm2 than the wild-type. 
Titration of p53-mCherry protein into GFP-Mdm2 and measurement of the GFP emission at 505 
nm yielded titration curves for both the wild-type and mutant (Figure 3.18), from which the 
dissociation constants for binding were found to be 3.7 ± 0.2 µM and 0.21 ± 0.11 µM 
respectively. 
Both the wild-type and mutant constructs have potential advantages. The wild-type, having the 
correct p53 sequence, should theoretically provide the best indication of which compounds 
compete most effectively with p53 for Mdm2. The higher affinity mutant, because it binds more 
strongly, can be used at a lower concentration, reducing the amount of protein needed for 
assays. 
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Figure 3.18: Titration of p53-mCherry into GFP-Mdm2.  Because the curves were unlikely to plateau 
at the very highest concentrations of p53-mCherry, many high concentrations were tested to ensure that 
the dissociation constant could still be determined accurately. Blue) Wild-type p53-mCherry. Red) 
Mutant p53-mCherry. 
 
3.4.5.2. Titration of potential inhibitors into a p53-mCherry and GFP-Mdm2 solution 
After the Kd of the p53-mCherry GFP-Mdm2 interaction had been found, Nutlin-3, R5C3 and 
unlabelled p53 peptide were each added to solutions containing GFP-Mdm2 and p53-Cherry to 
see if the system could be used to distinguish their relative binding affinities for Mdm2. Figure 
3.19 shows the effects of Nutlin-3 and R5C3 on the emission spectrum. As expected, adding the 
known inhibitor R5C3 abolished the FRET indicating that R5C3 displaced the p53-Cherry from 
the p53 binding site of GFP-Mdm2 (Figure 3.19B). However, adding a large amount of Nutlin-3 
only partially reduced the FRET (Figure 3.19A). The original spectrum of GFP-Mdm2 in 
isolation might not have been restored due to Nutlin-3 precipitation causing scattering, reducing 
the intensity of the fluorescence measured. 
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Figure 3.19: Emission spectra showing the effects of introducing Nutlin-3 and R5C3 into the GFP-
Mdm2 mutant p53-mCherry system. A) 13.5 µM Nutlin-3 added to 2 µM GFP-Mdm2 and 5 µM p53-
mCherry. B) 50 µM of R5C3 added to 1 GFP-Mdm2 µM and 1 µM p53-mCherry. In both A and B, the 
initial spectrum of GFP-Mdm2 is shown in green. The addition of p53-mCherry produced the red 
spectrum and addition of the inhibitor generated the blue spectrum. The dotted green line in B shows the 
spectrum of GFP-Mdm2 in the presence of R5C3 but no p53-mCherry, which indicates that the difference 
between the solid green and blue lines reflects absorption by the mCherry. 
 
Figure 3.20 shows the results of titrations carried out into GFP-Mdm2 and wild-type p53-
mCherry. Using 1 µM GFP-Mdm2 and 5 µM p53-mCherry, IC50 values of 1.4 ± 0.2 µM, 2.5 ± 
0.3 µM and 17 ± 5 µM were obtained for Nutlin-3, R5C3 and unlabelled p53 peptide 
respectively. These results correctly reflect the relative binding affinities of these inhibitors, 
which have Ki values of  72 nM
266
, 100 nM
275
 and 890 nM
273
 respectively. 
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Figure 3.20: GFP fluorescence during the titration of inhibitors in to a solution of 1 µM GFP-
Mdm2 and 5 µM p53-mCherry (wild-type). Results for Nutlin-3 are shown in blue, results for R5C3 are 
in red and results for the unlabelled p53 peptide are in purple.  
 
As described above, titration of the oligobenzamide PPY-2-75 into a mixture of GFP-Mdm2 
and p53-eosin caused an increase in GFP fluorescence. However, the presence of the 
oligobenzamide PPY-2-75 (at a concentration of 50 µM) in a mixture of 2 µM GFP-Mdm2 and 
5 µM p53-mCherry (Figure 3.21, p234) causes a drop in the GFP fluorescence of the mixture, 
rather than the expected increase. A control run was performed with no p53-mCherry and, in 
this test, the oligobenzamide did not reduce the GFP fluorescence, suggesting that the drop 
observed in the presence of p53-mCherry reflects an increase in the amount of FRET, an 
observation for which there is no obvious explanation. The increase is seen using both mutant 
and wild-type p53-mCherry and comparable results were obtained using the similar compound 
PPY-2-95 in place of PPY-2-75. (See Figure 3.8 for the structure of PPY-2-95.) These findings 
warrant further research. 
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Figure 3.21: The effect of oligobenzamide PPY-2-75 on the degree of FRET between GFP-Mdm2 
and p53-eosin. The emission spectrum of a 2 μM GFP-Mdm2, 5 μM wild-type p53-mCherry and 60 μM 
PPY-2-75 (an oligobenzamide) solution is shown in red. The other lines are controls which lack either the 
p53-mCherry component (replaced with buffer) or the PPY-2-75 (replaced with DMSO). PPY-2-75 
causes a decrease in GFP-Mdm2 fluorescence, but only in the presence of p53-mCherry. 
3.4.6. INVESTIGATION OF WHETHER OLIGOBENZAMIDES BIND TO P53-
EOSIN AS WELL AS TO GFP-MDM2 
The results involving PPY-2-75 so far described present an apparent inconsistency. This 
oligobenzamide causes a decrease in FRET when added to GFP-Mdm2 and p53-eosin but seems 
to cause an increase in FRET when added to GFP-Mdm2 and p53-mCherry. In the former case, 
the assumption has been that the PPY-2-75 causes the dissociation of GFP-Mdm2 and p53-eosin 
by binding to GFP-Mdm2 but similar results would be obtained if the oligobenzamide binds to 
the p53-eosin instead. This could explain why no reduction in FRET is apparent in the GFP-
Mdm2-p53-mCherry system and also implies that PPY-2-75 is unlikely to be an effective 
inhibitor of the p53-Mdm2 interaction.  
To test the hypothesis that the oligobenzamide interacts with p53-eosin, PPY-2-75 was titrated 
into a solution of p53-eosin alone (with no GFP-Mdm2) across a microwell plate (Figure 3.22). 
A 40% drop in eosin fluorescence was observed, which suggests that oligobenzamides in some 
way lead to quenching of the fluorescence. Given that saturation is observed at high 
oligobenzamide concentrations, interaction of the oligobenzamide with the p53-eosin molecule 
is almost certainly the cause of the drop in fluorescence. This would be consistent with 
previously published results which suggest that oligobenzamides bind to p53 labelled with 
fluorescein, a fluorophore similar to eosin
42
. 
Any interaction between oligobenzamides and p53-eosin should not directly influence FRET 
measurements in the GFP-Mdm2 and p53-eosin assay because the amount of FRET is 
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monitored using the GFP-Mdm2 fluorescence alone. However, if the interaction significantly 
reduces the amount of oligobenzamide available to bind to GFP-Mdm2 or contributes to the 
dissociation of GFP-Mdm2 and p53-eosin, then the calculated binding affinities would be 
affected. 
Establishing the Kd of the oligobenzamide-p53-eosin complex would provide a useful measure 
of the potential of this interaction to affect the validity of assays. In theory, it should be possible 
to derive Kd from results of the type shown in Figure 3.22, using Equation 3.1 (p205).  
Unfortunately, in this case, the apparent high affinity of oligobenzamide for p53-eosin coupled 
with the high concentration of p53-eosin required to produce detectable fluorescence in the plate 
reader combined to make this impossible in practice. 
 
 
Figure 3.22: The effect of PPY-2-75 concentration on the apparent fluorescence of microwell plate 
well solutions containing 1.6 µM p53-eosin. Excitation was at 492 nm and emission was measured at 
590 nm.  
 
Figure 3.11B (p225) shows the results of titrating inhibitors in to a mixture of p53-eosin and 
GFP-Mdm2. Whereas curves based on the Hill equation with the Hill coefficient fixed at 1 
could be fitted to the results obtained with both Nutlin-3 and R5C3, the oligobenzamide results 
were not consistent with a Hill coefficient of 1. A curve with the Hill coefficient fixed at 2 
(shown in the figure) fitted the oligobenzamide results much better. This suggests that two 
molecules of oligobenzamide might be involved in the dissociation of GFP-Mdm2 and p53-
eosin, one to bind to the GFP-Mdm2 and one to bind to the p53-eosin.  
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3.5. Conclusions and Further Work 
 
The aim of this practical section of the project was to produce a FRET assay which would be 
independent of the fluorescence anisotropy assay for the purpose of measuring the binding 
affinity of p53-Mdm2 inhibitors. Three different FRET acceptors were tested: p53-YFP, p53-
eosin and p53-mCherry. The first of these was found to be of limited use due to low FRET 
efficiency and the significant overlap of the GFP and YFP emission spectra, which meant that 
FRET caused only a small change in the fluorescence spectrum. 
Changing the acceptor fluorophore from YFP to eosin reduced the emission spectrum overlap. 
The GFP-Mdm2 and p53-eosin assay was tested using both a temporal titration in a 
spectrofluorimeter cuvette and a spatial titration across the wells of a microwell plate. The 
demonstrated success of the second method is crucial because it makes the assay amenable to 
high-throughput screening by a plate-handling robot and plate reader. 
Unfortunately, p53-eosin, like any fluorescently labelled peptide, is difficult to purify from 
unlabelled peptide following synthesis and cannot be expressed in a cell making it unsuitable 
for in vivo assays. Consequently, another attempt was made to find an efficient FRET pair 
involving a protein FRET acceptor. Two constructs of p53-mCherry were made, one based on 
wild-type p53 peptide and one based on a mutated p53 peptide. The wild-type protein produced 
good results with the known p53-Mdm2 inhibitors Nutlin-3 and R5C3. The mutant also 
produced good preliminary results but was not extensively tested, partly because very little of 
the protein was available. 
While the oligobenzamide PPY-2-75 inhibited FRET in the p53-eosin system, in contrast, it 
appeared to promote FRET when p53-mCherry was used as the acceptor. This was surprising 
given that the protein to which the oligobenzamide is thought to bind, GFP-Mdm2, is the same 
in both the eosin and mCherry assays. The possibility that dissociation of the GFP-Mdm2-eosin-
p53 complex could be caused primarily by the binding of the inhibitor to the labelled peptide 
and not the GFP-Mdm2 was considered.  Oligobenzamides had previously been found to bind to 
p53-peptide
42
 and a drop in p53-eosin fluorescence was observed when compound was added to 
p53-eosin in the absence of GFP-Mdm2. Such a situation would make it impossible to predict 
the relative abilities of different oligobenzamides to inhibit of the p53-Mdm2 interaction using 
molecular dynamics simulations of Mdm2 alone. A method was therefore required to confirm 
that oligobenzamides bind to Mdm2, a method not requiring the use of competing p53 peptide. 
Nuclear magnetic resonance (NMR) can be used to test for small molecule binding and can 
potentially reveal where binding is likely to occur. This is the subject of the next chapter. 
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Many inhibitors of protein-protein interactions have a low solubility. Consequently, assays 
which can be used to determine the affinity of potential inhibitors without the need to test them 
at high concentrations would be useful. The p53-eosin assay developed in this project for testing 
oligobenzamides is such an assay. The GFP fluorescence of each solution of GFP-Mdm2, eosin-
p53 and potential inhibitor is determined relative to that of a control lacking the p53-eosin. To 
ensure that the unbound FRET acceptor, which is present in the mixture but not the control, 
does not affect the fluorescence, the donor is excited at a wavelength at which there is no 
acceptor absorbance and its fluorescence is read at a wavelength at which there is no acceptor 
emission. If the small molecule causes dissociation, the fluorescence of the mixture and the 
control converge at high inhibitor concentrations, so the ratio of the fluorescences approaches 1. 
This known titration endpoint allows a curve to be fitted to titration results without the 
requirement to test very high compound concentrations. In future, this new method could be 
used to test other low solubility or high absorbance inhibitors which could then be developed 
into more soluble compounds. 
In the method above, the wavelengths used to excite the GFP and detect its fluorescence were 
chosen to avoid detection of eosin, not to produce the strongest signal. A quencher molecule 
could be used instead of an acceptor fluorophore, eliminating all background fluorescence from 
the acceptor
285
. This would make it easier to select the best measurement wavelengths, 
particularly when restricted to the small set of filters available in a plate reader. 
If colourless oligobenzamides are produced in the future then FRET could be monitored by 
observing the ratio of acceptor to donor fluorescence. This increases the signal to noise ratio in a 
FRET assay because variations in the absolute fluorescence during the experiment are taken into 
account. 
When measuring the ratio of donor to acceptor fluorescence, emission due to direct excitation of 
the acceptor can reduce the effect of FRET on the acceptor fluorescence. BRET 
(bioluminescence resonance energy transfer) is a solution to this problem. The luminescent 
donor molecule (typically Renilla reniformis luciferase) does not need to be excited with light 
so there can be no direct excitation of the acceptor
87,286
. 
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4. The Assignment of Mdm2 L33E NMR Peaks and Their Use to 
Characterise the Binding of Peptidomimetics to Mdm2 
 
 
 
4.1. Summary 
 
This chapter describes the production of 
15
N-labelled Mdm2 L33E for NMR, the assignment of 
its 
15
N-Heteronuclear Spin Quantum Correlation (HSQC) spectrum peaks and the movement of 
these peaks upon the addition of oligoamides. 
Addition of PPY-2-75 to Mdm2 L33E or the same molecule but with a polyethylene glycol 
(PEG) chain added to increase solubility (AB062) was found to have little if any effect on the 
HSQC peak positions, suggesting that there was no binding. The latter compound is soluble, so 
the lack of a 1D 
1
H-NMR spectrum for this compound, if not also PPY-2-75, reflects the 
formation of a large slowly-tumbling, soluble aggregate with a very broad spectrum rather than 
precipitation of the compound to the extent that there is none left in the solution to detect. 
A third compound, similar in structure but lacking the middle benzene ring (VA3-192) gave a 
visible proton-NMR spectrum and did, in contrast to PPY-2-75, cause peaks to shift on the 
HSQC spectrum. These corresponded to residues close to the p53 binding site and the binding 
position of the compound predicted by docking, a position in which the compound is acting as a 
peptidomimetic. Taken together, these findings suggest that the difficulty obtaining a proton 
spectrum with the other compounds might reflect a solubility or aggregation problem unique to 
some oligobenzamides rather than an inability of oligobenzamides to bind to Mdm2 in general. 
They suggest that if this problem can be resolved, oligobenzamides could bind in the p53 
binding site. 
The assignments for the L33E mutant will be useful for future work and the findings of this 
research, most notably the instability of the protein in DMSO concentrations above 5%, the 
formation of a large aggregate by some soluble oligobenzamides and the evidence of VA3-192 
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binding in the p53 binding site, provide insight into the type of oligoamides likely to be most 
useful for future inhibitor development. 
Key research outcomes described in this chapter: 
 Assignment of the HSQC peaks for Mdm2 L33E, a protein fixed in the open 
conformation potentially facilitating more accurate determination of where ligands bind 
in future. 
 Confirmation that VA3-192 binds in the p53 binding site of Mdm2, contacting residues 
which are consistent with the compound acting as a peptidomimetic. 
 Discovery that Mdm2 L33E starts to lose its native structure at DMSO concentrations 
above 6% and identification of an aggregation problem involving oligobenzamides 
which means that they are not free in solution. 
 
4.2. Introduction 
 
The docking results described in chapter 2 suggest that oligobenzamide compounds are able to 
bind to Mdm2 in many ways other than in the paradigmatic binding pose proposed at the start of 
this thesis, where the compound lies extended in the p53-binding site with each side chain 
mimicking that of a p53 residue. 
The fluorescence polarisation results of the previous chapter suggest that oligobenzamides bind 
in the p53 binding groove but these results are compromised by evidence of some 
oligobenzamides binding to the p53-fluorescein probe. The chapter describes how FRET-based 
assays were developed in an attempt to produce an orthogonal method, which could yield 
supporting results. While in FRET assays, the O-linked compound PPY-2-75 appeared to 
displace p53-eosin from the p53 binding groove, there was also evidence of the compound 
binding to the p53-eosin probe. Also, preliminary results with p53-Cherry were less clearly in 
favour of the compound binding to Mdm2. Given the potential impact of binding position on 
affinity and on the ability of a compound to prevent p53 binding, more evidence supporting the 
predicted binding location of oligobenzamides in the p53 binding site would be desirable. 
The movement of peaks in an HSQC NMR spectrum can indicate which residues a compound 
binds close to on the surface of a protein. In an HSQC spectrum, there is one peak per N-H bond 
so, with the exception of proline, which does not show up, and residues with amine or amide-
containing side chains, which have multiple peaks, there is one peak per residue. The position of 
each peak depends on the environment of the hydrogen and nitrogen atoms so is different for 
each amino acid. Conformational changes in the protein or direct binding of a compound can 
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affect the position of the residue peaks on the spectrum. Mapping residues associated with the 
shifting peaks to the 3D structure of the protein can therefore indicate where a small molecule 
might binds. 
An HSQC NMR titration has previously been performed using an oligobenzamide dimer with 
carbon-linked side chains and wild-type Mdm2
118
. This project builds on this research, testing 
oligoamide trimers which are much more easily synthesised because they have oxygen-linked 
side chains and which should bind more strongly because they are larger and the side chains are 
prearranged by intramolecular hydrogen bonds. 
This work is also novel because it uses the L33E mutant of Mdm2, a protein stabilised in the 
open, unbound conformation of the protein. Interpretation of HSQC spectrum peak movements 
can be complicated by the propagation of conformational change through a protein to residues 
some distance from a ligand binding site. The binding of peptides to wild-type Mdm2 is known 
to cause the movement of HSQC peaks created by residues some distance from the p53 binding 
site
126
. The L33E mutant of Mdm2 could therefore be useful because, if it does not undergo 
long-range conformational changes, only the peaks of residues directly involved in binding 
should move when a compound binds. Consequently, use of this protein in future, facilitated by 
its assignment in this project, could enable a better understanding of where potential inhibitors 
of the p53-Mdm2 interaction bind to Mdm2. 
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4.3. Methods 
4.3.1. CELLS 
E.coli DH5α and expression strains transformed with Novagen pET14b plasmid (Merck) 
carrying DNA encoding Mdm2 L33E were supplied as glycerol stocks by Geoffrey Plante and 
Alice Bartlett (University of Leeds). The plasmid was extracted from DH5α overnight stock 
cultures by Miniprep (Qiagen) according to the manufacturer’s protocol. The expression strains 
CodonPlus (Stratagene), GOLD (Stratagene) and Rosetta 2 (Merck) were transformed using 
heat shock according to the manufacturer’s instructions. 
4.3.2. MEDIA 
Overnight cultures were grown in 2xYT rich media comprising 16 gl
-1
 tryptone soya broth 
(Oxoid), 10 gl
-1
 yeast extract and 5 gl
-1
 sodium chloride solution. 
Large scale expression was performed in 99% standard minimal medium, 1% LB rich medium 
with 100 gl
-1
 (260 mM) Carbenicillin. Expression tests were performed using a variety of 
different LB concentrations as detailed in the results section, also using 100 gl
-1
 Carbenicillin. 
LB comprised 10 gl
-1
 tryptone soya broth, 5 gl
-1
 yeast extract and 10 gl
-1
 sodium chloride 
solution. 
Standard minimal medium contained 50 mM sodium phosphate, 0.4% w/w (22 mM) D-glucose, 
20 mM potassium phosphate, 1 gl
-1
 (18 mM) ammonium chloride (
15
N-labelled in large scale 
expressions), 0.5 gl
-1
 (8.6 mM) sodium chloride and 1 mM magnesium sulphate with trace 
elements and BME vitamins (Sigma Aldrich). The trace elements were, in their final 
concentrations, 50 µM iron(III) chloride, 20 µM calcium chloride, 10 µM manganese(II) 
chloride, 10 µM zinc sulphate, 2 µM cobalt(II) chloride, 2 µM copper(II) chloride, 2 µM 
nickel(II) chloride, 2 µM sodium molybdate and 2 µM boric acid. BME vitamin solution from 
Sigma Aldrich comprises 85 mgl
-1
 NaCl, 2 mgl
-1
 myo-inositol, 1 mgl
-1
 D-Biotin, 1 mgl
-1
 choline 
chloride, 1 mgl
-1
 folic acid,  1 mgl
-1
 niacinamide, 1 mgl
-1
 D-pantothenic acid-(50% Ca), 1 mgl
-1
 
pyridoxal-HCl, 1 mgl
-1
 thiamine-HCl and 0.1 mgl
-1
 riboflavin. 
Autoinduction medium was also used where indicated. This comprised 5% w/v (54 mM) 
glycerol, 50 mM potassium phosphate, 50 mM sodium phosphate, 2.5 gl
-1
 (46 mM) 
15
N-
ammonium chloride, 5 mM sodium sulphate, 2 gl
-1
 (5.8 mM) α-lactose, 0.5 gl-1 (2.8 mM) D-
glucose, 1 mM magnesium sulphate, trace elements as above and BME vitamins (Sigma 
Aldrich) as above. 
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4.3.3. EXPRESSION TESTING 
CodonPlus, GOLD or Rosetta 2 (see above) with pET14b carrying cDNA for Mdm2 L33E were 
grown up in 10 ml 2xYT broth overnight at 37°C, shaken at 200 rpm. 150 μl of the saturated 
culture was transferred into 15 ml of the growth medium containing 100 gl
-1
 Carbenicillin for 
testing. Cultures were grown as before at 37°C until the optical density of the solution at 600 
nm exceeded 0.5. Expression was then induced by the addition of isopropyl 
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and cells were grown at 18°C 
for 16 hours unless otherwise stated. Cells were pelleted using 15 minutes’ centrifugation at 
3000 × g and were re-suspended in 20 mM Tris buffer (pH 7.9) with 0.5 M sodium chloride and 
20 mM imidazole. Lysozyme and DNAse were added in excess. Then, the cells were lysed 
using repeated freezing in liquid nitrogen and thawing at room temperature until the viscosity of 
the solution appeared to drop indicating that lysis had occurred. The cell debris was pelleted by 
centrifugation at 16200 × g. The lysate was removed from each sample and analysed using 
polyacrylamide gel electrophoresis. Where stated, the composition of the cell debris pellet was 
similarly analysed after resuspension in 150 μl of phosphate buffered saline. Soluble proteins 
will be present in the supernatant. If the protein is not present in the supernatant, running the 
pellet on a gel in addition to the supernatant allows a lack of protein expression to be 
distinguished from expression followed by precipitation of the protein. 
4.3.4. POLYACRYLAMIDE GELS 
Protein samples were diluted using an equal volume of SDS reducing buffer (0.3 M Tris-HCl 
buffer (pH 6.8), 10% SDS, 0.05% w/v bromophenol blue and 50% glycerol). They were placed 
in a 95°C heat block for at least 3 minutes prior to loading. 15% polyacrylamide gels (described 
p214) were used, run in SDS running buffer comprising 25 mM Tris base, 192 mM glycine and 
0.1% w/v SDS. Gels were run using a constant current of 30 mA. 
4.3.5. LARGE SCALE EXPRESSION 
GOLD cells with pET14b carrying cDNA for Mdm2 L33E were grown up in 40 ml 2xYT broth 
overnight at 37°C, shaken at 200 rpm. Large scale expression was performed using 2 litres of 
99% standard minimal medium, 1% LB rich media with 100 gl
-1
 (260 mM) Carbenicillin. This 
was split between 4 baffled flasks. 10 ml of the 2xYT overnight culture was added to each flask. 
The cultures were grown as before at 37°C until the optical density of the solution at 600 nm 
exceeded 0.5. Expression was then induced by the addition of IPTG to a final concentration of 
0.5 mM and cells were grown at 18°C for 16 hours. Cells were pelleted using 15 minutes’ 
centrifugation at 6000 × g and were re-suspended in 20 mM Tris buffer (pH 7.9) with 0.5 M 
sodium chloride and 20 mM imidazole. Lysozyme and DNAse were added in excess. The cells 
were then lysed by sonication. The cell debris was subsequently pelleted by centrifugation at 
15000 × g leaving the expressed protein in the supernatant. 
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4.3.6. PROTEIN PURIFICATION 
Protein purification was carried out as described for p53-Cherry in chapter 3 (p214) but with 
two key differences. Firstly, the final storage buffer, hereinafter referred to as “NMR buffer”, 
was pH 7.3, 73 mM Na2HPO4, 27 mM NaH2PO4, 1 mM DTT and 2.5% v/v (340 mM) glycerol, 
so constituted to ensure that the pH and ionic strength of the solution were similar to those used 
in the production of previously published chemical shifts for Mdm2
287
. Secondly, 
15
N-Mdm2 is 
colourless so the protein concentration was determined using the UV absorbance, measured 
using a Nanodrop 1000 (Thermo Scientific) spectrophotometer. The construct contains no 
tryptophan but it has 7 tyrosine residues and a cysteine. The ProtParam tool
288
 
(http://web.expasy.org/protparam/, Swiss Institute of Bioinformatics) predicted the extinction 
coefficient to be 10430 M
-1
 cm
-1
 at 280 nm.  
4.3.7. COMPOUNDS 
The compounds PPY-2-75, AB062 and VA3-192 (Figure 4.13, p263) were supplied dissolved 
in DMSO by Panchami Prabhakaran, Anna Barnard and Valeria Azzarito (University of Leeds) 
respectively. PPY-2-75 is an oligobenzamide which fluorescence polarisation results suggest 
binds to Mdm2
42
. AB062 is identical to PPY-2-75 but for the addition of a polyethylene glycol 
chain intended to increase solubility. VA3-192 closely resembles PPY-2-75 but it has three 
changes intended to significantly increase solubility. Firstly, the central phenyl ring of the 
scaffold has been replaced with a single carbon which the middle side chain is attached to. 
Secondly, this middle side chain has been reduced in size to a benzyl group. The middle unit of 
the oligoamide has therefore become phenylalanine residue. Finally, a glycine residue has been 
added to the C-terminal end of the molecule. 
4.3.8. TESTING COMPOUND SOLUBILITY 
UV spectrophotometry was used to test the solubility of PPY-2-75 and AB062. In the case of 
PPY-2-75, 2 μl of 10 mM PPY-2-75 in DMSO was added to 3.3 ml of phosphate buffered saline 
with 10% DMSO in an attempt to make a 6 μM aqueous solution. After thorough vortex mixing, 
1 ml was loaded into a cuvette, and further 1.1 ml aliquots were loaded into each of two 
Eppendorf tubes. Using a Cary 300 UV-Vis spectrophotometer (Varian), a UV spectrum (from 
240 nm to 440 nm) of the sample in the cuvette was taken immediately. The other two samples 
were left at room temperature for 3 hours. One of these was then centrifuged at 16200 × g for 1 
minute. 1 ml of the supernatant was removed from the top of each Eppendorf tube and loaded 
into a separate cuvette. The cuvettes were scanned like the first. The buffer was used for 
blanking. 
The solubility of AB062 was also tested as follows. 338 μl of the NMR buffer (see “Protein 
purification” above) and 18.6 μl of pure DMSO were vortex mixed. Then, 3 μl of 10 mM 
AB062 was added in an attempt to make 360 μl of a 6% DMSO, 10 μM AB062 solution. After a 
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second vortex mix, 150 μl of the solution was removed and mixed into 3 ml of DMSO in a 
cuvette allowing the UV spectrum to be read from 280 nm to 400 nm. The remaining 210 μl 
was immediately centrifuged at 16200 × g for 1 minute. 150 μl of the supernatant was then 
removed and this was mixed into 3 ml of DMSO in a cuvette. The spectrum was read again. 150 
μl of NMR buffer was added to 3 ml of DMSO in a cuvette to make the blank. 
The experiment with AB062 was repeated using a DMSO concentration of only 1%. Again 360 
μl of solution was made; 3 μl of 10 mM AB062 in DMSO was added to 356 μl of NMR buffer 
and 0.6 μl DMSO. 
The spectra were compared to see if centrifugation had reduced the concentration of the 
compound in the solution, causing a drop in its UV absorption. Unless they have aggregated to 
form larger particles, soluble compounds stay in the solution so the spectra should be identical. 
4.3.9. NMR 
As described in the results section, three dimensional NOESY-HSQC and TOCSY-HSQC 
spectra were used to assign the amide peaks in the HSQC spectrum of Mdm2 L33E to their 
respective amino acids. The NOESY-HSQC and TOCSY-HSQC were collected on a 750 MHz 
NMR spectrometer (Varian) using 16 transients per increment. After assignment had been 
completed, potential ligands were titrated into a sample of the protein. HSQC spectra were 
collected after selected additions using either the 750 MHz spectrometer or a 500 MHz machine 
(Varian) with typically 12 to 16 transients; however the number of transients was increased for 
the last point of a titration if the signal to noise ratio was poor. 
Pulse sequences from the BioPack pulse sequence library (Varian) were used. Phasing was 
performed using NMRpipe (National Institutes of Health)
289
 and spectra were viewed using 
CcpNmr Analysis (CCPN)
290
. 
All measurements were taken at 15°C and, unless otherwise stated, spectra were obtained using 
solutions of 90% NMR buffer (see “Protein purification” above) and 10% deuterium oxide 
(Cambridge Isotope Laboratories). (The protein was stored in NMR buffer so the protein 
solution added formed part of this component.) Fresh dithiothreitol was added to the buffer 
used. 
For the 3D assignment spectra, 300 μl of solution was used in a Shigemi tube with a protein 
concentration of 300 μM. For 2D spectra, the protein concentration was reduced to 100 μM. In 
titrations, 300 μl was the initial volume but the volume increased as compound was added. The 
change in solution volume was factored in when calculating the volume of compound solution 
to add at each step of the titration. 
244
  
 
 
Ligands were added from 10 mM stock solutions with DMSO as the solvent with the exception 
of a few additions which would have required adding less than 0.5 μl of the stock solution. In 
these cases, a 100 times (0.1 mM) dilution of the stock solution was made using NMR buffer 
and was used to add the required amount of compound to the protein solution. As described in 
the methods, in an experiment testing AB062, the detergent CHAPS (3-[(3-
cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate) was used at a concentration of 20 
mM (before any dilution due to compound addition). This was incorporated by adding 10% w/v 
CHAPS when preparing the titrant and reducing the volume of NMR buffer accordingly. 
To quantify the difference in peak positions between two spectra, a distance metric, d, was 
defined, as shown in equation 4.1
291
. This is the root mean square of the chemical shift 
deviations, δH and δN for hydrogen and nitrogen respectively, after the hydrogen shifts have been 
multiplied by 5 to account for the difference in magnitude of the shifts for the two atom types. 
𝑑 = √
1
𝑁
∑ [(5𝛿𝐻)2 + 𝛿𝑁
2]
𝑝𝑒𝑎𝑘𝑠
 
4.1 
Where N is the number of peaks. 
  
245
  
 
 
4.4. Results and Analysis 
4.4.1. EXPRESSION AND PURIFICATION OF MDM2 L33E 
4.4.1.1. Expression testing 
Expression of Mdm2 was tested in three different host cell lines under a variety of conditions to 
identify which cell line and conditions would lead to most effective production of soluble 
Mdm2. The small size of the energy differences probed in NMR experiments leads to a high 
signal to noise ratio, necessitating the use of high protein concentrations. However, production 
of labelled protein necessitates the use of minimal media, which can lead to poor expression. 
Expression testing enables the optimal conditions for expression of soluble protein to be 
determined prior to the use of large volumes of media containing expensive labelled 
compounds. 
Cells of each cell line were transformed with recombinant pET14b containing Mdm2 L33E 
cDNA. This encoded a 6 His-tagged version of the protein. The ability of the cells to express 
soluble Mdm2 was assessed as described in the methods section. Good expression had 
previously been observed using Condon Plus cells with rich media; however, in minimal media, 
the results obtained with CodonPlus cells were inconsistent, suggesting that there was some 
tendency for plasmid loss. In addition, subsequent testing under a variety of conditions (Figure 
4.1) implied that Mdm2 was insoluble. (After centrifugation of the cell contents, polyacrylamide 
gel electrophoresis showed Mdm2 was present in the pellets but not the lysates.) 
No expression was evident in Rosetta cells. However, there was good expression of soluble 
protein in GOLD cells using several media. Initially GOLD cell expression was not observed in 
pure minimal medium (Figure 4.2); however, in further trials to establish the minimum 
concentration of LB necessary for expression in GOLD (Figure 4.3), expression was observed 
in entirely minimal medium. The latter suggested that the former result was anomalous and 
therefore that the LB medium was probably superfluous; however, large scale expression was 
carried out using cells from this last experiment with 1% LB in case the concentration of a trace 
LB medium constituent was a limiting factor.
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Figure 4.1: Expression of Mdm2 in CodonPlus: trials using different media. After cells had been lysed, both the lysates (left) and the cell debris pellets (right) were analysed by 
SDS-PAGE. The results show that Mdm2 was expressed but was insoluble. 
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Figure 4.2: SDS-PAGE gel showing samples from lysed GOLD, CodonPlus and Rosetta 2 cells after 
expression testing in different media. Soluble Mdm2 is present in every GOLD sample except the one 
from cells grown in minimal medium. The intense band in the GOLD minimal medium lane around 15 
kDa is lysozyme, which was added (in excess) to all samples prior to sonication to aid lysis. 
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Figure 4.3: SDS-PAGE gel showing samples from lysed GOLD cells grown in part-minimal, part-
LB medium. Two different expression times were tried and a variety of LB concentrations. Expression 
was observed under all conditions. 
 
4.4.1.2.  Large scale expression of Mdm2 
Based on the expression tests, a large scale expression of Mdm2 was set up using minimal 
medium supplemented with 1% LB to ensure all necessary trace elements and vitamins were 
present. For further details see the relevant methods section (p242). For the purpose of protein 
purification, GOLD cells were lysed by sonication and the homogenate was filtered. 
Subsequently, the His-tagged Mdm2 was separated from the filtrate by nickel affinity 
chromatography. Elution occurred at an imidazole concentration of 120 mM (Figure 4.4). After 
centrifugal concentration of the eluate, gel filtration, which separates proteins based on their 
size, was used to further purify the protein solution. The resulting UV absorption trace of the 
eluate (Figure 4.5A) was consistent with the presence of some aggregated material but it 
showed that a significant amount of protein had been eluted at the expected elution volume for 
Mdm2 of around 200 ml (based on its molecular weight of 15 kDa). Samples of the eluate 
responsible for the first peak revealed that Mdm2 did not contribute to this aggregate peak 
(Figure 4.5B). Contaminating DNA could have been responsible for the peak because the UV 
absorbance was measured at 280 nm, a frequency which is absorbed by DNA as well as protein. 
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Figure 4.4: SDS-PAGE gel showing samples eluted at different imidazole concentrations during the 
first part of the 15N-Mdm2 purification process, nickel-affinity chromatography. The eluate at 120 
nM was concentrated and then carried forward to the gel filtration stage. (FT=Flow through.) 
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Figure 4.5: Gel filtration of 
15
N-Mdm2. A) Graph of the eluate absorbance at 280 nm during the 
purification. B) SDS-PAGE gel showing samples from selected fractions of the eluate. 5.5 ml samples 
were taken so the first few lanes feature samples from the initial aggregate peak, the subsequent lanes 
with bands correspond to the main 200 ml peak and the sample in the final lane was eluted around the 360 
ml point. The gel confirms that Mdm2 came off in fractions 33 to 41. 
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4.4.2. ASSIGNMENT OF MDM2 HSQC SPECTRUM PEAKS TO RESIDUES 
In order to interpret the movement of HSQC spectrum peaks upon the addition of a potential 
peptidomimetic it is necessary to assign the amide peaks in the HSQC spectrum of Mdm2 L33E 
to their respective amino acids. 
Previously published amino-nitrogen and hydrogen resonances for wild-type Mdm2 were 
obtained from Biological Magnetic Resonance Bank (BMRB) (http://www.bmrb.wisc.edu/)
292
 
entry 6612
287
 (the Mdm2 N-terminal domain with no ligand). 
A Heteronuclear Spin Quantum Correlation (HSQC) spectrum of the purified Mdm2 L33E 
protein was obtained. Comparison of peak positions with those of the wild-type revealed many 
shifted resonances preventing full assignment from the wild-type resonances alone. Because the 
protein is fairly small, assignment of Mdm2 L33E could be completed using only 
15
N-labelled 
protein, without recourse to double labelling. 
Assignment was carried out primarily using a 3D 
1
H-
15
N NOESY-HSQC spectrum, a 2D 
projection of which is shown in Figure 4.6. This indicates where the nuclear Overhauser effect 
(p55) occurs between atoms of the protein and consequently, which atoms are in close 
proximity. The nuclear Overhauser effect has a distance dependence inversely proportional to 
the sixth power of the distance between the interacting nuclear dipoles
107(p26)
 so the atoms must 
be very close. 
Two types NOE of peak are visible in the spectrum. Firstly, there are sequential amide-amide 
NOE peaks. These occur in the 6-9 ppm region of the spectrum and are caused by magnetisation 
transfer between the alpha amino groups of adjacent residues. Secondly, there are amide-alpha 
proton NOEs. These are produced by magnetisation transfer between alpha amino groups and 
the aliphatic protons in the side chain of both the same residue and the preceding residue in the 
polypeptide chain. Consequently, NOEs can be identified between amide-alpha-1 proton and 
amide-beta-1 protons in addition to the aforementioned sequential amide-amide NOEs. 
Figure 4.7 illustrates the use of sequential amide-amide NOESY-HSQC peaks to identify 
adjacent residues. 
The expressed region of Mdm2 (Figure 4.8) is a mixed alpha/beta protein. Due to the different 
interatomic distances within alpha helices and beta-sheets, amide-amide NOESY peaks are 
particularly clear in alpha-helical regions whereas amide-aliphatic proton NOESY peaks appear 
strongest in beta-sheets. 
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Figure 4.6: A 2D projection of the 3D NOESY-HSQC spectrum of Mdm2 L33E, looking down the 
15
N axis 
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Figure 4.7: NOESY-HSQC spectra strip projections for residues 62 to 66 showing cross-peaks. The position of the peaks on the 
15
N axis is shown at the bottom of each strip. 
The unfiltered HSQC peaks lie on the diagonal. The cross-peaks indicate HSQC peaks caused by the transfer of magnetisation between adjacent residues, thereby facilitating their 
assignment of the residues. 
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   MGSSHHHHHHSSGLVPRGSHMSQIPASEQETLVRPKPELLKLLKSVGAQKDTYTMKEVLF 
   YLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQES 
   SDSGTSVSEN 
 
        ■ Alpha helix     ■ Beta strand     ■ Other Mdm2 residues 
 
Figure 4.8: The anticipated secondary structure of the 
15
N-labelled protein. The amino acids 
corresponding to residues 17-125 of Mdm2 are shown in colour. The regions which fold to make alpha-
helices and beta strands in Mdm2 are shown in orange and red respectively. This secondary structure 
annotation is based on UniProt entry Q00987 (wild-type Mdm2) and is consistent with the author 
secondary structure annotation of PDB X-ray structures 4DIJ
293
 and 3LBK
294
, which feature the L33E 
mutant.  
 
To aid identification of the amino acid residue responsible for each HSQC peak, a TOCSY 
(Total Correlation Spectroscopy)-HSQC spectrum was used. TOCSY-HSQC spectrum peaks 
result from the transfer of magnetisation between the amide group and protons within the same 
residue. Because the transfer is confined to a single residue, the resulting peaks can facilitate 
identification of the residue type. Furthermore, they enable the aliphatic proton peaks of 
residues in the NOESY-HSQC spectrum to be distinguished from the cross-peaks in this region 
created by the side chain of the preceding residue in the sequence. A 2D projection of the 3D 
TOCSY-HSQC spectrum is shown in Figure 4.9. 
By using the NOE based assignment strategy described above, 84 of the 109 p53 residues 
present in the construct could be assigned. The residues that are part of the His-tag and linker at 
the N-terminus could not be assigned and neither could the last 7 residues at the C-terminus. 
The other unassigned residues are distributed around the ends of the protein sequence, the 
longest unassigned stretch being residues 111 to 114.  
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Figure 4.9: A 2D projection of the 3D TOCSY-HSQC spectrum of Mdm2 L33E, looking down the 
15
N axis 
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Figure 4.10: The HSQC spectrum of Mdm2 L33E spectrum with peaks assigned. The Phe86, Val88 
and Leu103 peaks are not visible above because the cut-off is set high to remove all of the noise; these 
peaks are apparent if the cut-off is reduced and their positions are indicated. 
 
There were significant differences between the previously published wild-type shifts and those 
observed with the mutant (Figure 4.11). The location of these shifted residues is consistent with 
the L33E mutation being responsible for the movement; the affected residues are either near to 
the site of the mutation or are closely associated with residues near to the site. For example, 
Leu81 is next to and faces towards Leu33 in structure 1T4F and it has moved significantly. The 
reason why the Asp46 peak has moved is unclear. 
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Figure 4.11: The extent to which the HSQC peak 
chemical shifts of Mdm2 L33E deviate from those of 
the wild-type protein. A) Graph showing the difference 
in chemical shift for each residue assigned. The 7 residues 
with primary amino group HSQC peaks furthest from 
those in BMRB entry 6612 are highlighted in blue. Light 
grey regions indicate where residues could not be 
assigned to a peak on the spectrum. B) The 7 residues 
with the greatest shifts highlighted on Mdm2 from 
structure 1T4F. For clarity, only residues 32 to 48 and 73 
to 107 of the protein are shown. Leu33 in the structure is 
shown in red. The positions of the residues on the X-ray 
structure are consistent with their movement having been 
caused by the L33E mutation. The side chain of Leu85 is 
also shown, in white. This residue could play a role in the 
propagation of conformational change resulting from the 
Leu33 mutation into the alpha helix made by residues 81 
to 86. 
  
 
  
0
1
2
3
4
5
6
7
8
Q
1
8
 
I1
9
 
P
2
0
 
A
2
1
 
S2
2
 
E2
3
 
Q
2
4
 
E2
5
 
T2
6
 
L2
7
 
V
2
8
 
R
2
9
 
P
3
0
 
K
3
1
 
P
3
2
 
E3
3
 
L3
4
 
L3
5
 
K
3
6
 
L3
7
 
L3
8
 
K
3
9
 
S4
0
 
V
4
1
 
G
4
2
 
A
4
3
 
Q
4
4
 
K
4
5
 
D
4
6
 
T4
7
 
Y4
8
 
T4
9
 
M
5
0
 
K
5
1
 
E5
2
 
V
5
3
 
L5
4
 
F5
5
 
Y5
6
 
L5
7
 
G
5
8
 
Q
5
9
 
Y6
0
 
I6
1
 
M
6
2
 
T6
3
 
K
6
4
 
R
6
5
 
L6
6
 
Y6
7
 
D
6
8
 
E6
9
 
K
7
0
 
Q
7
1
 
Q
7
2
 
H
7
3
 
I7
4
 
V
7
5
 
Y7
6
 
C
7
7
 
S7
8
 
N
7
9
 
D
8
0
 
L8
1
 
L8
2
 
G
8
3
 
D
8
4
 
L8
5
 
F8
6
 
G
8
7
 
V
8
8
 
P
8
9
 
S9
0
 
F9
1
 
S9
2
 
V
9
3
 
K
9
4
 
E9
5
 
H
9
6
 
R
9
7
 
K
9
8
 
I9
9
 
Y1
0
0
 
T1
0
1
 
M
1
0
2
 
I1
0
3
 
Y1
0
4
 
R
1
0
5
 
N
1
0
6
 
L1
0
7
 
V
1
0
8
 
V
1
0
9
 
V
1
1
0
 
N
1
1
1
 
Q
1
1
2
 
Q
1
1
3
 
E1
1
4
 
S1
1
5
 
S1
1
6
 
D
1
1
7
 
S1
1
8
 
D
is
ta
n
ce
 M
e
tr
ic
 /
p
p
m
 
Residue 
258
  
 
 
4.4.3. TESTING OF POTENTIAL P53-MDM2 INTERACTION INHIBITORS 
Once peaks in the HSQC spectrum had been identified, small molecules were titrated in to the 
Mdm2 solution. Table 4.1 shows the concentrations used in each titration and summarises the 
degree of peak movement observed upon the addition of each compound. 
Initially DMSO was tested because it must be added with many potential inhibitors. 
Subsequently, three potential inhibitors were tested. To summarise the results, little peak 
movement was observed upon the addition of the oligobenzamides PPY-2-75 and AB062 
considering that these had to be added with DMSO and movement was observed when DMSO 
alone was added. In contrast, some peaks were seen to move a significant distance upon 
addition of the oligoamide VA3-192. The movement of peaks was assessed using the distance 
metric described by Equation 4.1 (p245). While there was little movement overall, some peaks 
moved a significant distance in a dose-dependent manner, with one peak seen to move a 
distance corresponding to a metric of 0.755 upon addition of VA3-192 to a concentration of 200 
μM. 
In the subsequent sections, the results are discussed in more detail. Specifically, the locations of 
residues with moving peaks are identified in PDB structure 1T4F for the purpose of assessing 
their position relative to the p53 binding site. 
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Table 4.1: The root mean square HSQC peak movement during titrations into Mdm2 L33E 
Addition Concentration 
(/µM unless 
otherwise stated) 
Compared to start of titration 
Shared 
α-amino peaks 
RMS distance 
metric /ppm 
Maximum distance 
metric /ppm 
DMSO 
 
2% 83 0.0866 0.1962 
4% 71 0.1219 0.3609 
6% 68 0.1734 0.4184 
8% 42 0.2266 0.3987 
PPY-2-75 
 
140 82 0.0379 0.0953 
270 89 0.0646 0.1568 
395 90 0.0875 0.3199 
AB062 
(no CHAPS) 
0.16 89 0.0667 0.1443 
4 76 0.0850 0.1721 
100 50 0.1340 0.2962 
VA3-192 1.56 66 0.0670 0.2346 
6.25 61 0.0679 0.3112 
25 51 0.0880 0.4607 
100 71 0.0984 0.5714 
200 70 0.1254 0.7551 
 
The root mean square (RMS) of the peak distance metrics (calculated using equation 4.1, p245) was used 
to assess the similarity of the spectrum obtained after each addition to the spectrum obtained at the start of 
the titration before any titrant had been added. The “Shared α-amino peaks” column shows the number of 
peaks used to calculate the root mean square (RMS) distance metric. The rightmost column shows the 
distance metric for the peak which moved the most. Little movement was observed when PPY-2-75 and 
AB062 were titrated in; however, some peaks moved a significant amount and in a dose-dependent 
manner upon addition of VA3-192. 
 
4.4.3.1. Premiliary testing with DMSO 
The potential inhibitors tested in this project were added from 10 mM stock solutions with 
DMSO as the solvent. Using DMSO ensures that the compounds are soluble both in these 
concentrated solutions and when diluted using an aqueous protein solution. 
To investigate the effect of DMSO alone on the position of the HSQC spectrum peaks, a 
titration was performed in which the DMSO concentration was increased from 0% to 8% 
inclusive, in increments of 2%. Changes in chemical shift were observed for residues all over 
the surface of the protein (Figure 4.12), particularly when the DMSO concentration was 
increased from 6% to 8%. As indicated in Table 4.2 (p262), this final increase was accompanied 
by a decrease in the total number of peaks which were visible above the background noise and 
an increase in the proportion of these peaks which could not be identified (because they had 
moved significantly). These results suggest that the protein is becoming denatured at 
concentrations above 6% DMSO. 
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Figure 4.12: Movement of Mdm2 L33E HSQC spectrum peaks upon 
addition of DMSO to a concentration of 4% . A) Graph showing the 
distance metrics for the movement of each residue (calculated using 
equation 4.1, p245). Bars for residues with a shift distance metric 
exceeding 0.13 ppm are shown in red. Those for residues with a shift 
metric greater than 0.06 ppm but less than 0.13 ppm are in purple and bars 
for residues with a shift metric of less than 0.06 ppm are coloured blue. 
Light grey regions indicate where residues could not be assigned to a peak 
on either of the spectra being compared. B) Diagram of the surface of 
Mdm2 from PDB structure 1T4F which has been coloured to reflect the 
shift distance metrics of the residues responsible for each part of the 
surface. Surface relating to residues which could not be assigned is shown 
in grey. 
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Table 4.2: Peak statistics for the titration spectra analysed 
Experiment Titrant 
concentration 
(µM unless %) 
Total peaks Recognised 
primary amino 
peaks* 
Assigned primary 
amino group 
peaks 
Initial HSQC N/A 140 100 84 
DMSO titration 0% 174 92 79 
2% 135 86 74 
4% 113 73 64 
6% 156 70 60 
8% 82 43 34 
PPY-2-75 
titration 
 
0 155 95 79 
140 113 83 72 
270 137 90 76 
395 176 93 80 
AB062 titration 0 148 94 80 
0.16 141 91 77 
4 138 76 71 
100 87 50 43 
VA3-192 
titration 
0 130 79 72 
1.56 112 71 62 
6.25 101 64 57 
25 96 52 47 
100 176 83 71 
200 177 81 70 
 
*”Recognised peaks” were peaks thought to be caused by primary amino groups that had been observed 
in the initial HSQC spectrum and which were tracked, where possible, through each experiment. They 
included assigned peaks but also some which could not be attributed to a particular residue. 
 
4.4.3.2. Inhibitor 1: PPY-2-75 
PPY-2-75 (Figure 4.13, compound a) was titrated into an Mdm2 solution to a concentration of 
395 M. Because it was added from a 10 mM stock solution with DMSO as the solvent, the 
Mdm2 solution was 4% DMSO at the end of the titration.  
If PPY-2-75 were binding to Mdm2, the peaks representing residues around the predicted 
binding site would be those most likely to move. In contrast, the observed peak movement 
(Figure 4.14) suggests residue perturbation all over the protein, as was seen after the addition of 
pure DMSO. Five of the fifteen residues whose peaks had shifted most by the end of the PPY-2-
75 titration were among the 15 peaks which had moved the most by the end of the DMSO-only 
titration: Ser92, Cys77, Met50, Leu54 and Arg29. Peaks corresponding to the compound PPY-
2-75 were not visible on a 1D proton spectrum of PPY-2-75 in 4% DMSO with no protein (not 
shown). This suggests that the HSQC peak movement was caused by the DMSO in which the 
compound was dissolved, rather than binding of the compound itself. 
The distance moved by the peaks over the course of the titration was similar to that observed in 
the DMSO-only titration over the 0% to 4% range. However, the PPY-2-75 (and 4% DMSO) 
262
  
 
spectrum bears more similarity to the spectrum taken at the start of the DMSO titration (the 0% 
DMSO spectrum) (distance metric 0.044 ppm) than the 4% DMSO spectrum in the DMSO-only 
titration (distance metric 0.105 ppm). This suggests that the observed peak movement when 
PPY-2-75 is added reflects random peak movement caused by DMSO-driven Mdm2 
denaturation. To summarise, the movement of the peaks does not constitute evidence that PPY-
2-75 would inhibit the p53-Mdm2 interaction. 
 
 
Figure 4.13: The structures of the potential inhibitors titrated into Mdm2. a) PPY-2-75 (R=H) and 
AB062, the same molecule but with a polyethylene glycol (PEG) chain attached (R=O(CH2CH2O)3CH3). 
b) VA3-192.  
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Figure 4.14: Movement of Mdm2 L33E HSQC spectrum peaks upon 
addition of PPY-2-75 to a concentration of 395 M (accompanied by an 
increase in DMSO concentration from 0% to 4%). A) Graph showing the 
distance metrics for the movement of each residue (calculated using 
equation 4.1, p245). Bars for residues with a shift distance metric 
exceeding 0.14 ppm are shown in red. Those for residues with a shift 
metric greater than 0.06 ppm but less than 0.14 ppm are in purple and bars 
for residues with a shift metric of less than 0.06 ppm are coloured blue. 
Light grey regions indicate where residues could not be assigned to a peak 
on either of the spectra being compared. B) Diagram of the surface of 
Mdm2 from PDB structure 1T4F which has been coloured to reflect the 
shift distance metrics of the residues responsible for each part of the 
surface. Surface relating to residues which could not be assigned is shown 
in grey. The p53-helix in structure 1T4F is depicted in green. The moving 
residues are spread over the protein surface as opposed to being centred on 
the p53 binding site. This result therefore suggests that the observed peak 
movement is not the result of PPY-2-75 binding but has instead been 
caused by the DMSO added with the compound. 
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To test the solubility of PPY-2-75, an attempt was made to make a 6 μM aqueous solution of the 
compound. Samples were taken from the top of the resulting solution immediately, after 3 hours 
and after a subsequent centrifugation. Each sample was immediately scanned using a UV 
spectrophotometer.) The significant reduction in absorbance evident in the centrifuged sample 
suggests that roughly half of the compound molecules initially in solution had precipitated. 
 
 
Figure 4.15: Testing the solubility of PPY-2-75: The absorption spectrum of an aqueous PPY-2-75 
solution before and after centrifugation. The initial spectrum is shown in blue. The spectrum after the 
sample had been left for three hours is shown in red. The sample was then immediately centrifuged at 
16200 × g for 1 minute before a final spectrum, shown in blue, was taken. 
 
4.4.3.3. Inhibitor 2: AB062 
A modified version of PPY-2-75 (AB062 supplied by Anna Barnard, University of Leeds), 
which differs from PPY-2-75 due to the presence of a short polyethylene glycol chain attached 
to the scaffold (Figure 4.13, p263), was subsequently tested  and this appeared to be soluble in 
the NMR buffer (p243) (Figure 4.16 below). However, titration of AB062 into Mdm2 still did 
not cause significant HSQC peak movement (Figure 4.17). 
Despite its solubility, a 1D proton NMR spectrum of AB062 could not be obtained suggesting 
that it existed in a slowly-tumbling, soluble but aggregated form when in the NMR buffer. In 
case adding detergent could disrupt this aggregated form, the detergent CHAPS (3-((3-
cholamidopropyl)dimethylammonio)-1-propanesulfonate) was titrated into Mdm2 in 
preparation for the addition of AB062. However, significant peak movement was observed 
when CHAPS was added (results not shown) so this idea was abandoned. 
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AB062 is an amphipathic molecule; it has a polar side and non-polar side. Aggregation of 
AB062 molecules could be energetically favourable if this hides their hydrophobic side from the 
solvent. 
 
 
Figure 4.16: Testing the solubility of AB062: The absorption spectrum of an aqueous AB062 solution 
before and after centrifugation. Attempts were made to dissolve the compound in the NMR buffer (p243) 
with 6% or with 1% DMSO (just the DMSO of the solution containing the compound in the latter case). 
Samples from each solution and a buffer blank were diluted with DMSO and then UV spectra were taken 
(the solid lines). After centrifugation of the 6% and 1% DMSO solutions at 16200 × g for 1 minute, 
samples were taken again, diluted with DMSO and scanned to produce two more spectra (the dotted 
lines). AB062 appears to be soluble in the assay buffer because centrifugation did not appear to cause a 
large drop in the absorbance of the AB062 solutions. 
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Figure 4.17: Distance metrics for the movement of each Mdm2 L33E alpha-amino group HSQC spectrum peak upon addition of AB062 to a concentration of 4 M (A) and 
100 μM (B). No detergent was used. The distances are relative to the spectrum before any compound had been added. Bars for residues with a shift distance metric exceeding 0.13 
ppm are shown in red. Those for residues with a shift metric greater than 0.06 ppm but less than 0.13 ppm are in purple and bars for residues with a shift metric of less than 0.06 ppm 
are coloured blue. Light grey regions indicate where residues could not be assigned to a peak on either of the two spectra being compared. 
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4.4.3.4. Inhibitor 3: VA3-192 
The next attempt to make a more soluble molecule entailed modification of the backbone itself. 
VA3-192 (Figure 4.13b, supplied by Valeria Azzarito, University of Leeds) lacks the central 
benzene ring of an oligobenzamide, a single carbon taking its place, as in a usual amino acid 
residue. A 1D spectrum was observed in the NMR buffer and titration of the compound into the 
protein caused significant peak movement (Figure 4.18). Figure 4.19 (p270) shows HSQC 
spectra before and after the addition overlaid and Figure 4.20 (p271) shows more clearly the 
movement of some selected peaks.  Spectra taken after each addition facilitated identification of 
peaks in the final spectrum where they had moved a significant distance. 
In a study published in 2006
118
, an ortho-substituted oligobenzamide dimer (with carbon-linked 
side chains) was titrated into wild-type Mdm2 in a similar 
15
N-
1
H HSQC experiment. The most 
mobile peaks in this study were those produced by residues His73 and Phe55. In the VA3-192 
titration described here, the three most mobile peaks were, in order of decreasing distance 
metric were those of, Phe55, Leu81 and His73. Furthermore, the fourth most mobile peak in the 
VA3-192 titration was Ser22 and, in the previous research, when p53 peptide was titrated into 
the protein solution, the fourth most mobile peak was also Ser22. Consequently, the results of 
this work are consistent with previously published results. 
As shown in Figure 4.21 (p272), the residues with moving peaks are close to the p53 binding 
site, with the exception of  Leu81 which is on the opposite side of the protein. As indicated at 
the bottom of the figure, interaction of positively charged Lys64 with negatively charged Asp80 
might facilitate the transfer of any conformational change in the helix containing Gln59 and 
Phe55 into the helix holding Leu81 when VA3-192 binds. The NMR results are therefore 
consistent with VA3-192 binding in the p53 binding pocket. 
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Figure 4.18: Distance metrics for the movement of each Mdm2 L33E alpha amino group HSQC spectrum peak upon addition of VA3-192 to a concentration of 200 M. 
The distances are relative to the spectrum before any compound had been added. Bars for residues with a shift distance metric exceeding 0.13 ppm are shown in red. Those for 
residues with a shift metric greater than 0.06 ppm but less than 0.13 ppm are in purple and bars for residues with a shift metric of less than 0.06 ppm are coloured blue. Light grey 
regions indicate where residues could not be assigned to a peak on either of the spectra being compared. 
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Figure 4.19: The HSQC spectrum of 
15
N-Mdm2 before and after addition of VA3-192 to a 
concentration of 200 μM. The initial spectrum is shown in black and the final spectrum is shown in red. 
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Figure 4.20: The HSQC spectrum around the Phe55 peak before and after addition of VA3-192 to a 
concentration of 200 μM. The initial spectrum is shown in black and the final spectrum is shown in red.  
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Figure 4.21: Diagram showing the position of Mdm2residues with peaks moving in response to 
addition of VA3-192 to a concentration of 200 µM. Mdm2 from structure 1T4F is shown in space-
filling form from both the back (top right) and front (middle). Phe91 is at the back of the p53 binding site. 
Residues for shifts with a distance metric exceeding 0.13 ppm are shown in red. Those with a shift metric 
greater than 0.06 ppm but less than 0.13 ppm are in purple and residues with a shift metric of less than 
0.06 are coloured blue. Residues with no assigned peak in either the spectrum before or the spectrum after 
compound addition are shown in grey. At the bottom is a ribbon representation of part of Mdm2 which 
shows how movements in the helix holding Phe55 and Gln59 might be propagated through Lys64 and 
Asp80 to Leu81, a residue some distance from the p53-binding site.  
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Docking of VA3-192 in AutoDock Vina places the compound in close proximity to those 
residues seen to move in the NMR spectra; in the top two poses (Figure 4.22, A and B) the N-
terminal end of the helix is close to Phe55 and the negatively charged C-terminal end is close to 
His73, which could have a positive charge. These top poses show VA3-192 acting as a 
peptidomimetic (Figure 4.23, p275). Although the alignment is antiparallel to the position of 
p53-helix in structure 1T4F, the first side chain of the compound is in the Leu26 binding pocket 
and the middle side chain is in the Leu23 binding site. The third side chain is close to the Phe19 
pocket but the phenylalanine ring appears to be being mimicked by the C-terminal benzene ring 
of the scaffold rather than the isopropyl side chain. Consequently, the NMR results are not just 
consistent with VA3-192 binding in the p53 binding groove but also with it acting as a 
peptidomimetic. While VA3-192 is not itself an oligobenzamide, these results suggest that 
oligobenzamides are also likely to bind in such a way to Mdm2 once they have been sufficiently 
modified to increase their solubility and decrease their propensity for aggregation. 
Although spectra of VA3-192 and AB062 in aqueous solution could not be obtained and the 
location of the mobile peaks in the titrations of these compounds were not centred on the p53 
binding site, the most mobile peak when PPY-2-75 was added was that of Phe55 (Figure 4.14A) 
and the Phe55 peak was also the most mobile upon addition of AB062 to a concentration of 4 
μM (Figure 4.17A). Consequently, some binding could have been occuring in the p53-binding 
site.  
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Figure 4.22: Computer generated images showing the three highest-scoring AutoDock Vina 
docking poses for compound VA3-192 and how they are close to the residues seen to move most in 
the NMR HSQC spectrum upon addition of the compound. The two highest scoring poses, (A and B) 
are antiparallel to the p53-helix orientation whereas the third highest-scoring pose (C) is arranged parallel 
to it. The residues seen to move most in the NMR HSQC spectrum are highlighted in red. In the top two 
poses the compound is seen to be close to all of the highlighted residues around the binding site. In the 
highest scoring pose (A) the first two side chains are in the binding pockets of p53 residues Phe19 and 
Trp23 and the third side chain is close to the Leu26 pocket, consistent with the compound acting as a 
peptidomimetic. 
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Figure 4.23: Computer generated images that show the extent to which the side chains of VA3-192 
mimic, in the highest scoring poses predicted by Autodock Vina, those of the bound p53 helix. The 
same poses are shown in Figure 4.22. A) The two highest scoring poses. B) The third highest scoring 
pose. The protein is shown in grey and semi-transparent so that the compound (black) and the p53-helix 
(cyan) side chains can be seen in the binding pockets. 
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4.5. Conclusions and Further Work  
4.5.1. EXPRESSION, PURIFICATION AND ASSIGNMENT OF 15N-MDM2 
L33E 
In this chapter, the successful expression and purification of 
15
N-labelled Mdm2 with the L33E 
mutation has been described.  Purification was straightforward and yielded adequate amounts of 
protein. The solubility of the expressed protein was sufficient for it to be concentrated 
sufficiently for use in 3D NMR experiments. Further work is required to determine the optimal 
conditions for effective and reliable production. 
There are no published amino acid peak assignments for Mdm2 L33E. There appear to be 
moderately large differences between the chemical shifts of the peaks for the mutant and the 
published chemical shifts for the wild-type protein, particularly for peaks corresponding to 
residues around the position of the mutation. Assignment was facilitated by NOESY-HSQC and 
TOCSY-HSQC spectra although the high signal to noise ratio made assignment challenging. 
The assignments determined should be useful in future work, especially if a higher protein 
concentration could be achieved to make peak identification easier. Double labelling with both 
15
N and 
13
C would allow CBCA(CO)NH and CBCANNH spectra
295
 to be obtained. These 3D 
spectra could potentially facilitate full assignment without recourse to previously published 
resonances, allowing every residue to be identified. 
4.5.2. SOLUBLE OLIGOBENZAMIDES MIGHT AGGREGATE WHEN THEY 
DISSOLVE 
During the NMR work, evidence emerged of significant changes to the structure of Mdm2 L33E 
at higher concentrations of DMSO. These changes occurred at concentrations below 10% 
DMSO, the concentration used in the FRET assays described earlier in this thesis. However, 
testing of the oligobenzamide PPY-2-75 suggested that a significant DMSO concentration is 
needed for this compound to dissolve, especially to produce free monomers. Thus, there may be 
no concentration of DMSO which will dissolve unmodified oligobenzamides while maintaining 
Mdm2 in its native conformation. If this is the case, the molecular dynamics simulations carried 
out prior to these experiments may have been modelling situations which cannot actually occur 
in vitro. Further work to produce more soluble compounds should resolve this issue. 
The NMR work carried out indicates that addition of a soluble chain to the scaffold, creating an 
amphipathic molecule, might not be the best way to increase oligobenzamide solubility. AB062, 
the oligobenzamide with a polyethylene glycol (PEG) chain attached to the scaffold core 
appears to be soluble at lower DMSO concentrations. However, the absence of a spectrum when 
it dissolves suggests that this compound forms a large structure which tumbles slowly. Large 
complexes do not show up on an NMR spectrum because they do not rotate fast enough for 
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time-averaging of the external magnetic field over all orientations of the structure. Instances of 
the complex in different orientations have different chemical shifts creating a very broad peak 
which is lost in the noise. 
There was no evidence of AB062 affecting the positions of the peaks in the HSQC spectrum of 
the protein. The intensity of peaks on the spectrum decreased with successive additions. This 
would be consistent with the protein being bound and incorporated into a large, slow-moving 
structure with a very broad peak. This could leave only the unbound protein visible in the 
HSQC spectrum. However, an alternative explanation is that, because it is amphipathic, this 
oligobenzamide causes denaturation and subsequent precipitation of the protein. In either case, 
it seems that though the attachment of a soluble group to an oligobenzamide might render the 
compound more soluble, it could also create an amphipathic molecule with adverse properties. 
Further work involving size exclusion chromatography of Mdm2 in the presence of 
oligobenzamide might reveal the size of any soluble aggregate formed. This might suggest how 
AB062 could be modified to prevent aggregation, for example, by the addition of bulky groups 
to create steric hindrance or charged groups, such as amino or carboxylic acid groups, to cause 
the repulsion of adjacent molecules. 
Both the FRET experiments and computational methods discussed earlier in this project assume 
a simple equilibrium between the free protein and compound in solution and the complex. The 
measured binding constant in FRET experiments will reflect any other, complicating 
phenomena such as binding of the ligand to the displaced p53 peptide or precipitation of the 
compound. The computational results will not however, because such factors are not included in 
the computational model. Such effects could therefore be responsible for the poor correlation 
between predicted and experimental results encountered with oligobenzamides in chapter 2 and 
the NMR experiments in this chapter with the oligobenzamides PPY-2-75 and PPY-2-95 
support this hypothesis in that they suggest that little of the unbound ligand is actually free in 
the solution. 
4.5.3. VA3-192 RESEMBLES AN OLIGOBENZAMIDE AND APPEARS TO 
ACT AS A PEPTIDOMIMETIC 
The compound VA3-192 resembles an oligobenzamide but for the fact that the central benzene 
ring has been replaced by a methyl group. This molecule appears to bind to Mdm2 L33E 
because the HSQC spectrum peaks corresponding to residues around the p53 binding site move 
when this compound is added to a solution of the protein in the spectrometer and the most 
mobile peaks are consistent with previously published work using an oligobenzamide dimer 
with carbon-linked side chains
118
. 
The inference from this evidence is that if precipitation and aggregation can be prevented, 
oligobenzamides should bind in this position. The HSQC peak movements observed specify the 
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residues around which the environment changes when VA3-192 binds but not whether these 
residues are in close contact with the compound. Titration of p53 into Mdm2 L33E would 
indicate which residues normally move when the p53-binding pocket is used and confirm 
whether or not VA3-192 attaches to the p53 binding groove of Mdm2. 
4.5.4. ADDITIONAL FURTHER WORK 
HSQC peak movement during repeated addition of a compound could be used to produce a 
titration curve from which the binding constant could be determined
296
. The RMSD of peaks 
from their position prior to compound addition could be plotted on the y-axis. 
Saturation transfer difference NMR can reveal which parts of a small molecule bind to a 
protein
297
. The protein is saturated, meaning that its nuclei are excited to excess so that the 
populations of nuclei in each spin quantum state become equal and no further net absorption by 
the system is possible. Magnetisation spreads to the ligand when it transiently contacts the 
protein, causing the nuclei of ligand atoms that interact with the protein to also become 
saturated. The spectrum of the bound ligand is subtracted from a reference spectrum of the 
unbound ligand to get a spectrum where the peaks made by these interacting ligand atoms have 
an increased intensity. Estevao et al.
298
 used saturation transfer to study indole based 
cyclooxygenase inhibitors of COX-2. They saw that the dealkylation at two adjacent positions 
on a compound was sufficient to change the binding pose significantly, moving a sulphonamide 
group out of a key pocket which confers selectivity. 
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5. Final Conclusions 
 
 
 
In many human tumours, aberrant down-regulation of p53 activity occurs due to overexpression 
of Mdm2. An effective inhibitor of the p53-Mdm2 interaction could potentially be developed 
into a pharmaceutical, in addition to being a useful laboratory tool. The original aim of this 
project was to demonstrate that computational methods could be used to predict the relative 
binding affinities of oligobenzamides for the p53 binding site of Mdm2. The use of computer 
predictions to streamline identification of possible inhibitors could make the process of drug 
development faster, more efficient and cheaper. 
To some extent, this primary aim was achieved. Binding energies predicted for oligobenzamides 
binding to Mdm2 showed a moderate correlation with experimental results when implicit 
solvent methods were used. Spearman’s rank correlation coefficients typically between 0.5 and 
0.6 were obtained. This finding suggests that such methods may be valuable for making future 
predictions. 
Despite its statistical significance, the correlation between computational predictions and 
experimental data was not particularly strong, reinforcing conclusions from earlier work which 
show that it is challenging to make reliable in silico predictions 
299
. Consequently, the scope of 
the project expanded to address the question of why it is difficult to establish correlations, and, 
by investigating the causes, provide insight into how the underlying problems might be solved.    
It became clear that the problem is two-fold; predicted affinities must be accurate but laboratory 
measurements must be equally so. Thus, the final project involved a mixture of computational 
and laboratory work. 
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5.1. Computational Work 
 
In this project, two computational approaches to predicting relative binding affinity were 
assessed, thermodynamic integration and implicit solvent methods. 
5.1.1. THERMODYNAMIC INTEGRATION 
The relative affinities of 31 oligobenzamides were predicted using TI. This method estimates 
the effect of small side chain modifications on the binding energy of a ligand. A prerequisite is 
that the two ligand structures involved bind in roughly the same place. Preliminary docking 
results were consistent with the proposal that all oligobenzamides do indeed bind to Mdm2 in 
the same position, namely the p53 binding site, with their side chains mimicking the key p53 
residues Phe19, Trp23 and Leu26. Nonetheless, there was a poor correlation between the TI 
predictions and the experimentally determined binding affinities. 
Subsequent analysis of more extensive docking results with approximately 25,000 
oligobenzamides revealed a possible explanation for the limited success of TI: oligobenzamides 
can actually bind in many different positions in and around the p53 binding site. Modification of 
the side chain combination appears to cause changes in molecular orientation and frame, 
straddling of binding pockets in some cases and, sometimes if the side chains are small, binding 
of the scaffold to Mdm2 as opposed to the side chains. If compounds bind in completely 
different poses, the contribution of functional groups to the binding energy of each side chain 
may not be additive and the influence of each side chain on affinity is unlikely to be 
independent of the other side chains present. 
5.1.2. IMPLICIT SOLVENT METHODS 
Using implicit solvent methods, a much stronger correlation between the predicted and 
laboratory-determined affinities of different oligobenzamides was observed. The MM-PBSA 
and MM-GBSA methods provide a useful compromise between speed and accuracy
129
 and their 
ability to yield an estimated binding energy from a single trajectory proved to be particularly 
useful in this project. Simulations were kept short to allow a large combinatorial library of 
compounds to be tested with the limited computing power available. 
To investigate whether the correlation between predicted and experimental results could be 
further improved, the MM-PBSA and MM-GBSA methods were tested with different settings to 
assess their robustness. The effect of changes was typically small, for example, variation in 
ionic strength had little effect. However, the success of the MM-PBSA method was dependent 
on the use of a low dielectric constant for the inside of the protein. 
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Further improvement can sometimes be achieved by using Normal mode analysis to estimate 
the changes in entropy when the protein and small molecule bind. However, this analysis is 
resource intensive and the results obtained in this project support earlier findings
249
  that 
factoring in the entropy component in this way typically does not significantly improve the 
accuracy of predictions. Similarly, simulation of the ligand in isolation, as opposed to using an 
approach based entirely on the trajectory of the complex, did not appear to improve the 
predictions, again consistent with earlier studies
265
. 
5.1.3. REFINING COMPUTATIONAL PREDICTION METHODS 
Analysis of variance (ANOVA) using the MM-PBSA results, treating the side chains as factors, 
confirms that there is a significant statistical interaction between the side chains of an 
oligobenzamide. This means that one side chain affects the affinity of those adjacent to it. The 
interaction is manifest in many of the components of the binding energy. 
There are two possible causes of this interaction. Firstly, a change in side chain could influence 
where binding occurs, changing the part of Mdm2 to which the side chains bind and therefore 
their affinity. Secondly, rather than changing the binding site, a modification could control how 
the other side chains bind within a particular binding position. 
The extensive docking results obtained in this project support the first option because they show 
that modification of a side chain affects where binding occurs, and by implication, the side 
chain affinity. Treatment of the pose as a factor in the MM-PBSA prediction ANOVA analysis 
confirms that the binding pose affects the affinity of the side chains. 
In support of the second effect, an interaction between the side chains remains when poses all 
associated with the same binding location are compared. However, the magnitude of the 
interactions in this case is smaller and, depending on the circumstances, could be ignored. 
To perform the analyses described herein, simulations of oligobenzamides with many different 
side chain combinations had to be performed. This was computationally time consuming and 
expensive. The small degree of interaction between the side chains of molecules within each 
binding position suggests that, to compare compounds binding within a particular location, it 
would be valid to predict the effect of each side chain individually, saving simulation time. In 
contrast to the difficulty of binding affinity prediction, docking can often find the correct pose 
of a ligand reasonably quickly and accurately
161,162
. Docking could thus be used to select, from a 
range of positions for which structure-activity relationships had been identified, the right one for 
predicting the affinity of a new ligand. Identification of quantitative relationships
134
 at each site 
could allow ligands binding at different sites to be compared to produce an overall ranking. 
The accuracy of predicted binding affinities would be improved by the use of longer simulation 
times. This would be facilitated by the independent treatment of each specific side chain in 
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every possible binding site because this would reduce the total number of simulations required 
and thus allow more time to be spent on each one. Oligobenzamides are flexible enough to bind 
in many different conformations but their rigidity is sufficient to extend the time needed for 
complete sampling of the conformational space to tens of nanoseconds
172
. The adjusted R-
squared values of many of the ANOVA models in this project suggest that much of the variation 
in the data is not accounted for by the model in question. Consequently, there is room for 
improvement, which might be achieved if the accuracy of the model parameters is increased by 
use of longer simulations or more repeats. 
The number of simulations required could also be reduced through use of a new method known 
as lambda dynamics
272
. This method could allow a single simulation to encompass both testing 
at multiple side chain attachment positions and assessment of numerous side chains at each 
position. Although very long simulations might be needed, the nature of this method means that 
simulation time would be spent testing the most potentially useful side chains. Furthermore, less 
simulation time would be spent on the equilibration of a large number of systems. 
5.1.4. WHICH OLIGOBENZAMIDES PROVIDE THE GREATEST 
POTENTIAL FOR FUTURE RESEARCH? 
The FlexX
149
 docking scores of an oligobenzamide library were used to investigate the specific 
properties likely to increase the affinity of ligands which bind in the expected, idealised pose 
occupying the Phe19, Trp23 and Leu26 binding sites of Mdm2. The results indicated that the 
first side chain should be small, the second large and the third flexible, in accordance with the 
side chains of the p53 residues they mimic. 
Of the three oligobenzamide scaffolds investigated, the sulphur-linked scaffolds could provide 
the greatest scope for future work. TI results suggest that the sulphur link atoms make more of a 
contribution to the binding energy of oligobenzamides based on the ortho-substituted sulphur 
scaffold than the corresponding oxygen atoms make to the binding of oligobenzamides with 
oxygen-linked side chains. This could be because the strength of the intramolecular hydrogen 
bonding in the latter prevents the molecule from achieving the optimum conformation for 
binding. While compounds based on the nitrogen-linked scaffold might bind strongly, the side 
chains in these compounds are attached to the amide nitrogen atoms so the parameters of the 
scaffold could be affected by the nature of the side chains present. Rigorous investigation with 
different scaffold torsion parameters for different side chains would not be straightforward and 
might yield results that were difficult to compare. 
The sulphur-containing scaffolds discussed in this work have received little attention in the 
laboratory. They should be investigated further. 
283
  
 
 
Whichever scaffolds are the focus of future research, evidence should be obtained to confirm 
that the parameters used generate predictions that reliably agree with experimentally determined 
affinities. Such validation relies on accurate experimental data from laboratory testing. 
 
5.2. Laboratory Work 
 
There are two stages to the computational prediction of a ligand’s binding affinity. The first is 
the determination of where and how the ligand binds. The second is the estimation of the 
strength with which the ligand will bind in the site identified. In the experimental part of this 
project, each of these stages was considered, with a view to the development of methods for the 
validation of computational predictions. 
5.2.1. NMR: A METHOD OF DETERMINING WHERE BINDING OCCURS 
Docking results suggest that oligobenzamides could bind to the p53 binding site of Mdm2 in 
various different ways. Correct establishment of the precise manner in which a particular 
oligobenzamide binds is essential for the prediction of accurate affinities for the molecule itself 
or similar oligobenzamides. A laboratory method to identify where oligobenzamides bind would 
consequently be useful. 
Unfortunately, it was not possible to perform NMR experiments with the oligobenzamides 
available. They either precipitated or were soluble but could not be detected by NMR, probably 
due to their aggregation. Even in the presence of 10% DMSO, a spectrum of them in aqueous 
solution could not be obtained. Given that the FRET assays used to test oligobenzamides 
involve aqueous buffer, this evidence of more complex interactions is of relevance to the 
interpretation of FRET results. A simple equilibrium is assumed in the FRET assays. If not all 
of the compound is in solution then the Kd for binding will be overestimated. 
Reliable availability of oligobenzamides soluble at a DMSO concentration in which the protein 
is stable would greatly facilitate future work. To this end, work to improve compound solubility 
has continued within the collaborating Chemistry group.  A possible method being investigated 
is the addition of soluble groups to the backbone of the scaffold. The NMR results suggest that 
the propensity for compound aggregation must also be minimised. Amphipathic molecules with 
polar side chains to increase solubility on one side and hydrophobic side chains to bind to 
Mdm2 on the other might have a tendency to interact with each other. 
In light of the solubility problems associated with the oligobenzamides, NMR was used to study 
the interaction of a compound resembling an oligobenzamide, VA3-192 (Figure 4.13B, p263) 
with Mdm2. The location of the residues which appeared to be perturbed suggested that VA3-
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192 bound in a manner consistent with the two highest scoring docking poses generated by 
Autodock Vina
152
. In these poses, the ligand is acting as a peptidomimetic. Due to their 
similarity, this is evidence that oligobenzamides also have the potential to act as 
peptidomimetics if the challenges of solubility and aggregation can be overcome. 
Crystals containing Mdm2 and VA3-192 or, ideally, an oligobenzamide could usefully be 
produced for X-ray diffraction. X-ray structures might provide more conclusive and detailed 
information about how oligobenzamides really bind and such an X-ray structure would be an 
excellent starting point for future computational work. 
The L33E form of Mdm2 was used for NMR because this mutant is stabilised in the open 
conformation. Upon compound binding, only the resonances of residues near to the site of 
binding are likely to change so those that do reveal the binding position. Because the amide 
nitrogen and amide proton resonances of L33E Mdm2 differ significantly from those of the wild 
type protein, their assignment was necessary. These assignments will be valuable for future 
work. 
5.2.2. FRET: A METHOD OF DETERMINING BINDING AFFINITY  
This project involved the development of a Förster resonance energy transfer (FRET) assay to 
test the affinity of p53-Mdm2 interaction inhibitors. This assay is orthogonal to the fluorescence 
polarisation assay currently in use
42
. It involves titration of the potential inhibitor into a solution 
of fluorescently labelled Mdm2 and fluorescently labelled p53 peptide. Before the titration, a 
sizeable proportion of the p53 molecules are bound to Mdm2 molecules causing FRET to occur 
between their fluorescent labels. During the titration, binding of an inhibitor to the Mdm2 
displaces any p53 peptide. This is observed as a decrease in FRET. 
Three possible labelled p53 peptides were tested, wild type p53-eosin, wild type p53-mCherry 
and a mutant p53-mCherry. Titration results show that the known inhibitor Nutlin-3 displaces 
all three of these proteins from GFP-Mdm2. This indicates that the fact these proteins are 
labelled does not prevent them from binding in the expected position. Further evidence of 
correct binding comes from comparison of the binding affinities of the Cherry-labelled mutant 
peptide and labelled wild type peptide with those of the two unlabelled peptides. In both cases, 
the mutant binds more strongly.  The binding strength of the mutant peptide construct could be 
particularly useful for testing the efficacy of high affinity inhibitors. 
A useful characteristic of the new FRET assay developed using p53-eosin is that it works in the 
presence of 10% DMSO. This allows it to be used with less soluble inhibitors and where a 
potential inhibitor has a significant absorbance. Furthermore, its adaptation for use on a 
microwell plate brings high throughput characterisation of accurate oligobenzamide affinities a 
step closer. 
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Although the FRET method is a useful orthogonal assay, the fluorescence polarisation assay has 
distinct advantages. p53-eosin binds significantly more strongly to unlabelled Mdm2 (measured 
by fluorescence polarisation) than to GFP-Mdm2 (measured by FRET) suggesting that the GFP 
label in the FRET assay hinders access to the Mdm2 binding pocket. Furthermore, the high Kd 
means that high concentrations of GFP-Mdm2 and p53 peptide are required to form enough of 
the complex for compound testing. Comparably high concentrations of each potential inhibitor 
are needed to compete with the peptide. In contrast, in the fluorescence polarisation assay, far 
less labelled peptide is required. Because concentrations of peptide and (unlabelled) Mdm2 do 
not need to be equivalent, the equilibrium can be shifted using a high concentration of 
unlabelled Mdm2 alone. Consequently, less inhibitor is needed. High IC50 values are a problem 
in the FRET assay when using oligobenzamides because of their low solubility and colour. In 
contrast, in the fluorescence polarisation assay, the results are unaffected by the absorbance of 
fluorescence by the inhibitor. Consequently, the FRET assay is not a good substitute for the 
fluorescence polarisation assay when testing compounds in vitro. Rather, it is a useful, 
complimentary method for use in conjunction with the polarisation method, to support its 
findings. 
In vivo, fluorescence polarisation cannot be used because there is no easy method of introducing 
the chemically labelled peptide into cells. In contrast, the p53-Cherry proteins could be co-
expressed with GFP-Mdm2 in a cell so the FRET assay could potentially be developed into an 
assay for in vivo testing. In this respect, the FRET assay is a significant advance. 
 
5.3. A combined approach 
 
The complexity of oligobenzamide binding advocates closer integration of in silico and in vitro 
work. These complimentary approaches would ideally form parts of a cyclical strategy such as 
that shown in Figure 5.1 where computational predictions are assisted by reliable laboratory data 
and synthetic work is driven by the resulting predictions. 
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Figure 5.1: A cyclical strategy for the development of oligobenzamide inhibitors. Each box represents 
a method which could be used and describes what its contribution to the process would be. The numbers 
relate to the points in the text below, which describe how progress in each area has been advanced by the 
findings or developments of this project. 
 
The unusual breadth of this project means that its findings and developments could be 
applicable to all stages of this broad, interdisciplinary problem, as shown in Figure 5.1: 
1. This project highlighted which scaffolds it might be most useful to use in future 
synthetic work on the grounds of their ease of parameterisation and expected stronger 
binding. Work with FlexX demonstrated how the properties of side chains best suited to 
a particular binding pose might be identified. Specific properties pertaining to the 
Phe19, Trp23 and Leu26 binding sites were determined. 
2. FRET-based assays were developed for in vitro analysis of compounds once they had 
been synthesised. A microwell plate assay was developed for high-throughput testing 
and p53-Cherry protein constructs were produced which could be used in the course of 
future in vivo work. 
3. The HSQC peaks of L33E Mdm2 were assigned to its residues. These assignments 
could enable future testing to determine the binding position of inhibitors. Structural 
binding information can indicate how an oligobenzamide might best be modified to 
generate a new set of possible inhibitors from which some can be selected for synthesis 
using in silico methods. 
Synthesis 
Produces inhibitors which 
might have higher affinity 
FRET Assay 
Reveals true 
affinities 
NMR 
Explains high 
affinities 
Screening and Docking 
Creates and positions 
molecules which might 
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3 3 
5 
287
  
 
 
4. The project demonstrated a method of computationally evaluating the broad range of 
binding poses obtained when docking a library of oligobenzamide peptidomimetics. 
5. MM-PBSA and MM-GBSA methods were shown to be of use for determining affinities 
in silico from docking poses. Various settings were tested and useful approaches were 
identified. A method was also suggested which would reduce the number of simulations 
required while still taking into account the effect of side chain choice on binding pose. 
In silico prediction allows compounds which are unlikely to bind to be eliminated. It 
thus reduces the number of compounds which must be synthesised for further testing. 
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6. Appendices 
 
 
 
6.1. Appendix A: Statistical Methods 
6.1.1. REGRESSION 
6.1.1.1. Measuring the Correlation between Continuous Variables 
6.1.1.1.1. Pearson’s Product Moment Correlation Coefficient 
Pearson’s Product Moment Correlation Coefficient250 for a population, ρ, is a measure of the 
extent to which there is a linear correlation between two variables, each normally distributed 
(distributed as a Gaussian distribution). For a sample from a population, the coefficient is 
denoted by r. In this work coefficients were calculated using the PEARSON function in 
Microsoft Excel (2010): 
𝑟 =
∑(𝑥 − ?̅?)(𝑦 − ?̅?)
√∑(𝑥 − ?̅?)2∑(𝑦 − ?̅?)2
 6.1 
Where the macron (line) above x and y indicates use of the arithmetic mean of that variable. 
Where there is a positive linear correlation, r is 1. Where there is a perfect negative linear 
correlation, r is -1. (If one of the variables is constant, making a perfect linear correlation which 
is neither positive nor negative, r is 0.) Where there is no correlation, r has a symmetrical 
probability distribution centred on 0. Testing to see if a correlation is significant involves testing 
the null hypothesis that ρ=0. 
6.1.1.1.2. Spearman’s Coefficient of Rank Correlation 
When one of two variables is not distributed according to a normal distribution or the 
relationship between the variables is not linear, Pearson’s Product Moment Correlation 
Coefficient is not appropriate. Here, Spearman’s Rank correlation coefficient251, a non-
parametric statistic, can be calculated. This is the Pearson’s Product Moment Correlation 
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Coefficient of the data where the values have been replaced by their rank, their order if the 
dataset were to be sorted by the variable in question. 
In this project, ranking was carried out in Microsoft Excel, using a VBA macro to ensure the 
correct treatment of ties if they were present. 
6.1.1.1.3. Confidence limits 
All confidence limits throughout this thesis are 95% confidence limits and are, unless otherwise 
stated, calculated using the standard error on x and the t distribution. 
95% confidence limits = ±𝑡𝑛−1 × 𝑆𝐸𝑥 = ±
𝑡𝑛−1𝑠𝑥
 𝑛
 6.2 
Where SEx is the standard error on x, sx is the standard deviation of the sample, n is the number 
of values and tn-1 is Student’s t for the probability 0.975 with n-1 degrees of freedom (which 
tends towards 1.96 as n increases). Standard deviations quoted in this project are the square root 
of the unbiased sample variance (the standard deviation obtained by dividing by N-1). 
Correlation coefficients are not normally distributed. This complicates the calculation of their 
confidence limits. Fisher
300
 derived a formula to transform correlation coefficients into a 
normally distributed variable, Fisher's z: 
𝑧 =
1
2
ln (
1 + r
1 − r
) 6.3 
Where z is Fisher's z for the sample correlation coefficient r. 
The standard error on any correlation coefficient can be calculated on Fisher-transformed 
coefficients as it can with any variable which is normally distributed and confidence limits can 
be converted back to correlation coefficients using the inverse of the formula above. This is 
described by Caruso and Cliff
301
. 
In this work, the variance of Fisher’s z was estimated using the formula of Bonett and Wright302: 
𝜎2(𝑧) =
1 + ρ
2𝑛 − 6
 6.4 
Where z is Fisher's z and n is the sample size. The population correlation coefficient ρ was 
assumed to equal the sample correlation coefficient for the purpose of estimating the variance of 
Fisher’s z. 
For calculating confidence limits on correlation coefficients, the cumulative normal distribution 
was used, as is standard practice. (1.96 was used in place of t in Equation 6.2.) 
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6.1.1.2. Logistic regression 
In this project, some docking results were analysed using logistic regression
252
 as detailed in the 
results section of the computational results chapter. This analysis was performed using IBM 
SPSS Statistics 20. 
Binary logistic models have the form:  
𝑃 =
1
1 + 𝑒−𝑦
 6.5 
P is the probability of “success”, which could be, for example, the probability of side chain 2 
being in the middle, Trp23 binding pocket. 
In this project, 
𝑦 = 𝛽𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 + 𝛽𝑀𝑊𝑥𝑀𝑊 + 𝛽𝑙𝑜𝑔𝑃𝑥𝑙𝑜𝑔𝑃 + 𝛽𝐻𝑥𝐻 + 𝛽𝑅𝑥𝑅 6.6 
The β variables are constants describing how each factor, x, affects the probability. 
Use of an equation in the form of Equation 6.5 ensures that P is always predicted to be between 
0 and 1, regardless of the values for the parameters. 
Rearrangement of Equation 6.5 and substitution of Equation 6.6 into it yields Equation 6.9. On 
the left side of Equation 6.9 is the odds ratio, the probability of success divided by the 
probability of failure, and on the right is the product of a term for each factor. e
β
 is a useful 
value to calculate for each factor because it indicates what the odds ratio is multiplied by if xi 
increases by 1 (and what it is divided by if xi decreases by 1). 
1
𝑃
 = 1 + exp −∑𝛽𝑖𝑥𝑖
𝑖
  6.7 
1 − 𝑃
𝑃
 = exp −∑𝛽𝑖𝑥𝑖
𝑖
  6.8 
𝑃
1 − 𝑃
 = exp ∑𝛽𝑖𝑥𝑖
𝑖
   
 =∏(𝑒
𝛽𝑖)
𝑥
𝑖
 6.9 
Fitting a binary logistic model involves finding the constants denoted by β. Making a prediction 
with the model here involves calculating P for a particular molecular weight, logP, number of 
heteroatoms and number of rings (substituting for x in the formula) and then looking to see 
whether P > 0.5. Testing the statistical significance of each factor involves testing the null 
hypothesis that β = 0 for the factor in question (after the effects of the other variables have been 
accounted for). 
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When fitting, SPSS identifies the maximum likelihood (most likely) value of β, β̂. SPSS also 
gives the Wald statistic, W, for β. This is the square of the maximum likelihood estimate of β 
divided by the estimated variance of this estimate (the standard error squared)
252
. 
W =
β̂2
σ̂
?̂?
2  6.10 
The variance of the likelihood at the observed maximum can be estimated from the second 
derivative of the function at this maximum
303
. The significance of the maximum likelihood 
estimate, β̂, can be assessed by comparing the Wald statistic with a critical value from the chi-
squared distribution with 1 degree of freedom (for large samples) or the F-distribution with 1 as 
the first degree of freedom (for small samples). 
6.1.2. ANALYSIS OF VARIANCE (ANOVA) 
6.1.2.1. The t-Test 
The t-test can be used to test whether two samples are drawn from populations with the same 
mean. In this project, the t-test was used to compare the predicted binding affinities of 
oligobenzamides differing in whether oxygen or sulphur was used to connect the side chains to 
the scaffold. 
To perform the test on two groups (sets of repeats in this context) a test statistic, t, is calculated 
and compared to the critical value for t from tables of Student’s t-distribution. 
t =
X̅1 − X̅2
𝑠X̅1−X̅2
 
6.11 
Where ?̅?1 and ?̅?2 are the means of the two groups and 𝑠X̅1−X̅2 is the standard deviation of 
X̅1 − X̅2 which would be obtained if the two groups were to be repeatedly sampled from their 
parent populations. 
𝑠X̅1−X̅2 =
√𝑠1
2 + 𝑠2
2
 𝑛
 6.12 
Where n is the size of each of the two groups and s1 and s2 are the unbiased sample standard 
deviations of the two groups. 
Usually, the two groups are assumed to have the same variance and the t statistic is evaluated 
using the t-distribution with 2n-2 degrees of freedom.  However the assumption of equal 
variances does not need to be made if the t-distribution is used with the number of degrees of 
freedom, d, given by the Welch–Satterthwaite equation261, which for two equally sized samples 
simplifies to 
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𝑑 =
(𝑠1
2 + 𝑠2
2)2(𝑛 − 1)
𝑠1
4 + 𝑠2
4 . 6.13 
A t-test is a test of whether the variation between two groups can be explained solely by the 
variation within the groups, as would be the case if the two groups were samples drawn from 
the same population. It is an analysis of the variance and the t-test is an example of a more 
general set of tests which can be applied to any number of factors and groups, tests known 
collectively as analysis of variance (ANOVA). 
6.1.2.2. Introduction to ANOVA 
There were many hypotheses which could be tested using the multivariate data produced in this 
project. ANOVA
215
 allows a large number of hypotheses to be assessed in a single test, ensuring 
rigor whilst allows statistical power to be maintained. 
ANOVA is the standard method for testing whether different nominal factors (factors with 
discrete unordered values) affect a normally distributed interval (continuous) variable. 
Performing an ANOVA significance test is similar to performing any statistical test in that it 
involves the calculation of a test statistic (F in the case of ANOVA) and then the comparison of 
this calculated statistic with a critical value which can be looked up from tables (of the inverse 
cumulative F-distribution function in this case). 
The first step is the calculation of what is referred to as the sums of squares for each source of 
variation (factor and factor combination). This is the sum of the squares of the deviations of a 
set of values from a particular mean. For a two factor ANOVA there are four sums of squares. 
Firstly, there is a sum of squares (SS) for each of the two factors: 
Where a and b are the numbers of possible values for two factors, A and B and r is the number 
of repeats per cell (combination of A and B values). 
Secondly, there is a sum of squares for the interaction between the variables, SSAB. 
Thirdly, there is a sum of squares for the within group variation (SSwithin) 
𝑆𝑆𝑤𝑖𝑡ℎ𝑖𝑛 =∑∑∑(𝑋𝑖𝑗𝑘 − ?̅?)
2
𝑟
𝑘=1
𝑏
𝑗=1
𝑎
𝑖=1
 
  
6.17 
𝑆𝑆𝐴 = 𝑏𝑟∑(𝑋?̅? − ?̅?)
2
𝑎
𝑖=1
 6.14 
𝑆𝑆𝐵 = 𝑎𝑟∑(𝑋?̅? − ?̅?)
2
𝑏
𝑗=1
 
  
6.15 
𝑆𝑆𝐴𝐵 = 𝑟∑∑(𝑋𝑖𝑗̅̅ ̅̅ − 𝑋?̅? − 𝑋?̅? + ?̅?)
2
𝑏
𝑗=1
𝑎
𝑖=1
 
 
6.16 
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For each sum of squares the “mean sum of the squares” must be calculated by dividing each 
sum of squares by the number of degrees of freedom for that sum of squares. Finally, F values 
can be calculated by dividing each between-group mean sums of squares by the within-group 
mean sums of squares. This is summarised in Table 6.1 for two factors, A and B. 
A significant interaction term F statistic indicates the presence of a statistical interaction 
between the factors. In the case of a two factor interaction term, this means that the manner in 
which each of the factors affects the dependent variable varies according to the value of the 
other factor. When the highest order interaction term in an ANOVA involving three or more 
factors is significant, this indicates that there is a deterministic relationship between the factors 
and the dependent variable which cannot be accounted for by the summation of independent 
effects caused by each of the factors individually, their pairwise interactions or any other 
possible lower order interaction. 
Table 6.1: A two-way ANOVA table 
Source of 
variation 
Degrees of 
freedom 
Sums of 
squares 
“Mean sums of squares” F statistic 
A 𝑎 − 1 𝑆𝑆𝐴 𝑀𝑆𝐴 =
𝑆𝑆𝐴
𝑎 − 1
 
𝑀𝑆𝐴
𝑀𝑆𝑤𝑖𝑡ℎ𝑖𝑛
 
B 𝑏 − 1 𝑆𝑆𝐵 𝑀𝑆𝐵 =
𝑆𝑆𝐵
𝑏 − 1
 
𝑀𝑆𝐵
𝑀𝑆𝑤𝑖𝑡ℎ𝑖𝑛
 
A × B (𝑎 − 1)(𝑏 − 1) 𝑆𝑆𝐴B 𝑀𝑆𝐴×B =
𝑆𝑆𝐴B
(𝑎 − 1)(𝑏 − 1)
 
𝑀𝑆𝐴B
𝑀𝑆𝑤𝑖𝑡ℎ𝑖𝑛
 
Within group 𝑎𝑏(𝑟 − 1) 𝑆𝑆𝑤𝑖𝑡ℎ𝑖𝑛 𝑀𝑆𝑤𝑖𝑡ℎ𝑖𝑛 =
𝑆𝑆𝑤𝑖𝑡ℎ𝑖𝑛
𝑎𝑏(𝑟 − 1)
  
 
A and B are factors. An interaction term and a residual variance are included in this model. a is the 
number of classes of factor A, b is the number of classes of factor B and r is the number of replicates 
within each cell (for each combination of values of A and B).  
 
There are different methods of calculating the sums of squares in an ANOVA. The different 
methods produce identical results for the last term in the model (SSAB above) and the same 
results for all terms (SSA, SSB, SSAB) where there is the same number of replicates for each 
combination of factor values. However, for the main effects (A and B), if the number of 
replicates differs per cell (an unbalanced design), the choice of formulae is important because it 
subtly changes the hypotheses tested. 
The expressions shown in the table are for type II sum of squares. Calculation of the type III 
sums of squares for each source of variation requires the formulation of a separate table similar 
to that above with the term in question placed last in the model. Type III sums of squares 
therefore indicate the degree of variation which can be explained by a term in the model after all 
of the other terms have been taken into account. 
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6.1.2.2.1. Missing values 
There were two types of missing data encountered when processing binding energies for 
different compounds. Firstly, there were differing numbers of repeats for each compound for 
each pose; docking was carried out three times but sometimes there was no suitable pose from 
one or two of the three repeats. Secondly, there were some occasions where there was no result 
because none of the three repeats yielded a suitable pose. 
The first type of imbalance was not a problem. Type III sums of squares (discussed above) were 
used, which give the size of a particular effect after all of the other factors of the model have 
been taken into account. These are not biased by such missing values and consequently are the 
most widely used type of sums of squares in ANOVA and the default in SPSS. 
The second type of imbalance is a significant problem and two strategies were used to overcome 
it. Firstly, the number of factors used in any single ANOVA was kept small. Where necessary, 
more than one ANOVA was performed. Problems with this method are that results for separate 
ANOVAs cannot be compared, reducing the number of questions which can be investigated, 
and also that, when multiple ANOVAs are performed, multiple hypotheses are being tested, so 
care must be taken to avoid the incorrect rejection of null hypotheses due to chance. 
The problem of missing values was resolved by impution (backward interpolative prediction) of 
a value for each empty cell. The model used for impution in this project (Equation 6.18) was 
one with only main effects to prevent the introduction of pairwise interactions. 
𝑌𝑖𝑗𝑘 = 𝑚 + 𝑎𝑖 + 𝑏𝑗 + 𝑐𝑘 + 𝜖𝑖𝑗𝑘 6.18 
Where Yijk is the predicted binding energy for the combination of factor values i, j and k, m is 
the mean binding energy over all of the cells (combinations), ai, bj and ck are coefficients 
describing the (assumed independent) contribution of each factor and ϵijk is an error term which 
accounts for effects not modelled by the parameters. 
To impute values, the coefficients are first calculated using the available data. There is one 
coefficient a for every possible side chain at position 1, one coefficient b for every possible side 
chain at position 2 and one coefficient c for every possible side chain at position 3. The model 
formula (Equation 6.18) is then used for each value to be imputed assuming ϵijk is 0. 
𝑚 =
1
𝑁
∑𝑦𝑖𝑗𝑘
𝑖,𝑗,𝑘
 6.19 
Where yijk is mean of the observations for the factor value combination i, j, k and N is the total 
number of cells (combinations). m is, as in Equation 6.18, the mean binding energy over of the 
cells. 
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𝑎𝑖 =
1
𝑁
∑𝑦𝑖𝑗𝑘
𝑗,𝑘
−𝑚 
6.20 
𝑏𝑗 =
1
𝑁
∑𝑦𝑖𝑗𝑘
𝑖,𝑘
−𝑚 
6.21 
𝑐𝑘 =
1
𝑁
∑𝑦𝑖𝑗𝑘
𝑖,𝑗
−𝑚 
6.22 
Where ai, bj and ck are coefficients of the model, as shown in Equation 6.18. 
When testing for two-way interactions, impution increases the chance of a type II statistical 
error (failure to reject the null hypothesis). 
To reduce the chance of a three-way interaction between two side chains and a third factor (the 
pose or scaffold choice) being created, values were deleted prior to impution such that an equal 
number of cell values were imputed for each value of the third factor (each pose or each 
scaffold). However, it is an assumption of the tests for three-way interactions following 
impution described in this thesis that (for oligobenzamides based on a particular scaffold in a 
particular pose) the probability of a prediction missing (due to docking not generating a pose) 
does not depend on the choice of side chains. This is known as the MCAR (missing completely 
at random) assumption
304
. 
Impution and ANOVA were performed using IBM SPSS Statistics 20. 
6.1.2.2.2. R-squared values 
When an ANOVA or logistic regression is carried out in SPSS, the software calculates an R-
squared value (R
2
, Equation 6.23) which indicates the goodness of fit of the model, more 
specifically, the proportion of the variation in the data described by the model. Standard 
(unadjusted) R-squared values range from 0 (no explanation of the results) to 1 (full explanation 
of the variation in the results). 
For ANOVA analyses: 
𝑅2 = 1 −
𝑆𝑆𝐸𝑟𝑟𝑜𝑟
∑(𝑥 − ?̅?)2
 6.23 
SSError is the sum of the squares of the residuals, the residual being the error term in the model, 
the difference between each value and its predicted value based on the fitted terms of the model. 
This sums of squares is, as shown, divided by the sum of the squares of the differences of each 
value, x, from the overall mean of all the data. In SPSS this denominator is referred to as the 
total adjusted sums of squares (SSTotal). 
Models with more terms are intrinsically more likely to fit data better than models with fewer 
terms. Adjusted R-squared values (R
2
adj, Equation 6.24), are also calculated by SPSS. These 
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take into account the number of coefficients in the model and thus allow a fair comparison of 
models with different numbers of terms. 
𝑅𝑎𝑑𝑗
2 = 1 −
(1 − 𝑅2)(𝑁 − 1)
𝑁 − 𝑘 − 1
 6.24 
N is the number of data points and k is the number of coefficients in the model. 
6.1.2.2.3. Necessary Assumptions for ANOVA 
It is an assumption of ANOVA that the residuals (ϵijk in Equation 6.18) are distributed normally 
(with no skew or excess kurtosis) and that the variance of the residuals is the same in each cell 
(the data are heteroscedastic). 
The Fisher g statistics g1 and g2 can be used to assess the skew and kurtosis (pointedness) of a 
distribution respectively
305
. 
𝑔1 =
𝑛
𝑛 − 2
∑(𝑋𝑖 − ?̅?)
3
(∑(𝑋𝑖 − ?̅?)2)
3
2⁄
 
6.25 
𝑔2 =
𝑛 − 1
(𝑛 − 2)(𝑛 − 3)
[𝑛(𝑛 + 1)
∑(𝑋𝑖 − ?̅?)
4
(∑(𝑋𝑖 − ?̅?)2)2
− 3(𝑛 − 1)] 6.26 
 
 
The g2 of samples randomly drawn from a normal distribution is distributed as a normal 
distribution with a variance approximately equal to 24 divided by the sample size, n
306(p89)
. 
𝑔2~𝑁 0,
24𝑛(𝑛 − 1)2
(𝑛 − 3)(𝑛 − 2)(𝑛 + 3)(𝑛 + 5)
  6.27 
 
 
In the computational results chapter, a kurtosis of 0.517 is described as small. This is because 
using Equation 6.27 it can be shown that, at the 5% significance level (|𝑧| > 1.96), the sample 
size must exceed 237 for such a kurtosis to be statistically significant. In the results described, 
the kurtosis was statistically significant because the sample size exceeded 237. However, the 
larger the sample size, the more robust ANOVA is to deviations from normality
307
 so the results 
of the ANOVA subsequently described in the results are as reliable as they would have been 
had the sample been smaller and thus had a statistically insignificant kurtosis. 
Similarly, the homoscedasticity of data was assessed prior to ANOVA using Levene’s test and 
in some cases a statistically significant result (indicating heteroscedasticity) was obtained but 
ignored because it was small in magnitude and only significant due to the large number of cells. 
Levene’s test generates F statistics, which are assessed using the F distribution. If the number of 
ANOVA cells (the first degree of freedom) is 25 (a typical value for an ANOVA study) or less, 
statistical tables for the F distribution show that, at the 5% significance level, the critical value 
is never less than 1.5, however large the sample size (which affects the second degree of 
freedom). Therefore, Levene’s test F values of 1.5 were considered sufficiently small for the 
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results of ANOVA tests to be reliable. Levene’s test is robust to deviations from normality 
(skew and kurtosis)
269
. 
Because tests for homogeneity of variance such as Levene’s test are very sensitive and the 
ANOVA test is reasonably robust to homogeneity of variances when there is a large amount of 
data, the importance of testing for homoscedasticity before ANOVA is controversial
270(p308)
. 
  
299
  
 
 
6.2. Appendix B: NMR In Terms of Product Operators 
 
The magnetic moments of the nuclei in a sample combine to create an overall magnet field 
parallel to the large external magnetic field in an NMR experiment. The radio frequency pulses 
applied cause rotation of the average magnetic moment around an axis in the plane 
perpendicular to the magnetic field. 
The position of the average magnetic moment can be described in terms of x, y and z 
components, Cartesian angular momentum operators
107(p150)
 which describe the components of 
the angular momentum in the x, y and z dimensions. They are operators because they describe 
how the spin system is changing with time. 
When a sample is placed in a magnetic field, a hydrogen nucleus within the system can be 
described as having an operator (a single-element operator) of 𝐻?̂?. The z indicates that the 
magnetisation is aligned with the z-axis, which, by definition is always parallel to the external 
magnetic field. 
If the net magnetisation is rotated into the xy-plane by a radio-frequency magnetic pulse then it 
will rotate around the z-axis as the magnetic moments of the nuclei do likewise, a process 
known as precession. This would complicate mathematical working so, by definition, the xy-
plane is treated as a rotating frame of reference, rotating such that nuclei precessing at the zero 
chemical shift frequency are stationary relative to it
107(p32)
. 
Pulses can be described using superoperators, which are operators acting on the operators. 
Superoperators can be parallel to the x-axis or y-axis, for example, for the H nucleus, 𝐻?̂? or 𝐻?̂?. 
Applying a 90° pulse, a pulse of the length required to rotate the hydrogen nucleus 90° (π/2 
radians) away from the z-axis, shifts the magnetisation into the xy-plane as shown here (using H 
to represent a hydrogen nucleus): 
𝐻?̂?
𝐻?̂?(
𝜋
2
)
→   −𝐻?̂? 6.28 
𝐻?̂?
𝐻?̂?(
𝜋
2
)
→   𝐻?̂? 6.29 
The length of time over which the superoperator acts is shown in brackets. 
180° pulses reverse the direction of the magnetisation. 
𝐻?̂?
𝐻?̂?(𝜋)
→   − 𝐻?̂? 6.30 
𝐻?̂?(Ω𝐻𝑡𝐻) is the superoperator for the evolution of chemical shift, the rotation of the nucleus 
around the z-axis relative to the xy-plane caused by the chemical shift of the nucleus not being 
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equal to 0. Chemical shift evolution occurs with respect to any magnetisation in the xy-plane 
whenever there is a delay between pulses. 
The effect of a 90°pulse followed by evolution of chemical shift in the xy-plane is shown below. 
𝐻?̂?
𝐻?̂?(
𝜋
2
)
→   𝐻?̂? cos (
𝜋
2
) − 𝐻?̂? sin (
𝜋
2
)= −𝐻?̂?
𝐻?̂?(Ω𝐻𝑡𝐻)
→      𝐻?̂? sin(Ω𝐻𝑡𝐻) − 𝐻?̂? cos(Ω𝐻𝑡𝐻) 6.31 
Detection occurs in the xy-plane. The −𝐻?̂? cos(Ω𝐻𝑡𝐻) term is the part of the resulting 
magnetisation which is detected here. A Fourier transform is performed on the oscillating 
magnetic field detected, turning the cos(Ω𝐻𝑡𝐻) wave into a peak at Ω𝐻, the chemical shift of the 
nucleus. 
2D and 3D NMR spectra are produced by combining many 1D spectra produced using different 
length delays (t1 (2D) or t1 and t2 (3D)) in the pulse sequence. The length of other delays in the 
pulse sequence is typically also important. For example, often two identical times are found 
either side of a 180° pulse. This refocusing sequence prevents chemical shift evolution because 
evolution in the first delay is reversed in the second part. 
The Zeeman splitting of the spin states of a nucleus is affected by the spins of adjacent nuclei 
that share bonding electrons with it. This is J-coupling, otherwise known as scalar 
coupling
107(p35)
 and it occurs because the spin of electrons is influenced by and influences the 
spin of their nuclei. It can be represented by the superoperator 𝑁?̂?𝐻?̂?. (N and H are shown here 
for coupling between a nitrogen atom and a hydrogen atom.) 
Like chemical shift, scalar coupling can be refocused. This requires a delay of the right length 
(which depends on the coupling constant (strength) of the coupling) with a 180° pulse 
somewhere in the middle of this period on each channel to be refocused. 
As well as scalar coupling, nuclei can experience dipolar coupling
107(p37)
. This is a through-space 
rather than through-bond effect resulting from the magnetic field of adjacent nuclei changing 
the overall field felt by each nucleus. Dipolar coupling is usually entirely cancelled out due to 
the isotropic tumbling of molecules in solution; however, partial arrangement of the molecules 
in a sample causes cancellation to be incomplete leaving residual dipolar couplings (RDCs).  
Table 6.2, Table 6.3 and Table 6.4 show using product operator notation, how the pulses in an 
HSQC, a NOESY-HSQC and a TOCSY-HSQC experiment affect the magnetisation of the 
nuclei. The reader might find it helpful to refer to Figure 1.10, Figure 1.11 and Figure 1.12 
(pp54-56) which show graphically the pulse sequences. 
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Table 6.2: The pulses and delays typically used to generate an HSQC spectrum 
 Step Super-operator Result 
 The initial state. 
(Nitrogen polarisation ignored.) 
𝐻?̂? 
P1 Transfer of 
polarisation from 
the sensitive proton 
nucleus to the 
insensitive nitrogen 
nucleus. 
𝐻?̂? (
𝜋
2
) −𝐻?̂? 
D1 𝑁?̂?𝐻?̂? (
𝜋
4
) −𝐻?̂?cos (
𝜋
4
) + 2𝑁?̂?𝐻?̂?sin (
𝜋
4
) 
= −
1
2
 2𝐻?̂? +  2𝑁?̂?𝐻?̂? 
P2 𝐻?̂?(𝜋) + 𝑁?̂?(𝜋) 
1
2
 2𝐻?̂? −  2𝑁?̂?𝐻?̂? 
D2 𝑁?̂?𝐻?̂? (
𝜋
4
) 1
2
 2𝐻?̂?cos (
𝜋
4
) −  2𝑁?̂?𝐻?̂?cos (
𝜋
4
)
−  2𝑁?̂?𝐻?̂?sin (
𝜋
4
)
−
1
2
 2𝐻?̂?sin (
𝜋
4
) 
=
1
2
𝐻?̂? −𝑁?̂?𝐻?̂? −𝑁?̂?𝐻?̂? −
1
2
𝐻?̂? 
= −2𝑁?̂?𝐻?̂? 
P3 𝐻?̂? (
𝜋
2
) + 𝑁?̂?(
𝜋
2
) = −2𝑁?̂?𝐻?̂? 
D3 Evolution of 
chemical shift on 
the nitrogen. 
𝑁?̂? (
1
2
Ω𝑁𝑡1) −2𝑁?̂?𝐻?̂? cos (
1
2
Ω𝑁𝑡1) + 2𝑁?̂?𝐻?̂? sin (
1
2
Ω𝑁𝑡1) 
P4 𝐻?̂?(𝜋) 2𝑁?̂?𝐻?̂? cos (
1
2
Ω𝑁𝑡1) − 2𝑁?̂?𝐻?̂? sin (
1
2
Ω𝑁𝑡1) 
D4 −𝑁?̂? (
1
2
Ω𝑁𝑡1) 2𝑁?̂?𝐻?̂? cos
2 (
1
2
Ω𝑁𝑡1)
− 2𝑁?̂?𝐻?̂? sin (
1
2
Ω𝑁𝑡1) cos (
1
2
Ω𝑁𝑡1)
+ 2𝑁?̂?𝐻?̂? sin (
1
2
Ω𝑁𝑡1) cos (
1
2
Ω𝑁𝑡1)
+ 2𝑁?̂?𝐻?̂? sin
2 (
1
2
Ω𝑁𝑡1) 
= 2𝑁?̂?𝐻?̂? (cos
2 (
1
2
Ω𝑁𝑡1)−sin
2 (
1
2
Ω𝑁𝑡1)) 
= 2𝑁?̂?𝐻?̂? cos(Ω𝑁𝑡1) 
P5 Transfer of 
polarisation back to 
the hydrogen for 
detection. 
𝐻?̂? (
𝜋
2
) + 𝑁?̂?(
𝜋
2
) −2𝑁?̂?𝐻?̂? cos(Ω𝑁𝑡1) 
D5 𝑁?̂?𝐻?̂? (
𝜋
4
) − 2𝑁?̂?𝐻?̂? cos(Ω𝑁𝑡1) +
1
2
 2𝐻?̂? cos(Ω𝑁𝑡1) 
P6 𝐻?̂?(𝜋) + 𝑁?̂?(𝜋) − 2𝑁?̂?𝐻?̂? cos(Ω𝑁𝑡1) +
1
2
 2𝐻?̂? cos(Ω𝑁𝑡1) 
D6 𝑁?̂?𝐻?̂? (
𝜋
4
) −𝑁?̂?𝐻?̂? cos(Ω𝑁𝑡1) +
1
2
𝐻?̂? cos(Ω𝑁𝑡1)
+
1
2
𝐻?̂? cos(Ω𝑁𝑡1)
+ 𝑁?̂?𝐻?̂? cos(Ω𝑁𝑡1) 
= 𝐻?̂? cos(Ω𝑁𝑡1) 
 
The leftmost column indicates whether the step relates to the application of a pulse (P) or to what happens 
in a delay (D). The application of the superoperator on row n transforms the operator on row n-1 in the 
rightmost column into the operator on row n. Evolution of chemical shift is not shown where it is 
refocused. The product operator expressions were derived with the help of Cavanagh et al.
109(p417)
. 
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Table 6.3: The pulses and delays typically used to generate a NOESY-HSQC spectrum 
 Step Super-operator Resulting product operators 
 Initial state (Nitrogen polarisation ignored.) 𝐻?̂? 
P1 Magnetisation 
brought into xy-
plane. 
𝐻?̂? (
𝜋
2
) −𝐻?̂? 
D1 Evolution of J 
coupling. 
𝑁?̂?𝐻?̂?(
1
2
Ω𝐻𝑡1) −𝐻?̂?cos(
1
2
Ω𝐻𝑡1) + 2𝑁?̂?𝐻?̂?sin(
1
2
Ω𝐻𝑡1) 
 
P2 Refocusing pulse 𝐻?̂?(𝜋) + 𝑁?̂?(𝜋) 𝐻?̂?cos(
1
2
Ω𝐻𝑡1) − 2𝑁?̂?𝐻?̂?sin(
1
2
Ω𝐻𝑡1) 
 
D2 Evolution of J-
coupling 
cancelling the 
previous 
evolution. 
𝑁?̂?𝐻?̂? (
1
2
Ω𝐻𝑡1) 𝐻?̂?cos
2(1
2
Ω𝐻𝑡1)
− 2𝑁?̂?𝐻?̂?sin(
1
2
Ω𝐻𝑡1)cos(
1
2
Ω𝐻𝑡1)
+ 2𝑁?̂?𝐻?̂?sin(
1
2
Ω𝐻𝑡1)cos(
1
2
Ω𝐻𝑡1)
− 𝐻?̂?sin
2(1
2
Ω𝐻𝑡1) 
= 𝐻?̂? (cos
2(1
2
Ω𝐻𝑡1) − sin
2(1
2
Ω𝐻𝑡1)) 
= 𝐻?̂? cos(Ω𝐻𝑡1) 
P3 Returning 
magnetisation to 
the z-axis 
𝐻?̂?(
𝜋
2
) 𝐻?̂? cos(Ω𝐻𝑡1) 
D3 Magnetisation 
transfer 
?̂̂? σH,H2(τm)cos(Ω𝐻2𝑡1) 𝐻?̂? σH,NH(τm)cos(Ω𝐻𝑡1) cos(Ω𝐻2𝑡1) 
Result after P1 to D6 from HSQC −𝐻?̂? σH,NH(τm)cos(Ω𝐻𝑡1) cos(Ω𝐻2𝑡1) cos(Ω𝑁𝑡2) 
 
Evolution of chemical shift is not shown where it is refocused. The product operator expressions were 
derived with the help of Cavanagh et al.
109(p448). σH.NH is the cross relaxation rate constant
109(p289)
. 
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Table 6.4: The pulses and delays typically used to generate a TOCSY-HSQC spectrum 
 Step Super-operator Resulting product operators 
 The initial state. 𝐻1?̂? 
P1 Bringing the net 
magnetisation 
into the xy-plane. 
𝐻1?̂? (
𝜋
2
) −𝐻1?̂? 
D2 Evolution of 
chemical shift 
𝐻1?̂?(
1
2
Ω𝐻𝑡1) −𝐻1?̂?cos(
1
2
Ω𝐻1𝑡1)
+ 2𝐻1?̂?sin(
1
2
Ω𝐻𝑡𝐻) 
(Latter term removed by phase 
cycling) 
Simultaneous 
evolution of J 
coupling between 
protons 
𝐻1?̂?𝐻2?̂?(Ω𝐻2𝑡1) −𝐻1?̂?cos(
1
2
Ω𝐻1𝑡1)cos(
1
2
Ω𝐻2𝑡1)
+ 2𝐻1?̂?𝐻2?̂?cos(
1
2
Ω𝐻𝑡1)sin(
1
2
Ω𝐻2𝑡1) 
(Latter term removed by 
interference during the 
composite pulse decoupling) 
CPD Transfer of 
magnetisation in 
the xy-plane 
?̂̂?(1 + cos(2πJH1,H2τm)) −𝐻1?̂?cos(
1
2
Ω𝐻1𝑡1)cos(
1
2
Ω𝐻2𝑡1) 
 
Result after P2 to D6 
from HSQC 
−𝐻1?̂?(1 + cos(2πJH1,H2τm)) cos(Ω𝐻1𝑡1) cos(Ω𝐻2𝑡1) cos(Ω𝑁𝑡2) 
 
The product operators for one of the two hydrogen atoms are shown. The end result would also contain a 
similar H2x product operator component. JH1,H2 is the J coupling parameter for the two hydrogen atoms in 
this example. 
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6.3. Appendix C: Additional methods diagrams 
 
The figures in this section show in detail how the methods described in the computational 
results chapter were used to generate the results shown. Figure 6.2 focusses on the methods. It 
shows what software was used and how the output of some programs was the input for others. 
Some steps in this diagram were performed multiple times with different data. Figure 6.3 
focusses on the results. It shows specifically how each set of results was generated. 
In these figures, each box represents a piece of data and the arrows between these nodes 
represent the application of methods to the data. Figure 6.1 below is a key to aid interpretation 
of the box styles in Figure 6.2 and Figure 6.3. 
 
 
Figure 6.1: Key for Figure 6.2 and Figure 6.3 showing how the shape and colour of the nodes 
reflects the amount and structure of the data at each point 
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Continued on the next page… 
Figure 6.2: The computational methods used in this project. 
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Figure 6.2 continued: The computational methods used in this project. The nodes (boxes) represent 
pieces of data. Arrows show how data was combined and processed to get from one node to the next. The 
diagram is generic, showing what methods were used but not exactly to what data sets they were applied 
and when; this additional detail is shown in Figure 6.3. Blue nodes depict a single piece of data. Green 
nodes indicate where there was a single data element or record per compound. Yellow nodes indicate 
multiple elements per compound, either multiple poses or multiple simulation trajectories from a single 
pose. Orange nodes indicate data for multiple trajectories started from multiple poses. Merging arrows 
indicate that two pieces of data were used together to generate the next, in contrast to where two separate 
arrows end at the same box, which indicates where there is more than one way by which the data in the 
box was produced. A similar distinction does not exist between multiple arrows coming from the same 
box and arrows resulting from the divergence of a single arrow; both show different uses of the data 
concerned. Arrows crossing the page boundary are numbered for clarity. A key for this figure and Figure 
6.3 is shown in Figure 6.1. 
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Continued on the next page… 
Figure 6.3: Data processing in this project. 
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Figure 6.3 continued: Data processing in this project. The nodes represent sets of data and the arrows 
represent processes converting each piece of data to the next. Further details of the methods used to carry 
out each conversion are shown in Figure 6.2. This figure shows more specifically how the methods were 
applied in this project. The end results are highlighted in bold. A key for this figure and Figure 6.2 is 
shown in Figure 6.1. Blue nodes show a single piece of data. Green nodes indicate where there is a single 
data element or record per compound. Yellow nodes indicate multiple elements per compound, either 
multiple poses or multiple simulation trajectories from a single pose and orange nodes indicate data for 
multiple trajectories from multiple poses. There can be one compound per scaffold (circles), or multiple 
compounds, with the number scaling linearly (rounded rectangle) or with the square (thin square blocks) 
or cube (cube) of the number of side chains at each side chain position. The number of side chains is 
indicated qualitatively by the dimensions for the squares and cubes. The opaque 3D nodes indicate where 
there was data for all combinations. 50% transparency signifies a degree of data sparsity. 
 
  
309
  
 
 
6.4. Appendix D: Additional results figures for computational work 
6.4.1. TORSION PARAMETER CALCULATION 
 
 
ca-ca-c-n 
 
 
c-n-ca-ca  
 
 
 
Figure 6.4:1-4 interaction energies for rotation around the amide carbon and adjacent aromatic 
ring carbon (c-ca) bond and the amide nitrogen and adjacent ring carbon (n-ca) bond of 
benzanilide (BA) and 4-(4-aminobenzamide)benzoic acid (AA). The structure of AA is shown in 
Figure 2.6 B (p114). Torsion parameters were calculated using the results for AA. In the simulations of 
this project, the ca-ca-c-n and c-n-ca-ca torsions were modelled using the AMBER force field by way of a 
single trigonometric term peaking at 90°. (Oligobenzamides are most stable when flat or close to flat.) 
The barrier height parameter was calculated using published barrier heights. In simple terms, the effect of 
the through-space interactions between the 1st and 4th atoms of each torsion (the electrostatic interaction 
and Leonard-Jones potentials which together constitute the 1-4 interaction energy) must be subtracted 
from the published barrier height to get the height for use in parameters (because the 1-4 interaction 
energy is added on again later by Amber during simulations). However, care must be taken to consider 
the phase and therefore sign of the 1-4 interaction energy with respect to the overall torsional barrier. 
With regard to the c-n-ca-ca torsion, the peak in 1-4 interaction energy at exactly 0° was ignored; the c-n-
ca-ca 1-4 interaction energy was assumed to vary with angle like a sine wave, peaking at 90°. Details of 
the parameter calculation are shown in Table 6.5 below. The torsion angles are indicated on an 
oligobenzamide in Figure 2.6A (p114) by red and green arrows (corresponding to the colours of the labels 
above). The torsion parameters calculated here were used where the c-ca and n-ca bonds were not 
restricted by intramolecular hydrogen bonding. For example, the ca-ca-c-n barrier height parameter was 
used in the O1 and S1 scaffolds and the c-n-ca-ca parameter was used in the O2 and S2 scaffolds. 
Previously published parameters were used for the torsions complicated by intramolecular hydrogen 
bonding, as shown in Table 2.2 (p115). 
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Table 6.5: Subtraction of the 1-4 interaction energy from the torsional barrier heights of the bonds 
either side of the ring in 3-aminobenzoic acid in order to generate estimated AMBER torsion 
parameters for the corresponding bonds in oligobenzamides 
 ca-ca-c-n torsion c-n-ca-ca torsion 
Total barrier height from literature175 /kJ mol-1 22.3 26.2 
Electrostatic 1-4 interaction energy  /kJ mol-1 -1.01 1.63 
Van der Waals 1-4 interaction energy /kJ mol-1 -5.58 -1.05 
Total 1-4 interaction energy /kJ mol-1 -6.60 0.58 
Barrier height /kJ mol-1 28.9 25.6 
PK parameter /kJ mol-1 14.4 12.8 
 
In Amber, the energy of through-space interactions (the electrostatic interaction and Leonard-Jones 
potentials) between atoms 3 bonds apart (1-4 interactions) are calculated and included in the non-bonded 
energy. Consequently, to calculate AMBER force field torsion angle parameters from the known barrier 
height for a particular torsion, the change in 1-4 interaction energy in going from the bottom to the top of 
the barrier must be subtracted so that, when it is added again during the simulation, the barrier height is 
correct. GAFF atom types are used here. “ca” represents aromatic carbon and “c” and “n” represent sp2-
hybridised carbon and nitrogen respectively. The torsion angles are indicated in Figure 2.6 (p114) by red 
and green arrows. The two parameters calculated here were used for the N-linked oligobenzamide and the 
bonds in the O and S-linked scaffold where there is not restriction due to intramolecular hydrogen 
bonding. The PK parameters are entered into AMBER in kcal mol
-1
. (1 J = 0.239 cal.) 
 
6.4.2. DOCKING EXHAUSTIVENESS EVALUATION 
 
 
Figure 6.5: The effect of the Autodock Vina “exhaustiveness” setting on docking score. Box and 
whisker plots for all docking scores obtained in four different Autodock Vina docking runs are shown. 
Runs 1, 2 and 3 were with the exhaustiveness set to 8: run 4 was with the exhaustiveness set to 16. There 
is a statistically significant improvement in the docking score between the first three runs and the fourth 
(P<0.01) but the increase is small (0.09). 
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